

Drug Expenditure in Canada 1985 to 2009



Who We Are

Established in 1994, CIHI is an independent, not-for-profit corporation that provides essential information on Canada's health system and the health of Canadians. Funded by federal, provincial and territorial governments, we are guided by a Board of Directors made up of health leaders across the country.

Our Vision

To help improve Canada's health system and the well-being of Canadians by being a leading source of unbiased, credible and comparable information that will enable health leaders to make better-informed decisions.

Drug Expenditure in Canada, 1985 to 2009

Table of Contents

List of Figures

Figure 1	Total Drug Expenditure as a Percentage of Total Health Expenditure, Canada, 1985 to 2009	. 3
Figure 2	Annual Growth Rate for Total Drug Expenditure, Total Health Expenditure and Consumer Price Index, Canada, 1985 to 2009	. 4
Figure 3	Total Health Expenditure and the Percentage Share by Use of Funds, Canada, 2009 (\$ Billions)	. 5
Figure 4	Total Drug Expenditure, Canada, 1985 to 2009	6
Figure 5	Total Drug Expenditure per Capita, Current and Constant Dollars, Canada, 1985 to 2009	. 7
Figure 6	Total Drug Expenditure by Type, Canada, 1985 to 2009	9
Figure 7	Total Drug Expenditure by Source of Finance and Type, Canada, 2009 1	10
Figure 8	Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2009 1	l 1
Figure 9	Annual Growth Rate for Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2009	12
Figure 10	Prescribed Drug Expenditure by Private-Sector Source of Finance, Canada, 1988 to 2009	14
Figure 11	Drug Expenditure as a Percentage of Total Health Expenditure, by Province/Territory and Canada, 1985 and 2009 ^f	19
Figure 12	Percentage of Total Drug Expenditure by Source of Finance, by Province/Territory and Canada, 2009	20
Figure 13	Total Drug Expenditure per Capita by Type and by Source of Finance, by Province/Territory and Canada, 2009	21
Figure 14	Annual Growth Rate for Public- and Private-Sector Prescribed (Rx) and Non-Prescribed (Non-Rx) Drug Expenditure per Capita, 2009	23
Figure 15	Average Annual Growth Rate for Prescribed Drug Expenditure per Capita by Source of Finance, by Province/Territory, Between 1985 and 2009 2	24
Figure 16	Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2009	25
Figure 17	Drug Expenditure per Capita, Selected Countries, 1985 to 2007	32
Figure 18	Composition of Total Health Expenditure, by Source of Finance	14
Figure 19	Patented Medicine Price Index (PMPI), Consumer Price Index (CPI) and Industrial Product Price Index (IPPI), 1985 to 2009 (1987 = 100)	19

List of Tables

Table 1	Distribution of Prescribed Drug Expenditure by Source of Finance, Canada, 1988 and 2009	. 13
Table 2	Drug Expenditure Summary, by Province/Territory and Canada, 2009	. 17
Table 3	Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Health Expenditure, Reporting OECD Comparator Countries, 2007	. 31
Table 4	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Reporting OECD Comparator Countries, 2007	. 34
Table 5	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Public-Sector Health Expenditure, Reporting OECD Comparator Countries, 2007	. 36
Table 6	Factors That May Influence Drug Expenditure in Canada	. 40
Table 7	Provincial/Territorial Government Drug Expenditure Data	. 51
Table 8	Quebec Drug Insurance Fund, in Millions of Dollars, 1997 to 2009	. 54
Table 9	Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009	130

Executive Summary

Total expenditure on drugsⁱ in Canada was \$26.5 billionⁱⁱ in 2007, and is forecast to have reached \$30.0 billion in 2009. Between 1985 and 2007, the share of drugs in total health expenditure increased from 9.5% to 16.5%. It is forecast to be 16.4% in 2009. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals.

At the national level, 2008 and 2009 forecast data indicates that

- The share of drugs in total health expenditure is forecast to be the same in 2008 and 2009, at 16.4%.
- Total drug expenditure is forecast to have reached \$28.5 billion in 2008 and \$30.0 billion in 2009, representing annual increases of 7.6% and 5.1%, respectively.
- Total drug expenditure per capita in Canada is expected to have reached \$857 in 2008 and \$893 in 2009, representing annual rates of increase of 6.4% and 4.2%, respectively.
- The share of prescribed drugs in total drug expenditure is forecast to have reached 84.1% in 2008 and 84.6% in 2009.
- Expenditure on prescribed drugs is expected to have reached \$24.0 billion in 2008 and \$25.4 billion in 2009, representing growth rates of 8.9% and 5.6%, respectively.
- Expenditure on non-prescribed drugs is forecast to have reached \$4.5 billion in 2008 and \$4.6 billion in 2009, representing increases of 1.0% and 2.1%, respectively.
- Public-sector expenditure on prescribed drugs is forecast to have reached \$11.0 billion in 2008 and \$11.4 billion in 2009, representing annual growth rates of 7.3% and 4.0%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$13.1 billion in 2008 and \$14.0 billion in 2009, with corresponding annual growth rates of 10.4% and 7.0%.

At the provincial level, 2009 forecast data indicates that

- Total drug expenditure per capita is forecast to have ranged from \$714 in British Columbia and \$782 in Alberta to \$1,014 in Newfoundland and Labrador and \$1,057 in Nova Scotia.
- The share of prescribed drug spending in total drug expenditure is forecast to have ranged from 80.9% in Alberta and 83.0% in Prince Edward Island to 87.8% in Quebec and 89.6% in Newfoundland and Labrador.

CIHI 2010 v

i. Drug expenditure data in this report is obtained from the National Health Expenditure Database (NHEX) and is composed of estimates that represent the final costs to Canadian consumers, including dispensing fees, markups and appropriate taxes. Total drug expenditure, in this report, includes expenditure on prescribed drugs and non-prescribed drugs (over-the-counter drugs and personal health supplies). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

ii. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

 The proportion of prescribed drugs financed by the public sector in 2009 varied across the provinces and is forecast to have ranged from 31.8% in Newfoundland and Labrador and 33.6% in New Brunswick to 49.0% in Quebec and 54.5% in Saskatchewan.

At the international level in 2007, the most recent year for which data was available, among 23 Organisation for Economic Co-operation and Development (OECD) comparator countriesⁱⁱⁱ

- Canada had the second-highest level of total drug expenditure per capita, after the United States.
- The public sector funded 38.0% of total drug expenditure in Canada. This was the fourth-lowest share, ahead of Poland (37.5%), the U.S. (31.4%) and Mexico (21.2%). The share of public drug expenditure in total drug expenditure was highest in Germany, at 75.9%.
- Public drug expenditure accounted for 9.6% of public-sector health expenditure in Canada. This proportion places Canada ahead of Sweden (9.5%), the U.S (8.3%), New Zealand (8.3%), Iceland (7.3%), Denmark (5.7%) and Norway (5.1%). The share of public drug expenditure in public-sector health expenditure was highest in the Slovak Republic, at 28.9%.

Factors affecting drug expenditure:

Numerous factors, many of which are inter-related, may influence drug expenditure.
Since drug prices, as measured by several price indices, have been relatively stable
over the past 10 years, factors affecting increased drug spending in Canada essentially
relate to the volume of drug use and the entry of new drugs (typically introduced to the
market at higher prices).

vi CIHI 2010

-

iii. Comparator countries are Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Japan, Korea, Mexico, New Zealand, Norway, Poland, Portugal, the Slovak Republic, Spain, Sweden, Switzerland and the United States.

Introduction

Pharmaceutical drugs play an essential role in modern medicine. Through the treatment of various diseases, they have become an increasingly significant component of the Canadian health care system.

Drug expenditure data in this report is primarily obtained from the National Health Expenditure Database (NHEX) maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1975. Drug expenditure data in NHEX is macro-level data and does not allow for decomposition of prescription costs or drug classes.

The Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from retail outlets. Drug expenditure data in NHEX consists of estimates that represent the final costs to Canadian consumers, including dispensing fees, markups and appropriate taxes. NHEX data does not include drug expenditure by non-Canadian residents (for example, Americans purchasing drugs via Canadian internet pharmacies). This classification system used in NHEX is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

Drug expenditure estimates within NHEX provide insight into total drug expenditure^{iv} by public and private payers and by type of drugs (prescribed and non-prescribed) at the provincial/territorial and national levels. All drug expenditure estimates stated in this report are in current dollars (unadjusted for inflation) unless otherwise stated.

Drug Expenditure in Canada, 1985 to 2009 is an annual publication and provides updated information on drug expenditure trends in Canada. This publication includes

- National drug expenditure;
- Provincial and territorial drug expenditure;
- International comparisons; and
- Factors that may affect drug expenditure.

More information on drug expenditure and the methods used in the preparation of this document is available by contacting the Pharmaceuticals department at CIHI by phone at 613-241-7860 or by email at drugs@cihi.ca.

CIHI 2010 1

.

iv. Total drug expenditure in this report includes expenditure on prescribed drugs and non-prescribed drugs. Non-prescribed drugs are composed of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.


National Drug Expenditure Overview

The Share of Drugs in Total Health Expenditure

Outlook - 2008 and 2009

The share of drugs in total health expenditure is forecast to be 16.4% in both 2008 and 2009 (Figure 1).

Figure 1 Total Drug Expenditure as a Percentage of Total Health Expenditure, Canada, 1985 to 2009



Source


National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Highlights - 2007

Drugs have been one of the growing components of total health expenditure in Canada. From 1985 to 2007, total health spending grew at an average annual rate of 6.6%. During this period, total drug expenditure increased at an average annual rate of 9.2%. In every year prior to 2005, the annual rate of growth for drugs exceeded the rate for total health expenditure (Figure 2). Since 2005, the annual rate of growth for drugs was slightly less than the rate for total health expenditure every year, with the exception of 2006.

Drug expenditure grew at an annual rate beyond what can be attributed to economy-wide inflation (as measured by the Consumer Price Index or CPI) in every year between 1985 and 2007 (Figure 2). Total health expenditure grew at an annual rate above the rate of inflation in all years during this period, with the exception of 1995 and 1996.

Figure 2 Annual Growth Rate for Total Drug Expenditure, Total Health Expenditure and Consumer Price Index, Canada, 1985 to 2009



Sources

National Health Expenditure Database, 2009, Canadian Institute for Health Information; Consumer Price Index, Statistics Canada.




Figure 3 Total Health Expenditure and the Percentage Share by Use of Funds, Canada, 2009^f (\$ Billions)

Note

f: forecast.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

NHEX provides an overview of all health spending in Canada by spending category and source of funding. Total health expenditure comprises nine major spending categories. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals (Figure 3).

Total drug expenditure grew at a higher rate than total hospital expenditure every year between 1985 and 2006, with the exception of 2005. In 2007, total hospital expenditure had a slightly higher rate of growth (5.6%) than total drug expenditure (5.3%). Between 1985 and 2007, total drug expenditure grew at an average annual rate of 9.2%, while total hospital expenditure grew at an average annual rate of 4.8%.


See Data Tables in Series A for more data on national drug expenditure from 1985 to 2009.

Total Drug Expenditure

Outlook - 2008 and 2009

Total drug expenditure is forecast to have reached \$28.5 billion in 2008 and \$30.0 billion in 2009, representing annual increases of 7.6% and 5.1%, respectively.

Figure 4 Total Drug Expenditure, Canada, 1985 to 2009



Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Highlights - 2007

Canada's total drug expenditure increased steadily from \$3.8 billion in 1985 to \$26.5 billion in 2007 (Figure 4). The average annual rate of growth during this period was 9.2%.

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2009.


v. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

Total Drug Expenditure per Capita

Outlook - 2008 and 2009

Total drug expenditure per capita in Canada is expected to have reached \$857 in 2008 and \$893 in 2009, representing annual rates of increase of 6.4% and 4.2%, respectively.

Figure 5 Total Drug Expenditure per Capita, Current and Constant* Dollars, Canada, 1985 to 2009



Note

Sources

National Health Expenditure Database, 2009, Canadian Institute for Health Information; Consumer Price Index, Statistics Canada.

Highlights - 2007

Per capita drug expenditure trends are similar to those of total drug spending, reflecting a 1.1% average annual rate of growth in the overall population in Canada from 1985 to 2007. Total drug expenditure increased from \$147 per capita in 1985 to \$806 in 2007 (Figure 5). The average annual growth rate during this period was 8.0%.

^{*} Figures are deflated using the Consumer Price Index to reflect 1985 dollars.

Typically, expenditure is deflated by a price index to measure change in quantity. There is no authoritative composite price index for all drugs sold in Canada. However, measuring drug expenditure in constant dollars (adjusted for inflation) using the CPI reported by Statistics Canada gives a sense of change in drug expenditure in the context of economywide inflation. Readers should cautiously interpret inflation-adjusted trends in expenditure, since drug-specific inflation may differ from that depending upon the broad basket of goods and services purchased by Canadians.

In terms of constant (1985) dollars, per capita drug expenditure increased from \$147 in 1985 to \$455 in 2007, reflecting an average annual growth rate of 5.3%. Trends in per capita drug expenditure measured in constant dollars are similar to those of per capita drug expenditure measured in current dollars, though growth between 1985 and 2007 is less pronounced when it is considered relative to economy-wide inflation (Figure 5).

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2009.

Drug Expenditure: Prescribed and Non-Prescribed Drugs Outlook – 2008 and 2009

Expenditure on prescribed drugs^{viii} is expected to have reached \$24.0 billion in 2008 and \$25.4 billion in 2009, representing growth rates of 8.9% and 5.6%, respectively. Expenditure on non-prescribed drugs is forecast to have reached \$4.5 billion in 2008 and \$4.6 billion in 2009, representing increases of 1.0% and 2.1%, respectively.

Non-prescribed drugs, which are typically financed by consumers (households), include over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). Since NHEX consists of macro-level health expenditure data, some over-the-counter drugs and personal health supplies that are covered under some drug benefit plans may be counted as prescribed drug expenditures.

Prescribed drugs are expected to have accounted for 84.1% of total drug expenditure in Canada in 2008 and 84.6% in 2009. Conversely, the share of non-prescribed drugs in total drug expenditure is expected to have accounted for 15.9% in 2008 and 15.4% in 2009.

8 CIHI 2010

_

vi. For more information on drug prices, see the Data Limitations section of the Methodological Notes.

vii. A measure of the average percentage change over time in the cost of a fixed basket of goods and services purchased by Canadian consumers.

viii. A prescribed drug is a substance considered to be a drug under the *Food and Drugs Act*, which is sold for human use as the result of a prescription from a health professional.

ix. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

x. For example, diabetic test strips, where covered under drug benefit plans, may be included in prescribed drug expenditure, subject to source of data.




Figure 6 Total Drug Expenditure by Type, Canada, 1985 to 2009

Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure includes spending on over-the-counter drugs and personal health supplies. This expenditure is financed by the private sector, typically out-of-pocket by consumers (households). For detailed definitions please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Highlights — 2007

From 1985 to 2007, expenditure on prescribed drugs grew from \$2.6 billion to \$22.1 billion, at an average annual rate of 10.3%. Spending on non-prescribed drugs increased from \$1.2 billion to \$4.5 billion, at an average of 6.0% per year (Figure 6). During this period, with the exception of 1987 and 1994, annual growth in drug spending was higher in prescribed drugs than in non-prescribed drugs. As a result, prescribed drugs captured a larger share of total drug spending, rising from 67.5% in 1985 to 83.1% in 2007.

Non-prescribed drug expenditure represented 16.9% of total drug expenditure in 2007. Over-the-counter drugs accounted for \$2.5 billion, or 9.4% of total drug expenditure, and personal health supplies accounted for \$2.0 billion, or 7.5%.

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2009.

Prescribed Drug Expenditure by Source of Finance

While non-prescribed drugs are typically financed out-of-pocket by consumers (households), multiple payers are involved in the financing of prescribed drugs. In the public sector, these payers include provincial/territorial and federal drug subsidy programs and social security funds (such as workers' compensation boards, or WCBs). In the private sector, they include private insurers and households.

In 2009, \$11.4 billion in prescribed drugs are expected to have been financed by the public sector, while expenditure by the private sector is for both prescribed drugs (\$14.0 billion) and non-prescribed drugs (\$4.6 billion). In the private sector, prescribed drugs financed by private insurers are expected to have been \$9.4 billion, with the remainder financed by Canadian households (\$4.6 billion). Non-prescribed drugs are composed of over-the-counter drugs (\$2.6 billion) and personal health supplies (\$2.0 billion) (Figure 7).




Figure 7 Total Drug Expenditure by Source of Finance and Type, Canada, 2009^f

Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. Non-prescribed drugs include over-the-counter drugs and personal health supplies. For detailed definitions please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Outlook - 2008 and 2009

Public-sector expenditure on prescribed drugs is forecast to have reached \$11.0 billion in 2008 and \$11.4 billion in 2009 (Figure 8), representing annual growth rates of 7.3% and 4.0%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$13.1 billion in 2008 and \$14.0 billion in 2009, with corresponding annual growth rates of 10.4% and 7.0%.

The share of prescribed drug expenditure financed by the public sector is forecast to have fallen to 45.7% in 2008 and 45.0% in 2009, from a 10-year high of 46.8% in 2005.




Figure 8 Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2009

Notes

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector. For detailed definitions please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Highlights - 2007

The intersections of the two series depicted in Figure 9 (excluding forecasts for 2008 and 2009) identify four distinct periods of growth in publicly and privately financed prescribed drug expenditure.




Figure 9 Annual Growth Rate for Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2009

Notes

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector. For detailed definitions please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Between 1985 and 1992, expenditure on prescribed drugs in the public sector grew by an average annual rate of 14.6%, while this rate was 12.0% for prescribed drug expenditure financed by the private sector. Consequently, the share of prescribed drugs financed from public sources increased from 43.6% in 1985 to 47.7% in 1992.

From 1992 to 1997, spending on prescribed drugs by the private sector grew at an average annual rate of 9.1%, more than twice the 4.3% average annual rate of growth in publicly financed prescribed drug expenditure. Fiscal restraint introduced in several provinces led to negative growth in publicly financed prescribed drug expenditure in 1996. By 1997, the share of prescribed drugs financed from public sources had declined to 42.2%, below its share in 1985 (43.6%).

Between 1997 and 2005, expenditure on prescribed drugs by the public sector grew at an average annual rate of 12.1%, compared to 9.5% in the private sector. The share of prescribed drug expenditure financed by the public sector reached 46.8% in 2005.

A fourth period appears to have commenced in 2006. In 2006, the average growth of private-sector funding (10.0%) of prescribed drugs exceeded that of the public sector (7.9%), and in 2007 both private- and public-sector spending experienced the same growth rate (5.5%).

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2009.

Two levels of government—provincial/territorial and federal—as well as social security funds, such as WCBs and the premium component of the Fonds de l'assurance médicaments (Drug Insurance Fund) in Quebec, infinance spending on prescribed drugs by the public sector. Private-sector expenditure on prescribed drugs is financed by two sources: private insurers and households (out-of-pocket). Table 1 shows the distribution of prescribed drug expenditure by these sources of finance.

Table 1 Distribution of Prescribed Drug Expenditure by Source of Finance, Canada, 1988 and 2009^f

	1988		2009	f	
	\$ Millions	Percent	\$ Millions	Percent	
Provincial/Territorial Governments	1,592.7	42.6	9,782.6	38.5	
Federal Direct	89.3	2.4	677.5	2.7	
Social Security Funds:					
Workers' Compensation Boards	20.8	0.6	215.5	0.8	
Quebec Drug Insurance Fund*	N/A	N/A	732.2	2.9	
(Premium Component)					
Subtotal Public Sources	1,702.8	45.6	11,407.8	45.0	
Private Insurers	1,130.3	30.2	9,363.4	36.9	
Households (Out-of-Pocket)	903.7	24.2	4,606.8	18.2	
Subtotal Private Sources	2,034.0	54.4	13,970.3	55.0	
Total All Sources	3,736.8	100.0	25,378.1	100.0	

Notes

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

f: forecast.

^{*} Data not available prior to January 1, 1997, when the program was first introduced in Quebec.

xi. Since July 1, 2002, the public plan has been financed both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premium component of the Quebec drug insurance fund is considered to be a social security scheme, while the remaining portion of the program that is paid through the ministère de la Santé et des Services sociaux is included as a provincial government expenditure. For more information, see the General Methods section of the Methodological Notes.

Provincial/territorial government expenditure on prescribed drugs was almost \$1.6 billion in 1988, accounting for 42.6% of total expenditure on prescribed drugs. By 2009, provincial/territorial government expenditure is forecast to have grown to \$9.8 billion, while its share of total expenditure on prescribed drugs is expected to have diminished to 38.5%.

All provinces/territories provide some form of prescribed drug coverage to seniors and social assistance recipients (see Appendix A for an overview of provincial and territorial drug subsidy programs).

Federal direct expenditure was \$89.3 million in 1988, equivalent to 2.4% of total expenditure on prescribed drugs. Federal direct expenditure is forecast to have increased to \$677.5 million in 2009, representing 2.7% of total expenditure on prescribed drugs. The federal government provides drug benefits to Aboriginal Canadians (as of the end of March 2008, about 799,200 Aboriginal Canadians had drug coverage through the Non-Insured Health Benefits Program of Health Canada),² veterans, members of the military and the RCMP, prisoners in federal correctional facilities and refugees.




Figure 10 Prescribed Drug Expenditure by Private-Sector Source of Finance, Canada, 1988* to 2009

Note

* Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Expenditure by social security funds was \$20.8 million in 1988, equivalent to 0.6% of total prescribed drug expenditure. In 2009, expenditure by social security funds is forecast to have reached \$947.7 million and to have accounted for 3.7% of total expenditure on prescribed drugs. Social security funds' figures have largely represented spending by the premium component of the Quebec Drug Insurance Fund since its institution in 1997. Seniors (65 and older) and other residents, who do not receive social assistance benefits and are not covered by private group insurance, are required to pay a premium. The amount of the premium varies according to net family income.

Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988.

Expenditure on prescribed drugs by private insurers amounted to more than \$1.1 billion in 1988, or 30.2% of prescribed drug expenditure. Private insurers' spending increased to \$9.4 billion in 2009, and their share of prescribed drug expenditure increased to 36.9%. Private insurers include group and individual insurance. Many employers offer group benefit plans covering prescribed drugs for employees and their families. In some cases, individuals will continue to be covered by a group plan even after they retire.

Out-of-pocket spending by households was an estimated \$0.9 billion in 1988, representing 24.2% of total expenditure on prescribed drugs. By 2009, out-of-pocket prescribed drug expenditure is estimated to have risen to \$4.6 billion, while its share of prescribed drug expenditure will have decreased to 18.2% (Figure 10).

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2009.

Drug Expenditure in the Provinces and Territories

There is considerable variation in the level and growth of drug expenditure across the provinces and territories. These variations are influenced by several factors (see Table 6), including differences in provincial/territorial drug subsidy programs (see Appendix A for an overview of provincial and territorial drug subsidy programs), the extent of private insurance coverage, age and sex distribution of provincial/territorial populations, the health needs of targeted populations and the manner in which health care is delivered (including the balance between institutional and ambulatory care). Other possible sources of variation in drug expenditure are described in the section Factors Affecting Drug Expenditure in Canada. Table 2 provides an overview of provincial/territorial drug expenditure forecast for 2009.

Table 2 Drug Expenditure Summary, by Province/Territory and Canada, 2009^f

	Total Drug Expenditure per Capita		Prescribe	Prescribed Drug Expenditure per Capita			Public Prescribed Drug Expenditure per Capita		
	Amount (Dollars)	Percent Change Over 2008	Percent of Total Health Exp. per Capita	Amount (Dollars)	Percent Change Over 2008	Percent of Total Drug Exp. per Capita	Amount (Dollars)	Percent Change Over 2008	Percent of Prescribed Drug Exp. per Capita
N.L.	1,013.97	9.3	17.0	908.20	10.4	89.6	289.22	7.6	31.8
P.E.I.	890.39	7.6	15.4	738.92	8.8	83.0	264.39	13.9	35.8
N.S.	1,057.11	6.7	18.1	902.89	8.0	85.4	349.23	7.0	38.7
N.B.	941.32	3.5	17.1	802.76	4.1	85.3	269.48	6.1	33.6
Que.	1,001.62	6.1	20.5	878.95	6.6	87.8	431.09	5.8	49.0
Ont.	913.46	2.4	16.5	762.11	2.7	83.4	330.79	-0.8	43.4
Man.	809.41	4.5	13.9	676.71	4.9	83.6	310.99	1.9	46.0
Sask.	849.95	5.2	14.6	728.19	5.7	85.7	396.55	8.4	54.5
Alta.	781.92	5.0	12.9	632.72	6.0	80.9	298.96	8.4	47.2
B.C.	713.85	4.2	13.6	595.62	5.0	83.4	250.33	3.1	42.0
Y.T.	824.88	5.4	10.3	672.76	6.0	81.6	428.10	5.3	63.6
N.W.T.	665.10	5.9	6.7	571.11	6.3	85.9	339.94	7.0	59.5
Nun.	674.38	12.5	5.7	580.23	14.1	86.0	363.71	11.5	62.7
Canada	893.13	4.2	16.4	755.62	4.8	84.6	339.66	3.2	45.0

Notes

f: forecast.

Total drug expenditure consists of prescribed drugs and non-prescribed products purchased outside an institutional setting. Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector. Public prescribed drug expenditure is the amount of prescribed drug expenditure financed by provincial, territorial and federal governments, as well as spending from social security funds. For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2009, Canadian Institute for Health Information; Population, Statistics Canada.

In 2009, per capita expenditure on drugs is forecast to have accounted for 16.4% of total health expenditure in Canada. Among the provinces and territories, the share of drugs in total health expenditure is expected to have ranged from 5.7% in Nunavut and 6.7% in the Northwest Territories to 18.1% in Nova Scotia and 20.5% in Quebec.

Total drug expenditure per capita in Canada is expected to have been \$893 in 2009. Per capita spending on drugs in the provinces and territories is forecast to have ranged from \$665 and \$674 by the residents of the Northwest Territories and Nunavut, respectively, to \$1,014 and \$1,057 by the residents of Newfoundland and Labrador and Nova Scotia, respectively.

Prescribed drug expenditure per capita is forecast to have accounted for 84.6% of total expenditure on drugs in Canada in 2009. Among the provinces and territories, the share of prescribed drugs in total drug expenditure is forecast to have ranged from 80.9% in Alberta and 81.6% in the Yukon to 87.8% in Quebec and 89.6% in Newfoundland and Labrador.

In 2009, the proportion of prescribed drugs in Canada financed by the public sector is expected to be 45.0%. It is forecast that the proportion will be highest in the Yukon and Nunavut, at 63.6% and 62.7%, respectively, and the lowest in Newfoundland and Labrador and New Brunswick, at 31.8% and 33.6%, respectively.

The Share of Drugs in Total Health Expenditure

The share of drugs in total health expenditure is forecast to have been higher in 2009 than in 1985 in all provinces and territories except P.E.I. and the Northwest Territories and Nunavut (Figure 11). It should be noted that in P.E.I. between 1986 and 2009, the share of drug expenditure in total health expenditure is expected to have grown.

In 1985, expenditure on drugs accounted for 9.5% of total health expenditure in Canada. Newfoundland and Labrador, P.E.I., Nova Scotia, New Brunswick and Ontario exceeded the national average. P.E.I. had the highest share, at 18.0%, followed by Newfoundland and Labrador, at 16.3%, while among the other provinces and territories, shares ranged from 7.1% in the Northwest Territories and Nunavut to 9.3% in Manitoba.




Figure 11 Drug Expenditure as a Percentage of Total Health Expenditure, by Province/Territory and Canada, 1985 and 2009^f

Notes

f: forecast.

* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories.

Source


National Health Expenditure Database, 2009, Canadian Institute for Health Information.


In 2009, Newfoundland and Labrador, Nova Scotia, New Brunswick, Quebec and Ontario are forecast to have had drug expenditure as a percentage of total health expenditure above the Canadian average (16.4%), with Quebec (20.5%) and Nova Scotia (18.1%) having the highest share. P.E.I., Manitoba, Saskatchewan, Alberta and B.C. are expected to have been below the Canadian average, with Alberta (12.9%) and B.C. (13.6%) having the lowest share among the provinces. The Yukon and the Northwest Territories and Nunavut are forecast to have had lower shares than the provinces, at 10.3% and 6.2%, respectively.

See Data Tables in Series B for more data on drug expenditure by province/territory from 1985 to 2009.

Total Drug Expenditure by Source of Finance

In 2009, Quebec, Manitoba, Saskatchewan, Alberta, the Yukon, the Northwest Territories and Nunavut are forecast to have had public shares of total drug expenditure that exceeded the national average (38.0%). The share of total drug expenditure funded by the public sector is expected to have ranged from 28.5% in Newfoundland and Labrador and 28.6% in New Brunswick to 51.9% in the Yukon and 53.9% in Nunavut (Figure 12).





Note

f: forecast.


Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Total Drug Expenditure per Capita by Source of Finance

In 2009, total drug expenditure per capita in Canada is forecast to have been \$893. Per capita prescribed drug spending financed by the public and private sectors is forecast to have amounted to \$340 and \$416, respectively (Figure 13).

Figure 13 Total Drug Expenditure per Capita by Type and by Source of Finance, by Province/Territory and Canada, 2009^f



Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure includes spending on over-the-counter drugs and personal health supplies. This expenditure is financed by the private sector, typically out-of-pocket by consumers (households). For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2009, Canadian Institute for Health Information; Population, Statistics Canada.

In 2009, per capita spending on drugs by the public sector is forecast to have ranged from \$250 in B.C. and \$264 in P.E.I. to \$428 in the Yukon and \$431 in Quebec. In the same year, it is expected that Nova Scotia (\$349), Quebec (\$431), Saskatchewan (\$397), the Yukon (\$428), the Northwest Territories (\$340) and Nunavut (\$364) will have had publicly financed drug expenditure per capita above the Canadian average (\$340).

Prescribed drug expenditure per capita financed by the private sector is expected to have ranged from \$216 in Nunavut and \$231 in the Northwest Territories to \$554 in Nova Scotia and \$619 in Newfoundland and Labrador. Newfoundland and Labrador (\$619), P.E.I. (\$475), Nova Scotia (\$554), New Brunswick (\$533), Quebec (\$448) and Ontario (\$431) are forecast to have had privately financed prescribed drug expenditure per capita higher than the Canadian average (\$416).

It should be noted that public spending per capita may or may not accurately reflect the amount spent per person eligible for coverage because the proportion of the population eligible for coverage by the public sector varies significantly across provinces and territories.

See Data Tables in Series B for more data on drug expenditure by province/territory from 1985 to 2009.

Drug Expenditure by Type of Drug and by Source of Finance

Public- and Private-Sector Prescribed and Non-Prescribed Drug^{xii} Expenditure

In 2009, in P.E.I., New Brunswick, Saskatchewan, Alberta and the Northwest Territories, the annual growth rate for prescribed drug spending per capita is forecast to have been higher in the public sector than in the private sector (Figure 14). For the remaining provinces and territories, private-sector growth is forecast to have been higher than that of the public sector.

The annual growth rate for prescribed drug spending per capita in the public sector ranged from -0.8% in Ontario and 1.9% in Manitoba to 11.5% in Nunavut and 13.9% in P.E.I. The annual growth rate for prescribed drug spending per capita in the private sector ranged from 2.7% in Saskatchewan and 3.1% in New Brunswick to 11.8% in Newfoundland and Labrador and 18.8% in Nunavut.

All provinces and territories except Manitoba, B.C. and Ontario are expected to have had annual growth of publicly financed prescribed drug expenditure per person above the Canadian average (3.2%).

Prescribed drug spending per capita is expected to have experienced a higher annual growth rate than non-prescribed drug spending per capita in all provinces and territories for 2009.

xii. Non-prescribed drugs are composed of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.




Figure 14 Annual Growth Rate for Public- and Private-Sector Prescribed (Rx) and Non-Prescribed (Non-Rx) Drug Expenditure per Capita, 2009^f

Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure includes spending on over-the-counter drugs and personal health supplies. This expenditure is financed by the private sector, typically out-of-pocket by consumers (households). For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2009, Canadian Institute for Health Information; Population, Statistics Canada.

The analysis of annual growth rates should be interpreted cautiously. The actual change in drug spending associated with a given growth rate varies based on the initial level of expenditure. For example, a 10% growth rate for a higher initial level of expenditure would translate into a larger growth in dollar amounts than for a lower initial level of expenditure.

Public- and Private-Sector Prescribed Drug Expenditure

Between 1985 and 2009, publicly financed prescribed drug expenditure per capita grew at a lower average annual rate than privately financed prescribed drug expenditure per capita in Nova Scotia, New Brunswick, Saskatchewan and B.C. (Figure 15). During this period, average annual growth in public-sector prescribed drug spending per capita ranged from 7.3% in B.C. and in New Brunswick to 11.5% in P.E.I. and 13.3% in the Yukon. Per capita prescribed drug expenditure financed by the private sector grew at average annual rates ranging from 4.8% in P.E.I. and 6.3% in Newfoundland and Labrador to 11.2% in Nova Scotia and in Saskatchewan.




Figure 15 Average Annual Growth Rate for Prescribed Drug Expenditure per Capita by Source of Finance, by Province/Territory, Between 1985 and 2009f

Notes

f: forecast.

* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional.

■ Public Rx

☐ Private Rx

This expenditure can be financed by either the public or the private sector.

For detailed definitions please refer to the Methodological Notes.

National Health Expenditure Database, 2009, Canadian Institute for Health Information; Population, Statistics Canada.

Figure 16 illustrates provincial/territorial trends in the share of publicly financed prescribed drug expenditure as a percentage of prescribed drug expenditure, from 1985 to 2007, with forecasts to 2009.

Figure 16 Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2009





Figure 16 Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2009 (cont'd)



Note

* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Between 1985 and 2007, the share of prescribed drug expenditure financed by the public sector increased in Newfoundland and Labrador, P.E.I., Quebec, Ontario, Manitoba, Alberta and the Yukon. Increases ranged from 3.1 and 7.2 percentage points in Ontario and Quebec, respectively, to 22.8 and 36.7 percentage points in P.E.I. and the Yukon, respectively. Decreases in the share of prescribed drug expenditure financed by the public sector occurred in Nova Scotia, New Brunswick, Saskatchewan, B.C. and the Northwest Territories. Decreases ranged from less than 0.1 and 7.9 percentage points in the Northwest Territories and B.C., respectively, to 14.8 and 21.9 percentage points in Nova Scotia and Saskatchewan, respectively.

In 2009, the share of prescribed drug expenditure financed by the public sector in Canada is expected to have been 45.0%. This is forecast to have been exceeded by Quebec (49.0%), Manitoba (46.0%), Saskatchewan (54.5%), Alberta (47.3%), the Yukon (63.6%), the Northwest Territories (59.5%) and Nunavut (62.7%).

International Comparisons

Comparability of Health Expenditure Across Countries

In general, international comparisons should be interpreted with caution, as variation exists between countries with regard to reporting, inclusion and classification of health expenditure.

For the last nine annual updates of the health database maintained by the Organisation for Economic Co-operation and Development (OECD), member countries were asked to report health expenditure according to concepts presented in the OECD manual *A System of Health Accounts* (SHA), released in May 2000. Countries are at varying stages of reporting total health expenditure according to the boundary of health care proposed in the SHA manual. This means that data presented in *OECD Health Data 2009* is at varying levels of comparability.

There are 26 countries with health expenditure information that most closely follow the health care boundary proposed in the OECD manual. The OECD states that the data for those countries is believed to be fairly comparable, although some deviations from SHA definitions may still exist among the sub-aggregate variables of total health expenditure. The 26 countries are Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Japan, Korea, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, the Slovak Republic, Spain, Sweden, Switzerland, Turkey and the United States.

Analysis in this section will exclude Luxembourg, the Netherlands and Turkey due to the non-availability of data by use of funds from 2006 onwards.

Level of income and institutional characteristics also cause differences in drug expenditure across countries. Drugs consumed in low- or middle-income countries often originate from more developed countries with high living standards and high labour costs. Consequently, the share of drugs in total health expenditure tends to be higher in low- or middle-income countries because of the high price of drugs relative to other health goods and services. Differences in service delivery across countries will also cause differences in the share of drugs in total health expenditure.

Share of Drugs in Total Health Expenditure

The OECD maintains a comparative database on health-related statistics, including health expenditure. This database captures information on expenditure for pharmaceuticals and other medical non-durables outside an institutional setting (equivalent to drugs purchased in retail establishments in Canada). Pharmaceutical and other medical non-durables comprise prescribed drugs, over-the-counter drugs and a wide range of medical non-durables such as bandages, elastic stockings, incontinence articles, condoms and other mechanical contraceptive devices.

In 1985, drug expenditure in Canada represented $9.6\%^{xiii}$ of total health expenditure. Portugal had the largest share of drug expenditure in total health expenditure, at 25.4%, and Denmark had the lowest, at 6.6%. x^{iiv} , x^{iv}

By 2007, the most recent year for which data was available, drug expenditure in Canada had increased its share in total health expenditure by about eight percentage points, to 17.7%. Norway had the lowest share of drug expenditure in total health expenditure, at 8.0%, and Hungary had the highest, at 31.2% (Table 3).

30 CIHI 2010

-

xiii. OECD data is standardized for international comparability; consequently, figures calculated from this data may differ from those calculated from the national health accounts of member countries. Specific to Canada, expenditure on health research and the training of health care workers with concomitant care of patients is included in the national health accounts but excluded from OECD health expenditure data.

xiv. The OECD did not provide data for Austria, the Czech Republic, Hungary, Mexico, Poland or the Slovak Republic in 1985.

xv. Of the comparator countries, only Canada and Korea conformed to SHA guidelines in 1985.

Table 3 Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Health Expenditure, Reporting OECD Comparator Countries, 2007*

Country	GDP per Capita		Total Drug Expenditure per Capita		Total Hea Expendit per Cap	ure	Total Drug Expenditure as a Percentage of Total Health Expenditure	
	(CA\$, PPP) [†]	Rank		Rank	(CA\$, PPP) [†]	Rank	Percent	Rank
Australia	45,731	5	582	9	4,061	10	14.3	14
Austria	44,900	6	605	8	4,552	5	13.3	18
Belgium	42,794	10	685	4	4,348	7	15.7	12
Canada	46,568	4	836	2	4,711	4	17.7	10
Czech Republic	29,062	18	422	19	1,967	19	21.5	7
Denmark	43,518	8	364	20	4,248	9	8.6	22
Finland	41,969	11	484	17	3,435	13	14.1	15
France	39,533	14	711	3	4,356	6	16.3	11
Germany	41,601	12	656	6	4,340	8	15.1	13
Hungary	22,684	21	525	15	1,679	21	31.2	1
Iceland	43,177	9	542	12	4,015	12	13.5	16
Japan [‡]	40,645	13	610	7	3,110	15	19.6	9
Korea	32,456	17	503	16	2,042	18	24.7	3
Mexico	16,921	23	239	23	995	23	24.0	5
New Zealand	32,828	16	292	22	2,968	16	9.8	21
Norway	64,643	1	461	18	5,761	2	8.0	23
Poland	19,461	22	306	21	1,252	22	24.5	4
Portugal [‡]	27,607	19	564	10	2,591	17	21.8	6
Slovak Republic	24,280	20	526	14	1,881	20	27.9	2
Spain	38,205	15	679	5	3,231	14	21.0	8
Sweden	44,309	7	539	13	4,019	11	13.4	17
Switzerland	49,443	3	549	11	5,343	3	10.3	20
United States	55,107	2	1,062	1	8,818	1	12.0	19

Notes

Source

OECD Health Data 2009, November 2009. Organisation for Economic Co-operation and Development and IRDES, Paris.

^{*} Canadian data reported by the OECD is as of November 2008. In November 2009, updated and revised Canadian data was released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2010.

[†] Converted to Canadian dollars using purchasing power parities (PPPs) for gross domestic product (GDP).

^{‡ 2006} data was used for Total Drug Expenditure per Capita and Total Drug Expenditure as a Percentage of Total Health Expenditure.

Figure 17 illustrates the trends of drug expenditure per capita (CA\$, PPP)^{xvi} in five selected OECD comparator countries.^{xvii}




Figure 17 Drug Expenditure per Capita, Selected Countries,* 1985 to 2007

Notes

- * Comparator countries that are also G8 members. 2007 data not available in Japan.
- † Converted to Canadian dollars using purchasing power parities (PPPs) for gross domestic product (GDP).

Source

OECD Health Data 2009, November 2009. Organisation for Economic Co-operation and Development and IRDES, Paris.

Between 1985 and 2007, per capita drug expenditure grew at a faster average annual rate in Korea (10.5%) and Australia (8.3%) than in Canada (8.2%). During this period, all other comparative countries experienced a lower average annual growth rate in per capita drug expenditure than Canada, with Iceland being the lowest (3.8%). **viiii*

32 CIHI 2010

_

xvi. Although using purchasing power parity-adjusted dollars (PPP\$) accounts for the relative change in inflation between countries, average annual growth rates should still be considered in the context of economy-wide inflation.

xvii. Comparator countries that are also G8 members.

xviii. The average annual rate between 1985 and 2006 could not be calculated for Austria, the Czech Republic, Hungary, Mexico, Poland and the Slovak Republic as data for 1985 was not available.

Share of Public Expenditure in Total Expenditure on Drugs

The OECD database on health contains statistics on total expenditure on pharmaceutical goods and public expenditure on pharmaceutical goods. In Canada, drug expenditure by the public sector rose from 29.4% of total expenditure on pharmaceutical goods in 1985 to 38.0% in 2007.

In OECD countries, with the exception of those in North America, the entire population usually has coverage for prescribed drugs through public insurance. Most countries have formularies restricting the number of drugs covered under public insurance and impose cost-sharing (deductibles, co-insurance or copayments) with waivers for certain groups of beneficiaries.

Table 4 shows that, among the 23 OECD comparator countries in 2007, Germany had the highest level of public drug spending per capita (\$497), the U.S. had the highest level of total drug expenditure per capita (\$1,062) and Germany had the highest public share of total drug spending (75.9%).

The high share of total drug expenditure financed by the public sector in some European countries (for example, Germany and Spain) reflects the inclusion of drug benefits provided through employment-related social security funds in publicly financed drug expenditure (see Series C for more data on international comparisons). These funds are social insurance programs covering the community as a whole or large sections of the community and are imposed or controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. In some European countries, expenditure by social security funds represents the major share of public expenditure on drugs (for example, 94.3% in Germany⁵ and 97.9% in France⁵ in 2006).

By contrast, in Canada, until 1996, drug benefits under social security funds included only spending by WCBs and they represented less than 2% of public expenditure on drugs in retail establishments. Starting in 1997, they also included expenditure by the premium component of the Quebec Drug Insurance Fund. The share of social security funds in public expenditure on drugs in Canada increased from 5.9% in 1997 to 8.2% in 2007. The premium component of the Quebec Drug Insurance Fund is financed by the mandatory payment of premiums by seniors (65 and older) and other residents not covered by private group insurance. Social assistance recipients are not required to pay a premium.

xix. Since July 1, 2002, the public plan has been financed both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premium component of the Quebec Drug Insurance Fund is considered to be a social security scheme, while the remaining portion of the program that is paid through the ministère de la Santé et des Services sociaux is included as a provincial government expenditure. For more information, see the General Methods section of the Methodological Notes.

Group insurance plans offered by employers, unions and professional associations that resemble the European model do exist in Canada; however, since a government authority does not impose group health insurance in Canada, and policy-holders may voluntarily opt out (except in Quebec), they are considered privately financed. Private health insurance, composed mainly of group insurance, accounted for 29.8% of total drug expenditure in retail establishments in Canada in 2007.

Table 4 Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Reporting OECD Comparator Countries, 2007*

Country	Public Dr Expenditure Capita	e per	Total Dru Expenditure Capita	•	Public Drug Expenditure as a Percentage of Total Drug Expenditure		
	(CA\$, PPP) [†]	Rank	(CA\$, PPP) [†]	Rank	Percent	Rank	
Australia	314	12	582	9	54.0	17	
Austria	396	5	605	8	65.3	9	
Belgium	386	6	685	4	56.3	12	
Canada	318	10	836	2	38.0	20	
Czech Republic	278	15	422	19	66.0	8	
Denmark	203	20	364	20	55.8	14	
Finland	267	17	484	17	55.1	15	
France	494	2	711	3	69.4	4	
Germany	497	1	656	6	75.9	1	
Hungary	307	14	525	15	58.5	10	
Iceland	243	19	542	12	44.8	19	
Japan [‡]	437	4	610	7	71.7	3	
Korea	275	16	503	16	54.6	16	
Mexico	51	23	239	23	21.2	23	
New Zealand	194	21	292	22	66.8	7	
Norway	247	18	461	18	53.7	18	
Poland	115	22	306	21	37.5	21	
Portugal [‡]	316	11	564	10	55.9	13	
Slovak Republic	363	8	526	14	69.1	5	
Spain	492	3	679	5	72.6	2	
Sweden	313	13	539	13	58.1	11	
Switzerland	371	7	549	11	67.6	6	
United States	334	9	1,062	1	31.4	22	

Notes

Source

OECD Health Data 2009, November 2009. Organisation for Economic Co-operation and Development and IRDES, Paris.

^{*} Canadian data reported by the OECD is as of November 2008. In November 2009, updated and revised Canadian data was released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2010.

[†] Converted to Canadian dollars using purchasing power parities (PPPs) for gross domestic product (GDP).

^{‡ 2006} data.

Share of Drugs in Public Expenditure on Health

In Canada, drugs accounted for only 3.8% of health expenditure by the public sector in 1985. This proportion increased to 9.6% in 2007, reflecting substantially higher growth in drug expenditure than in other types of public-sector health expenditure between 1985 and 2007. Among the comparator countries for which data was available^{xx} in 1985, the share of drugs in public-sector health expenditure ranged from 2.1% in the U.S. to 30.1% in Portugal. In 2007, the share of drugs in public-sector health expenditure ranged from 5.1% in Norway to 28.9% in the Slovak Republic.

In 2007, the share of drug spending in public-sector health expenditure was lower than the share of drug spending in total health expenditure in each of the comparator countries except the Slovak Republic, Spain and Switzerland, reflecting generally higher cost-sharing for drugs than for other health expenditure. **i In the case of Canada, the low share of drugs in total public expenditure on health (9.6% in 2007), when compared with the share of drugs in total health expenditure (17.7% in 2007), also reflects the absence of universal coverage of prescribed drugs by public insurance, while there exists universal and full coverage of medically necessary hospital and physician services.

xx. The OECD did not provide data for Austria, Belgium, the Czech Republic, Hungary, Mexico, Poland, the Slovak Republic or Switzerland in 1985.

xxi. The OECD did not provide data for public drug expenditure as a percentage of public health expenditure for Belgium.

Table 5 Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Public-Sector Health Expenditure, Reporting OECD Comparator Countries, 2007*

Country	Public Drug Expend per Capi		Public-Sec Health Expen per Capit	diture	Public Drug Expenditure as a Percentage of Public- Sector Health Expenditure		
	(CA\$, PPP) [†]	Rank	(CA\$, PPP) [†]	Rank	Percent	Rank	
Australia	314	12	2,741	11	11.5	12	
Austria	396	5	3,477	4	11.4	13	
Belgium [‡]	386	6	N/A	N/A	N/A	N/A	
Canada	318	10	3,297	8	9.6	16	
Czech Republic	278	15	1,675	17	16.6	7	
Denmark	203	20	3,590	3	5.7	21	
Finland	267	17	2,564	12	10.4	15	
France	494	2	3,440	5	14.3	9	
Germany	497	1	3,336	6	14.9	8	
Hungary	307	14	1,185	19	25.9	2	
Iceland	243	19	3,313	7	7.3	20	
Japan⁵	437	4	2,527	13	17.3	5	
Korea	275	16	1,121	20	24.5	3	
Mexico	51	23	450	22	11.3	14	
New Zealand [§]	194	21	2,334	14	8.3	18	
Norway	247	18	4,844	1	5.1	22	
Poland	115	22	887	21	13.0	10	
Portugal⁵	316	11	1,853	16	17.0	6	
Slovak Republic	363	8	1,258	18	28.9	1	
Spain	492	3	2,319	15	21.2	4	
Sweden	313	13	3,285	9	9.5	17	
Switzerland	371	7	3,167	10	11.7	11	
United States	334	9	4,000	2	8.3	18	

Notes

- * Canadian data reported by the OECD is as of November 2008. In November 2009, updated and revised Canadian data was released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2010.
- † Converted to Canadian dollars using purchasing power parities (PPPs) for gross domestic product (GDP).
- ‡ The OECD did not provide data on public health expenditure for Belgium from 1997 onwards.
- § 2006 data used for Public-Sector Health Expenditure per Capita and Public Drug Expenditure as a Percentage of Public-Sector Health Expenditure.

Source

OECD Health Data 2009, November 2009. Organisation for Economic Co-operation and Development and IRDES, Paris.

Factors Affecting Drug Expenditure in Canada

Numerous factors (see Table 6), many of which are inter-related, may influence drug expenditure. Since drug prices, as measured by several price indices, ***ii have been relatively stable over the past 10 years, factors affecting increased drug spending in Canada essentially relate to the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices).

Although some literature exists on the effects of various factors on drug expenditure, more research is required to quantify the effect of each factor and to inform the relationship between drug expenditure and other health care spending.

The following review of some of the factors affecting drug expenditure is intended to facilitate discussion and is not meant to be a systemic review of all relevant literature.

Cost-Related Factors

Although the ingredient prices of drugs, once on the market, are relatively stable, the introductory price and overall cost of drugs may be influenced by several factors. These factors include international pricing, inflation, changes in retail or wholesale markups and other market forces. Market forces can be competitive forces (for example, the introduction of new products can increase drug expenditures while generics can decrease drug expenditure by offering a lower-priced alternative) or regulatory forces (for example, changes in price controls or extending patent legislation that prevents a less-expensive alternative from coming to the market).

Quantity-Related Factors

There are many factors that can affect the quantity of drugs dispensed. A change in quantity can be a result of a change in the number of users or a change in the volume of drugs used.

Population-Related Factors

Population size affects the number of potential users in an area (for example, P.E.I. versus Ontario). Demographics such as age, gender and ethnic distribution, as well as changes in health status, also play a role in determining levels of drug expenditure. Changes in the health status of the population can be the result of the emergence of new diseases, epidemics and changes in the prevalence or severity of existing disease. Typically, healthier populations use fewer drugs.

CIHI 2010 37

xxii. For more information on price indices, see the Data Limitations section of the Methodological Notes.

Health System-Related Factors

The health system also plays a role in drug expenditure. Changes in policies and programs, including regulations around drug plan eligibility and co-insurance, the extent of formulary listings and the availability of and access to third-party insurance coverage can all affect drug spending.⁶ In general, the more accessible and more generous insurance coverage is, the less costly drugs are to the end consumer and the more likely people are to consume drugs.

New Drugs

New drugs introduced to the market have an influence on drug expenditure. New drugs can result in switching between classes of drugs used to treat similar conditions or switching between drugs within a class. Provided there is a difference in price, any switching will affect drug expenditure.

New drugs may be safer or have fewer potential side effects than existing drugs. As well, they may offer an alternative to, or even a replacement for, existing non-drug therapies (for example, surgery). In addition, new drugs may be used to treat or slow the progression of diseases or symptoms of diseases that were previously undertreated or untreatable.

Other Factors

Aside from the development of new drugs, the pharmaceutical industry plays a role in influencing the trends in drug expenditure. Pharmaceutical companies promote their products to prescribers (for example, physicians, dentists, nurse practitioners) and pharmacists through a practice known as detailing, as well as by advertising to the general public, known as direct-to-consumer advertising (DTCA). Although regulated in Canada, Canadians are exposed to DTCA through international media.

Changes in clinical practice guidelines, prescribing practices or consumer preferences can also lead to changes in the amount or types of drugs dispensed. Changes in pharmaceutical care practices by pharmacists can improve a person's compliance with a treatment regimen, resulting in improved health outcomes, improved utilization of first-line therapies (thereby decreasing use of more costly alternative treatments) or decreasing the use of other health care resources that may be more costly, such as hospital visits. Adoption of primary prevention strategies, such as promoting improved diet, exercise or other forms of healthy living, can improve the health status of the population.

What We Know

- Drug expenditure rose every year between 1985 and 2009, with an average annual growth rate of 9.0%.
- New drugs are often introduced at much higher prices than existing therapies.⁷
- In 2008, 78 new patented drugs were introduced to the market for human consumption in Canada.⁸
- Since 1988, the price of patented medicines in Canada rose at a lower rate than economy-wide inflation in every year but one (1992).^{9, xxiii}
- Some new drugs have reduced overall medical expenditures.^{9, 10}
- An increasing number of drug therapies is being administered outside of the hospital setting, thereby shifting costs from hospitals^{xxiv} to the community (for example, in-home cancer treatments).¹¹
- The Canadian population has been growing at roughly 1.1% per year since 1985.
 The proportion of the population age 65 and older increased by just more than one percentage point between 1997 and 2007.¹² These changes were gradual and did not have a great impact on drug expenditure.¹³

What We Don't Know

- Whether increases in total drug expenditure negatively or positively affect overall health outcomes.
- How drug use impacts spending in other sectors of health care (for example, decreased hospitalization).
- To what degree each of the possible influencing factors discussed in the section above affects drug expenditure.
- How direct-to-consumer advertising affects the marketplace, prescribing practices, physician-patient communication and the public's understanding of drug therapy in Canada.¹⁴

CIHI 2010 39

.

xxiii. For more information on drug prices, see the Data Limitations section of the Methodological Notes.

xxiv. Drugs paid through hospital budgets are not identified separately in the NHEX database but are classified as hospital expenditure.

Table 6 Factors That May Influence Drug Expenditure in Canada

Prices

- Changes in the unit prices of drugs (both patented and non-patented)
- Changes in retail and wholesale markups and professional fees
- Availability of generics
- International prices
- Inflation

Entry of New Drug Chemicals

Volume of Drug Use

- Population Related
 - Changes in population size
 - Changes in population structure/distribution
 - Age, gender and ethnicity
 - Changes in health status of a population
 - Emergence of new diseases
 - Epidemics
 - Prevalence and severity of disease
- System Related
 - Changes and transition associated with health system reform
 - Availability of and access to third-party insurance coverage
 - Changes in policies and programs
 - The extent of formulary listings
 - Eligibility and copayments
- Research and Technology Related
 - New treatment approaches
 - Drugs replacing surgery
 - Drug therapy for previously untreatable or undertreated diseases
 - Availability of more and/or improved diagnostic technology
 - Outcomes research, evidence-based preventive or curative approaches in diagnosis or treatment
 - Use of programs and technology in monitoring patients

Table 6 Factors That May Influence Drug Expenditure in Canada (cont'd)

- Pharmaceutical Industry
 - Development of new drug products (for example, new strengths, new drug forms and presentations)
 - Promotion of drugs to physicians
 - Drug sampling
 - Direct-to-consumer advertising
- Practice and People Related (Health Care Providers and Consumers)
 - Changes in prescribing and dispensing practices
 - Number and mix of prescribers (specialists, general practitioners, nurse practitioners and others)
 - Multiple doctoring
 - Consumers' expectations and behaviours
 - Adherence to treatment

Methodological Notes

Background

Drug expenditure data in this report is obtained from the National Health Expenditure Database (NHEX), which is maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1975. Drug expenditure data in NHEX is macro-level data and does not allow for decomposition of prescription costs or drug classes.

The Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from community pharmacies. Drug expenditure data in NHEX consists of estimates that represent the final costs to Canadian consumers, which include dispensing fees, markups and appropriate taxes. NHEX data does not account for drug expenditure by non-Canadians (for example, Americans' purchases from Canadian pharmacies). The classification system employed is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

National Health Expenditure Database

The mandate of the NHEX database is twofold:

- 1. To support the development and evaluation of health programs in Canada by all levels of government and within the private sector.
- 2. To compile information on health expenditure that will accurately portray the importance of health care as a component of national expenditure.

Health Expenditure—includes any type of expenditure for which the primary objective is to improve or prevent the deterioration of health status.

This definition allows economic activities to be measured according to primary purpose and secondary effects. Activities that are undertaken with the direct purpose of improving or maintaining health are included. Other activities are not included, even though they may impact health. For example, housing and income support policies have social welfare goals as their primary purpose and are not considered to be health expenditure, yet they are recognized as powerful factors in determining population health.

Source of Finance

National health expenditures are reported based on the principle of *responsibility for payment* rather than on the source of the funds. It is for this reason, for example, that federal health transfers to the provinces/territories are included in the provincial/territorial government sector, since it is the responsibility of provincial/territorial governments to expend federal transfers on health services. The exception to this principle is that provincial/territorial government health transfers to municipal governments are included in the provincial/territorial government sector. The following figure depicts the composition of total health expenditure by source of finance.




Figure 18 Composition of Total Health Expenditure, by Source of Finance

Public Sector—includes health care spending by governments and government agencies.***
It is subdivided into provincial government sector and other public sector, as described below:

- 1. The *provincial government sector* includes health spending from provincial/territorial government funds, federal health transfers to the provinces/territories and provincial/territorial government health transfers to municipal governments.
- 2. The *federal direct sector* refers to direct health care spending by the federal government in relation to health care services for special groups, such as Aboriginal People, the Canadian Forces and veterans, as well as expenditures for health research, health promotion and health protection. Federal direct health expenditure does not include federal health transfers to the provinces.
- 3. The municipal government sector expenditure includes health care spending by municipal governments for institutional services, public health, capital construction and equipment, and dental services provided by municipalities in the provinces of Nova Scotia, Manitoba and British Columbia. Designated funds transferred by provincial governments for health purposes are not included in the municipal sector but are included with provincial government expenditure. Currently, no estimates of drug spending are included in this sector.

44 CIHI 2010

_

xxv. Statistics Canada (Public Sector Statistics Division) publishes estimates of government health expenditure as part of its comprehensive reporting system of all government expenditure, the Financial Management System (FMS). The FMS public-sector health spending estimates are lower than those reported by CIHI because different classification methods are applied and a narrower definition of health expenditure is used in the FMS.

- 4. Social security funds are social insurance programs that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by workers' compensation boards (WCBs) and the premium component of the Quebec Drug Insurance Fund.
 - Health spending by WCBs includes what the provincial boards commonly refer to as medical aid. Non-health related items often reported by the WCBs as medical aid expenditure—such as funeral expenses, travel and clothing—are removed.
 - On January 1, 1997, the government of Quebec created a basic drug insurance plan with the objective of ensuring the population of Quebec has access to drugs as required by health status. All residents of Quebec must be covered by drug insurance, whether by private group insurance or by the public plan administered by the Régie de l'assurance maladie du Québec (RAMQ). At the beginning of the plan, the Drug Insurance Fund was the chosen mechanism to pay all drug and pharmaceutical service costs provided to subscribers** insured by the RAMQ, as well as their children. Since July 1, 2002, the Drug Insurance Fund has also covered persons age 65 or older and social assistance recipients insured by the RAMQ. Accordingly, the public plan has been financed since then both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premiums are paid by the subscribers of the Quebec Drug Insurance Fund and by persons age 65 or older insured by this plan.

Private Sector—includes health care spending by individuals and private sources as described below:

- Non-consumption includes non-patient revenues received by health care institutions, such as donations and investment income, private spending on health-related capital construction and equipment and health research funded by private sources. Currently, no estimates of drug spending are included in this portion of the private sector.
- 2. Out-of-pocket includes health expenditures made by individuals for health care goods and services.
- 3. Private health insurance includes health expenditure paid by commercial and not-for-profit insurance firms, as well as the cost of administering those claims.

Hierarchy of Classification

National health expenditure in Canada is based on a system of classification that is consistent with international standards developed by the OECD for reporting health expenditure.

National health expenditure is grouped within the broad categories of personal health care or other health expenses:

xxvi. Subscribers are defined as Quebec residents younger than age 65 who do not receive social assistance benefits and who do not have access to private group insurance.

Personal health care consists of expenditure for health goods and services used by individuals.

Other health expenses consist of expenditure on behalf of society, such as public health; expenditure made as investments for purposes of future consumption, such as capital expenditure; the administrative expenses of planning and managing the health care system; and research.

Personal health expenditure is classified within categories that describe the type of health care used. Certain categories overlap. The hierarchy of classification that is used to allocate overlapping categories of expenditure is as follows:

Institutional setting—health care services consumed in hospitals or other institutions are allocated to the institutional category if the institution purchases the services on behalf of its patients. For example, drugs paid through hospital budgets are classified as hospital expenditure. This allocates expenditure to the supplier actually paid by patients or their agents in the form of government or insurance companies. It also reflects data availability.

Self-employed provider of service—for example, all expenses of physicians' practices are considered to be expenditure for physician services, even though some of these expenses would be for employment of other health professionals, drugs or personal health supplies.

Type of good or service—drugs and personal health supplies are examples.

One of the categories of health expenditure within NHEX is Drugs. Other categories include Hospitals, Other Institutions, Physicians, Other Professionals, Capital, Public Health and Administration, and Other Health Spending. In NHEX, these categories are also named Use of Funds.

Below is a description of the Drugs category within NHEX; it is not a definition supplied by the OECD.

Drugs—at the aggregate level, include expenditure on prescribed drugs and nonprescribed products purchased in retail stores. Estimates represent the final costs to consumers, including dispensing fees, markups and appropriate taxes. The breakdown of prescribed drugs, over-the-counter drugs and personal health supplies in NHEX is parallel with the breakdown in the OECD. This category has been disaggregated at the Canada level in the data tables to provide information on the following sub-categories:

Prescribed drugs - substances considered as drugs under the Food and Drugs Act and sold for human use as the result of a prescription from a health professional.

Non-prescribed drugs*xvii-include two sub-components: over-the-counter drugs and personal health supplies.

Over-the-counter drugs - therapeutic drug products not requiring a prescription and purchased as such.

xxvii. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

Personal health supplies—include items used primarily to promote or maintain health; for example, oral hygiene products, diagnostic items such as diabetic test strips and medical items such as incontinence products.

The Drugs category in NHEX does not include drugs dispensed in hospitals and generally in other institutions. These are included in health expenditure figures for Hospitals or Other Institutions.

Other Terms

Gross domestic product (GDP)¹⁵—GDP implicit price index (in 1997 dollars) is used to compare annual percentage change of drug expenditure with inflation in the Canadian economy. GDP is the unduplicated value of production originating within the boundaries of Canada, regardless of the ownership of the factors of production.

Purchasing power parity (PPP)¹⁶—PPPs are the rates of currency conversion that equalize the purchasing power of different currencies. This means that a given sum of money, when converted into different currencies at the PPP rates, will buy the same basket of goods and services in all countries. Thus PPPs are the rates of currency conversion, which eliminate differences in price levels between countries.

Data Limitations

Data contained in NHEX is estimated. The data is collected from diverse sources and includes varying classes of financial information. The data is collected and classified according to methods established by a review committee. CIHI analysts and external experts continue to improve the comprehensiveness, accuracy and currency of the data in order to provide the most complete and objective estimates possible. Notwithstanding these improvements, national health expenditure data consists of estimates and should be used accordingly.

Most private-sector expenditure is estimated from survey data. Prior to 1996, the Family Expenditure Survey by Statistics Canada, ¹⁷ an important source of private-sector data, was not carried out annually; therefore, trend data was imputed for years between surveys. Private-sector data was revised following a methodology review in the early 1990s. The revised private-sector data incorporated information estimated directly from new sources for 1988 and subsequent years. Prior years were estimated using trend data. As a result, readers should use caution when using the private-sector expenditure data for small provinces and for years prior to 1988.

Drugs in Hospitals


The NHEX database at CIHI uses a classification system that is consistent with international standards developed by the OECD for the reporting of health expenditure. Similar to the functional category Pharmaceutical and Other Medical Non-Durables in the OECD *System of Health Accounts*, the Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from retail outlets. Drugs in hospitals are considered as inputs (intermediate consumption) to the production of health care in hospitals. Consequently, drugs paid through hospital budgets are not identified separately in NHEX but are classified

as hospital expenditure. Similarly, drugs purchased by residential care facilities for their residents are classified as institutional expenditure. All expenses of physicians' and dentists' practices, including drugs, are considered to be expenditure for physicians' and dentists' services. Some drug expenditure is also included in the NHEX category of public health (for example, vaccines). While the above hierarchy of classification is essential in allocating overlapping categories of expenditure, it also reflects data availability. For example, data on expenditure by provincial/territorial governments is usually extracted from provincial/territorial government public accounts. In the accounts, it is generally not possible to isolate drug spending from other categories of expenditure within program areas (for example, hospitals or public health). While there exist other possible data sources, the use of a single data source for the different categories of provincial government health expenditure—such as the provincial/territorial public accounts—has the major advantage of minimizing the risk of double counting.

Measuring Drug Prices

There is no authoritative composite price index for all drugs sold in Canada. The difficulty lies in the fact that traditional statistical measurement considers the price of tablets or capsules rather than measuring the nature of the product itself (that is, its therapeutic properties). In pure economic terms, the price of a drug is the price per unit of health gain attained. From a practical perspective, however, people buy tablets, capsules or other forms of medication, some of which may contain multiple active ingredients.





Sources

Consumer Price Index and Industrial Product Price Index, Statistics Canada; Patented Medicine Price Index, Patented Medicine Prices Review Board.

There are several commonly accepted price indices that can potentially be used to measure shifts in drug prices at the retail level. These include the Consumer Price Index (CPI), the pharmaceutical component of the Industrial Product Price Index (IPPI [pharma]) and the Patented Medicine Price Index (PMPI). Each index is built upon a unique set of assumptions pertaining to inclusion criteria, definitions, updating and weighting methodologies. As a result, these indices produce differing results (Figure 19).

It is important to determine whether two different products with similar therapeutic elements used to treat similar health conditions are essentially different. Several price indices assume they are different products. The consequence is that when new products enter the market, price indices do not compare their prices to existing products; they are simply added to the basket of goods.

Collection and Non-Response

The definitions and methods used in the preparation of this document are for the most part based on those adopted in 1994 by the National Health Expenditure Methodology Review Committee. This committee included representation from Health Canada, Statistics Canada, the Quebec ministère de la Santé et des Services sociaux, the Canadian Medical Association and the Canadian Healthcare Association. Some of the recommendations for change made during that process are still under development.

General Methods

The following is intended as a general overview of the methods applied to calculate estimates of drug expenditure in Canada. More detailed information can be obtained by contacting the National Health Expenditures program area by phone at 613-241-7860, by fax at 613-241-8120 or by email at nhex@cihi.ca.

Provincial/Territorial Government

Provincial/territorial government expenditure principally includes drugs that are dispensed through provincial/territorial drug subsidy programs (see Appendix A). This drug expenditure data is extracted predominantly from audited and consolidated provincial/territorial documents detailing provincial government expenditure (Table 7).

Provincial/territorial government drug spending figures include spending by the provincial/territorial ministry responsible for health, as well as by other departments that may provide drug coverage. CIHI's estimates of provincial and territorial government drug expenditure were submitted to provincial and territorial departments of health for review and validation.

Provincial/territorial government figures identified as forecasts are based on the growth rates of major programs reported in provincial and territorial government main estimates and budgets.

Table 7 Provincial/Territorial Government Drug Expenditure Data

Province/ Territory		Description
Newfoundland and Labrador	Drug Expenditure Data Source	Drug expenditure data is collected from the <i>Provincial Public Accounts Volume III, Consolidated Revenue Fund</i> supplementary statements and schedules for three drug programs: indigents, seniors and the special drug programs.
Prince Edward Island	Drug Expenditure Data Source	The Drug Cost Assistance Program is reported under the Provincial Pharmacy program in the Queens Region Health and Community Services operating statement, which is reported in <i>P.E.I. Provincial Public Accounts Volume II</i> .
Nova Scotia	Drug Expenditure Data Source	Drugs data is extracted from three sources: the <i>N.S. Supplementary Estimates Details</i> , special tabulations from the N.S. Seniors' Pharmacare Program and the N.S. Department of Community Services, Income Assistance and Employment Support Services.
New Brunswick	Drug Expenditure Data Source	Drugs data is provided through special reports from the Department of Health and Community Services and the Department of Human Resources. A small component of drug expenditure by the provincial government is from the <i>N.B. Public Accounts Volume 2</i> , under Payments to Vendors and Grants and Contribution Payments.
Quebec	Drug Expenditure Data Source	Provincial government expenditure is extracted from Volume 2 of the Quebec provincial public accounts. Spending on drugs by the provincial government is represented by total transfers of Program 5, Régie de l'assurance maladie du Québec, for "médicaments et services pharmaceutiques." See also the section, below, on social security funds and the Quebec Drug Insurance Fund.
Ontario	Drug Expenditure Data Source	Data is collected from Volume 1 of the <i>Ontario Provincial Public Accounts</i> . Information is collected for the drug programs provided by the Ministry of Health and Long-Term Care (Ontario Drug Benefit Program, Trillium Drug Program, Special Drug Program) and by the Ministry of Community and Social Services, under Social Assistance and Employment under the Adult and Children's Service Program.
Manitoba	Drug Expenditure Data Source	Data is from Manitoba Health's Pharmacare Program under the Health Services Insurance Fund. Data is also collected from the annual report of the Manitoba Department of Family Services under Income Assistance of the Employment and Income Assistance Program.

Table 7 Provincial/Territorial Government Drug Expenditure Data (cont'd)

Province/ Territory		Description
Saskatchewan	Drug Expenditure Data Source	Data sources include the Saskatchewan Public Accounts Volume 2 and the Saskatchewan Health Annual Statistical Report for the Drug Plan and Extended Benefits Branch. Data is collected for the Saskatchewan Prescription Drug Plan from the annual report. A total for the Supplementary Health Program (SHP) is also extracted from the annual report. The distribution of detailed expenditure of the SHP provided in the Statistical Report for the Drug Plan and Extended Benefits is applied to the total for the SHP extracted from the public accounts. One of the components of the SHP that is also collected is "non-formulary drugs." Drug expenditure amounts are collected under the Ministry of Social Services in the Supplier Payments section of the public accounts.
Alberta	Drug Expenditure Data Source	Drug expenditure data from Alberta Health and Wellness is extracted from its annual report. Detailed claims summary data is provided by Alberta Blue Cross Non-Group Benefits. The largest single expenditure component of Alberta Blue Cross Non-Group Benefits is drug benefits. The detailed claims distribution is applied to the total for Blue Cross Non-Group Benefits under Practitioner Services, extracted from the annual report of the Ministry of Health and Wellness.
		Drug expenditure information is also collected from Children's Services, the Department of Community Development and the Department of Human Resources and Employment. Drug expenditure amounts are compiled from various income assistance programs, including Income Support to Individuals and Families, Social Support to Individuals and Families and Services to Persons With Disabilities.
British Columbia	Drug Expenditure Data Source	Data is received in the <i>Financial Management Reports</i> (FMRs) from the Ministry of Health Services. Control totals for major programs are from the public accounts. With few exceptions, expenditure items from the FMRs sum to the control totals. The Ministry of Health Services administers drug subsidization for all targeted groups (seniors, income assistance recipients and families) under the Medical Services Program.
Yukon	Drug Expenditure Data Source	Control totals on major programs are extracted from the Yukon public accounts. Additional details are in a special tabulation provided by the territorial Ministry of Health and Social Services on spending for pharmacare, prescription drugs, under the Chronic Disease Program and Extended Health Benefits for Seniors.

Province/ Territory		Description
Northwest Territories	Drug Expenditure Data Source	Drug expenditure data is provided by the Finance Division of the Department of Health and Social Services under the Extended Health Benefits of the Supplementary Health Programs.
Nunavut	Drug Expenditure Data Source	The government of Nunavut is unable to provide drug expenditure amounts to CIHI. The method used to estimate expenditure in Nunavut was to allocate the same proportion that drugs were in the Northwest Territories of the aggregate of individual programs in the Northwest Territories that make up the Supplementary Health Benefits Program in Nunavut.

Federal Direct

Prescribed drug data is derived from information provided by federal government organizations supplemented with information from the national public accounts. Federal government health care spending is generally provided according to the province in which the expenditure was made. Some data, however, is provided only at the national level; in these cases, it is distributed by the appropriate provincial or territorial population.

Social Security Funds

Social security funds are financially autonomous social insurance schemes that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms by which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by WCBs and the premium component of the Quebec Drug Insurance Fund.

Workers' compensation boards—prescribed drug expenditure for the WCBs and the Commission de la santé et de la sécurité du travail du Québec is collected through special tabulations from contacts in each provincial or territorial WCB.

Quebec Drug Insurance Fund—on January 1, 1997, the government of Quebec created a basic drug insurance plan with the objective of ensuring the population of Quebec has access to drugs as required by health status. All residents of Quebec must be covered by drug insurance, whether by private group insurance or by the public plan administered by the RAMQ. At the beginning of the plan, the Drug Insurance Fund was the chosen mechanism to pay all drug and pharmaceutical service costs provided to subscribers insured by the RAMQ, as well as their children. Since July 1, 2002, the Drug Insurance Fund has also covered persons age 65 or older and social assistance recipients insured by the RAMQ. Accordingly, the public plan has been financed since then both by the

xxviii. Subscribers are defined as Quebec residents younger than age 65 who do not receive social assistance benefits and who do not have access to private group insurance.

expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premiums are paid by the subscribers of the Quebec Drug Insurance Fund and by persons age 65 or older insured by this plan.

The premium component of the Quebec drug program is considered to be a social security scheme, while the remaining portion of the program that is paid through the ministère de la Santé et des Services sociaux (MSSS) is included as a provincial government expenditure.

Table 8 presents estimates from 1997 to 2009 for the Quebec Drug Insurance Fund.

The premiums are calculated as the difference between the total Drug Insurance Fund, extracted from RAMQ annual reports, and the fund financed by the MSSS, extracted from Quebec public accounts.

Table 8 Quebec Drug Insurance Fund, in Millions of Dollars, 1997 to 2009

Year	Financed Through Premiums	Financed by ministère de la Santé et des Services sociaux (Quebec)	Total
1997	169.1	700.3	869.4
1998	213.4	779.8	993.2
1999	262.7	918.3	1,181.0
2000	327.9	1,118.3	1,446.2
2001	367.4	1,309.4	1,676.8
2002	433.2	1,439.5	1,872.7
2003	577.8	1,538.9	2,116.7
2004	615.5	1,678.1	2,293.6
2005	618.7	1,798.7	2,417.5
2006	669.0	1,955.6	2,624.5
2007	676.4	2,164.9	2,841.2
2008f	708.7	2,348.5	3,057.3
2009f	732.2	2,517.6	3,249.8

Note

f: forecast.

Source

National Health Expenditure Database, 2009, Canadian Institute for Health Information.

Private Sector

Private-sector drug data was revised in 1995 following a methodology review that began in the early 1990s. Private-sector data under the revised methodology incorporated information estimated directly from new sources for 1988 and subsequent years. Expenditure amounts prior to 1988 were estimated using trend data. Therefore, readers should exercise caution when using the private-sector expenditure data for small provinces and for years prior to 1988.

The recommendations pertaining to prescribed and non-prescribed drugs that were ultimately implemented included the following:

- Data on drug benefits paid by private insurers was to be estimated based on information provided by the Canadian Life and Health Insurance Association (CLHIA) and from surveys of non-profit insurers.
- Out-of-pocket expenditure on prescribed drugs was to be estimated from Statistics Canada's Family Expenditure in Canada survey (FAMEX), renamed in 1997 to the Survey of Household Spending (SHS).
- Non-prescribed drug estimates would include two components: over-the-counter drugs and personal health supplies. Estimates would be based on information from the market research firm A. C. Nielsen.

As part of the original agreement with the not-for-profit insurance firms that provide data to NHEX, the administrators of NHEX agreed not to report the components of the private sector—insurance and out-of-pocket expenditure—at the provincial/territorial level. The purpose was to protect the proprietary nature of the information of the not-for-profit insurance firms. Consequently, CIHI only reports the private-sector sum of components by province and the out-of-pocket and insurance components of the private sector at the national level.

The data sources and methodologies related to these recommendations are described below.

Health insurance drug claims paid are collected from eight not-for-profit insurance companies and the CLHIA. The CLHIA data is based on its survey of member companies. Currently, drug spending that may occur by insurance companies providing casualty insurance is not included in the estimates.

Out-of-pocket prescribed drug expenditure is based on purchased data from the SHS fielded by Statistics Canada. Specifically, average household costs associated with question 14, in Section P of the SHS, relating to medicines, drugs and pharmaceutical products **prescribed by a doctor** are the basis of the estimates. The average household expenditure of prescribed drugs is multiplied by the number of estimated households reported in the survey.

The SHS is an annual survey which began in 1996. Prior to 1996, full surveys that included both urban and rural areas were carried out in 1986 and 1992. In 1990, a survey was conducted that included only metropolitan areas. In years when complete surveys were carried out, data is available for the 10 provinces and for 17 urban centres. The urban centres included Yellowknife and Whitehorse, which were used to derive estimates of expenditure in the territories. Metropolitan expenditure per household tends to be somewhat higher than provincial estimates. All relevant categories were updated in complete survey years. In years when only urban surveys were carried out, the percentage changes in urban expenditure within each province or territory were used to update category estimates from complete survey years. Between 1992 and 1996, when no surveys were conducted, historical provincial growth rates of the SHS variables of drug and drug sundries were used to impute missing years.

The non-prescribed drug estimate is based on data from the market research firm A. C. Nielsen, which tracks consumer sales of non-prescribed drugs sold in Canada at retail. Each year, A. C. Nielsen reports retail sales data for two consistent years for more than 48 non-prescribed drug categories. Data is reported by sales channel,*** total dollar sales volume and regional sales distribution for five regions that include nine provinces. Newfoundland and Labrador and the territories are not included. The data is processed by classifying the non-prescribed drug categories as either over-the-counter drugs or personal health supplies. Regional sales amounts are separated into nine provinces, and estimates for Newfoundland and Labrador and the territories are calculated using provincial distributions of "direct costs for health care" from the SHS. Appropriate provincial and federal sales taxes are incorporated into the estimates.

The following list provides the various drug classes that are supplied to CIHI by A. C. Nielsen. The choice of classes to be included in the non-prescribed drug expenditure estimate and the classification according to which drugs are included as over-the-counter or personal health supplies was made by the NHEX Drug Expenditure Review Committee during the NHEX methodology review and adopted in 1995.

xxix. As a general rule, Statistics Canada definitions govern the classification of stores by class of trade. Sales channels include drug stores; food stores with pharmacies; grocery banners; mass merchandiser and warehouse clubs, which are estimated from A. C. Nielsen's household panel data.

Over-the-Counter Drugs

Analgesic rubs Adhesive bandages and dressing strips

Personal Health Supplies

Anti-fungals (external)

Antiperspirants

Athletes' foot products (included in Artificial sweeteners

anti-fungals in later years)

Athletic supports/braces

Cold remedies Condoms

Cough remedies Contact lens preparations

Diarrhea remedies Cotton swabs

Dietary aids Cover and tape products

Headache remedies Dental floss
Headache remedies—child's acetaminophen Dentifrice

Hemorrhoidal remedies

Infant feeding products

Laxatives

Denture adhesives

Denture cleansers

Diabetic test strips

Medical nutritional supplements Disposable diabetic syringes

Milk-intolerant products Elastic bandages

Nasal preparations Eye drops and lotions

Oral backache remedies Feminine hygiene products

Pediculicides Fever thermometers
Personal lubricants Incontinence products
Premenstrual products Medical supports/braces

Sleeping aids Oral antiseptics
Throat remedies Pregnancy test kits

Topical wound care Sanitary pads

Upset stomach remedies Selected hot/cold compresses

Vitamins—children's Selected insoles

Vitamins—adults' Tampons

Wart removers Toothbrushes (includes denture brushes)

Calculation Methods

Calculation of Average Annual Rate of Growth

The average annual rate of growth is the constant annual rate necessary for a value at the beginning of a period to grow to a value at the end of a period over the number of compounding years in the period. The formula used to calculate the average annual rate of growth is

$$= e^{\frac{\ln(\text{value at end of period}) - \ln(\text{value at beginning of period})}{T}} - 1$$

Where the constant e equals 2.718, which is the base of the natural logarithm, and T equals the number of years in the period (that is, year at end of period – year at beginning of period).

Calculation of Calendar Year

Some information sources provide data in fiscal years. Calendar-year data was derived by adding three-quarters of one fiscal year to one-quarter of the previous fiscal year.

Calculation of per Capita Dollars

Per capita expenditure was calculated using the most recent revised population estimates and forecasts from the Demography Division of Statistics Canada. These take into account the results of the census adjustment for net census under-count, non-permanent residents and returning Canadians.

Calculation of Total Health Expenditure

"Total health expenditure" refers to the sum of the public and private sectors. "Canada" refers to the sum of the 10 provinces and three territories. "Canada average" is the sum of provincial and territorial expenditure divided by the sum of provincial and territorial data of another variable, such as population.

Calculation of Deflated Drug Expenditure per Capita Using CPI

Where drug expenditure per capita is presented in constant 1985 dollars, constant dollar drug expenditure per capita was calculated using the CPI, provided by Statistics Canada. A more complete explanation of the methodology for calculating the CPI is available from Statistics Canada. ¹⁸

Forecasting Methods

Provincial government–sector drug spending forecasts are based on the growth rates of drug subsidy programs of provincial health departments reported in provincial main estimates and budgets. In the case of territorial government forecasts of the Northwest Territories and Nunavut, estimates were based on amounts reported in their main estimates. In other sectors, the figures for these two territories were calculated by developing a forecast for the Northwest Territories, including Nunavut. The share of Nunavut spending in the last year of actual data of the combined total of the Northwest Territories and Nunavut was used as a proxy to break out the forecasts for the Northwest Territories and Nunavut.

Forecasts for federal direct, WCBs and private sector were entirely based on econometric analysis of time series trends. For each series, up to 40 different univariate forecasting specifications were evaluated, and the best one (based on the root mean square error of prediction) was selected. The functional forms studied included the exponential smoothing family (simple, double, Holt, Brown, Winters, damped trend, etc.); time trends; ARIMA specifications; etc. Logarithmic transformations were used when the data warranted their use.

Forecasts of health expenditure are identified in the figures by special symbols and in the data tables by the letter "f."

Sources of Data

Drug expenditure estimates from NHEX are compiled based on information from the following sources.

Provincial Government Sector

- Provincial public accounts and main estimates
- Provincial departments of health annual reports and statistical supplements, where available
- Annual reports of various foundations, agencies and commissions
- Special tabulations and specific information from various provincial departments reporting health expenditure

Federal Direct Sector

- Public Accounts of Canada
- Special tabulations and information from
 - Health Canada
 - Veterans Affairs Canada
 - Department of National Defence
 - Solicitor General of Canada
 - Statistics Canada
 - Citizenship and Immigration Canada

Social Security Funds Sector

- Special tabulations on medical aid spending provided by the provincial and territorial WCBs
- Annual reports of provincial and territorial WCBs
- Annual report of the RAMQ

Private Sector

- Private insurance component:
 - The not-for-profit portion is captured from special tabulations provided by the not-for-profit insurance companies.
 - The commercial portion is captured by a special tabulation provided by the CLHIA.
- Out-of-pocket component:
 - SHS, Statistics Canada (formerly the FAMEX)
 - Over-the-Counter Drugs and Personal Health Supplies—Market Review of Selected Drug Categories at Retail, a special tabulation purchased from A. C. Nielsen Canada

Economic and Demographic Data

- Gross domestic product:
 - Purchased from National Accounts and Environment Division, Statistics Canada, for all years except the latest
 - Purchased from the Conference Board of Canada (GDP growth rates) for the latest year
- Population—purchased from Demography Division, Statistics Canada
- Provincial government expenditure—special tabulation purchased from Public Institutions Division, Statistics Canada
- · Price indices:
 - PMPI: from Patented Medicine Prices Review Board
 - CPI and Industrial IPPI: purchased from the Prices Division, Statistics Canada

Series A

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2009

Table A Canada—Total Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2009

	Dir		Prescribed	Prescribed Drugs Private					Non-Prescribed Drugs Private (Out-of-Pocket)			
-	Provincial/	Federal	Public Social S	Security Funds	Sub-Total	Insurers	Out-of-	Sub-Total	Total	Over-	Personal	Total
	Territorial	_	WCB	Drug Insurance Funds	Public		Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Presc. Drugs
Year				(Premium Component)		(\$ Millions)			Diago	Drugs	Саррисс	Diago
	4.040.4	50.0	40.0		4 440 7	(V Willions)			0.500.5			4 005 0
1985 1986	1,048.1 1,240.6	58.0 63.3	12.6 15.2		1,118.7 1,319.2			1,447.7 1,698.8	2,566.5 3,018.0			1,235.9 1,399.0
1987	1,406.7	68.2	17.8		1,492.7			1,800.4	3,293.1			1,621.7
1988	1,592.7	89.3	20.8		1,702.8	1,130.3	903.7	2,034.0	3,736.8			1,784.9
1989	1,838.0	110.0	22.9		1,970.9	1,260.6	1,031.4	2,292.0	4,262.9			1,975.6
1990	2,120.2	130.3	27.5		2,278.0	1,466.8	1,127.0	2,593.9	4,871.8			2,058.7
1991	2,428.0	145.6	33.2		2,606.7	1,671.5	1,190.4	2,861.9	5,468.7			2,236.6
1992	2,710.7	159.7	38.1		2,908.5	1,947.3	1,244.9	3,192.3	6,100.7	1,290.0		2,418.1
1993 1994	2,817.0 2,845.0	187.6 207.1	40.2 35.5		3,044.9 3,087.6	2,089.3 2,105.2	1,469.4 1,568.2	3,558.7 3,673.3	6,603.5 6,760.9	1,373.0 1,475.1	1,203.1 1,288.9	2,576.0 2,764.0
1995 1996	3,099.7 3,053.4	227.8 234.0	37.8 41.4		3,365.3 3,328.8	2,350.1 2,476.6	1,683.6 1,796.7	4,033.8 4,273.3	7,399.0 7,602.1	1,474.2 1,508.0		
1996	3,053.4	252.5	41.4	169.1	3,528.0	2,785.2	2,148.0	4,273.3	8,531.2	1,568.2	,	
1998	3,462.5	283.7	47.9	213.4	4,007.5	3,220.5	2,223.0	5,443.5	9,451.1	1,661.7	1,509.7	3,171.3
1999	3,914.2	321.0	53.7	262.7	4,551.6	3,387.0	2,302.0	5,689.0	10,240.6	1,782.1	1,576.7	3,358.8
2000	4,559.3	343.3	64.8	327.9	5,295.3	3,866.8	2,562.5	6,429.3	11,724.7	1,815.3	1,605.0	3,420.3
2001	5,228.8	392.0	75.8	367.4	6,064.1	4,489.0	2,613.5	7,102.5	13,166.6	1,882.4		
2002	5,865.5	448.2	86.5	433.2	6,833.5	5,009.4	2,934.4	7,943.9	14,777.3	1,972.2		
2003 2004	6,417.0 7,048.8	508.2 528.6	102.8 121.2	577.8 615.5	7,605.8 8,314.0	5,692.6 6,229.2	3,155.9 3,364.8	8,848.5 9,594.0	16,454.3 17,908.0	2,047.5 2,159.3		
2005 2006	7,658.2 8,259.5	564.3 609.9	133.6 148.7	618.7 669.0	8,974.9 9,687.0	6,714.3 7,269.4	3,484.1 3,945.5	10,198.4 11,214.9	19,173.3 20,901.8	2,245.5 2,361.5		
2007	8,751.2	626.7	166.7	676.4	10,221.0	7,896.8	3,934.9	11,831.7	22,052.6	2,500.1	1,978.7	4,478.8
2008 f	9,420.6	648.2	189.6	708.7	10,967.1	8,738.4	4,318.2	13,056.6	24,023.8	2,541.6		4,525.3
2009 f	9,782.6	677.5	215.5	732.2	11,407.8	9,363.4	4,606.8	13,970.3	25,378.1	2,582.4	2,035.9	4,618.4
-						(Annual Percentage Char	nge)					
1985 1986	18.4	9.2	20.9		 17.9			 17.3	 17.6			13.2
1987	13.4	7.7	16.9		17.9			6.0	9.1			15.2
1988	13.2	30.9	16.6		14.1			13.0	13.5			10.1
1989	15.4	23.2	10.0		15.7	11.5	14.1	12.7	14.1			10.7
1990	15.4	18.4	20.0		15.6	16.4	9.3	13.2	14.3			4.2
1991	14.5	11.7	20.8		14.4	14.0	5.6	10.3	12.3			8.6
1992	11.6	9.7	14.8	***	11.6	16.5	4.6	11.5	11.6			8.1
1993 1994	3.9 1.0	17.5 10.4	5.7 -11.9		4.7 1.4	7.3 0.8	18.0 6.7	11.5 3.2	8.2 2.4	6.4 7.4		6.5 7.3
1995 1996	9.0 -1.5	10.0 2.7	6.5 9.6		9.0 -1.1	11.6 5.4	7.4 6.7	9.8 5.9	9.4 2.7	-0.1 2.3		
1997	2.6	7.9	3.3		8.1	12.5	19.6	15.4	12.2	4.0		4.5
1998	10.5	12.4	12.0	26.2	11.4	15.6	3.5	10.3	10.8	6.0		
1999	13.0	13.1	12.1	23.1	13.6	5.2	3.6	4.5	8.4	7.2	4.4	5.9
2000	16.5	7.0	20.8	24.8	16.3	14.2	11.3	13.0	14.5	1.9		
2001	14.7	14.2	17.0	12.1	14.5	16.1	2.0	10.5	12.3	3.7		3.4
2002	12.2 9.4	14.3 13.4	14.1 18.8	17.9 33.4	12.7 11.3	11.6 13.6	12.3 7.5	11.8 11.4	12.2 11.3	4.8 3.8		4.2 2.1
2004	9.8	4.0	17.9	6.5	9.3	9.4	6.6	8.4	8.8	5.5		
2005	8.6	6.8	10.3	0.5	7.9	7.8	3.5	6.3	7.1	4.0	3.8	3.9
2006	7.9	8.1	11.3	8.1	7.9	8.3	13.2	10.0	9.0	5.2		
2007	6.0	2.8	12.1	1.1	5.5	8.6	-0.3	5.5	5.5	5.9		4.5
2008 f	7.6	3.4	13.7	4.8	7.3	10.7	9.7	10.4	8.9	1.7		
2009 f	3.8	4.5	13.7	3.3	4.0	7.2	6.7	7.0	5.6	1.6	2.6	2.1
-						age Share of Total Drug	Expenditure)					
1985 1986	27.6 28.1	1.5 1.4	0.3		29.4 29.9			38.1 38.5	67.5 68.3			32.5 31.7
1987	28.6	1.4	0.4		30.4			36.6	67.0			33.0
1988	28.8	1.6	0.4		30.8	20.5	16.4	36.8	67.7			32.3
1989	29.5	1.8	0.4		31.6	20.2	16.5	36.7	68.3			31.7
1990	30.6	1.9	0.4		32.9	21.2	16.3	37.4	70.3			29.7
1991	31.5	1.9	0.4		33.8	21.7	15.4	37.1	71.0			29.0
1992 1993	31.8 30.7	1.9 2.0	0.4 0.4		34.1 33.2	22.9 22.8	14.6 16.0	37.5 38.8	71.6 71.9	15.1 15.0	13.2 13.1	28.4 28.1
1994	29.9	2.2	0.4		32.4	22.1	16.5	38.6	71.9	15.5		
1995	30.4	2.2	0.4	***	33.0	23.1	16.5	39.6	72.6	14.5		
1996	29.2	2.2	0.4		31.9	23.7	17.2	40.9	72.8	14.4		
1997	27.2	2.2	0.4	1.5	31.3	24.2	18.7	42.9	74.1	13.6	12.2	25.9
1998	27.4	2.2	0.4	1.7	31.7	25.5	17.6	43.1	74.9	13.2		
1999	28.8	2.4	0.4	1.9	33.5	24.9	16.9	41.8	75.3	13.1		
2000	30.1	2.3	0.4	2.2	35.0	25.5	16.9	42.5	77.4	12.0		
2001 2002	31.3 31.8	2.3 2.4	0.5 0.5	2.2 2.3	36.3 37.0	26.9 27.1	15.6 15.9	42.5 43.0	78.8 80.0	11.3 10.7		
2002	31.7	2.5	0.5	2.9	37.6	28.2	15.6	43.8	81.4	10.1	8.5	
2004	32.3	2.4	0.6	2.8	38.1	28.5	15.4	43.9	82.0	9.9	8.1	18.0
2005	32.9	2.4	0.6	2.7	38.6	28.9	15.0	43.9	82.4	9.7		
2006	32.8	2.4	0.6	2.7	38.5	28.9	15.7	44.5	83.0	9.4		17.0
2007 2008 f	33.0 33.0	2.4 2.3	0.6 0.7	2.5 2.5	38.5 38.4	29.8 30.6	14.8	44.6 45.7	83.1	9.4 8.9		
2008 f	33.0	2.3	0.7	2.5	38.4	30.6	15.1 15.4	45.7 46.6	84.1 84.6	8.9		
f: forecast.											Source	e: CIHI, 2009.

			Total Health E	xpenditure, Ca	mada, 1985 to	2009 (cont'd)	_		
_		All Drugs			Health Expenditure		Total He	in Public, Private a alth Expenditures	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
			(\$ Million	s)			(Perci	entage Share)	
	1,118.7	2,683.6	3,802.3	30,094.9	9,746.9	39,841.7	3.7	27.5	
	1,319.2 1,492.7	3,097.9 3,422.2	4,417.1 4,914.9	32,528.6 35,054.7	10,808.7 11,733.5	43,337.3 46,788.2	4.1 4.3	28.7 29.2	
	1,702.8	3,818.9	5,521.7	38,162.8	12,796.4	50,959.2	4.5	29.8	
	1,970.9	4,267.7	6,238.5	41,911.1	14,184.3	56,095.5	4.7	30.1	
	2,278.0	4,652.5	6,930.5	45,445.5	15,577.1	61,022.6	5.0	29.9	
	2,606.7	5,098.5	7,705.3	49,382.2	16,906.9	66,289.1	5.3	30.2	
	2,908.5 3,044.9	5,610.4 6,134.7	8,518.8 9,179.6	51,637.3 51,920.8	18,112.0 19,578.1	69,749.2 71,498.9	5.6 5.9	31.0 31.3	
	3,087.6	6,437.4	9,524.9	52,535.5	20,574.2	73,109.7	5.9	31.3	
	3,365.3	6,822.2	10,187.4	52,719.1	21,370.1	74,089.2	6.4	31.9	
	3,328.8	7,120.0	10,448.9	52,823.0	21,910.5	74,733.5	6.3	32.5	
	3,598.1	7,908.9	11,507.0	55,223.9	23,532.1	78,755.9	6.5	33.6	
	4,007.5 4,551.6	8,614.9 9,047.9	12,622.4 13,599.4	59,208.0 63,197.2	24,768.3 26,998.8	83,976.3 90,196.1	6.8 7.2	34.8 33.5	
	5,295.3	9,849.6	15,144.9	69,266.8	29,160.7	98,427.5	7.6	33.8	
	6,064.1 6,833.5	10,638.9 11,628.6	16,703.0 18,462.1	75,006.6 80,176.7	32,061.0 34,997.1	107,067.6 115.173.8	8.1 8.5	33.2 33.2	
	7,605.8	12,610.5	20,216.3	86,968.5	36,869.1	123,837.6	8.7	34.2	
	8,314.0	13,524.2	21,838.2	92,574.1	39,357.4	131,931.5	9.0	34.4	
	8,974.9	14,282.5	23,257.4	99,168.3	41,892.8	141,061.1	9.1	34.1	
	9,687.0	15,499.3	25,186.3	105,816.2	45,588.8	151,405.0	9.2	34.0	
	10,221.0	16,310.4	26,531.4	113,198.7	47,774.8	160,973.5	9.0	34.1	
	10,967.1 11,407.8	17,582.0 18,588.6	28,549.1 29,996.4	121,829.2 128,597.3	51,755.9	173,585.1 183,120.9	9.0 8.9	34.0 34.1	
_	11,407.6	10,500.0	(Annual Percentaç		54,523.6	183,120.9	6.9	34.1	
	 17.9	 15.4	 16.2	 8.1	10.9	 8.8			
	13.2	10.5	11.3	7.8	8.6	8.0			
	14.1	11.6	12.3	8.9		8.9			
	15.7	11.8	13.0	9.8	10.8	10.1			
	15.6	9.0	11.1	8.4	9.8	8.8			
	14.4	9.6	11.2	8.7	8.5	8.6			
	11.6 4.7	10.0 9.3	10.6 7.8	4.6 0.5	7.1 8.1	5.2 2.5			
	1.4	4.9	3.8	1.2		2.3			
	9.0	6.0	7.0	0.3	3.9	1.3			
	-1.1	4.4	2.6	0.2		0.9			
	8.1	11.1	10.1	4.5		5.4			
	11.4 13.6	8.9 5.0	9.7 7.7	7.2 6.7	5.3 9.0	6.6 7.4			
	16.3 14.5	8.9 8.0	11.4 10.3	9.6 8.3		9.1 8.8			
	12.7	9.3	10.5	6.9		7.6			
	11.3	8.4	9.5	8.5	5.3	7.5			
	9.3	7.2	8.0	6.4	6.7	6.5			
	7.9	5.6	6.5	7.1	6.4	6.9			
	7.9	8.5	8.3	6.7	8.8	7.3			
	5.5 7.3	5.2 7.8	5.3 7.6	7.0 7.6		6.3 7.8			
	7.3 4.0	7.8 5.7	7.6 5.1	7.6 5.6		7.8 5.5			
		ge Share of Total Dr		5.0	0.0				
_	29.4	70.6	100.0	_					
	29.4	70.1	100.0						
	30.4	69.6	100.0						
	30.8	69.2	100.0						
	31.6	68.4	100.0						
	32.9	67.1	100.0						
	33.8	66.2	100.0						
	34.1 33.2	65.9 66.8	100.0 100.0						
	32.4	67.6	100.0						
	33.0								
	33.0 31.9	67.0 68.1	100.0 100.0						
	31.3	68.7	100.0						
	31.7	68.3	100.0						
	33.5	66.5	100.0						
	35.0	65.0	100.0						
	36.3	63.7	100.0						
	37.0	63.0	100.0						
	37.6 38.1	62.4 61.9	100.0 100.0						
	38.6 38.5	61.4	100.0						
	38.5 38.5	61.5 61.5	100.0 100.0						
	38.4	61.6	100.0						

Table A Canada—per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Canada, 1985 to 2009

		Tarritanial		Prescribed Drugs Private						Non-Prescribed Drugs Private (Out-of-Pocket)		
	Provincial/	Federal	Territor Social	ial Security Funds	Sub-Total	Insurers	Private Out-of-	Sub-Total	Total	Privat Over-	e (Out-of-Po	ocket) Total
	Territorial	_	WCB	Drug Insurance Funds	Public		Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Presc. Drugs
Year				(Premium Component)		(\$ per Capita)			Diugs	Drugs	Supplies	Drugs
1985	40.56	2.24	0.49		43.29	(4 per Capita)		56.02	99.31			47.82
1986	47.53	2.43	0.58		50.54			65.09	115.63			53.60
1987 1988	53.18 59.44	2.58 3.33	0.67 0.78		56.44 63.55	42.18	33.72	68.07 75.91	124.51 139.46			61.32 66.61
1989	67.37	4.03	0.78		72.24	46.21	37.81	84.01	156.25			72.42
1990	76.55	4.70	0.99	***	82.24	52.96	40.69	93.65	175.89			74.33
1991	86.62	5.19	1.18		92.99	59.63	42.47	102.10	195.09			79.79
1992 1993	95.56 98.22	5.63 6.54	1.34 1.40		102.53 106.16	68.65 72.84	43.89 51.23	112.53 124.07	215.07 230.23	45.48 47.87	39.77 41.95	85.24 89.81
1994	98.11	7.14	1.22		106.47	72.59	54.08	126.67	233.14	50.87	44.45	95.31
1995	105.78	7.78	1.29	***	114.85	80.20	57.46	137.66	252.51	50.31	44.85	95.16
1996 1997	103.12 104.78	7.90 8.44	1.40 1.43	 5.65	112.42 120.31	83.64 93.13	60.68 71.82	144.32 164.95	256.73 285.26	50.93 52.43	45.21 47.07	96.14 99.50
1997	114.81	9.41	1.43	7.08	132.89	106.79	71.62	180.51	313.39	55.10	50.06	
1999	128.74	10.56	1.77	8.64	149.70	111.40	75.71	187.12	336.82	58.61	51.86	110.47
2000	148.57	11.19	2.11	10.68	172.55	126.00	83.50	209.50	382.05	59.15	52.30	
2001 2002	168.56 186.96	12.64 14.29	2.44 2.76	11.84 13.81	195.48 217.82	144.71 159.68	84.25 93.53	228.96 253.21	424.44 471.03	60.68 62.86	53.32 54.59	
2003	202.58	16.04	3.24	18.24	240.11	179.71	99.63	279.34	519.46	64.64	54.13	
2004	220.31	16.52	3.79	19.24	259.85	194.69	105.17	299.86	559.71	67.49	55.35	122.84
2005	237.01	17.46	4.13	19.15	277.76	207.80	107.83	315.62	593.38	69.49	56.90	
2006 2007	253.54 265.77	18.72 19.03	4.56 5.06	20.54 20.54	297.37 310.41	223.15 239.82	121.11 119.50	344.27 359.33	641.63 669.74	72.49 75.93	59.03 60.09	
2008 f	282.80	19.46	5.69	21.28	329.23	262.33	129.63	391.96	721.19	76.30	59.55	135.85
2009 f	291.27	20.17	6.42	21.80	339.66	278.79	137.17	415.96	755.62	76.89	60.62	137.51
						nnual Percentage Char						
1985 1986	 17.2	8.1	 19.7		16.8			16.2	16.4			 12.1
1987	11.9	6.3	15.4		11.7			4.6	7.7			14.4
1988 1989	11.8 13.3	29.2 21.0	15.1 8.1		12.6 13.7	9.5	 12.1	11.5 10.7	12.0 12.0			8.6 8.7
1990 1991	13.6 13.2	16.7 10.4	18.2 19.4		13.8 13.1	14.6 12.6	7.6 4.4	11.5 9.0	12.6 10.9			2.6 7.3
1992	10.3	8.4	13.4		10.3	15.1	3.3	10.2	10.2			6.8
1993 1994	2.8 -0.1	16.2 9.2	4.5 -12.8		3.5 0.3	6.1 -0.3	16.7 5.6	10.3 2.1	7.1 1.3	5.3 6.3	5.5 6.0	5.4 6.1
1995	7.8	8.9	5.4		7.9	10.5	6.3	8.7	8.3	-1.1	0.9	
1996	-2.5	1.6	8.5		-2.1	4.3	5.6	4.8	1.7	1.2	0.8	1.0
1997	1.6	6.8	2.2		7.0	11.3	18.4	14.3	11.1	3.0	4.1	3.5
1998 1999	9.6 12.1	11.4 12.2	11.1 11.2	25.2 22.1	10.5 12.7	14.7 4.3	2.6 2.7	9.4 3.7	9.9 7.5	5.1 6.4	6.4 3.6	5.7 5.1
2000	15.4	6.0	19.6	23.6	15.3	13.1	10.3	12.0	13.4	0.9	0.9	0.9
2001	13.5	13.0	15.7	10.9	13.3	14.8	0.9	9.3	11.1	2.6	1.9	2.3
2002 2003	10.9 8.4	13.1 12.3	12.8 17.7	16.6 32.1	11.4 10.2	10.3 12.5	11.0 6.5	10.6 10.3	11.0 10.3	3.6 2.8	2.4 -0.8	3.0 1.1
2003	8.8	3.0	16.7	5.5	8.2	8.3	5.6	7.3	7.7	4.4	2.3	
2005	7.6	5.7	9.2	-0.5	6.9	6.7	2.5	5.3	6.0	3.0	2.8	2.9
2006	7.0	7.2	10.4	7.2	7.1	7.4	12.3	9.1	8.1	4.3	3.7	4.1
2007 2008 f	4.8 6.4	1.7 2.2	10.9 12.4	0.0 3.6	4.4 6.1	7.5 9.4	-1.3 8.5	4.4 9.1	4.4 7.7	4.7 0.5	1.8 -0.9	3.4 -0.1
2009 f	3.0	3.7	12.8	2.5	3.2	6.3	5.8	6.1	4.8	0.8	1.8	
				(Annual	Percentage Chang	ge in Excess of Inflation	n in the Cana	dian Economy	()			
1985 1986	14.4	5.3	16.9		14.0			13.4	13.6			9.3
1987	7.1	1.6	10.6		6.9			-0.2	2.9			9.7
1988 1989	7.2 8.8	24.7 16.4	10.6 3.5		8.1 9.1			7.0 6.1	7.5 7.5			4.1 4.1
1990	10.6	13.6	15.2		10.8	***		8.4	9.5			-0.4
1991	10.4	7.6	16.6		10.3			6.3	8.2			4.6
1992 1993	9.1 1.3	7.1 14.7	12.2 3.1		9.0 2.1			9.0 8.8	9.0 5.6	3.8	4.0	5.6 3.9
1993	-1.2	8.1	-13.9		-0.8			1.0	0.2	5.2	4.0	5.0
1995	5.5	6.5	3.0		5.5			6.3	6.0	-3.4	-1.4	-2.5
1996	-4.2	0.0	6.8		-3.8			3.2	0.0	-0.4	-0.9	-0.6
1997 1998	0.6 10.0	5.8 11.9	1.2 11.5	25.6	6.0 10.9			13.3 9.9	10.1 10.3	2.0 5.5	3.1 6.8	2.5 6.1
1999	10.3	10.4	9.4	20.3	10.8			1.9	5.7	4.6	1.8	
2000	11.3	1.9	15.5	19.5	11.2			7.9	9.3	-3.2	-3.3	-3.2
2001	12.1	11.6	14.4	9.5	11.9			7.9	9.7	1.2	0.6	
2002 2003	9.9 5.5	12.0 9.4	11.8 14.8	15.6 29.2	10.4 7.3			9.5 7.4	9.9 7.4	2.6 -0.1	1.3 -3.7	
2004	6.2	0.4	14.1	2.9	5.6			4.8	5.2	1.8	-0.3	
2005	4.7	2.8	6.3	-3.4	4.0			2.3	3.1	0.1	-0.1	
2006 2007	4.1 1.5	4.3 -1.7	7.5 7.6	4.3 -3.3	4.2 1.1			6.2 1.0	5.2 1.1	1.4 1.4	0.9 -1.5	
2008 f	1.8	-2.4	7.8	-1.1	1.4			4.4	3.0	-4.2	-5.6	-4.8
2009 f f: forecast.	4.9	5.5	14.6	4.3	5.0			8.0	6.7	2.7	3.7 Source	3.1 E: CIHI, 2009.
IUIGUASI.											Jource	51111, 2009.

		F	D	. h T h	Course of Fin	and Dubit		Canada – per Capita
		Expenditur	e on Drugs per Capita Total Health Expe				C, Private and GDP Implicit	
<u>-</u>	Public	All Drugs Private	Total	H Public	Private	Total	Price Index—Canada	
Year			(\$ per Capita)				(1997 = 100)	
1985	43.29	103.84	147.13	1,164.54	377.16	1,541.70	73.6	
1986	50.54	118.69	169.23	1,246.25	414.11	1,660.36	75.6	
1987	56.44	129.39	185.82	1,325.38	443.63	1,769.01	79.2	
1988 1989	63.55 72.24	142.52 156.43	206.07 228.67	1,424.23 1,536.23	477.56 519.92	1,901.79 2,056.15	82.8 86.6	
1990 1991	82.24 92.99	167.98 181.89	250.22 274.88	1,640.78 1,761.68	562.40 603.14	2,203.18 2,364.82	89.2 91.6	
1992	102.53	197.78	300.31	1,820.34	638.49	2,458.83	92.8	
1993	106.16	213.89	320.05	1,810.23	682.59	2,492.83	94.1	
1994	106.47	221.98	328.46	1,811.62	709.48	2,521.10	95.2	
1995	114.85	232.82	347.67	1,799.15	729.30	2,528.45	97.4	
1996	112.42	240.45	352.87	1,783.90	739.95	2,523.85	99.0	
1997 1998	120.31 132.89	264.45 285.67	384.75 418.56	1,846.50 1,963.32	786.83 821.31	2,633.33 2,784.63	100.0 99.6	
1999	149.70	297.59	447.29	2,078.59	888.01	2,966.60	101.4	
2000	172.55	320.95	493.50	2,257.05	950.20	3,207.25	105.5	
2000	172.55	342.96	538.44	2,257.05	1,033.52	3,207.25	106.9	
2002	217.82	370.66	588.48	2,555.63	1,115.53	3,671.16	108.1	
2003	240.11	398.11	638.22	2,745.56	1,163.94	3,909.50	111.2	
2004	259.85	422.69	682.55	2,893.37	1,230.10	4,123.48	114.1	
2005	277.76	442.02	719.77	3,069.08	1,296.51	4,365.59	117.4	
2006 2007	297.37	475.79	773.15	3,248.28	1,399.46	4,647.74	120.8	
2007 2008 f	310.41 329.23	495.35 527.81	805.75 857.04	3,437.83 3,657.28	1,450.91 1,553.70	4,888.74 5,210.98	124.8 130.6	
2009 f	339.66	553.47	893.13	3,828.94	1,623.42	5,452.37	128.2	
=			(Annual	Percentage Change	e)			
1985							***	
1986	16.8	14.3	15.0	7.0	9.8	7.7	2.8	
1987 1988	11.7 12.6	9.0 10.2	9.8 10.9	6.3 7.5	7.1 7.6	6.5 7.5	4.7 4.5	
1989	13.7	9.8	11.0	7.9	8.9	8.1	4.6	
1990	13.8	7.4	9.4	6.8	8.2	7.2	3.0	
1991	13.1	8.3	9.9	7.4	7.2	7.3	2.8	
1992	10.3	8.7	9.3	3.3	5.9	4.0	1.3	
1993	3.5	8.1	6.6	-0.6	6.9	1.4	1.4	
1994	0.3	3.8	2.6	0.1	3.9	1.1	1.1	
1995	7.9	4.9	5.8	-0.7	2.8	0.3	2.3	
1996 1997	-2.1 7.0	3.3 10.0	1.5 9.0	-0.8 3.5	1.5 6.3	-0.2 4.3	1.7 1.0	
1998	10.5	8.0	8.8	6.3	4.4	5.7	-0.4	
1999	12.7	4.2	6.9	5.9	8.1	6.5	1.8	
2000	15.3	7.8	10.3	8.6	7.0	8.1	4.1	
2001	13.3	6.9	9.1	7.1	8.8	7.6	1.4	
2002	11.4	8.1	9.3	5.7	7.9	6.4	1.0	
2003 2004	10.2 8.2	7.4 6.2	8.5 6.9	7.4 5.4	4.3 5.7	6.5	2.9 2.6	
						5.5		
2005	6.9	4.6	5.5	6.1	5.4	5.9	2.9	
2006 2007	7.1 4.4	7.6 4.1	7.4 4.2	5.8 5.8	7.9 3.7	6.5 5.2	2.9 3.3	
2008 f	6.1	6.6	6.4	6.4	7.1	6.6	4.7	
2009 f	3.2	4.9	4.2 tage Change in Excess of Inflati	4.7	4.5	4.6	-1.9	
1005		(Allitual Ferceit						
1985 1986	14.0	11.5	12.2	4.2	7.0	4.9		
1987	6.9	4.3	5.1	1.6	2.4	1.8		
1988	8.1	5.6	6.4	2.9	3.1	3.0		
1989	9.1	5.2	6.4	3.3	4.3	3.6		
1990	10.8	4.4	6.4	3.8	5.1	4.1		
1991	10.3	5.5	7.1	4.6	4.5	4.6		
1992 1993	9.0 2.1	7.5 6.7	8.0 5.1	2.1 -2.0	4.6 5.5	2.7 -0.1		
1993 1994	2.1 -0.8	6.7 2.7	5.1 1.5	-2.0 -1.0	5.5 2.8	-0.1 0.0		
1995 1996	5.5 -3.8	2.5 1.6	3.5 -0.2	-3.0 -2.5	0.5 -0.2	-2.0 -1.9		
1997	6.0	9.0	8.0	2.5	5.3	3.3		
1998	10.9	8.5	9.2	6.8	4.8	6.2		
1999	10.8	2.4	5.1	4.1	6.3	4.7		
2000	11.2	3.7	6.2	4.5	2.9	4.0		
2001	11.9	5.5	7.8	5.8	7.4	6.3		
2002 2003	10.4 7.3	7.0 4.5	8.2 5.6	4.7 4.5	6.9 1.4	5.3 3.6		
2004	5.6	3.6	4.4	2.8	3.1	2.9		
2005	4.0	1.7	2.5	3.2	2.5	3.0		
2006	4.2	4.7	4.5	2.9	5.0	3.6		
2007	1.1	0.8	0.9	2.5	0.4	1.9		
2008 f	1.4	1.9	1.7	1.7	2.4	1.9		
2009 f f: forecast.	5.0	6.7	6.1	6.6	6.4	6.5		Source: CIHI, 2009
								222.00. 0111, 2003

Series B

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2009

N.L.

Table B N.L.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and
Total Health Expenditure, Newfoundland and Labrador, 1985 to 2009

			D.L.F.		Prescribed D	rugs	D				Prescribed D	
	Provincial	Federal	Public Social S WCB	Security Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	te (Out-of-Po Personal Health Supplies	Total Non-Presc. Drugs
Year			•	(Premium Component)		(\$ Millions)			-	Drugs		
1985	18.0	2.3	0.1		20.4			82.8	103.2			24.9
1986 1987	21.4 24.7	2.7 3.1	0.2		24.4 28.1			51.6 55.1	76.0 83.2			28.2 32.7
1988	28.2	1.6	0.4		30.2			58.7	88.9			32.3
1989	31.2	1.3	0.4		32.9			62.5	95.4			32.0
1990 1991	35.3 40.3	1.6	0.6		37.5			64.7 65.8	102.2 108.5			34.3 37.8
1991	43.9	1.7 1.7	0.8 1.1		42.8 46.6			72.9	119.5	20.6	17.9	
1993	47.8	2.2	1.2		51.1			76.1	127.2	21.7	18.2	
1994	52.1	2.5	1.2	***	55.8			77.9	133.7	22.9	18.3	
1995 1996	54.5 54.5	2.8 2.7	1.5 1.8		58.8 59.0			85.6 90.0	144.4 149.0	22.5 24.7	19.9 21.9	
1997	53.6	3.3	1.9		58.8			87.9	146.7	21.1	18.9	40.0
1998 1999	56.1 60.0	3.7	2.4 2.8		62.1 66.9			93.7 103.3	155.8 170.2	23.3 25.6	21.0 22.5	
		4.1										
2000 2001	68.0 77.9	5.8 6.6	3.8 4.2		77.6 88.7			119.9 129.2	197.5 217.9	26.1 25.8	22.2 22.6	
2002	86.9	7.4	5.0		99.3			150.2	249.5	26.6	23.0	
2003 2004	96.0 101.7	8.1	4.9 4.9		109.0 114.4			169.0 178.4	278.0 292.8	26.9 27.8	22.4 23.1	
		7.8										
2005 2006	106.0 108.1	8.0 7.7	5.1 5.1		119.0 121.0			196.7 208.4	315.8 329.4	27.4 30.1	22.4 23.1	
2007	116.9	7.3	5.1		129.4			241.2	370.6	29.8	23.5	53.3
2008 f 2009 f	123.6 133.3	7.7 8.2	5.2 5.3		136.5 146.8			281.3 314.1	417.8 460.8	30.0 30.1	23.4 23.5	
2009 1	133.3	0.2	5.5					314.1	400.8	30.1	23.5	55.7
						(Annual Percentage C						
1985 1986	19.2	20.4	35.5		19.4				-26.3			13.2
1987	15.4	13.5	34.3		15.3			6.7	9.4			16.0
1988	13.9	-48.0	50.0		7.4			6.6	6.8			-1.0
1989	10.6	-20.2	14.5		9.0			6.6	7.4			-1.0
1990 1991	13.4 14.1	21.5 9.6	38.7 25.5		14.0 14.1			3.4 1.7	7.1 6.2			7.1 10.3
1992	8.8	-3.5	40.5		8.9			10.8	10.1			2.0
1993 1994	8.9	31.4	9.2		9.7			4.5	6.5	5.4	1.1	
	9.1	12.4	7.4		9.2			2.3	5.1	5.3	0.8	
1995 1996	4.6 0.0	12.3 -2.7	22.5 18.8		5.4 0.4			9.9 5.1	8.0 3.2	-1.8 10.1	8.6 10.3	
1997	-1.6	23.0	3.4		-0.4			-2.3	-1.5	-14.5	-14.0	-14.3
1998 1999	4.6 7.0	10.5 12.0	28.6 16.0		5.6 7.7			6.5 10.3	6.2 9.3	10.1 9.9	11.5 7.0	
2000 2001	13.4 14.5	40.7 15.5	37.7 8.8		16.1 14.3			16.0 7.8	16.0 10.3	2.2 -1.4	-1.4 1.7	
2002	11.5	11.9	20.2		12.0			16.2	14.5	3.3	2.1	
2003 2004	10.6 5.9	8.3 -3.0	-1.8 -1.2		9.8 4.9			12.5 5.5	11.4 5.3	1.0 3.4	-2.6 2.8	
2005	4.2	1.8	4.6		4.1			10.3	7.9	-1.6	-2.9	
2006	2.0	-3.1	1.5		1.6			5.9	4.3	9.9	3.0	
2007	8.1	-5.0	-0.8		6.9			15.7	12.5	-1.0	1.7	
2008 f 2009 f	5.7 7.9	5.3 5.7	1.0 2.4		5.5 7.5			16.6 11.6	12.7 10.3	0.5 0.6	-0.3 0.6	
						tage Share of Total Dr	ua Expendit					
1985	14.0	1.8	0.1		15.9			64.6	80.6			19.4
1986	20.6	2.6	0.2		23.4			49.6	73.0			27.0
1987 1988	21.3 23.2	2.7 1.3	0.2		24.3			47.5	71.8			28.2 26.7
1989	24.4	1.0	0.3		24.9 25.8			48.4 49.1	73.3 74.9			25.1
1990	25.9	1.2	0.4		27.5			47.4	74.9			25.1
1991	27.5	1.2	0.5		29.2			44.9	74.2			25.8
1992 1993	27.8 28.6	1.1 1.3	0.7 0.7		29.5 30.6			46.1 45.6	75.6 76.1	13.0 13.0	11.4 10.9	
1994	29.8	1.4	0.7		31.9			44.6	76.5	13.1	10.5	
1995	29.2	1.5	0.8		31.5			45.9	77.3	12.0	10.6	22.7
1996	27.9	1.4	0.9		30.2			46.0	76.2	12.6	11.2	23.8
1997 1998	28.7 28.0	1.8 1.8	1.0 1.2		31.5 31.0			47.1 46.8	78.6 77.9	11.3 11.6	10.1 10.5	
1999	27.5	1.9	1.3		30.6			47.3	78.0	11.7	10.3	
2000	27.7	2.3	1.6		31.6			48.8	80.3	10.6	9.0	19.7
2001	29.3	2.5	1.6		33.3			48.5	81.8	9.7	8.5	18.2
2002 2003	29.0 29.3	2.5 2.5	1.7 1.5		33.2 33.3			50.2 51.6	83.4 84.9	8.9 8.2	7.7 6.9	
2004	29.6	2.3	1.4		33.3			51.9	85.2	8.1	6.7	
2005	29.0	2.2	1.4		32.6			53.8	86.4	7.5	6.1	13.6
2006	28.3	2.0	1.3		31.6			54.5	86.1	7.9	6.0	
2007 2008 f	27.6 26.2	1.7 1.6	1.2 1.1		30.5 29.0			56.9 59.7	87.4 88.7	7.0 6.4	5.5 5.0	
2009 f	25.9	1.6	1.0		28.5			61.0	89.6	5.9	4.6	
f: forecast. * Confidentiali	ty precludes repor	tina provincial	level incurence	lata							Paire	e: CIHI, 2009.
Commutational	., produces repor	19 PLOVILLOIDI"	dille (June	2003.

		-	Health Expenditur	re. Newfoundla	f Finance and as and Labrado				
		All Drugs	Ticardi Experiental	ic, itewioundia	Health Expenditure	1, 1505 to 2000	Share of Drug	gs in Public, Private a ealth Expenditures	and
_	Public	Private	Total	Public	Private	Total	Public	Private	Т
			(\$ Millio	ne)			(Pool	centage Share)	
_	20.4	107.7	128.1	588.8	3 197.1	785.8	3.5	54.6	
	24.4	79.8	104.2	642.9	169.6	812.5	3.8	47.1	
	28.1 30.2	87.8 91.0	115.9 121.2	693.6 733.8		881.6 930.9	4.1 4.1	46.7 46.2	
	32.9	94.6	127.4	787.7		991.6	4.2	46.4	
	37.5	99.0	136.5	875.9	220.6	1,096.4	4.3	44.9	
	42.8	103.6	146.4	905.7		1,153.2	4.7	41.8	
	46.6 51.1	111.4 116.0	158.0 167.1	928.3 924.9		1,197.4 1,209.1	5.0 5.5	41.4 40.8	
	55.8	119.1	174.9	948.1		1,249.3	5.9	39.6	
	58.8	128.0	186.7	973.1	296.4	1,269.4	6.0	43.2	
	59.0	136.7	195.6	974.4		1,253.4	6.1	49.0	
	58.8 62.1	127.9 138.0	186.7 200.1	1,020.8 1,107.8		1,305.1 1,431.9	5.8 5.6	45.0 42.6	
	66.9	151.4	218.3	1,250.8		1,581.2	5.3	45.8	
	77.6	168.2	245.8	1,318.7	366.4	1,685.1	5.9	45.9	
	88.7	177.5	266.2	1,415.5	385.7	1,801.2	6.3	46.0	
	99.3 109.0	199.8 218.3	299.2 327.3	1,510.4		1,925.3 2,061.4	6.6 6.8	48.2 46.5	
	109.0 114.4	218.3 229.2	327.3 343.6	1,592.2 1,630.0		2,061.4 2,137.4	6.8 7.0	46.5 45.2	
	119.0	246.5	365.5	1,686.9		2,235.6	7.1	44.9	
	121.0	261.6	382.6	1,785.3	562.3	2,347.6	6.8	46.5	
	129.4	294.4	423.8	1,929.6		2,565.0	6.7	46.3	
	136.5 146.8	334.7 367.7	471.1 514.5	2,107.4 2,278.5		2,810.0 3,028.9	6.5 6.4	47.6 49.0	
_			(Annual Percenta			<u> </u>			
	 19.4	-25.9		9.2		3.4			
	15.3	9.9	11.2	7.9		8.5			
	7.4	3.7	4.6	5.8		5.6			
	9.0	3.9	5.1	7.4		6.5			
	14.0 14.1	4.7 4.7	7.1 7.3	11.2 3.4		10.6 5.2			
	8.9	7.6	8.0	2.5		3.8			
	9.7	4.1	5.8	-0.4		1.0			
	9.2	2.7	4.7	2.5		3.3			
	5.4 0.4	7.4 6.8	6.8 4.8	2.6 0.1		1.6 -1.3			
	-0.4	-6.4	-4.6	4.8		4.1			
	5.6	7.8	7.2	8.5		9.7			
	7.7	9.7	9.1	12.9		10.4			
	16.1 14.3	11.1 5.6	12.6 8.3	5.4 7.3		6.6 6.9			
	12.0	12.6	12.4	6.7		6.9			
	9.8	9.2	9.4	5.4		7.1			
	4.9	5.0	5.0	2.4		3.7			
	4.1	7.5	6.4	3.5		4.6			
	1.6 6.9	6.1 12.6	4.7 10.8	5.8 8.1		5.0 9.3			
	5.5	13.7	11.2	9.2	10.6	9.6			
	7.5	9.9	9.2	8.1	6.8	7.8			
_	(Percenta	ge Share of Total Dr	ug Expenditure)	_					
	15.9	84.1	100.0						
	23.4 24.3	76.6 75.7	100.0 100.0						
	24.9	75.1	100.0						
	25.8	74.2	100.0						
	27.5	72.5	100.0						
	29.2 29.5	70.8 70.5	100.0 100.0						
	30.6	69.4	100.0						
	31.9	68.1	100.0						
	31.5	68.5	100.0						
	30.2	69.8	100.0						
	31.5 31.0	68.5 69.0	100.0 100.0						
	30.6	69.4	100.0						
	31.6	68.4	100.0						
	33.3 33.2	66.7 66.8	100.0 100.0						
	33.3	66.7	100.0						
	33.3	66.7	100.0						
	32.6	67.4	100.0						
	31.6	68.4	100.0						
	30.5 29.0	69.5 71.0	100.0 100.0						
	28.5	71.5	100.0						

Table B N.L.—per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Newfoundland and Labrador, 1985 to 2009

					Prescribed I	Orugs					n-Prescribed D	
	Provincial	Federal	Public Social	Security Funds	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Priv. Over-	ate (Out-of-Po Personal	ocket) Total
	TTOVITICIAL	- Cuciai	WCB	Drug Insurance	Public	madrera	Pocket	Private	Prescribed	the-	Health	Non-Presc.
				Funds (Premium Component)					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ per Capita)						
1985	31.05	3.94	0.24		35.23			142.89	178.12			42.96
1986 1987	37.19 43.00	4.77 5.42	0.32 0.44		42.28 48.86			89.58 95.77	131.86 144.63			48.89 56.82
1988	49.00	2.82	0.66		52.48			102.08	154.56			56.25
1989	54.05	2.25	0.75		57.04			108.52	165.56			55.53
1990	61.11	2.72	1.03		64.87			111.92	176.79			59.30
1991 1992	69.56 75.61	2.97 2.87	1.30 1.82		73.83 80.30			113.48 125.66	187.30 205.95	35.54	30.94	65.26 66.48
1993	82.36	3.77	1.99		88.12			131.28	219.40	37.46		
1994	90.69	4.28	2.15		97.12			135.64	232.75	39.83	31.86	71.69
1995	96.05	4.86	2.67		103.58			150.89	254.47	39.59		
1996 1997	97.36 97.30	4.80 6.00	3.22 3.38		105.37 106.67			160.78 159.58	266.15 266.25	44.17 38.38		
1998	103.81	6.76	4.43		115.01			173.46	288.47	43.13		
1999	112.49	7.67	5.20		125.36			193.70	319.07	47.96	42.18	90.14
2000	128.84	10.90	7.24		146.98			226.98	373.96	49.52		
2001 2002	149.21 167.25	12.73 14.32	7.97 9.63		169.91 191.20			247.46 289.07	417.37 480.27	49.41 51.30		
2003	185.27	15.54	9.48		210.29			325.97	536.27	51.89		
2004	196.64	15.11	9.38		221.14			344.79	565.92	53.78		
2005	206.17	15.48	9.87		231.52			382.64	614.16	53.25		
2006 2007	211.91 230.91	15.11	10.09		237.10 255.47			408.42 476.20	645.53	58.98		
2007 2008 f	243.33	14.47 15.20	10.09 10.16		255.47 268.68			553.87	731.66 822.55	58.86 59.00		
2009 f	262.74	16.08	10.41		289.22			618.98	908.20	59.40	46.37	
						(Annual Percentage C	Change)					
1985												
1986 1987	19.8 15.6	21.0 13.7	36.2 34.7		20.0 15.6			-37.3 6.9	-26.0 9.7			13.8 16.2
1988	14.0	-48.0	50.0		7.4			6.6	6.9			-1.0
1989	10.3	-20.4	14.2		8.7			6.3	7.1			-1.3
1990	13.1	21.2	38.3		13.7			3.1	6.8			6.8
1991 1992	13.8 8.7	9.3 -3.5	25.2 40.4		13.8 8.8			1.4 10.7	5.9 10.0			10.0 1.9
1993	8.9	31.4	9.3		9.7			4.5	6.5	5.4	1.2	
1994	10.1	13.4	8.4		10.2			3.3	6.1	6.3	1.8	3 4.3
1995	5.9	13.7	24.1		6.7			11.2	9.3	-0.6		
1996 1997	1.4 -0.1	-1.3 25.0	20.4 5.1		1.7 1.2			6.6 -0.7	4.6 0.0	11.6 -13.1	11.8 -12.6	
1998	6.7	12.8	31.2		7.8			8.7	8.3	12.4		
1999	8.4	13.4	17.4		9.0			11.7	10.6	11.2	8.3	9.8
2000	14.5	42.2	39.1		17.2			17.2	17.2	3.2		
2001 2002	15.8 12.1	16.8 12.5	10.1 20.8		15.6 12.5			9.0 16.8	11.6 15.1	-0.2 3.8		
2003	10.8	8.5	-1.6		10.0			12.8	11.7	1.2		
2004	6.1	-2.8	-1.0		5.2			5.8	5.5	3.6	3.0	3.4
2005	4.8	2.5	5.2		4.7			11.0	8.5	-1.0		
2006 2007	2.8	-2.4	2.2 0.0		2.4			6.7 16.6	5.1	10.8		
2007 2008 f	9.0 5.4	-4.2 5.0	0.0		7.7 5.2			16.3	13.3 12.4	-0.2 0.2		
2009 f	8.0	5.8	2.5		7.6			11.8	10.4	0.7	0.7	
				(Ann	ual Percentage Cl	nange in Excess of Infla	ation in the (Canadian Econo	omy)			
1985 1986	17.0	18.2	33.4		17.2			-40.1	-28.8			11.0
1987	10.9	9.0	29.9		10.8			2.2	4.9			11.5
1988 1989	9.4	-52.5 -25.0	45.5		2.9			2.1	2.3			-5.5
	5.7		9.6		4.1			1.7	2.6			-5.8
1990 1991	10.0 11.1	18.2 6.6	35.3 22.4		10.7 11.1			0.1 -1.4	3.8 3.2			3.8 7.3
1992	7.4	-4.8	39.1		7.5			9.5	8.7			0.6
1993 1994	7.5	29.9	7.8		8.3			3.0	5.1	4.0		
	9.0	12.3	7.3		9.1			2.2	5.0	5.2		
1995 1996	3.6 -0.3	11.4 -3.0	21.7 18.7		4.3 0.1			8.9 4.9	7.0 2.9	-2.9 9.9		
1997	-1.1	24.0	4.1		0.1			-1.7	-1.0	-14.1	-13.6	-13.9
1998	7.1	13.2	31.7		8.3			9.1	8.8	12.8		
1999	6.6	11.6	15.6	***	7.2			9.9	8.8	9.4		
2000 2001	10.4 14.5	38.1 15.4	35.0 8.8		13.1 14.2			13.1 7.7	13.1 10.3	-0.9 -1.6		
2002	11.0	11.4	19.8		11.5			15.8	14.0	2.8	1.6	3 2.2
2003 2004	7.9 3.5	5.6 -5.4	-4.5 -3.6		7.1 2.6			9.9 3.2	8.8 2.9	-1.7 1.1	-5.3 0.4	

2005 2006	1.9 -0.1	-0.5 -5.3	2.3 -0.7		1.8 -0.5			8.1 3.8	5.6 2.2	-3.9 7.9		
2007	5.6	-7.6	-3.3		4.4			13.3	10.0	-3.5	-0.8	-2.4
2008 f 2009 f	0.7 9.9	0.4 7.6	-3.9 4.4		0.5 9.5			11.7 13.6	7.8 12.3	-4.4 2.6		
f: forecast.	9.9	7.0	4.4		9.5			13.6	12.3	2.6	2.6	2.6
	y precludes repor	ting provincial-l	level insurance	data.							Sour	ce: CIHI, 2009.

N.L.

		Total I		apita by Type, by re, Newfoundland	l and Labrador		lic, Private and 09 (cont'd) GDP Implicit	able B N.L.—per Cap
-	Public	All Drugs Private	Total	Public	ealth Expenditure Private	Total	Price Index — Canada	
ear			(\$ per Ca	pita)			(1997 = 100)	
85	35.23	185.85	221.08	1,016.34	340.16	1,356.50	73.6	
86	42.28	138.46	180.75	1,115.18	294.15	1,409.34	75.6	
87	48.86	152.59	201.45	1,205.91	326.89	1,532.79	79.2	
88 89	52.48 57.04	158.33 164.05	210.81 221.09	1,276.14 1,366.63	342.81 353.75	1,618.95 1,720.39	82.8 86.6	
90	64.87 73.83	171.22 178.73	236.09 252.56	1,515.29 1,562.86	381.55 427.13	1,896.84 1,989.99	89.2 91.6	
92	80.30	192.14	272.44	1,600.38	463.99	2,064.37	92.8	
93	88.12	200.04	288.16	1,594.84	489.99	2,084.83	94.1	
94	97.12	207.33	304.44	1,650.45	524.20	2,174.65	95.2	
95	103.58	225.50	329.08	1,714.87	522.27	2,237.14	97.4	
96 97	105.37 106.67	244.12 232.18	349.49 338.85	1,740.60 1,852.68	498.31 515.86	2,238.91 2,368.53	99.0 100.0	
98	115.01	255.52	370.54	2,051.73	600.30	2,652.03	99.6	
99	125.36	283.85	409.21	2,344.87	619.49	2,964.36	101.4	
00	146.98	318.50	465.48	2,497.29	693.97	3,191.26	105.5	
01	169.91	340.09	510.00	2,711.82	738.88	3,450.70	106.9	
02	191.20	384.72	575.92 631.42	2,907.60 3,071.16	798.83	3,706.44	108.1	
03 04	210.29 221.14	421.13 443.14	631.42 664.27	3,071.16 3,150.95	905.01 980.77	3,976.16 4,131.72	111.2 114.1	
05 06	231.52 237.10	479.42 512.60	710.95 749.71	3,280.92 3,498.45	1,067.26 1,101.87	4,348.18 4,600.32	117.4 120.8	
07	255.47	581.39	836.85	3,810.02	1,254.53	5,064.54	124.8	
08 f	268.68	658.91	927.59	4,149.22	1,383.37	5,532.59	130.6	
09 f	289.22	724.75	1,013.97	4,490.51	1,478.95	5,969.47	128.2	
				Annual Percentage Chang				
36	20.0	-25.5	-18.2	9.7	-13.5	3.9	2.8	
37	15.6	10.2	11.5	8.1	11.1	8.8	4.7	
38 39	7.4 8.7	3.8 3.6	4.6 4.9	5.8 7.1	4.9 3.2	5.6 6.3	4.5 4.6	
90 91	13.7 13.8	4.4 4.4	6.8 7.0	10.9 3.1	7.9 11.9	10.3 4.9	3.0 2.8	
92	8.8	7.5	7.9	2.4	8.6	3.7	1.3	
93	9.7	4.1	5.8	-0.3	5.6	1.0	1.4	
94	10.2	3.6	5.6	3.5	7.0	4.3	1.1	
95	6.7	8.8	8.1	3.9	-0.4	2.9	2.3	
96 97	1.7 1.2	8.3 -4.9	6.2 -3.0	1.5 6.4	-4.6	0.1 5.8	1.7 1.0	
98	7.8	10.1	9.4	10.7	3.5 16.4	12.0	-0.4	
99	9.0	11.1	10.4	14.3	3.2	11.8	1.8	
00	17.2	12.2	13.7	6.5	12.0	7.7	4.1	
01	15.6	6.8	9.6	8.6	6.5	8.1	1.4	
02	12.5	13.1	12.9	7.2	8.1	7.4	1.0	
03	10.0	9.5	9.6	5.6	13.3	7.3	2.9	
04	5.2	5.2	5.2	2.6	8.4	3.9	2.6	
05	4.7	8.2	7.0	4.1	8.8	5.2	2.9	
06 07	2.4 7.7	6.9 13.4	5.5 11.6	6.6 8.9	3.2 13.9	5.8 10.1	2.9 3.3	
08 f	5.2	13.3	10.8	8.9	10.3	9.2	4.7	
09 f	7.6	10.0	9.3	8.2	6.9	7.9	-1.9	
-		(Annual Percent	age Change in Excess of	f Inflation in the Canadian	Economy)			
35	17.3	20.2	21.0					
36 37	17.2 10.8	-28.3 5.5	-21.0 6.7	6.9 3.4	-16.3 6.4	1.1 4.0		
38	2.9	-0.8	0.1	1.3	0.4	1.1		
39	4.1	-1.0	0.3	2.5	-1.4	1.7		
0	10.7	1.3	3.8	7.9	4.8	7.2		
1	11.1	1.6	4.2	0.4	9.2	2.2		
12 13	7.5	6.2	6.6	1.1	7.4	2.5		
4	8.3 9.1	2.7 2.5	4.3 4.6	-1.8 2.4	4.2 5.9	-0.4 3.2		
5 6	4.3 0.1	6.4 6.6	5.8 4.5	1.6 -0.2	-2.7 -6.3	0.5 -1.6		
7	0.2	-5.9	-4.0	5.4	2.5	4.8		
8	8.3	10.5	9.8	11.2	16.8	12.4		
9	7.2	9.3	8.6	12.5	1.4	10.0		
10	13.1	8.1	9.6	2.4	7.9	3.6		
11	14.2	5.4	8.2	7.2	5.1	6.8		
3	11.5 7.1	12.1 6.6	11.9 6.7	6.2 2.7	7.1 10.4	6.4 4.4		
14	7.1 2.6	2.6	2.6	0.0	10.4 5.8	1.3		
5								
5 6	1.8 -0.5	5.3 4.0	4.1 2.6	1.2 3.7	5.9 0.3	2.3 2.9		
7	4.4	10.1	8.3	5.6	10.5	6.8		
08 f	0.5	8.7	6.2	4.3	5.6	4.6		
9 f	9.5	11.9	11.2	10.1	8.8	9.8		

P.E.I.

Table B P.E.I.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Prince Edward Island, 1985 to 2009

	1.7 2.1 3.5 4.6 5.5 6.5 7.4 7.6 7.7 8.5 8.5 10.4 12.0 14.0 15.7 16.9 19.9 22.3 24.2	0.8 0.9 1.0 0.6 0.5 0.6 0.7 0.7 0.8 0.9 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.7 2.9 2.9	0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.3 0.4 0.4 0.4 0.5 0.6 0.7 0.8	Security Funds	2.5 3.1 4.6 5.3 6.0 7.3 8.2 8.6 8.9 9.8 9.8 10.6 12.2 13.9	(\$ Millions)	Private Out-of- Pocket	19.5 12.9 10.2 12.4 15.0 18.0 17.1 18.8 21.8 23.8 28.4 29.7	Total Prescribed Drugs 22.0 16.0 14.7 17.7 21.0 25.3 27.5 30.5 32.8 38.3	Over- the- Counter Drugs	te (Out-of-Pocs Personal Health Supplies	Total Non-Presc. Drugs 10.7 12.1 14.0 11.8 9.9 10.6 13.5 16.4 17.4 17.9
Year 1985 1986 1987 1988 1990 1991 1992 1993 1994 1995 1996 1997 1998 2000 2001 2001 2002	1.7 2.1 3.5 4.6 5.5 6.5 7.4 7.6 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 22.3 22.4.2	0.8 0.9 1.0 0.6 0.5 0.7 0.7 0.7 0.8 0.9 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.3 0.4 0.4 0.4 0.5 0.6 0.7 0.8	Drug Insurance Funds (Premium Component)	2.5 3.1 4.6 5.3 6.0 7.3 8.2 8.6 8.9 9.8 9.8 10.6 12.2 13.9	(\$ Millions)	Pocket	19.5 12.9 10.2 12.4 15.0 18.0 17.1 18.8 21.8 23.8	22.0 16.0 14.7 17.7 21.0 25.3 27.5 30.5 32.8 38.3	the-Counter Drugs	Health Supplies	Non-Presc. Drugs 10.7 12.1 14.0 11.8 9.9 10.6 13.5 16.4 17.4 17.9
1985 1986 1987 1988 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1998 1999 2000 2001 2001 2002 2002	2.1 3.5 4.6 5.5 6.5 7.4 7.6 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.9 1.0 0.6 0.5 0.6 0.7 0.8 0.9 1.0 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.3 0.3 0.4 0.4 0.5 0.6 0.7		3.1 4.6 5.3 6.0 7.3 8.2 8.6 8.6 8.9 9.8 9.8 10.6 12.2 13.9			12.9 10.2 12.4 15.0 18.0 17.1 18.8 21.8 23.8	16.0 14.7 17.7 21.0 25.3 25.3 27.5 30.5 32.8 38.3	8.6 9.0 9.2	7.8 8.4 8.7	12.1 14.0 11.8 9.9 10.6 13.5 16.4 17.4
1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999	2.1 3.5 4.6 5.5 6.5 7.4 7.6 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.9 1.0 0.6 0.5 0.6 0.7 0.8 0.9 1.0 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.3 0.3 0.4 0.4 0.5 0.6 0.7		3.1 4.6 5.3 6.0 7.3 8.2 8.6 8.6 8.9 9.8 9.8 10.6 12.2 13.9			12.9 10.2 12.4 15.0 18.0 17.1 18.8 21.8 23.8	16.0 14.7 17.7 21.0 25.3 25.3 27.5 30.5 32.8 38.3	8.6 9.0 9.2	7.8 8.4 8.7	12.1 14.0 11.8 9.9 10.6 13.5 16.4 17.4
1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2002	3.5 4.6 5.5 7.4 7.6 7.5 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 19.9 22.3 24.2	1.0 0.6 0.5 0.6 0.7 0.7 0.8 0.9 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.1 0.1 0.1 0.1 0.4 0.3 0.3 0.4 0.4 0.4 0.5 0.6 0.7		4.6 5.3 6.0 7.3 8.2 8.6 8.6 8.9 9.8 9.8 10.6 12.2			10.2 12.4 15.0 18.0 17.1 18.8 21.8 23.8	14.7 17.7 21.0 25.3 25.3 27.5 30.5 32.8 38.3	8.6 9.0 9.2	 7.8 8.4 8.7 8.3	14.0 11.8 9.9 10.6 13.5 16.4 17.4 17.9
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003	4.6 5.5 6.5 7.4 7.6 7.5 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.6 0.5 0.6 0.7 0.7 0.8 0.9 1.0 1.0 1.2 1.4 2.3 2.7 2.7	0.1 0.1 0.1 0.1 0.4 0.3 0.3 0.4 0.4 0.5 0.6		5.3 6.0 7.3 8.2 8.6 8.9 9.8 9.8 10.6 12.2 13.9			12.4 15.0 18.0 17.1 18.8 21.8 23.8	17.7 21.0 25.3 25.3 27.5 30.5 32.8 38.3	 8.6 9.0 9.2	7.8 8.4 8.7	11.8 9.9 10.6 13.5 16.4 17.4 17.9
1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2001 2002 2002	5.5 6.5 7.4 7.6 7.5 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.5 0.6 0.7 0.8 0.9 1.0 1.0 1.2 1.4 2.3 2.7 2.9	0.1 0.1 0.4 0.3 0.3 0.4 0.4 0.5 0.6 0.7		6.0 7.3 8.2 8.6 8.6 8.9 9.8 10.6 12.2			15.0 18.0 17.1 18.8 21.8 23.8 28.4	21.0 25.3 25.3 27.5 30.5 32.8 38.3	 8.6 9.0 9.2 8.5	 7.8 8.4 8.7	9.9 10.6 13.5 16.4 17.4 17.9
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003	7.4 7.6 7.5 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.7 0.7 0.8 0.9 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.1 0.4 0.3 0.3 0.4 0.4 0.5 0.6 0.7 0.8		8.2 8.6 8.6 8.9 9.8 9.8 10.6 12.2 13.9			17.1 18.8 21.8 23.8 28.4	25.3 27.5 30.5 32.8 38.3	8.6 9.0 9.2 8.5	7.8 8.4 8.7	10.6 13.5 16.4 17.4 17.9
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003	7.4 7.6 7.5 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.7 0.7 0.8 0.9 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.1 0.4 0.3 0.3 0.4 0.4 0.5 0.6 0.7 0.8		8.2 8.6 8.6 8.9 9.8 9.8 10.6 12.2 13.9			17.1 18.8 21.8 23.8 28.4	25.3 27.5 30.5 32.8 38.3	8.6 9.0 9.2 8.5	7.8 8.4 8.7	13.5 16.4 17.4 17.9 16.8
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003	7.5 7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.7 0.8 0.9 1.0 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.4 0.3 0.3 0.4 0.4 0.5 0.6 0.7 0.8		8.6 8.6 8.9 9.8 9.8 10.6 12.2			18.8 21.8 23.8 28.4	30.5 32.8 38.3	9.0 9.2 8.5	8.4 8.7 8.3	16.4 17.4 17.9 16.8
1994 1995 1996 1997 1998 1999 2000 2001 2002 2002 2003	7.7 8.5 8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	0.9 1.0 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.3 0.4 0.4 0.5 0.6 0.7 0.8 0.7		8.9 9.8 9.8 10.6 12.2 13.9			23.8 28.4	32.8 38.3	9.2 8.5	8.7 8.3	17.9 16.8
1995 1996 1997 1998 1999 2000 2001 2002 2003	8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	1.0 1.0 1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.4 0.4 0.4 0.5 0.6 0.7 0.8		9.8 9.8 10.6 12.2 13.9			28.4	38.3	8.5	8.3	16.8
1996 1997 1998 1999 2000 2001 2002 2003	8.5 9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	1.0 1.0 1.2 1.4 2.3 2.7 2.7	0.4 0.5 0.6 0.7 0.8 0.7		9.8 10.6 12.2 13.9							
1997 1998 1999 2000 2001 2002 2003	9.1 10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	1.0 1.2 1.4 2.3 2.7 2.7 2.9	0.4 0.5 0.6 0.7 0.8 0.7		10.6 12.2 13.9			29.7				
1998 1999 2000 2001 2002 2003	10.4 12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	1.2 1.4 2.3 2.7 2.7 2.9	0.5 0.6 0.7 0.8 0.7		12.2 13.9			28.8	39.5 39.4	6.8 7.1	6.3 6.9	
1999 2000 2001 2002 2003	12.0 14.0 15.7 16.9 18.4 19.9 22.3 24.2	1.4 2.3 2.7 2.7 2.9	0.6 0.7 0.8 0.7		13.9			33.0	45.1	8.6	8.5	
2001 2002 2003	15.7 16.9 18.4 19.9 22.3 24.2	2.7 2.7 2.9	0.8 0.7					33.6	47.6	9.1	8.5	
2001 2002 2003	15.7 16.9 18.4 19.9 22.3 24.2	2.7 2.7 2.9	0.8 0.7		17.0			36.0	53.0	8.8	8.0	16.8
2002 2003 2004	18.4 19.9 22.3 24.2	2.9			19.1			43.0	62.2	9.7	8.4	18.1
	19.9 22.3 24.2		^ -		20.3			38.1	58.4	10.4	9.0	
2004	22.3 24.2	2.9	0.7		22.0			43.7	65.7	10.6	9.0	19.6
	24.2		0.7		23.4			47.8	71.2	10.7	8.9	19.6
2005		2.9	0.7		25.9			52.2	78.1	10.2	8.4	18.5
2006 2007		2.8 2.8	0.8		27.8 29.4			56.8 56.9	84.6 86.3	10.6 11.3	8.8 9.0	
2007 2008 f	28.7	2.8	0.9		32.4			62.5	94.9	11.6	9.2	
2009 f	33.1	3.0	1.0		37.1			66.6	103.7	11.9	9.4	
						(Annual Percentage	Change)					
1985												
1986	27.8	16.1	44.0		24.4			-34.1	-27.5			13.2
1987 1988	63.7	12.6	39.7		48.5			-21.0	-7.6			16.0
1989	32.4 17.9	-40.9 -17.4	20.2 0.9		16.1 13.7			21.5 21.5	19.8 19.1			-16.1 -16.1
1990 1991	19.8 13.5	30.7 7.0	20.5 -0.4		20.7 12.7			19.8 -4.7	20.1 0.3			7.5 27.3
1992	2.5	-4.5	218.0		5.2			10.0	8.5			21.5
1993	-1.7	24.8	-13.7		-0.3			15.9	10.8	4.9	7.8	6.3
1994	2.8	12.0	-1.5		3.5			9.2	7.6	1.7	3.7	2.7
1995	10.2	8.6	9.8		10.0			19.2	16.7	-7.1	-5.1	-6.1
1996 1997	0.0	-3.8	4.4		-0.2			4.3	3.2	-20.6	-24.1	-22.3
1997	7.4 14.6	8.3 16.2	14.7 21.0		7.8 15.1			-3.0 14.5	-0.3 14.6	5.4 21.2	9.2 23.2	
1999	14.7	14.0	11.9		14.5			2.0	5.4	5.7	0.1	3.0
2000	16.8	66.4	26.3		22.1			7.2	11.6	-3.7	-6.0	-4.8
2001	12.4	16.8	4.4		12.6			19.4	17.2	10.0	5.3	
2002	7.7	0.7	-9.4		6.0			-11.5	-6.1	7.4	7.2	7.3
2003	9.2	6.4	-1.6		8.4			14.8	12.6	2.1	-0.1	1.1
2004	7.7	0.4	-2.8		6.5			9.3	8.3	1.0	-0.6	0.3
2005	12.4	-0.1	7.6		10.7			9.3	9.8	-5.0	-6.4	-5.6
2006 2007	8.2	-1.4 -1.0	9.7 7.0		7.1			8.8 0.3	8.2 2.1	4.6 5.8	5.0 2.2	
2007 2008 f	6.6 11.3	0.8	10.8		5.9 10.3			9.8	9.9	3.0	2.2	2.6
2009 f	15.5	5.0	6.6		14.3			6.6	9.2	2.5	2.3	
					(Percenta	age Share of Total D	Orug Expendit	ture)				
1985	5.1	2.3	0.1		7.6			59.7	67.3			32.7
1986	7.6	3.2	0.2		11.0			45.9	56.9			43.1
1987 1988	12.1	3.5	0.3		15.9			35.3	51.3 60.0			48.7 40.0
1988	15.7 17.6	2.0 1.6	0.3		18.1 19.6			42.0 48.5	60.0 68.1			40.0 31.9
1990 1991	18.2 19.1	1.8 1.8	0.3		20.3 21.2			50.1 44.1	70.4 65.2			29.6 34.8
1992	17.3	1.5	0.3		19.7			42.9	62.6	19.6	17.8	
1993	15.6	1.7	0.7		18.0			45.6	63.6	18.8	17.6	36.4
1994	15.2	1.8	0.7		17.6			47.1	64.7	18.1	17.2	35.3
1995	15.4	1.8	0.7		17.8			51.6	69.5	15.5	15.1	30.5
1996	16.1	1.8	0.7		18.7			56.5	75.1	12.9	12.0	
1997	17.0	1.9	0.8		19.8			54.0 53.0	73.8 72.5	13.4	12.9	26.2
1998 1999	16.8 18.4	1.9 2.1	0.9 0.9		19.5 21.4			53.0 51.6	72.5 73.0	13.9 14.0	13.6 13.0	
2000 2001	20.0 19.6	3.3 3.3	1.1		24.4 23.9			51.6 53.6	76.0 77.5	12.6 12.1	11.4 10.5	
2001	21.7	3.3	0.9		26.1			49.0	77.5 75.1	13.4	11.6	
2003	21.6	3.4	0.8		25.8			51.2	77.0	12.4	10.5	
2004	21.9	3.2	0.7		25.8			52.6	78.4	11.8	9.8	
2005	23.1	3.0	0.8		26.8			54.0	80.8	10.5	8.6	19.2
2006	23.2	2.7	0.8		26.7			54.6	81.3	10.2	8.4	18.7
2007	24.2	2.6	0.8		27.6			53.4	81.0	10.6	8.4	
2008 f	24.8	2.4	0.8		28.0			54.0	82.1	10.0	7.9	
2009 f f: forecast.	26.5	2.4	0.8		29.7			53.3	83.0	9.5	7.5	17.0
: rorecast. Confidentiality preclu	udes repo	rting provincial-	level insuran	ce data.							Source	ce: CIHI, 2009.

72

		All Daves			Hoolth France Pr			igs in Public, Private	ana
_	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Public	Health Expenditures Private	Total
			(\$ Millions)				(Pe	ercentage Share)	
_	2.5	30.2	32.7	128.3	3 52.9	181.2	1.9	57.1	
	3.1	25.0	28.0	138.0	49.6	187.6	2.2	50.3	
	4.6 5.3	24.2 24.1	28.8 29.4	149.7 163.0		202.9 219.5	3.1 3.3	45.4 42.6	
	6.0	24.9	30.9	174.4		239.3	3.5	38.3	
	7.3	28.6	35.9	186.3	70.0	256.2	3.9	40.9	
	8.2	30.6	38.8	203.8		280.6	4.0	39.9	
	8.6 8.6	35.2 39.3	43.9 47.9	209.2 218.2		295.0 311.7	4.1 4.0	41.1 42.0	
	8.9	41.8	50.7	217.0	96.7	313.7	4.1	43.2	
	9.8	45.2	55.1	222.8		327.4	4.4	43.2	
	9.8 10.6	42.7 42.8	52.5 53.4	233.0 229.9		339.1 340.3	4.2 4.6	40.3 38.8	
	12.2	50.1	62.2	245.5		361.4	5.0	43.2	
	13.9	51.2	65.2	259.0	119.7	378.7	5.4	42.8	
	17.0	52.8	69.8	278.1		401.8	6.1	42.7	
	19.1 20.3	61.1 57.5	80.2 77.7	329.0 366.8		476.4 506.5	5.8 5.5	41.4 41.1	
	22.0	63.3	85.3	381.2	161.3	542.5	5.8	39.3	
	23.4	67.4	90.8	377.6	162.3	539.8	6.2	41.5	
	25.9	70.7	96.7	414.8		578.0	6.3	43.3	
	27.8 29.4	76.2 77.2	104.0 106.6	435.8 468.3		623.6 659.5	6.4 6.3	40.6 40.3	
	32.4	83.2	115.7	522.3	3 208.2	730.5	6.2	40.0	
	37.1	87.8	124.9 (Annual Percentage CI	589.8 hange)	3 219.6	809.4	6.3	40.0	
	 24.4	 -17.3	 -14.2	7.6		3.5			
	48.5	-3.1	2.6	8.8		8.2			
	16.1	-0.3	2.3	8.9		8.2			
	13.7	3.1	5.0	7.0		9.0			
	20.7 12.7	14.9 7.2	16.0 8.3	6.8 9.4		7.0 9.5			
	5.2	15.1	13.0	2.7	7 11.6	5.1			
	-0.3 3.5	11.4 6.3	9.1 5.8	4.3 -0.6		5.7 0.6			
	10.0	8.4	8.7	2.7		4.4			
	-0.2	-5.6	-4.6	4.6		3.5			
	7.8	0.2	1.6	-1.3		0.4			
	15.1 14.5	17.0 2.3	16.6 4.7	6.8 5.5		6.2 4.8			
	22.1	3.1	7.1	7.4	3.3	6.1			
	12.6	15.7	14.9	18.3	19.3	18.6			
	6.0 8.4	-6.0 10.2	-3.1 9.7	11.5 3.9		6.3 7.1			
	6.5	6.5	6.5	-1.0		-0.5			
	10.7	5.0	6.4	9.9	0.6	7.1			
	7.1	7.7	7.6	5.1	15.1	7.9			
	5.9 10.3	1.2 7.9	2.5 8.5	7.5 11.5		5.8 10.8			
	14.3	5.5	8.0	12.9		10.8			
_	(Percenta	ge Share of Total Dr	ug Expenditure)						
	7.6	92.4	100.0						
	11.0	89.0	100.0						
	15.9 18.1	84.1 81.9	100.0 100.0						
	19.6	80.4	100.0						
	20.3	79.7	100.0						
	21.2	78.8	100.0						
	19.7 18.0	80.3 82.0	100.0 100.0						
	17.6	82.4	100.0						
	17.8	82.2	100.0						
	18.7 19.8	81.3 80.2	100.0 100.0						
	19.5	80.5	100.0						
	21.4	78.6	100.0						
	24.4	75.6	100.0						
	23.9	76.1	100.0						
	26.1 25.8	73.9 74.2	100.0 100.0						
	25.8	74.2	100.0						
	26.8	73.2	100.0						
	26.7	73.3	100.0						
	27.6 28.0	72.4 72.0	100.0 100.0						
	29.7	70.3	100.0						

Confidentiality precludes reporting provincial-level insurance data

P.E.I.

Table B P.E.I. - per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Prince Edward Island, 1985 to 2009 Non-Prescribed Drugs Prescribed Drugs Public Private (Out-of-Pocket) Private Sub-Total Sub-Total Provincial Federal Social Security Funds Insurers* Out-of Total Over-Personal Total Drug Insurance Private the-Non-Preso Funds Drugs Counter Supplies Drugs (Premium Component) Drugs (\$ per Capita) 1985 13.08 152.95 83.63 6.01 0.33 19.42 172.37 16.61 27.17 6.94 7.80 24.02 35.62 100.25 124.27 114.72 986 0.47 987 109.04 0.66 1988 35.77 4.59 0.79 41.15 95.54 136.69 90.98 46.48 41.92 3.77 0.79 75.86 115.34 161.82 1990 50.03 4.91 0.95 55.88 137.70 193.59 81.26 1991 56.89 5.26 0.94 63.09 194.50 103.63 131.41 1992 58 12 5.01 2 99 66 12 144 08 210 20 65.73 59 68 125 41 63.70 56.53 6.18 2.56 65.27 165.28 230.55 68.24 131.94 1994 57.56 6.86 2.49 66.91 178.75 245.65 68.75 65.44 134.19 1995 61.67 62.95 7.39 2.72 73.06 211.56 284.62 63.37 125.04 218.51 211.50 290.71 289.13 1996 62.35 7.04 2.81 72.20 49 84 46.35 96.19 1997 7.61 77.64 52.38 50.46 102.85 66.82 3.21 1998 76.76 8.86 3.90 89.52 242.67 332.19 63.65 62.32 125.97 87.75 246.71 2000 102.36 16.74 5 48 124 58 264.09 388.67 64 46 58.37 122.84 2001 114.85 19.53 5.72 140.10 314.79 454.89 70.80 61.36 132.16 2002 123.41 19.63 5.17 148.21 278.01 426.22 75.90 65.64 141.54 ---2004 77.74 144.18 20.83 4.91 169.92 346.45 516.37 64.73 142.46 2005 161.68 20.75 5.28 187.71 377.81 565.52 73.65 60.47 134.12 2006 175.23 20.49 5.80 201.52 411.68 613.20 77.21 63.63 140.84 186.59 20.26 6.20 625.19 64.91 2008 f 205.08 20.18 6.78 232.05 446.88 678.93 82.98 65.47 148.45 474.53 151.47 (Annual Percentage Change) 1985 1986 27.0 15.4 43.2 23.7 -34.5 -27.9 12.6 12.4 48.3 -21.1 63.5 39.5 15.8 1988 31.7 -41.2 19.5 15.5 20.8 19.2 -16.6 17.2 -17.9 13.0 20.7 18.4 -16.6 1990 19.3 30.2 20.1 20.2 19.4 19.6 13.7 7.2 27.5 1991 -0.2 12.9 -4.6 0.5 1992 2.2 -4.8 216.8 4.8 9.6 8.1 21.0 23.5 6.7 1994 1.7 1.8 10.9 -2.4 2.5 8.1 6.6 0.8 2.7 18.4 1996 -0.9 -4.7 3.4 -1.2 3.3 2.1 -21.4 -24.8 -23.1 14.7 21.5 23.5 22.5 1998 14.9 16.5 21.3 15.3 14.9 1999 14.3 13.6 11.5 14.1 1.7 5.0 5.3 -0.2 2.6 16.7 66.2 26.2 -5.0 2000 21.9 7.0 11.4 -3.9 -6.1 2001 12.2 16.7 12.5 19.2 17.0 9.8 7.6 4.3 2002 7.5 0.5 -9.6 5.8 -11.7 -6.3 7.2 7.0 7.1 2003 2004 7.3 0.0 -3.2 6.0 8.8 7.9 0.6 -1.0 -0.1 2005 12.1 -0.3 7.4 9.1 9.5 -5.3 -6.6 -5.9 10.5 8.4 6.5 -1.3 -1.1 4.8 5.6 2006 9.9 6.9 7.4 5.7 9.0 5.2 5.0 4.0 2007 2.0 2.0 2008 f 9.9 -0.4 9.5 8.9 8.4 8.6 1.8 0.9 1.4 2009 f 13.9 (Annual Percentage Change in Excess of Inflation in the Canadian Econo 1985 1986 24.2 12.6 40.4 20.9 -37.3 -30.7 9.8 58.8 43.6 -25.8 12.4 1988 27.2 -45.7 15.0 11.0 16.3 14.6 -21.1 12.6 -22.4 16.2 13.8 -21.2 1990 16.3 27.2 17.1 17.2 16.4 16.6 4.1 10.9 -7.3 10.1 1992 0.9 -6.1 215.6 3.5 8.4 6.8 19.8 22.1 2.4 3.8 0.6 -0.3 1994 0.7 9.8 -3.5 1.4 7.0 5.5 1.6 1995 7.0 5.5 6.7 16.0 13.5 -10.2 -8.1 1996 -2.6 -6.4 -2.8 1.6 0.5 -23.0 -26.5 -24.7 1998 21.7 15.2 21.9 22.9 15.3 16.9 15.7 15.3 23.9 1999 12.5 11.8 9.7 12.3 -0.1 3.2 3.5 -2.0 0.8 12.5 62.1 17.8 -9. 2000 22.1 2.9 7.3 -8.0 -10.2 8.5 6.1 2002 -10.6 5.9 6.4 -0.6 -12.7 -7.3 6.0 4.7 5.2 3.5 2003 3.2 -4.7 11.6 9.4 -1.1 -3.3 -2.1 -5.8 -2.0 -3.6 -2. 2005 9.2 -3.3 -4.1 4.4 7.5 6.1 6.6 -8.2 1.9 -9.5 -8.8 2.1 6.1 2.3 2006 7.0 2007 3.2 -4.4 3.6 2.4 -3.2 -1.4 2.3 -1.3 -3.3 3.9 15.8 2009 f 17.0 6.5 8.1 8.1 10.7 4.0 3.8

74 CIHI 2010

Source: CIHI, 2009.

		-	e on Drugs per Capit tal Health Expenditu		-		lic, Private and cont'd)	P.E.I. — per Cap
-	Public	All Drugs Private	Total	Public H	lealth Expenditure Private	Total	GDP Implicit Price Index—Canada	
_			(\$ per Capita)				(1997 = 100)	
	19.42	236.58	256.00	1,004.74	414.66	1,419.40	73.6	
	24.02 35.62	194.39 188.13	218.41 223.76	1,074.57 1,164.10	386.13 414.24	1,460.70 1,578.34	75.6 79.2	
	41.15	186.53	227.67	1,260.71	437.42	1,698.12	82.8	
	46.48	191.20	237.68	1,340.84	499.18	1,840.01	86.6	
	55.88	218.96	274.84	1,426.83	535.91	1,962.74	89.2	
	63.09	235.04	298.14	1,563.81	589.69	2,153.50	91.6	
	66.12	269.50	335.62	1,599.57	655.88	2,255.45	92.8 94.1	
	65.27 66.91	297.22 312.94	362.49 379.85	1,651.43 1,626.43	707.51 724.66	2,358.94 2,351.09	95.2	
	73.06 72.20	336.60 314.70	409.66 386.90	1,657.77 1,716.36	778.40 781.25	2,436.16 2,497.61	97.4 99.0	
	77.64	314.34	391.98	1,689.18	811.16	2,500.34	100.0	
	89.52	368.63	458.15	1,807.78	853.14	2,660.92	99.6	
	102.17	375.95	478.12	1,900.33	878.29	2,778.63	101.4	
	124.58	386.93	511.51	2,037.89	905.97	2,943.87	105.5	
	140.10	446.95	587.05	2,407.05	1,078.93	3,485.98	106.9	
	148.21	419.55	567.76	2,678.41	1,020.75	3,699.16	108.1	
	160.24 169.92	460.98 488.91	621.22 658.83	2,775.96 2,738.72	1,174.34 1,176.96	3,950.30 3,915.68	111.2 114.1	
	187.71	511.94	699.64	3,001.41	1,181.22	4,182.63	117.4	
	201.52 213.05	552.52 558.59	754.03 771.64	3,159.72 3,390.67	1,361.90 1,384.59	4,521.62 4,775.26	120.8 124.8	
	232.05	595.33	827.37	3,735.39	1,488.92	5,224.31	130.6	
	264.39	626.00	890.39	4,203.06	1,565.02	5,768.08	128.2	
_			(Annu	al Percentage Chang	ge)			
	23.7	-17.8	-14.7	7.0	-6.9	2.9	2.8	
	48.3 15.5	-3.2 -0.9	2.4 1.7	8.3 8.3	7.3 5.6	8.1 7.6	4.7 4.5	
	13.0	2.5	4.4	6.4	14.1	8.4	4.6	
	20.2 12.9	14.5 7.3	15.6 8.5	6.4 9.6	7.4 10.0	6.7 9.7	3.0 2.8	
	4.8	14.7	12.6	2.3	11.2	4.7	1.3	
	-1.3	10.3	8.0	3.2	7.9	4.6	1.4	
	2.5	5.3	4.8	-1.5	2.4	-0.3	1.1	
	9.2	7.6	7.8	1.9	7.4	3.6	2.3	
	-1.2	-6.5	-5.6	3.5	0.4	2.5	1.7	
	7.5	-0.1	1.3	-1.6	3.8	0.1	1.0	
	15.3	17.3 2.0	16.9 4.4	7.0	5.2 2.9	6.4 4.4	-0.4 1.8	
	14.1			5.1				
	21.9	2.9	7.0	7.2	3.2	5.9	4.1	
	12.5 5.8	15.5 -6.1	14.8 -3.3	18.1 11.3	19.1 -5.4	18.4 6.1	1.4 1.0	
	8.1	9.9	9.4	3.6	15.0	6.8	2.9	
	6.0	6.1	6.1	-1.3	0.2	-0.9	2.6	
	10 E	4.7	6.2	0.6	0.4	6.0	3.0	
	10.5 7.4	4.7 7.9	6.2 7.8	9.6 5.3	0.4 15.3	6.8 8.1	2.9 2.9	
	5.7	1.1	2.3	7.3	1.7	5.6	3.3	
	8.9	6.6	7.2	10.2	7.5	9.4	4.7	
	13.9	5.2	7.6	12.5	5.1	10.4	-1.9	
-		(Annual Percent	age Change in Excess of Infla	ation in the Canadian	n Economy)			
	20.9	-20.6	 -17.5	4.1	 -9.7	0.1		
	43.6	-8.0	-2.3	3.6	2.5	3.3		
	11.0	-5.4	-2.8	3.8	1.1	3.1		
	8.4	-2.1	-0.2	1.8	9.6	3.8		
	17.2	11.5	12.6	3.4	4.3	3.6		
	10.1	4.6	5.7	6.8	7.3	7.0		
	3.5	13.4	11.3	1.0	10.0	3.5		
	-2.7 1.4	8.8 4.2	6.6 3.7	1.8 -2.6	6.4 1.3	3.1 -1.4		
	6.9	5.2	5.5	-0.4	5.1	1.3		
	-2.8 6.5	-8.2 -1.1	-7.2 0.3	1.9	-1.3 2.8	0.9		
	6.5 15.7	-1.1 17.7	0.3 17.3	-2.6 7.5	2.8 5.6	-0.9 6.9		
	12.3	0.2	2.5	3.3	1.1	2.6		
	17.8	-1.2	2.9	3.1	-1.0	1.8		
	17.8 11.1	-1.2 14.2	2.9 13.4	3.1 16.8	-1.0 17.7	1.8 17.1		
	4.7	-7.2	-4.3	10.2	-6.4	5.1		
	5.2	7.0	6.5	0.7	12.1	3.9		
	3.5	3.5	3.5	-3.9	-2.4	-3.5		
	7.5	1.8	3.3	6.7	-2.6	3.9		
	4.5	5.0	4.9	2.4	12.4	5.2		
	2.4	-2.2	-1.0	4.0	-1.7	2.3		
	4.3	1.9	2.6	5.5	2.9 7.0	4.8		
	15.8	7.0	9.5	14.4	7.0	12.3		

Table B N.S.—Total Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Nova Scotia, 1985 to 2009

					Prescribed D	rugs					-Prescribed D	
	Provincial	Federal	Publi	c I Security Funds	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Priva Over-	te (Out-of-Po Personal	cket) Total
	Trovincial	- Cuciai	WCB	Drug Insurance Funds	Public	maurera	Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Presc. Drugs
ear				(Premium Component)		(\$ Millions)				Drugs		
985	45.5	2.3	0.2		48.0			38.7	86.7			61.1
1986	53.1	2.4	0.2		55.7			59.6	115.3			69.2
1987	62.3	2.6	0.2		65.1			67.7	132.8			80.2
1988	72.2	3.4	0.3		76.0			74.8	150.8			78.9
1989	82.1	4.2	0.3		86.6			82.5	169.1			77.7
1990	83.0	5.0	0.3		88.3			96.0	184.2			79.3
1991	83.0	5.6	0.5		89.1			106.2	195.3	40.7	44.2	80.6
1992 1993	89.0 88.5	5.9 6.8	0.5 0.6		95.4 95.9			118.4 132.7	213.8 228.6	48.7 51.3	44.3 47.9	
1994	83.2	7.3	0.6		91.1			137.8	228.9	51.8	49.3	
1995	83.9	8.9	0.7		93.5			148.7	242.2	47.8	46.5	94.2
1996	83.3	8.4	0.7		92.5			159.4	251.8	53.8	50.0	
1997	86.8	9.8	0.7		97.3			170.5	267.9	49.2	47.4	
998	99.5	14.4	0.8		114.7			198.7	313.4	54.8	53.7	
1999	110.7	14.8	1.1		126.5			201.5	328.0	55.5	51.5	107.0
2000	117.3	18.8	1.4		137.4			227.3	364.7	55.3	50.1	105.4
2001	128.7	22.3	1.9		152.9			247.5	400.4	60.5	52.4	
2002	140.8	24.2	2.2		167.2			282.2	449.5	64.6	55.9	
2003 2004	156.2 170.0	25.9 26.4	2.5 3.0		184.6 199.4			299.5 324.5	484.1 523.9	68.7 72.1	58.1 60.0	126.9 132.1
2005	186.1	27.4	3.4		216.8			359.9	576.7	71.6	58.8	
2006 2007	231.8 252.3	34.7 30.4	4.8 5.6		271.3 288.3			396.8 423.5	668.1 711.8	74.1 81.3	61.0 64.7	
2007 2008 f	267.9	31.5	6.8		306.2			478.4	784.6	81.2	64.0	
2009 f	286.6	33.6	8.1		328.3			520.4	848.7	80.8	64.2	
	-					(Annual Percentage	Change)					
1985												
1986	16.7	3.8	16.4		16.1			54.0	33.0			13.2
1987 1988	17.2	8.3 32.7	4.2 48.7		16.8			13.6	15.1 13.5			16.0 -1.6
1989	16.0 13.7	21.9	-7.8		16.8 14.0			10.4 10.4	12.2			-1.6
1990 1991	1.0	20.1	6.4		1.9			16.3	8.9			2.1 1.7
1991	0.1 7.2	12.4 5.3	41.5 2.6		0.9 7.1			10.6 11.5	6.0 9.5			15.4
1993	-0.5	15.4	20.2		0.6			12.1	6.9	5.2	8.1	
1994	-6.0	6.6	6.1		-5.0			3.9	0.1	1.0	3.0	1.9
1995	0.8	21.6	15.7		2.6			7.9	5.8	-7.8	-5.7	-6.8
1996	-0.7	-5.0	5.2		-1.1			7.2	4.0	12.7	7.7	
1997	4.2	16.2	-1.0		5.3			7.0	6.4	-8.6	-5.4	
1998 1999	14.5 11.3	47.4 2.5	16.2 27.0		17.9 10.3			16.5 1.4	17.0 4.7	11.6 1.2	13.4 -4.1	
					10.3			1.4	4.7			
2000	5.9	27.1	28.6		8.6			12.8	11.2	-0.3	-2.7	
2001 2002	9.8 9.4	18.6 8.6	39.0 18.0		11.3 9.4			8.9 14.0	9.8 12.2	9.3 6.8	4.6 6.6	
2003	10.9	7.0	12.3		10.4			6.1	7.7	6.4	4.0	
2004	8.8	2.0	19.2		8.0			8.4	8.2	4.9	3.3	
2005	9.5	3.7	12.0		8.7			10.9	10.1	-0.7	-2.1	-1.3
2006	24.6	26.9	41.6		25.1			10.2	15.8	3.4	3.8	
2007	8.9	-12.5	17.6		6.3			6.7	6.5	9.8	6.0	
2008 f	6.1	3.7	21.3		6.2			13.0	10.2	-0.2	-1.0	
2009 f	7.0	6.6	19.7		7.2			8.8	8.2	-0.5	0.2	-0.2
	-				(Percent	tage Share of Total D	rug Expendit	ture)				
1985	30.8	1.5	0.1		32.5			26.2	58.7			41.3
1986 1987	28.8 29.2	1.3 1.2	0.1 0.1		30.2 30.5			32.3 31.8	62.5 62.3			37.5 37.7
988	31.5	1.5	0.1		33.1			32.5	65.6			34.4
989	33.3	1.7	0.1		35.1			33.4	68.5			31.5
1990	31.5	1.9	0.1		33.5			36.4	69.9			30.1
1991	30.1	2.0	0.2		32.3			38.5	70.8			29.2
1992	29.0	1.9	0.2		31.1			38.6	69.7	15.9	14.4	
1993	27.0	2.1	0.2		29.3			40.5	69.8	15.6	14.6	
1994	25.2	2.2	0.2		27.6			41.8	69.4	15.7	14.9	30.6
1995	24.9	2.6	0.2		27.8			44.2	72.0	14.2	13.8	
1996	23.4	2.4	0.2		26.0			44.8	70.8	15.1	14.1	
1997 1998	23.8	2.7	0.2		26.7			46.8	73.5	13.5	13.0	
1998 1999	23.6 25.4	3.4 3.4	0.2		27.2 29.1			47.1 46.3	74.3 75.4	13.0 12.8	12.7 11.8	
2000 2001	24.9 25.1	4.0 4.3	0.3 0.4		29.2 29.8			48.4 48.2	77.6 78.0	11.8 11.8	10.7 10.2	
2001	25.1	4.3	0.4		29.8			48.2	78.0 78.9	11.8	9.8	
2002	25.6	4.2	0.4		30.2			49.0	79.2	11.3	9.5	
2004	25.9	4.0	0.5		30.4			49.5	79.9	11.0	9.2	
	26.3	3.9	0.5		30.7			50.9	81.6	10.1	8.3	18.4
	28.9	4.3	0.6		33.8			49.4	83.2	9.2	7.6	
1005 1006			0.7		33.6			49.4	83.0	9.5	7.5	
006	29.4	3.5										
006 007 008 f	28.8	3.4	0.7		32.9			51.5	84.4	8.7	6.9	
006 007					32.9 33.0			51.5 52.4	84.4 85.4	8.7 8.1	6.9 6.5	

		Expenditure	0 , ,,			a Share of Public,	Private and	Table B N.S	J. 10
		All Drugs	i otal Health Ex	penaiture, Nov	Health Expenditure	to 2009 (cont'd)		in Public, Private a	nd
	Public	Private	Total	Public	Private	Total	Public	Private	Total
			(\$ Millio	ns)			(Perc	entage Share)	
	48.0	99.8	147.8	947.2	285.3	1,232.5	5.1	35.0	1
	55.7 65.1	128.8 147.9	184.5 213.0	1,023.2 1,165.5		1,376.9 1,560.6	5.4 5.6	36.4 37.4	1
	76.0	153.7	229.7	1,165.0	420.3	1,585.2	6.5	36.6	1
	86.6	160.2	246.8	1,281.5		1,751.8	6.8	34.1	1
	88.3 89.1	175.3 186.8	263.5 275.9	1,376.6 1,451.2		1,866.9 1,970.0	6.4 6.1	35.7 36.0	1
	95.4	211.4	306.8	1,477.0	554.5	2,031.6	6.5	38.1	1
	95.9 91.1	231.8 238.9	327.7 330.0	1,445.5 1,413.1		2,025.0 2,023.4	6.6 6.4	40.0 39.1	1
	93.5	242.9	336.4	1,440.0		2,061.3	6.5	39.1	1
	92.5	263.2	355.7	1,438.2	650.8	2,089.0	6.4	40.4	1
	97.3 114.7	267.1 307.2	364.4 421.9	1,669.3 1,786.8		2,363.8 2,544.2	5.8 6.4	38.5 40.6	1
	126.5	308.5	435.0	1,899.7		2,665.3	6.7	40.3	1
	137.4	332.7	470.1	1,968.4		2,824.3	7.0	38.9	1
	152.9 167.2	360.4 402.7	513.3 569.9	2,082.7 2,269.5		3,004.5 3.304.8	7.3 7.4	39.1 38.9	1
	184.6	426.4	611.0	2,491.4	1,106.4	3,597.7	7.4	38.5	1
	199.4	456.7	656.1	2,594.2	1,131.0	3,725.2	7.7	40.4	1
	216.8	490.3	707.1 803.2	2,830.5		4,033.0	7.7 8.5	40.8	1
	271.3 288.3	531.8 569.5	803.2 857.8	3,178.1 3,407.6		4,507.2 4,816.0	8.5 8.5	40.0 40.4	1
f	306.2	623.6	929.8	3,598.8		5,164.5	8.5	39.8	1
f 	328.3	665.4	993.7 (Annual Percenta	3,811.6 age Change)	1,678.8	5,490.4	8.6	39.6	,
	 16.1	29.1	24.9	 8.0	24.0	 11.7			
	16.8	14.9	15.4	13.9		13.3			
	16.8	3.9	7.8	-0.1	6.4	1.6			
	14.0	4.2	7.5	10.0		10.5			
	1.9 0.9	9.4 6.6	6.8 4.7	7.4 5.4		6.6 5.5			
	7.1	13.2	11.2	1.8	6.9	3.1			
	0.6 -5.0	9.6 3.1	6.8 0.7	-2.1 -2.2	4.5 5.3	-0.3 -0.1			
	2.6	1.7	2.0	1.9		1.9			
	-1.1	8.3	5.7	-0.1	4.7	1.3			
	5.3 17.9	1.5 15.0	2.4 15.8	16.1 7.0		13.2 7.6			
	10.3	0.4	3.1	6.3		4.8			
	8.6	7.9	8.1	3.6		6.0			
	11.3 9.4	8.3 11.7	9.2 11.0	5.8 9.0		6.4 10.0			
	10.4	5.9	7.2	9.8	6.9	8.9			
	8.0	7.1	7.4	4.1	2.2	3.5			
	8.7 25.1	7.4 8.5	7.8 13.6	9.1 12.3	6.3 10.5	8.3 11.8			
	6.3	7.1	6.8	7.2		6.9			
f f	6.2 7.2	9.5 6.7	8.4 6.9	5.6 5.9		7.2 6.3			
		ge Share of Total Dr		5.5	7.2	0.3			
	32.5	67.5	100.0						
	30.2 30.5	69.8	100.0 100.0						
	30.5 33.1	69.5 66.9	100.0						
	35.1	64.9	100.0						
	33.5	66.5	100.0						
	32.3 31.1	67.7 68.9	100.0 100.0						
	29.3	70.7	100.0						
	27.6	72.4	100.0						
	27.8 26.0	72.2 74.0	100.0 100.0						
	26.7	73.3	100.0						
	27.2 29.1	72.8 70.9	100.0 100.0						
	29.2	70.8	100.0						
	29.8	70.2	100.0						
	29.3 30.2	70.7 69.8	100.0 100.0						
	30.4	69.6	100.0						
	30.7	69.3	100.0						
	33.8 33.6	66.2 66.4	100.0 100.0						
		66.4							
f f	32.9 33.0	67.1 67.0	100.0 100.0						

N.S.

Table B N.S.—per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Nova Scotia, 1985 to 2009

					Prescribed Dru	ugs					-Prescribed D	
	Provincial	Federal	Publ	ic I Security Funds	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Priva Over-	te (Out-of-Po	cket) Total
	FIOVIIICIAI	rederai _	WCB	Drug Insurance Funds	Public	msurers	Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Presc. Drugs
.,				(Premium Component)					Diaga	Drugs	опринез	Diago
Year						(\$ per Capita						
1985 1986	51.41 59.72	2.59 2.67	0.21 0.24		54.21 62.63			43.74 67.05	97.94 129.68			69.01 77.77
1987	69.69	2.88	0.24		72.82			75.80	148.61			89.77
1988	80.51	3.81	0.37		84.68			83.31	167.99			87.95
1989	90.89	4.61	0.34		95.83			91.30	187.13			85.92
1990	91.20	5.50	0.36		97.05			105.50	202.55			87.16
1991 1992	90.73 96.80	6.14 6.44	0.50 0.51		97.37			116.04 128.74	213.41 232.49	 53.01	48.13	88.07 101.14
1992	95.81	7.39	0.61		103.75 103.82			143.56	247.38	55.48	51.79	
1994	89.76	7.86	0.65		98.27			148.69	246.96	55.85	53.16	
1995	90.40	9.54	0.75		100.69			160.23	260.92	51.45	50.07	101.52
1996	89.46	9.03	0.78		99.28			171.12	270.39	57.77	53.72	
1997	93.13	10.48	0.78		104.39			182.88	287.28	52.72	50.79	
1998 1999	106.74 118.53	15.46 15.82	0.90 1.14		123.11 135.49			213.19 215.75	336.30 351.24	58.85 59.42	57.63 55.12	
2000 2001	125.55 138.03	20.11 23.89	1.47 2.05		147.13 163.96			243.42 265.49	390.56 429.45	59.24 64.85	53.64 56.20	
2002	150.66	25.89	2.41		178.95			302.01	480.96	69.13	59.79	
2003	166.78	27.63	2.70		197.11			319.83	516.95	73.40	62.08	
2004	181.22	28.16	3.21		212.59			346.01	558.60	76.87	64.01	140.88
2005	198.78	29.26	3.60		231.64			384.51	616.15	76.53	62.83	
2006 2007	247.14 269.59	37.04 32.46	5.09 6.00		289.27 308.05			422.99 452.39	712.26 760.44	78.95 86.85	65.06 69.13	
2008 f	285.47	33.57	7.26		326.29			509.88	836.17	86.51	68.25	
2009 f	304.86	35.71	8.67		349.23			553.65	902.89	85.93	68.29	154.22
						(Annual Percentage	Change)					
1985												
1986 1987	16.2 16.7	3.3 7.8	15.8 3.7		15.5 16.3			53.3 13.0	32.4 14.6			12.7 15.4
1988	15.5	32.1	48.1		16.3			9.9	13.0			-2.0
1989	12.9	21.0	-8.5		13.2			9.6	11.4			-2.3
1990	0.3	19.3	5.8		1.3			15.6	8.2			1.4
1991	-0.5	11.7	40.7		0.3			10.0	5.4			1.0
1992	6.7	4.8	2.1		6.5			10.9	8.9			14.8
1993 1994	-1.0 -6.3	14.8 6.3	19.7 5.7		0.1 -5.3			11.5 3.6	6.4 -0.2	4.7 0.7	7.6 2.6	
1995	0.7	21.4	15.6		2.5			7.8	5.7	-7.9	-5.8	
1996	-1.0	-5.3	4.8		-1.4			6.8	3.6	12.3	7.3	
1997	4.1	16.0	-1.1		5.2			6.9	6.2	-8.7	-5.5	-7.2
1998	14.6	47.5	16.3		17.9			16.6	17.1	11.6	13.5	
1999	11.0	2.3	26.7		10.1			1.2	4.4	1.0	-4.3	
2000	5.9	27.1	28.5		8.6			12.8	11.2	-0.3	-2.7	
2001 2002	9.9 9.1	18.8 8.4	39.3 17.7		11.4 9.1			9.1 13.8	10.0 12.0	9.5 6.6	4.8 6.4	
2003	10.7	6.8	12.0		10.2			5.9	7.5	6.2	3.8	
2004	8.7	1.9	19.0		7.9			8.2	8.1	4.7	3.1	4.0
2005	9.7	3.9	12.2		9.0			11.1	10.3	-0.5	-1.8	-1.1
2006	24.3	26.6	41.2		24.9			10.0	15.6	3.2	3.5	
2007 2008 f	9.1 5.9	-12.4 3.4	17.8 21.0		6.5 5.9			7.0 12.7	6.8 10.0	10.0 -0.4	6.3 -1.3	
2009 f	6.8	6.4	19.5		7.0			8.6	8.0	-0.7	0.1	
				(Ann	ual Percentage Cha	ange in Excess of Inf	lation in the	Canadian Econo	omy)			
1985												
1986 1987	13.4 11.9	0.5 3.1	13.0 -1.0		12.7 11.5			50.5 8.3	29.6 9.9			9.9 10.7
1988	11.0	27.6	43.6		11.8			5.4	8.5			-6.5
1989	8.3	16.4	-13.1		8.6			5.0	6.8			-6.9
1990	-2.7	16.3	2.7		-1.8			12.5	5.2			-1.6
1991	-3.3	9.0	37.9		-2.4			7.2	2.6			-1.7
1992 1993	5.4 -2.5	3.6 13.4	0.9 18.2		5.3 -1.4			9.7 10.1	7.7 5.0	3.2	6.2	13.6 4.6
1994	-7.4	5.2	4.6		-6.4			2.5	-1.3	-0.4	1.5	
1995	-1.6	19.1	13.3		0.1			5.4	3.3	-10.2	-8.2	-9.2
1996	-2.7	-7.0	3.1		-3.1			5.1	2.0	10.6	5.6	8.2
1997	3.1	15.1	-2.1		4.2			5.9	5.3	-9.7 13.1	-6.5	
1998 1999	15.0 9.2	48.0 0.5	16.7 24.9		18.4 8.2			17.0 -0.6	17.5 2.6	12.1 -0.8	13.9 -6.2	
2000	1.8	23.0	24.4		4.5			8.7	7.1	-4.4	-6.8	
2001	8.6	17.4	37.9		10.1			7.7	8.6	8.1	3.4	5.9
2002	8.1	7.3	16.7		8.1			12.7	11.0	5.6	5.3	
2003 2004	7.8 6.1	3.9 -0.7	9.1 16.4		7.3 5.3			3.0 5.6	4.6 5.5	3.3 2.1	0.9 0.5	
2005	6.8	1.0	9.3		6.0			8.2	7.4	-3.4	-4.8	
2006	21.4	23.7	38.4		22.0			7.1	12.7	0.3	-4.8 0.7	
2007	5.8	-15.7	14.5		3.2			3.6	3.4	6.7	2.9	5.0
2008 f	1.2	-1.2	16.4		1.3			8.1	5.3	-5.0	-5.9	
2009 f f: forecast.	8.7	8.2	21.4		8.9			10.5	9.9	1.2	1.9	1.5
	ality precludes repo	rting provincial-	level insuranc	e data.							Source	ce: CIHI, 2009.

79 **CIHI 2010**

8.9

8.0

Source: CIHI, 2009.

8.6

2009 f

Table B N.B.—Total

N.B.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, New Brunswick, 1985 to 2009

		Publ	t_	Prescribed Dr	ugs	Private				-Prescribed Di ite (Out-of-Po	
Provincial	Federal		l Security Funds Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed	Over- the-	Personal Health	Total Non-Presc.
			Funds (Premium Component)					Drugs	Counter Drugs	Supplies	Drugs
-					(\$ Millions)						
33.9 39.6		0.1 0.2		35.7 41.5			38.8 45.6	74.4 87.1			48.4 54.1
46.2		0.2		48.4			56.1	104.5			63.
48.5		0.2		51.4			61.4	112.7			61.6
52.7	3.1	0.3		56.0			67.1	123.1			59.
58.3	3.7	0.4		62.4			80.3	142.7			61.
62.4	4.1	0.4		67.0			88.8	155.8			66.
60.0 56.8	4.2 5.2	0.5 0.6		64.8 62.5			102.2 111.3	167.0 173.8	35.6 37.0	32.3 34.5	
56.0		0.6		62.3			118.4	180.7	37.3	35.5	
58.3	6.4	0.6		65.4			127.8	193.1	34.4	33.5	
54.8	6.4	0.6		61.9			127.8	188.6	32.9	30.6	
56.1	7.1	0.7		64.0			143.9	207.9	44.2	42.6	
62.1	8.6	0.9		71.6			149.7	221.3	42.5	41.6	
69.0	10.8	1.1		80.8			167.0	247.8	47.6	44.1	91.
78.4	14.2	1.4		94.0			187.7	281.6	47.6	43.1	90.
90.1	17.2	1.7		109.0			218.9	327.9	46.5	40.3	
101.3 112.3	18.8 21.0	2.1 2.6		122.2 135.9			241.9 271.4	364.1 407.2	49.7 50.6	43.0 42.8	
124.4	21.6	3.3		149.3			271.4	425.4	52.2	43.5	
135.8 146.4	22.3 22.7	3.7 4.0		161.9 173.0			327.0 343.7	488.9 516.7	50.0 52.9	41.1 43.6	91. 96.
152.7	23.3	4.0		180.0			349.6	529.6	57.0	45.4	102.
161.4	24.1	4.2		189.7			386.6	576.4	57.6	45.4	
172.0	25.1	4.5		201.6			398.9	600.5	57.8	45.8	103.
					(Annual Percentage	Change)					
16.9	7.6	14.5	***	16.4			17.6	 17.1			13.
16.8	9.3	15.9		16.4			23.0	19.9			16.
5.0	36.1	18.5		6.3			9.3	7.9			-3.
8.6	17.3	15.6		9.1			9.3	9.2			-3.
10.7	18.6	56.5		11.4			19.7	15.9			2.:
7.0	12.5	11.2		7.4			10.6	9.2			8.3
-3.9	2.0	24.7		-3.4			15.1	7.1			2.8
-5.4 -1.4	22.5 10.6	3.7 5.4		-3.5 -0.4			8.9 6.4	4.1 4.0	3.9 0.9	6.8 2.9	
4.2		8.4 13.1		4.9 -5.2			7.9 -0.8	6.9 -2.3	-7.8 -4.2	-5.7 -8.5	-6.8 -6.3
-6.0 2.5	0.1 11.0	0.1		3.3			13.6	10.2	34.1	38.9	
10.7	21.1	19.3		12.0			4.0	6.4	-3.7	-2.1	-3.0
11.0	25.2	23.4		12.9			11.6	12.0	11.8	6.0	8.9
13.6	31.9	28.3		16.2			12.4	13.6	0.1	-2.3	-1.0
14.9	20.8	25.8		16.0			16.6	16.4	-2.3	-6.5	
12.5	9.3	19.0		12.1			10.5	11.0	6.7	6.5	
10.8	11.7	25.8		11.2			12.2	11.8	2.0	-0.3	
10.8	3.1	25.2		9.9			1.8	4.5	3.1	1.5	
9.2	3.3	13.9		8.4			18.4	14.9	-4.2	-5.5	
7.8 4.3	1.7 2.4	6.6 1.5		6.9 4.0			5.1 1.7	5.7 2.5	5.7 7.8	6.1 4.1	5.9 6.2
4.3 5.7	3.4	5.7		5.4			10.6	8.8	1.0	0.1	0.6
6.6	4.1	6.4		6.2			3.2	4.2	0.4	0.9	
				(Percent	age Share of Total D	rug Expendit	ture)				
27.6	1.3	0.1		29.0			31.6	60.6			39.4
27.9	1.3	0.1		29.2			32.1	61.4			38.0
27.5 27.8	1.2 1.5	0.1 0.1		28.8 29.5			33.4 35.2	62.2 64.7			37.8 35.3
28.8	1.7	0.1		30.7			36.7	67.4			32.6
28.6	1.8	0.2		30.6			39.4	70.1			29.9
28.1	1.9	0.2		30.2			40.0	70.1			29.8
25.5	1.8	0.2		27.6			43.5	71.1	15.2	13.8	
23.1	2.1	0.2		25.5			45.4	70.9	15.1	14.1	29.
22.1	2.3	0.2		24.6			46.7	71.3	14.7	14.0	28.7
22.3	2.5	0.2		25.0			49.0	74.0	13.2	12.8	
21.7	2.5	0.3		24.6			50.2	74.8	13.1	12.1	25.2
19.1 20.3	2.4 2.8	0.2		21.7 23.4			48.9 49.0	70.6 72.4	15.0 13.9	14.4 13.6	29.4 27.6
20.3	3.2	0.3		23.8			49.2	73.0	14.0	13.0	
21.0	3.8	0.4		25.2			50.4	75.6	12.8	11.6	
21.0	3.8 4.1	0.4		26.3			50.4 52.8	75.6 79.1	11.2	9.7	20.
22.2	4.1	0.5		26.7			53.0	79.7	10.9	9.4	
22.4	4.2	0.5		27.1			54.2	81.3	10.1	8.6	18.
23.9	4.1	0.6		28.6			53.0	81.6	10.0	8.3	18.
23.4	3.9	0.6		27.9			56.4	84.3	8.6	7.1	15.
23.9	3.7	0.6		28.2			56.0	84.3	8.6	7.1	15.7
04.0	3.7	0.6		28.5			55.3	83.8	9.0	7.2	
24.2		0.6		27.9			56.9	84.8	8.5	6.7	15.2
23.8	3.5						E0 7	00.0	0.0	0.5	4.4.5
	3.6	0.6		28.6			56.7	85.3	8.2	6.5	14.

		Expenditure	•	•		a Share of Public, F to 2009 (cont'd)	Private and	Table B N	.o.—10
			TOTAL DESITE EXPE			O TO ZOOS (CONT Q)		in Public, Private	and
_	Public	All Drugs Private	Total	Public	Private	Total	Public	alth Expenditures Private	Total
			(\$ Million	ns)			(Perc)	entage Share)	
_	35.7	87.2	122.9	752.2	274.1	1,026.2	4.7	31.8	1
	41.5	100.4	142.0	805.3	285.9	1,091.1	5.2	35.1	1
	48.4 51.4	119.7 122.9	168.1 174.3	888.9 961.0	305.1 330.5	1,194.0 1,291.5	5.4 5.3	39.2 37.2	
	56.0	126.7	182.8	1,047.7	352.4	1,400.1	5.3	36.0	
	62.4	141.2	203.7	1,136.1	397.4	1,533.5	5.5	35.5	
	67.0	154.9	221.9	1,186.9	442.4	1,629.3	5.6	35.0	
	64.8 62.5	170.1 182.8	234.9 245.3	1,233.1 1,236.1	466.7 503.0	1,699.8 1,739.1	5.3 5.1	36.4 36.3	1
	62.3	191.2	253.5	1,272.2	520.8	1,793.0	4.9	36.7	1
	65.4	195.6	261.0	1,323.0	496.4	1,819.3	4.9	39.4	1
	61.9	190.3	252.2	1,325.3	488.4	1,813.7	4.7	39.0	
	64.0 71.6	230.7 233.8	294.6 305.5	1,305.7 1,370.6	551.1 553.6	1,856.8 1,924.2	4.9 5.2	41.9 42.2	1
	80.8	258.7	339.5	1,469.5	607.0	2,076.5	5.5	42.6	1
	94.0	278.4	372.3	1,580.0	638.6	2,218.6	5.9	43.6	1
	109.0	305.8	414.7	1,740.0	727.8	2,467.8	6.3	42.0	1
	122.2	334.6 364.8	456.7 500.7	1,833.2	786.5 840.9	2,619.7	6.7	42.5	1
	135.9 149.3	364.8 371.8	500.7 521.1	1,953.3 2,120.5	840.9 864.5	2,794.2 2,985.0	7.0 7.0	43.4 43.0	
	161.9	418.1	579.9	2,316.5	984.1	3,300.6	7.0	42.5	1
	173.0	440.1	613.2	2,510.5	1,055.1	3,588.1	6.8	41.7	1
	180.0	452.0	631.9	2,655.2	1,087.2	3,742.4	6.8	41.6	1
	189.7 201.6	489.7 502.6	679.4 704.2	2,805.0 2,885.5	1,177.8 1,233.6	3,982.7 4,119.1	6.8 7.0	41.6 40.7	1
	201.0	502.5	(Annual Percenta		1,200.0	1,110.1	7.0	10.7	

	16.4	15.2	15.6	7.1	4.3	6.3			
	16.4 6.3	19.2 2.7	18.4 3.7	10.4 8.1	6.7 8.3	9.4 8.2			
	9.1	3.1	4.8	9.0	6.6	8.4			
	11.4	11.5	11.4	8.4	12.8	9.5			
	7.4	9.6	9.0	4.5	11.3	6.2			
	-3.4	9.8	5.8	3.9	5.5	4.3			
	-3.5 -0.4	7.4 4.6	4.4 3.3	0.2 2.9	7.8 3.5	2.3 3.1			
	4.9	2.3	3.0	4.0	-4.7	1.5			
	-5.2 3.3	-2.7 21.2	-3.3 16.8	0.2 -1.5	-1.6 12.8	-0.3 2.4			
	12.0	1.4	3.7	5.0	0.5	3.6			
	12.9	10.6	11.1	7.2	9.6	7.9			
	16.2	7.6	9.7	7.5	5.2	6.8			
	16.0 12.1	9.8 9.4	11.4 10.1	10.1 5.4	14.0 8.1	11.2 6.2			
	11.2	9.1	9.6	6.6	6.9	6.7			
	9.9	1.9	4.1	8.6	2.8	6.8			
	8.4	12.4	11.3	9.2	13.8	10.6			
	6.9	5.3	5.7	9.3	7.2	8.7			
	4.0 5.4	2.7 8.3	3.1 7.5	4.8 5.6	3.0 8.3	4.3 6.4			
	6.2	2.6	3.6	2.9	4.7	3.4			
_	(Percenta	ge Share of Total D	rug Expenditure)	_					
	29.0	71.0	100.0						
	29.2	70.8	100.0						
	28.8 29.5	71.2	100.0						
	29.5 30.7	70.5 69.3	100.0 100.0						
	30.6	69.4	100.0						
	30.2	69.8	100.0						
	27.6	72.4	100.0						
	25.5 24.6	74.5	100.0 100.0						
		75.4							
	25.0 24.6	75.0 75.4	100.0 100.0						
	21.7	78.3	100.0						
	23.4	76.6	100.0						
	23.8	76.2	100.0						
	25.2	74.8	100.0						
	26.3 26.7	73.7	100.0						
	26.7 27.1	73.3 72.9	100.0 100.0						
	28.6	71.4	100.0						
	27.9	72.1	100.0						
	28.2	71.8	100.0						
	28.5 27.9	71.5 72.1	100.0 100.0						
	28.6	71.4	100.0						

Table B N.B.—per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, New Brunswick, 1985 to 2009

					Prescribed D	rugs					n-Prescribed I	
	Provincial	Federal	Public Social	Security Funds	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Over-	rate (Out-of-Personal	Total
	Trovincial		WCB	Drug Insurance	Public	modroro	Pocket	Private	Prescribed	the-	Health	Non-Presc.
				Funds (Premium Component)					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ per Capita	a)					
1985 1986	46.80 54.59	2.29 2.46	0.19 0.22		49.28 57.26			53.60 62.92	102.88 120.18			66.89 75.59
1987	63.50	2.40	0.22		66.43			77.12	143.55			87.3
1988	66.43	3.63	0.30		70.36			84.01	154.37			84.30
1989	71.66	4.23	0.34		76.23			91.22	167.45			81.1:
1990	78.82	4.99	0.53		84.34			108.44	192.78			82.40
1991 1992	83.75 80.19	5.57 5.66	0.59 0.73		89.90 86.57			119.11 136.60	209.01 223.17	47.57	7 43.20	88.63 90.7
1993	75.83	6.92	0.75		83.50			148.60	232.11	49.37		
1994	74.59	7.64	0.79		83.03			157.80	240.84	49.72	2 47.3	97.0
1995	77.65	8.52	0.86		87.02			170.11	257.14	45.80		
1996 1997	72.83 74.59	8.51 9.45	0.97 0.97		82.31 85.01			168.45 191.27	250.76 276.28	43.79 58.69		
1998	82.80	11.47	1.16		95.43			199.42	294.85	56.66		
1999	91.89	14.36	1.43		107.68			222.50	330.18	63.36		
2000	104.41	18.94	1.84		125.19			250.06	375.25	63.43	57.4	120.8
2001	120.09	22.90	2.31		145.31			291.92	437.23	62.06		
2002 2003	135.05 149.49	25.01 27.91	2.75 3.46		162.81 180.86			322.44 361.25	485.25 542.11	66.19 67.41		
2004	165.45	28.74	4.33		198.52			367.17	565.69	69.43		
2005	180.77	29.73	4.93		215.43			435.23	650.66	66.58	54.66	3 121.24
2006	196.29	30.47	5.30		232.05			460.87	692.93	70.92	58.44	129.3
2007 2008 f	204.85	31.21	5.38		241.44			469.02	710.46	76.49 77.08		
2008 f	216.03 229.96	32.20 33.50	5.67 6.03		253.90 269.48			517.38 533.28	771.28 802.76	77.29		
						(Annual Percentage	Change)					
1985												
1986	16.6	7.4	14.3		16.2			17.4	16.8			13.0
1987 1988	16.3	8.9	15.5		16.0			22.6	19.4			15.
1989	4.6 7.9	35.6 16.6	18.1 14.8		5.9 8.3			8.9 8.6	7.5 8.5			-3.! -3.
1990	10.0	17.8	55.5		10.6			18.9	15.1			1.0
1991	6.3	11.6	10.4		6.6			9.8	8.4			7.0
1992	-4.3	1.6	24.3		-3.7			14.7	6.8			2.4
1993 1994	-5.4 -1.6	22.4 10.4	3.6 5.2		-3.5 -0.6			8.8 6.2	4.0 3.8	3.8 0.7		
1995	4.1	11.5	8.3		4.8			7.8	6.8	-7.9		
1996	-6.2	-0.1	12.9		-5.4			-1.0	-2.5	-4.4		
1997	2.4	11.0	0.1		3.3			13.5	10.2	34.0		
1998 1999	11.0 11.0	21.4 25.2	19.6 23.4		12.3 12.8			4.3 11.6	6.7 12.0	-3.5 11.8		
2000 2001	13.6 15.0	31.9 20.9	28.3 25.9		16.3 16.1			12.4 16.7	13.6 16.5	0.1 -2.2		
2002	12.5	9.2	18.9		12.0			10.5	11.0	6.7		
2003	10.7	11.6	25.7		11.1			12.0	11.7	1.8		
2004	10.7	3.0	25.0		9.8			1.6	4.4	3.0) 1.4	1 2.3
2005	9.3	3.4	14.0		8.5			18.5	15.0	-4.1		
2006 2007	8.6 4.4	2.5 2.4	7.4 1.6		7.7 4.0			5.9 1.8	6.5 2.5	6.5 7.5		
2008 f	5.5	3.2	5.4		5.2			10.3	8.6	0.8		
2009 f	6.4	4.0	6.3		6.1			3.1	4.1	0.3	0.7	7 0.!
						ange in Excess of In						
1985 1986	13.8	4.6	 11.5		13.4			14.6	14.0			10.2
1987	11.6	4.2	10.7		11.3			17.8	14.7			10.8
1988	0.1	31.1	13.6		1.4			4.4	3.0			-8.0
1989	3.3	12.0	10.3		3.8			4.0	3.9			-8.3
1990 1991	7.0 3.5	14.8 8.9	52.5 7.6		7.6 3.8			15.8 7.1	12.1 5.7			-1.! 4.8
1992	-5.5	0.3	23.0		-5.0			13.4	5.5			1.5
1993	-6.9	21.0	2.2		-5.0			7.3	2.6	2.3		
1994	-2.7	9.3	4.1		-1.7			5.1	2.7	-0.4		
1995	1.8	9.1	6.0		2.5			5.5	4.4	-10.2		
1996 1997	-7.9 1.4	-1.8 10.0	11.2 -0.9		-7.1 2.3			-2.7 12.6	-4.2 9.2	-6.1 33.1		
1998	11.4	21.8	20.1		12.7			4.7	7.2	-3.0	-1.5	-2.3
1999	9.2	23.4	21.5		11.0			9.8	10.2	10.0) 4.	7.
2000	9.5	27.8	24.2		12.2			8.3	9.5	-4.0		
2001 2002	13.7 11.4	19.6 8.2	24.6 17.9		14.7 11.0			15.4 9.4	15.2 9.9	-3.5 5.6		
2003	7.8	8.7	22.8		8.2			9.4	8.8	-1.0		
2004	8.1	0.4	22.4		7.2			-0.9	1.8	0.4	-1.3	2 -0.3
2005	6.3	0.5	11.1		5.6			15.6	12.1	-7.0		
2006	5.7 1.0	-0.4 -0.9	4.5 -1.8		4.8 0.7			3.0 -1.6	3.6 -0.8	3.6 4.5		
2007	1.0	-0.9			0.7			-1.6 5.7	-0.8 3.9	4.t -3.9		
2007 2008 f	0.8	-1.5	0.8						3.9	5.5	-4.8	-4
	0.8 8.3	-1.5 5.9	8.1		8.0			5.0	6.0	2.2		

N.B.

		•	e on Drugs per Capi Total Health Expend		-		ic, Private and t'd)	e B N.B.—per Capita
		All Drugs			Health Expenditure		GDP Implicit Price Index—Canada	
	Public	Private	Total	Public	Private	Total		
Year			(\$ per Capita))			(1997 = 100)	
1985	49.28	120.48	169.76	1,039.37	378.68	1,418.05	73.6	
1986	57.26	138.51	195.77	1,110.46		1,504.71	75.6	
1987 1988	66.43 70.36	164.45 168.31	230.88 238.67	1,221.26 1,315.80		1,640.40 1,768.26	79.2 82.8	
1989	76.23	172.34	248.57	1,425.04		1,904.32	86.6	
1990	84.34	190.84	275.18	1,535.00	536.96	2,071.96	89.2	
1991	89.90	207.73	297.63	1,592.01		2,185.39	91.6	
1992 1993	86.57 83.50	227.37 244.07	313.94 327.57	1,648.30 1,650.79		2,272.21 2,322.46	92.8 94.1	
1994	83.03	254.85	337.88	1,695.79		2,389.97	95.2	
1995	87.02	260.48	347.50	1,761.67	660.95	2,422.62	97.4	
1996 1997	82.31 85.01	252.96 306.51	335.27 391.52	1,761.66 1,735.08		2,410.86 2,467.36	99.0 100.0	
1998	95.43	311.55	406.98	1,826.14		2,563.77	99.6	
1999	107.68	344.63	452.31	1,957.71		2,766.37	101.4	
2000	125.19	370.93	496.12	2,105.17		2,956.07	105.5	
2001 2002	145.31 162.81	407.76 445.88	553.07 608.69	2,320.35 2,443.17		3,290.91 3,491.37	106.9 108.1	
2003	180.86	485.67	666.53	2,600.15		3,719.57	111.2	
2004	198.52	494.42	692.94	2,819.65		3,969.24	114.1	
2005	215.43	556.47	771.90	3,083.24		4,393.05	117.4	
2006 2007	232.05 241.44	590.23 606.39	822.28 847.83	3,397.01 3,562.28		4,811.95 5,020.92	120.8 124.8	
2008 f	253.90	655.27	909.18	3,753.45		5,329.49	130.6	
2009 f	269.48	671.84	941.32	3,857.10		5,506.08	128.2	
1985			(Annu	aar Percentage Cn	ange)			
1986 1987	16.2 16.0	15.0 18.7	15.3 17.9	6.8 10.0		6.1 9.0	2.8 4.7	
1988	5.9	2.4	3.4	7.7		7.8	4.5	
1989	8.3	2.4	4.1	8.3	5.9	7.7	4.6	
1990	10.6	10.7	10.7	7.7		8.8	3.0	
1991 1992	6.6 -3.7	8.9 9.5	8.2 5.5	3.7 3.5		5.5 4.0	2.8 1.3	
1993	-3.5	7.3	4.3	0.2	7.7	2.2	1.4	
1994	-0.6	4.4	3.1	2.7	3.4	2.9	1.1	
1995 1996	4.8 -5.4	2.2 -2.9	2.8	3.9 0.0		1.4	2.3	
1997	3.3	21.2	-3.5 16.8	-1.5		-0.5 2.3	1.7 1.0	
1998	12.3	1.6	3.9	5.2		3.9	-0.4	
1999	12.8	10.6	11.1	7.2		7.9	1.8	
2000 2001	16.3 16.1	7.6 9.9	9.7 11.5	7.5 10.2		6.9 11.3	4.1 1.4	
2002	12.0	9.3	10.1	5.3		6.1	1.0	
2003	11.1	8.9	9.5	6.4		6.5	2.9	
2004	9.8	1.8	4.0	8.4		6.7	2.6	
2005 2006	8.5 7.7	12.5 6.1	11.4 6.5	9.3 10.2		10.7 9.5	2.9 2.9	
2007	4.0	2.7	3.1	4.9		4.3	3.3	
2008 f	5.2	8.1	7.2	5.4		6.1	4.7	
2009 f	6.1	2.5 (Annual Percent	3.5 tage Change in Excess of Infl	2.8 ation in the Canad		3.3	-1.9	
1985								
1986	13.4	12.2	12.5	4.0		3.3		
1987 1988	11.3 1.4	14.0 -2.2	13.2 -1.1	5.2 3.2		4.3 3.3		
1989	3.8	-2.2	-0.4	3.7		3.1		
1990	7.6	7.7	7.7	4.7		5.8		
1991 1992	3.8 -5.0	6.1 8.2	5.4 4.2	1.0 2.3		2.7 2.7		
1993	-5.0 -5.0	5.9	2.9	-1.3		0.8		
1994	-1.7	3.3	2.0	1.6	2.3	1.8		
1995	2.5	-0.1	0.5	1.5		-1.0		
1996 1997	-7.1 2.3	-4.6 20.2	-5.2 15.8	-1.7 -2.5		-2.2 1.4		
1998	12.7	2.1	4.4	5.7		4.3		
1999	11.0	8.8	9.3	5.4	7.8	6.1		
2000	12.2	3.5	5.6	3.4		2.8		
2001 2002	14.7 11.0	8.6 8.3	10.1 9.0	8.9 4.2		10.0 5.0		
2003	8.2	6.0	6.6	3.5	3.9	3.6		
2004	7.2	-0.8	1.4	5.9	0.1	4.1		
2005	5.6	9.6	8.5	6.4		7.8		
2006 2007	4.8 0.7	3.2 -0.6	3.6 -0.2	7.3 1.5		6.6 1.0		
2008 f	0.5	3.4	2.6	0.7	3.4	1.5		
2009 f	8.0	4.4	5.4	4.6	6.5	5.2		
f: forecast.								Source: CIHI, 2009.



Table B Que.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Quebec, 1985 to 2009

Non-Prescribed Drugs Private (Out-of-Pocket) Private Sub-Total Provincial Federal Social Security Funds Insurers* Sub-Total Over Total Out-of-Total Personal WCB Pocket escribed Health Drug Insura Druas Funds Drugs Counter Supplies (Premium Component) Drugs (\$ Millions) 985 250.4 260.0 230.5 342.6 602.6 986 291.2 2.7 301.9 463.0 764.9 261.0 333.8 8.8 3.2 345.8 466.6 812.4 302.7 1988 384.1 10.7 3.2 398.0 523.3 921.4 366.9 1989 437.1 453.4 582.4 1,035.8 444.8 1990 502.9 15.3 4.2 522.4 638.9 1.161.2 468.3 306.5 264.2 1992 650.5 18.1 5.1 673.7 770.9 1.444.6 570.7 1993 686.1 742.1 21.1 712.3 882.3 898.5 1,594.6 1,669.2 312.4 280.8 306.6 593.1 633.4 23.0 1994 770.7 326.8 5.6 807.0 837.4 1,005.9 1,843.3 334.4 649.0 1996 734.5 24.0 6.9 765.4 1.079.9 1.845.2 322.1 314.6 636.7 700.6 169.1 903.1 1,227.2 2,130.2 293.5 588. 1998 779.8 29.5 213.4 1,030.8 1,228.4 2,259.2 312.2 316.7 628.9 1999 918.6 34.4 9.3 262.7 1,225.0 1,433.5 2,658.5 334.1 332.4 666.6 2000 1.118.4 35.0 11.1 327.9 1.492.5 1.612.8 3.105.3 321.2 324.3 645.4 38.4 44.7 1,309.4 367.4 1,728.6 1,752.2 3,480.8 337.0 2002 1,439.5 15.4 433.2 1,932.8 1,968.7 3,901.6 347.1 340.6 687.6 2003 1.538.9 50.7 53.5 18.0 577.8 2,185.4 2,130.9 4.316.3 350.7 371.7 340.4 352.4 691.0 724.1 2004 1,678.1 21.1 615.5 2,368.2 2,357.0 4,725.2 1,798.7 23.0 618.7 2,497.8 2,492.4 4,990.1 426.3 385.1 811.4 62.2 441.5 401.0 2006 1,955.6 26.4 669.0 2,713.1 2,706.9 5,420.0 842.5 2007 2.164.9 66.2 29 6 676.4 2.936.9 2.894.0 5 830 9 468 6 406.2 874.8 2,348.5 3,232.9 501.1 421.8 2008 32.8 708.7 3,159.4 6,392.4 922.9 69.4 2009 f 2.517.6 72.4 36.4 732.2 3.358.5 3,489.1 6.847.6 516.7 439.1 955.7 (Annual Percentage Change) 1985 16.3 14.6 35.1 0.8 1986 8.4 27.3 16.1 26.9 13.2 19.2 1988 15.1 21.6 1.0 15.1 12.2 13.4 21.2 1989 13.8 7.2 13.9 11.3 12.4 1990 15.0 19.2 20.8 15.2 9.7 12.1 5.3 11.0 20.1 16.6 19.8 15.0 1992 7.7 8.2 3.3 7.7 8.7 8.2 6.8 11.7 1994 8.2 8.7 8.2 1.8 4.7 4.6 9.2 6.8 1995 8.7 12.1 8.7 11.9 10.4 2.3 2.6 2.5 5.0 1996 -9.0 -0.7 9.7 -8.6 0.1 -3.7 0.0 -1.9 -4.6 15.4 1998 11.3 13.4 10.0 26.2 14.1 0.1 6.1 6.4 7.5 6.9 1999 17.8 16.6 15.1 23.1 18.8 16.7 17.7 7.0 5.0 6.0 2000 21.8 1.9 19.7 24.8 21.8 12.5 16.8 -3.9 -2.5 -3.2 17.1 12.1 12.1 2002 9.9 16.6 14.3 17.9 11.8 12.4 12.1 3.0 2.7 2.8 2003 6.9 9.0 13.4 17.1 33.4 6.5 13.1 10.6 1.0 -0.1 0.5 17.3 2004 8.4 10.6 9.5 6.0 3.5 4.8 7.2 5.7 14.7 0.5 2006 8.7 8.6 14.7 8.1 8.6 8.6 8.6 3.6 4.1 3.8 2007 10.7 2008 f 8.5 4.9 10.8 4.8 7.6 11.7 9.6 6.9 3.8 5.5 2009 7.2 4.3 11.0 3.3 6.3 7.9 7.1 3.1 4.1 3.6 (Per of Total Drug Expenditu 1985 30.1 0.9 0.3 31.2 41.1 72.3 27.7 1986 28.4 0.8 0.3 29.4 45.1 74.6 25.4 29.9 0.8 0.3 31.0 41.8 72.9 27.1 1988 29.8 0.8 0.3 30.9 40.6 71.5 28.5 29.5 71.3 71.4 1990 30.9 0.9 0.3 32.1 39.2 28.7 32.3 33.5 28.6 0.9 15.2 1992 32.3 0.9 0.3 33.4 38.3 71.7 13.1 28.3 14.3 14.2 1994 32.2 1.0 0.2 33.5 39.0 72.5 13.3 27.5 1995 32.4 1.0 0.3 74.0 13.4 12.6 26.0 33.6 40.4 1996 29.6 1.0 0.3 30.8 43.5 74.3 13.0 12.7 25.7 6.2 33.2 78.4 10.8 10.8 1998 27.0 1.0 0.3 7.4 35.7 42.5 78.2 10.8 11.0 21.8 27.6 7.9 43.1 10.0 39.8 41.7 2000 29.8 0.9 0.3 8.7 43.0 82.8 8.6 17.2 31.6 8.9 42.2 0.9 83.9 8.1 8.0 2002 31.4 1.0 0.3 9.4 42.1 42.9 85.0 7.6 7.4 15.0 2004 30.8 1.0 0.4 11.3 43.5 43.3 86.7 6.8 6.5 13.3 2005 31.0 1.0 0.4 10.7 43.1 43.0 86.0 7.3 14.0 6.6 10.7 10.1 2006 31.2 1.0 0.4 43.3 43.2 86.5 7.0 6.4 13.5 2007 32.3 1.0 43.8 43.2 87.0 7.0 13.0 2008 32.1 0.9 0.4 9.7 43.2 44.2 87.4 6.8 5.8 12.6 : forecast Source: CIHI

Que.

Que.

		Expenditure	on Drugs by Typ		f Finance and as uebec, 1985 to		ic, Private and	Table B Qu	ıe.—
		All D	TOtal Health	Expenditure, Q	•	2009 (cont u)		gs in Public, Private	and
-	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Public	ealth Expenditures Private	Tot
_	200.0	570.4	(\$ Millio		0.404.4	40.004.0	·	centage Share)	
	260.0 301.9	573.1 724.0	833.0 1,025.9	7,927.6 8,051.3		10,031.9 10,537.4	3.3 3.7	27.2 29.1	
	345.8	769.3	1,115.1	8,636.4		11,268.6	4.0	29.2	
	398.0 453.4	890.3 1,027.2	1,288.3 1,480.7	9,428.4 10,108.6		12,279.2 13,290.3	4.2 4.5	31.2 32.3	
	522.4	1,107.1	1,629.5	10,814.1		14,311.5	4.8	31.7	
	625.6	1,243.8	1,869.5	11,815.3	3,819.3	15,634.6	5.3	32.6	
	673.7 712.3	1,341.6 1,475.4	2,015.3 2,187.7	12,234.5 12,459.6		16,376.1 16,904.2	5.5 5.7	32.4 33.2	
	770.7	1,532.0	2,302.6	12,459.6		17,327.9	6.1	32.9	
	837.4	1,654.9	2,492.3	12,708.9		17,372.5	6.6	35.5	
	765.4	1,716.6	2,481.9	12,254.7	4,727.9	16,982.6	6.2	36.3	
	903.1	1,815.2	2,718.3 2,888.0	13,038.3		18,014.3	6.9 7.3	36.5 37.1	
	1,030.8 1,225.0	1,857.3 2,100.1	3,325.1	14,128.3 14,462.3		19,128.8 20,013.3	8.5	37.8	
	1,492.5	2,258.3	3,750.7	15,705.7	5,905.4	21,611.1	9.5	38.2	
	1,728.6	2,420.9	4,149.5	16,992.0		23,553.5	10.2	36.9	
	1,932.8	2,656.4	4,589.2	17,958.3		25,037.6	10.8	37.5	
	2,185.4 2,368.2	2,822.0 3,081.0	5,007.4 5,449.3	19,043.6 20,258.0		26,650.4 28,091.0	11.5 11.7	37.1 39.3	
	2,497.8	3,303.8	5,801.5	21,340.6		29,854.1	11.7	38.8	
	2,713.1	3,549.4	6,262.5	22,668.3	9,055.3	31,723.7	12.0	39.2	
	2,936.9 3,159.4	3,768.7 4,155.8	6,705.7 7,315.2	23,964.3 25,764.3		33,496.9 36,071.5	12.3 12.3	39.5 40.3	
	3,358.5	4,155.6	7,803.4	25,764.3	10,307.3	38,102.8	12.3	40.7	
			(Annual Percenta	age Change)					

	16.1 14.5	26.3 6.3	23.2 8.7	1.6 7.3		5.0 6.9			
	15.1	15.7	15.5	9.2		9.0			
	13.9	15.4	14.9	7.2		8.2			
	15.2	7.8	10.0	7.0	9.9	7.7			
	19.8	12.3	14.7	9.3		9.2			
	7.7 5.7	7.9 10.0	7.8 8.6	3.5 1.8		4.7 3.2			
	8.2	3.8	5.3	1.7		2.5			
	8.7	8.0	8.2	0.3		0.3			
	-8.6 18.0	3.7 5.7	-0.4 9.5	-3.6 6.4		-2.2 6.1			
	14.1	2.3	6.2	8.4		6.2			
	18.8	13.1	15.1	2.4	11.0	4.6			
	21.8	7.5	12.8	8.6		8.0			
	15.8 11.8	7.2 9.7	10.6 10.6	8.2 5.7		9.0 6.3			
	13.1	6.2	9.1	6.0		6.4			
	8.4	9.2	8.8	6.4	3.0	5.4			
	5.5	7.2	6.5	5.3		6.3			
	8.6 8.2	7.4 6.2	7.9 7.1	6.2 5.7		6.3 5.6			
	7.6	10.3	9.1	7.5		7.7			
	6.3	7.0	6.7	5.6	5.8	5.6			
_	(Percenta	ge Share of Total Dr	ug Expenditure)	<u>—</u> ,					
	31.2	68.8	100.0						
	29.4 31.0	70.6 69.0	100.0 100.0						
	30.9	69.1	100.0						
	30.6	69.4	100.0						
	32.1	67.9	100.0						
	33.5 33.4	66.5 66.6	100.0 100.0						
	32.6	67.4	100.0						
	33.5	66.5	100.0						
	33.6	66.4	100.0						
	30.8 33.2	69.2 66.8	100.0 100.0						
	35.7	64.3	100.0						
	36.8	63.2	100.0						
	39.8	60.2	100.0						
	41.7 42.1	58.3 57.9	100.0 100.0						
	43.6	56.4	100.0						
	43.5	56.5	100.0						
	43.1	56.9	100.0						
	43.3 43.8	56.7 56.2	100.0 100.0						
	43.2	56.8	100.0						
	43.0	57.0	100.0						

Table B Que. - per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Quebec, 1985 to 2009

Prescribed Drugs Non-Prescribed Drugs Public Private Private (Out-of-Pocket) Sub-Total Sub-Total Provincial Social Security Funds Insurers* Out-of-Total Over Total Drug Insurance Private rescribe Non-Preso Funds Drugs Counter Supplies Drugs (Premium Component) Drugs (\$ per Capita) 1985 37.57 39.00 34.58 1.12 0.32 51.40 90.40 1986 1987 1.20 69.01 68.80 114.02 119.78 43.40 0.40 45.00 38.91 49.21 0.47 50.98 44.62 1988 56.16 1.56 0.47 58.20 76.52 134.72 53.65 1989 1.85 0.50 63.09 84.06 149.50 64.20 91.21 100.41 1990 71.80 2.18 0.60 74.58 165.80 66.86 1991 85.50 0.69 88.56 188.97 75.65 2.37 1992 91 52 2 55 0.71 94 78 108 46 203 23 43 12 37 17 80.29 123.31 95.89 2.95 99.55 222.86 43.65 39.24 82.89 1994 103.18 3.20 0.78 107.16 124.94 232.10 45.44 42.63 88.07 1995 111.78 116.00 139.34 255.33 46.32 43.57 89.89 3.34 0.88 101.35 96.31 3.31 1996 0.96 105 61 149.01 254 62 44 45 43.42 87 86 1997 23.25 124.14 168.69 292.83 40.34 40.50 1.01 80.84 1998 106.88 4.04 1.11 29.25 141.28 168.37 309.65 42.79 43.40 86.19 125.43 1.27 167.27 195.75 2000 152.02 4.76 1.51 44 57 202.86 219.22 422 09 43.66 44.07 87.73 2001 177.02 5.19 49.67 233.69 236.88 470.57 45.56 44.84 90.40 1.82 2002 193.33 6.01 2.07 58.19 259.59 264.41 524.00 46.61 45.74 92.35 291.60 2004 7.09 46.68 222.29 2.80 81.53 313.71 312.23 625.94 49.24 95.91 2005 236.74 7.53 3.03 81.43 328.74 328.03 656.77 56.11 50.68 106.79 2006 256.25 8.15 3.46 87.66 355.52 354.70 710.22 57.85 52.54 110.39 281.66 8.61 3.85 88.00 382.11 376.52 52.85 2008 f 303.02 8.96 4.23 91.44 407.64 417.13 824.77 64.65 54.42 119.07 323.15 4.67 93.98 431.09 (Annual Percentage Change) 1985 1986 15.5 7.7 26.4 15.4 34.3 26.1 12.5 13.4 7.9 14.7 17.9 13.3 -0.3 1988 14.1 20.6 0.1 14.1 11.2 12.5 20.2 12.3 18.4 12.4 11.0 19.7 5.8 1990 13.8 17.9 195 14 0 8.5 10.9 Δ. 19.1 13.2 1991 18.7 10.1 14.0 8.4 15.6 6.1 3.2 1992 7.0 7.6 2.6 7.0 8.0 7.5 9.7 15.9 5.0 1994 4.1 7.6 8.2 11.2 7.6 1.3 8.6 6.2 11.7 ---11.5 10.0 1.9 1996 -9.3 -1.1 9.2 -9.0 6.9 -0.3 -4.1 -0.3 -2.3 13.2 -9.2 25.8 6.6 1998 11.0 13.1 13.8 -0.2 6.1 7.2 1999 17.4 16.2 14.6 22.6 18.4 16.3 17.2 6.6 4.6 21.2 -4.3 -3.6 2000 1.4 19.1 24.2 21.3 12.0 16.3 -2.9 2001 16.4 9.0 11.4 11.5 4.4 1.7 3.0 20.1 15.2 11.6 2002 9.2 15.8 13.5 17.1 11.1 11.4 2.3 2.0 2.2 2003 6.2 12.7 12.3 9.9 2004 8.3 4.7 16.4 5.8 7.6 9.8 8.7 5.2 2.8 4.0 2005 6.5 8.3 -0.1 4.8 5.1 4.9 8.6 11.3 6.3 14.0 8.2 5.7 14.2 11.1 7.6 0.4 8.1 7.5 8.1 6.2 2006 8.2 9.9 3.1 5.4 3.7 3.4 6.8 0.6 2007 2008 f 7.6 4.0 9.9 3.9 6.7 10.8 8.7 6.0 3.0 4.6 2009 f 5.8 (Annual Percentage Change in Excess of Inflation in the Canadian Econo 1985 1986 12.7 4.9 23.6 12.6 31.5 23.3 9.7 13.1 -5.1 0.3 10.0 9.6 7.8 1988 16.0 -4.4 9.6 6.7 8.0 15.7 1.2 1990 10.8 14.9 16.4 10.9 5.5 7.9 1.1 11.2 16.3 12.9 1992 5.8 6.3 1.4 5.8 6.8 6.3 4.9 3.3 1.8 -0.2 1994 7.1 10.1 6.5 0.2 3.0 3.0 7.5 1995 2.2 7.7 6.0 9.3 ---5.9 9.2 -0.4 -0.1 -0.3 1996 -11.0 -2.7 7.6 -10.6 5.3 -1.9 -5.7 -2.0 -3.9 12.2 14.0 10.2 -9.0 7.1 26.3 1998 11.4 13.5 10.1 14.2 0.2 6.2 6.5 7.6 1999 15.6 14.4 12.8 20.8 16.6 14.5 15.4 4.8 2.8 3.8 -2.7 7.6 14.8 17.1 20.1 17.2 12.2 -8.4 -7.7 2000 15.0 7.9 -7.0 10.1 3.0 8.2 10.0 10.6 1.0 12.5 16.1 3.3 5.7 9.8 2.1 -2.5 2.6 2003 13.5 29.6 9.4 4.6 7.0 -3.6 -3.1 1.4 13.8 3.2 5.0 7.2 2005 3.6 5.3 3.3 5.4 -3.0 1.9 2.1 2.0 11.0 5.7 8.4 4.8 5.2 0.2 0.5 2006 5.3 11.3 0.8 5.3 2007 6.6 2.3 7.7 -2.9 4.2 2.8 3.5 2.1 -2.7 -0.2 6.1 9.2

Que.

2009 f

8.5

Confidentiality precludes reporting provincial-level insurance data

5.7

12.3

4.7

7.6

86 **CIHI 2010**

8.4

4.5

5.4

4.9

Que.

		Expenditur	e on Drugs per Capi Total Health Ex					Que. – per Capita
		A !! D	Total Health Ex		•	2003 (cont u)	GDP Implicit	
=	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Price Index — Canada	
Year			(\$ per Capita)				(1997 = 100)	
1985	39.00	85.97	124.97	1,189.31	315.70	1,505.01	73.6	
1986 1987	45.00 50.98	107.92 113.42	152.93 164.40	1,200.16 1,273.33	370.59 388.08	1,570.76 1,661.41	75.6 79.2	
1988	58.20	130.18	188.37	1,378.61 1,458.95	416.85	1,795.46 1,918.16	82.8	
1989	65.44	148.26	213.70		459.21		86.6	
1990 1991	74.58 88.56	158.07 176.07	232.66 264.62	1,544.02 1,672.46	499.35 540.63	2,043.36 2,213.09	89.2 91.6	
1992	94.78	188.75	283.53	1,721.23	582.66	2,303.89	92.8	
1993 1994	99.55 107.16	206.20 213.01	305.75 320.17	1,741.32 1,762.32	621.16 647.05	2,362.48 2,409.37	94.1 95.2	
1995	116.00	229.23	345.22	1,760.37	645.98	2,406.35	97.4	
1996	105.61	236.87	342.48	1,691.02	652.41	2,343.43	99.0	
1997 1998	124.14 141.28	249.53 254.56	373.67 395.84	1,792.30 1,936.45	684.03 685.38	2,476.32 2,621.83	100.0 99.6	
1999	167.27	286.77	454.04	1,974.83	757.99	2,732.82	101.4	
2000	202.86	306.95	509.82	2,134.79	802.69	2,937.47	105.5	
2001 2002	233.69 259.59	327.28 356.76	560.97 616.35	2,297.15 2,411.89	887.04 950.78	3,184.20 3,362.67	106.9 108.1	
2003	291.60	376.53	668.13	2,540.94	1,014.97	3,555.91	111.2	
2004	313.71	408.14	721.85	2,683.54	1,037.62	3,721.17	114.1	
2005	328.74	434.82	763.56	2,808.70	1,120.48	3,929.18	117.4	
2006 2007	355.52 382.11	465.09 490.34	820.61 872.45	2,970.34 3,117.90	1,186.57 1,240.25	4,156.91 4,358.14	120.8 124.8	
2008 f	407.64	536.20	943.84	3,324.21	1,329.88	4,654.09	130.6	
2009 f	431.09	570.53	1,001.62 (Annu	3,490.70	1,400.08	4,890.78	128.2	
1985				-				
1986	15.4	25.5	22.4	0.9	17.4	4.4	2.8	
1987 1988	13.3 14.1	5.1 14.8	7.5 14.6	6.1 8.3	4.7 7.4	5.8 8.1	4.7 4.5	
1989	12.4	13.9	13.4	5.8	10.2	6.8	4.6	
1990	14.0	6.6	8.9	5.8	8.7	6.5	3.0	
1991	18.7	11.4	13.7	8.3	8.3	8.3	2.8	
1992 1993	7.0 5.0	7.2 9.2	7.1 7.8	2.9 1.2	7.8 6.6	4.1 2.5	1.3 1.4	
1994	7.6	3.3	4.7	1.2	4.2	2.0	1.1	
1995	8.2	7.6	7.8	-0.1	-0.2	-0.1	2.3	
1996 1997	-9.0 17.5	3.3 5.3	-0.8 9.1	-3.9 6.0	1.0 4.8	-2.6 5.7	1.7 1.0	
1998	13.8	2.0	5.9	8.0	0.2	5.9	-0.4	
1999	18.4	12.7	14.7	2.0	10.6	4.2	1.8	
2000 2001	21.3 15.2	7.0 6.6	12.3 10.0	8.1 7.6	5.9 10.5	7.5 8.4	4.1 1.4	
2001	11.1	9.0	9.9	5.0	7.2	5.6	1.4	
2003	12.3	5.5	8.4	5.4	6.8	5.7	2.9	
2004	7.6	8.4	8.0	5.6	2.2	4.6	2.6	
2005 2006	4.8 8.1	6.5 7.0	5.8 7.5	4.7 5.8	8.0 5.9	5.6 5.8	2.9 2.9	
2007	7.5	5.4	6.3	5.0	4.5	4.8	3.3	
2008 f 2009 f	6.7 5.8	9.4 6.4	8.2 6.1	6.6 5.0	7.2 5.3	6.8 5.1	4.7 -1.9	
_	3.0		age Change in Excess of Infla				-1.3	
1985								
1986 1987	12.6 8.5	22.7 0.4	19.6 2.8	-1.9 1.4	14.6 0.0	1.6 1.0		
1988	9.6	10.3	10.1	3.7	2.9	3.5		
1989	7.9	9.3	8.9	1.3	5.6	2.3		
1990	10.9	3.6	5.8	2.8	5.7	3.5		
1991 1992	16.0 5.8	8.6 5.9	11.0 5.9	5.6 1.7	5.5 6.5	5.5 2.8		
1993	3.6	7.8	6.4	-0.3	5.2	1.1		
1994	6.5	2.2	3.6	0.1	3.1	0.9		
1995 1996	5.9 -10.6	5.3 1.7	5.5 -2.5	-2.4 -5.6	-2.5 -0.7	-2.5 -4.3		
1997	16.6	4.4	-2.5 8.1	5.0	3.9	4.7		
1998	14.2	2.5	6.4	8.5	0.6	6.3		
1999	16.6	10.8	12.9	0.2	8.8	2.4		
2000 2001	17.2 13.8	2.9 5.3	8.2 8.7	4.0 6.3	1.8 9.2	3.4 7.0		
2002	10.0	8.0	8.8	4.0	6.1	4.6		
2003 2004	9.4 5.0	2.6 5.8	5.5 5.5	2.5 3.0	3.9 -0.4	2.9 2.1		
2005	1.9	3.6	2.9	1.7	5.1	2.7		
2006	5.3	4.1	4.6	2.9	3.0	2.9		
2007 2008 f	4.2	2.1	3.0	1.6	1.2	1.5		
2008 f 2009 f	2.0 7.6	4.7 8.3	3.5 8.0	2.0 6.9	2.6 7.2	2.1 7.0		
								Pe 0"" 2022
forecast.								Source: CIHI, 2009.

Table B Ont.—Total

Ont.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Ontario, 1985 to 2009

Prescribed Drugs

Personal Property						Prescribed D	rugs					Prescribed D	
THE COLOR OF THE C		Provincial	Federal	Social	Security Funds Drug Insurance Funds		Insurers*			Prescribed	Over- the- Counter	Personal Health	Total Non-Presc.
1986 4912 145	Year				(Fremium Component)		(\$ Millions)				Diugs		
1982 1984 1984 1984 1985	1985												487.9
1989													640.6
1980 1981 1972 278 292 293 29 294 295 29	1988												711.0
1991 1917 278 902													
1982 1,1856 410 233 - 1,2478 - 1,3788 2,078 1,2481 2016 403 275 1,0481 2018 403 2018 403 1,0481 2018 403 1,0481 2018 403 1,0481 1,0481 2018 403 1,0481 2018 40	1990 1991												
1,228	1992	1,183.6							1,376.9				976.7
1398													
1986 1,562.7 23.9 21.6 - 1,459.2 1,725.3 3,173 541.2 540.5 1,181.7 1989 1,700 0,74 23.3 - 1,461.5 2,101.6 3,800.3 1,181.7 1989 1,700 7.2 23.4 - 1,729.2 2,101.6 3,800.3 1,181.7 1989 1,700 7.2 25.4 - 1,729.2 2,277 1,479.4 1989 1,700 27.2 25.4 - 1,729.2 2,277 1,479.4 1989 2,710 3,800.3 34.4 - 2,559.9 1,015.0 5,446 44.6 1,710 2,710 3,800.3 2,279.4 1,800 3,44 - 2,559.9 1,015.0 5,446 44.6 1,800 3,44 - 2,579.4 2,279.4 1,800 3,44 - 2,579.4 2,279.4 1,800 3,44 - 2,579.4 4,200.4 1,800 3,44 - 2,579.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44 3,500.4 4,200.4 1,800 3,44													
1988 1,580, 0 8,9 23,9	1996	1,362.7	53.9	21.6		1,438.2			1,735.3	3,173.5	641.2	540.5	1,181.7
1989 1,700 1,70 2,7 2,4 - 1,799.2 - 2,239.7 4,199.9 789.7 1,799.2													
2001 22126 830 39.4	1999												
2002 2.56.2 2.56.2 2.56.2 3.5 41.4 2.072.1 3.344 0.16.5 87.7 2.05.5 1.08.10 2.00.10 2.	2000	1,943.4	72.6	31.1		2,047.0			2,719.9	4,767.0	824.7	699.8	1,524.6
2020	2001												
2020 3,941 2031 371.7 3,8521	2002												
1,000 1,00	2004	3,141.0	108.8	63.3		3,313.0			4,034.1	7,347.1	954.0	750.1	1,704.1
1975 1976	2005												
20091													
	2008 f	4,063.1	139.5	109.0		4,311.6			5,282.1	9,593.7	1,101.9	842.6	1,944.5
1986	2009 f	4,050.4	144.4	127.7		4,322.5			5,636.1	9,958.6	1,114.4	863.4	1,977.7
1986 20.5		-					(Annual Percentage (Change)					
1987 19.4 5.9 19.2 18.9 5.9 11.3 11.0 11.0 11.0 11.0 11.0 11.0 11.	1985												
1989 12-9 25.3 12.6 - 13.3 - 12.6 12.9 - 1.0	1987												16.0
1980	1988												11.0
1989													
1992 16.9 8.0 15.4 16.6 14.6 15.5 10.9 1993 5.4 13.9 3.9 5.7 7.0 6.7 7.2 5.1 6.2 1994 1.10 8.7 22.3 1.10 1.8 0.5 10.3 7.8 3.1 1996 1.12 1.8 10.9 11.3 10.0 1.8 2.0 4.1 2.2 3.3 1.9 1996 1.12 1.8 10.9 1.10 4.5 2.0 4.1 2.2 3.3 1.9 1.10 1.10 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13													
1994 1.0 8.7 22.3	1992	16.9	8.0	15.4		16.5			14.6	15.5			10.6
1986 116 43 5.1 113 100 106 0.1 2.5 1.1 1986 12 12 18 10.9 10 10 10 10 10 10 10 11 2.2 1.1 1987 3.3 7.0 2.9 3.4 10.2 17 3.4 3.5 7.7 1.1 1988 10.1 14.4 7.4 10.2 17 17.3 14.3 5.7 7.1 1989 9.7 11.9 6.3 9.7 13.2 2.0 6.5 5.2 5.9 1999 9.7 11.9 6.3 9.7 13.9 13.9 13.9 13.9 13.9 13.1 1000 14.3 1.6 2.3 13.8 13.9 13.9 10.9 12.2 1.9 2.8 2.9 1001 13.9 14.3 13.8 13.8 13.9 10.9 12.2 1.9 2.8 2.2 1001 13.9 14.3 13.8 13.8 13.9 14.6 10.9 12.2 5.6 6.2 5.9 1001 13.9 14.3 13.8 13.8 13.9 10.9 12.2 5.6 6.2 5.9 1002 14.6 13.9 17.0 14.6 10.9 12.5 5.6 2.9 14.8 2.2 1003 11.6 12.8 25.2 11.8 13.9 10.9 12.2 5.6 2.9 14.8 2.2 1004 11.0 2.0 22.0 10.9 17.1 8.8 4.8 3.0 4.0 1005 9.5 11.5 13.3 9.6 10.9 12.5 5.6 2.9 4.0 10.9 10.9 11.0 1.0 2.0 22.0 10.9 10.9 12.6 12.3 2.5 1.8 2.9 1006 7.4 6.1 10.7 7.5 6.7 8.1 7.8 2.6 2.7 2.2 1007 3.3 3.0 15.9 3.5 5.6 6.4 7.8 2.6 2.7 2.2 1008 1 6.5 3.3 17.2 0.3 3.5 6.7 3.8 11.1 2.5 17. 1985 26.8 0.9 0.5 28.8 10.9 Expenditure 1986 27.3 0.8 0.5 28.8 10.9 Expenditure 1987 28.9 0.8 0.5 28.8 40.1 6.7 37.8 68.9 37.9 19.9 19.9 19.9 19.9 19.9 19.9 19.9 1													
1986 1-12 1.8 10.9 1.0 4.5 2.0 4.1 2.2 3.3 1987 3.3 7.0 2.9 3.4 4 1.0 4.5 1.2 13.2 10.8 11.6 11.2 11.9 1988 10.1 14.4 7.4 10.2 1.7 1.7 3 14.3 5.7 7.1 6.5 5.2 5.5 1989 10.1 14.4 17.4 10.2 1.7 1.7 3 14.3 5.7 7.1 6.5 5.2 5.5 5.5 1989 10.1 14.4 17.4 10.2 1.7 1.7 3 14.3 5.7 7.1 10.3 10.0 11.1 11.1 11.1 11.1 11.1 11													
1989 10.1 14.4 7.4 10.2 17.3 14.3 5.7 7.1 6.3 1989 9.7 11.9 6.3 8.7 12.2 13.2 2.0 6.5 5.2 5.5 2.0 13.9 9.7 11.9 6.3 8.7 13.8 13.9 13.9 13.9 3.1 3.0 3.1 2001 13.9 14.3 13.8 13.8 13.9 10.9 12.2 13.9 2.8 2.3 2002 14.6 13.9 17.0 14.6 10.9 12.5 5.6 5.6 2.9 4.4 2003 11.6 12.8 25.2 11.8 12.8 12.8 12.3 2.5 5.6 2.9 4.4 2003 11.6 12.8 25.2 11.8 10.9 12.5 5.6 5.6 2.9 4.4 2003 11.6 12.8 25.2 11.8 10.9 12.6 12.3 2.5 5.6 2.9 4.4 2003 11.6 12.8 25.2 11.8 10.9 12.6 12.3 2.5 5.6 2.9 4.4 2003 11.6 12.8 25.2 11.8 10.9 12.6 12.3 2.5 1.6 0.0 2005 9.5 11.5 13.3 9.6 10.9 17.1 0.8 4.8 4.8 3.0 4.0 2005 11.0 2.0 22.0 10.9 17.5 11.8 12.8 12.3 2.5 1.6 0.0 2005 0.5 11.5 13.3 9.6 0.6 4.7 6.7 11.7 0.8 4.5 4.4 4.4 2007 3.3 3.0 16.9 31.7 2 0.3 0.5 0.5 8.4 4.7 9.0 7.0 8.1 2006 1.0 3.3 3.5 17.2 0.3 0.5 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 0.5 8.4 4.7 9.0 7.0 8.1 2008 1 0.3 3.8 17.2 0.3 0.3 8.9 6.7 2 0.3 8.1 1.1 2.5 17.7 1995 1 0.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	1996												
997 11.9 6.3 9.7 3.2 2 0.0 6.5 5.2 5.9 5.9 5.0 5.0 5.0 5.0 5.2 5.0 5.9 5.0 5.0 5.0 5.0 5.2 5.0 5.9 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0	1997												
2001 13.9 14.3 13.8 13.9 13.9 10.9 12.2 1.9 2.8 2.3 2002 11.6 13.9 17.0 14.6 10.9 12.5 5.6 5.6 2.9 4.4 2003 11.6 12.8 25.2 11.8 10.9 12.6 12.3 2.5 1.1.6 0.0 2004 11.0 2.0 2.0 2.0 10.9 10.9 12.6 12.3 2.5 1.1.6 0.0 2005 11.0 2.0 2.0 2.0 10.9 17.1 8.8 4.8 3.0 4.0 2005 9.5 11.5 13.3 9.6 10.9 6.4 7.8 2.6 2.7 2.6 2006 7.4 8.1 10.7 7.5 8.1 7.8 4.5 4.4 4.4 4.4 2007 3.3 3.0 16.9 3.5 5.5 8.1 7.8 4.5 4.4 4.4 4.4 2007 3.3 3.0 16.9 3.5 6.7 7.7 7.2 1.1 2.0 1.5 2009 1 6.5 3.3 17.4 6.7 7.5 8.1 7.8 4.5 4.4 4.4 4.4 2009 1 6.5 3.3 17.4 6.7 7.7 7.2 1.1 2.0 1.5 2009 1 6.5 3.3 17.4 6.7 8.1 8.8 8.9 67.2 11.1 2.5 1.7 20.9 1 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8 2.8	1999												
14.6 13.9 17.0	2000	14.3	-1.6	22.3		13.8			13.9	13.9	3.1	3.0	3.1
11.6 12.8 25.2 11.8 12.6 12.3 2.5 1.6 0.0	2001												
2005 9.5 11.5 13.3 9.6 6.4 7.8 2.6 2.7 2.6 2006 7.4 8.1 10.7 7.5 8.1 7.8 4.5 4.4 4.4 2007 3.3 3.0 16.9 3.5 5.8 4.7 9.0 7.0 8.1 20081 6.5 3.3 17.4 6.7 7.7 7.7 7.2 1.1 2.0 1.5 20091 0.3 3.5 17.2 0.3 6.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 6.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 8.1 8.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 8.1 8.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 8.1 8.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 3.0 1.0 1.0 8.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 3.0 1.0 8.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 3.0 1.0 1.0 8.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 3.0 1.0 1.0 8.7 3.8 1.1 2.5 17.7 20091 0.3 3.5 17.2 0.3 3.0 1.0 1.0 8.7 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1	2002												
2006	2004	11.0	2.0	22.0		10.9			7.1	8.8	4.8	3.0	4.0
2007 3.3 3.0 16.9 3.5 5.8 4.7 9.0 7.0 8.1 2008 f 6.5 3.3 17.4 6.7 6.7 3.8 1.1 2.5 1.7	2005												
2008 f 6.5 3.3 17.4 6.7 7.7 7.2 1.1 2.0 1.15 2.0 1.15 2.00 1.15 2.00 1.15 2.00 1.15 2.00 1.15 2.00 1.15 2.15 2.15 2.15 2.15 2.15 2.15 2.15													
1985 26.8 0.9 0.5 28.3 38.9 67.2 32.8 1986 27.3 0.8 0.5 28.6 40.1 68.7 31.3 1987 28.9 0.8 0.5 30.2 37.5 68.5 31.3 1988 29.4 1.1 0.5 31.0 37.5 68.5 31.1 1989 29.6 1.2 0.5 31.3 0.6 32.9 38.1 72.0 28.8 1991 32.1 1.2 0.6 33.9 38.1 72.0 28.8 1992 32.9 1.1 0.6 34.4 38.5 72.9 14.5 12.6 27.1 1993 32.5 1.2 0.6 34.4 38.6 73.0 14.6 12.5 27.0 1994 31.3 1.3 0.5 34.1 38.6 73.0 14.6 12.5 27.0 1995 32.4 1.2 0.5 34.1 38.9 72.9 14.7 12.4 29.9 1996 31.3 1.2 0.5 33.0 38.8 72.9 14.7 12.4 29.9 1997 28.7 1.2 0.5 33.0 39.8 72.9 14.7 12.4 29.9 1998 32.4 1.2 0.5 33.0 39.8 72.9 14.7 12.4 29.9 1999 31.3 1.2 0.5 30.3 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 29.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 29.8 44.9 80.5 10.8 87.7 13.5 1900 30.9 1.2 0.5 35.6 44.9 80.5 10.8 87.7 13.5 2001 32.0 1.2 0.5 35.6 44.9 80.5 10.8 87.7 13.5 2003 33.7 1.3 0.6 37.7 44.9 81.9 10.2 7.9 11.5 2004 34.7 1.2 0.5 35.6 44.9 81.9 10.2 7.9 11.5 2005 35.6 1.3 0.8 37.7 44.9 81.9 10.2 7.9 7.8 17.8 2006 35.6 1.3 0.8 37.7 44.9 81.9 10.2 7.9 7.8 17.8 2007 34.9 1.2 0.8 37.7 44.9 81.9 10.2 7.9 7.8 17.8 2008 35.6 1.3 0.8 37.7 44.9 81.9 10.2	2008 f	6.5	3.3	17.4		6.7			7.7	7.2	-1.1	-2.0	-1.5
1986	2009 f	-0.3	3.5	17.2						3.8	1.1	2.5	1.7
1986		-				(Percer	tage Share of Total D	rug Expendit	cure)				
1987	1985												32.8 31.3
1989	1987	28.9	0.8	0.5		30.2			37.6	67.8			32.2
1990 31.0 1.3 0.6 32.9 38.4 71.2 28.8 1991 32.1 1.2 0.6 33.9 38.1 72.0 28.0 1992 32.9 1.1 0.6 34.6 34.6 38.6 73.0 14.6 12.5 27.0 1994 31.3 1.3 0.5 34.4 38.6 73.0 14.6 12.5 27.0 1994 31.3 1.3 0.5 33.1 38.2 71.3 15.6 13.1 28.7 1995 32.4 1.2 0.5 33.1 39.0 73.1 14.5 12.4 26.9 1996 31.3 1.2 0.5 33.0 39.0 73.1 14.5 12.4 26.9 1997 28.7 1.2 0.5 33.0 39.8 72.9 14.7 12.4 27.1 1998 28.2 1.2 0.4 29.8 42.9 73.2 14.5 12.3 26.8 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 2000 30.9 1.2 0.5 33.7 44.8 74.6 13.6 11.1 12.0 26.1 2000 30.9 1.2 0.5 35.0 33.7 44.7 77.4 12.2 10.4 22.6 2001 32.0 1.2 0.5 35.0 35.0 44.9 80.5 10.8 8.7 11.6 9.7 21.3 2004 34.7 1.2 0.7 35.6 35.0 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.9 80.5 10.8 8.7 19.5 2005 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 11.6 2006 35.6 1.3 0.8 37.7 44.9 80.5 10.8 8.7 19.5 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.1 8.0 18.1 2008 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1	1988												31.5 31.1
1991 32.1 1.2 0.6 33.9 38.1 72.0 28.0 1992 32.9 1.1 0.6 34.6 34.6 38.2 72.9 14.5 12.6 27.1 1993 32.5 1.2 0.6 34.4 38.6 73.0 14.6 12.5 27.0 1994 31.3 1.3 0.5 34.1 38.2 71.3 15.6 13.1 28.7 1995 32.4 1.2 0.5 34.1 39.0 73.1 14.5 12.4 28.9 1996 31.3 1.2 0.5 33.0 39.8 72.9 14.5 12.4 28.9 1997 28.7 1.2 0.5 33.0 42.9 73.2 14.5 12.3 26.8 1998 28.2 1.2 0.4 29.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.1 12.0 26.1 2000 30.9 1.2 0.5 33.7 43.7 77.4 12.2 10.4 22.6 2001 32.0 1.2 0.5 35.0 35.0 44.9 81.9 14.1 11.6 9.7 21.3 2003 33.7 1.3 0.6 35.6 35.0 44.9 80.5 10.8 8.7 11.6 9.7 21.3 2004 34.7 1.2 0.7 35.6 35.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.8 37.7 44.4 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.9 80.5 10.8 8.7 19.5 2007 34.9 1.2 0.8 37.7 44.9 81.9 10.1 8.0 18.1 2006 13.5 1.2 0.8 37.7 44.9 81.9 10.1 8.0 18.1 2006 13.5 1.2 0.8 37.7 44.9 81.9 10.2 7.9 18.1 2006 13.5 1.2 0.8 37.7 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 37.0 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 37.4 44.9 81.9 81.9 10.2 7.9 18.1 2006 13.5 2.1 2 0.9 0.9 1.2 1.1 2 0.8 37.4 44.9 81.9 81.9 10.2 7													
1992 32,9 1.1 0.6 34.6 34.6 38.2 72,9 14.5 12.6 22.1 1993 32.5 1.2 0.6 34.4 38.6 73.0 14.6 12.5 27.0 1994 31.3 1.3 0.5 33.1 38.2 71.3 15.6 12.1 28.7 1995 32.4 1.2 0.5 34.1 39.0 73.1 14.5 12.4 26.9 1996 31.3 1.2 0.5 33.0 39.8 72.9 14.7 12.4 27.1 1997 28.7 1.2 0.5 33.0 39.8 72.9 14.7 12.4 27.1 1998 28.2 1.2 0.5 30.3 42.9 73.2 14.5 12.3 26.8 1998 28.2 1.2 0.4 29.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 11.7 25.4 1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 44.8 44.8 74.6 13.6 11.7 25.4 19.9 14.1 12.0 26.1 11.1 24.2 10.4 14.1 14.0 14.1 14.1	1990 1991												28.8 28.0
1994 31.3 1.3 0.5 33.1 38.2 71.3 15.6 13.1 28.7 1995 32.4 1.2 0.5 34.1 39.0 73.1 14.5 12.4 26.9 1996 31.3 1.2 0.5 33.0 39.8 72.9 14.7 12.4 27.1 1997 28.7 1.2 0.5 30.3 42.9 73.2 14.5 12.3 26.8 1998 28.2 1.2 0.4 29.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 1999 30.0 30.9 1.2 0.5 32.5 43.7 77.4 12.2 10.4 22.6 2000 30.9 1.2 0.5 33.7 43.7 77.4 12.2 10.4 22.6 2001 32.0 1.2 0.5 33.7 43.7 77.4 12.2 10.4 22.6 2002 33.2 1.2 0.5 35.0 43.7 77.4 12.2 10.4 22.6 2003 33.7 1.3 0.6 35.6 35.0 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.9 80.5 10.8 8.7 19.5 2005 35.6 1.3 0.7 36.6 44.4 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.1 8.0 18.1 2008 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1	1992	32.9	1.1	0.6		34.6			38.2	72.9			27.1
1995 32.4 1.2 0.5 34.1 39.0 73.1 14.5 12.4 26.9 1996 31.3 1.2 0.5 33.0 39.8 72.9 14.7 12.4 27.1 1997 28.7 1.2 0.5 30.3 42.9 73.2 14.5 12.3 26.8 1998 28.2 1.2 0.4 29.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 2000 30.9 1.2 0.5 32.5 43.7 77.4 12.2 10.4 22.6 2001 32.0 1.2 0.5 33.7 43.7 77.4 12.2 10.4 22.6 2001 32.0 1.2 0.5 35.0 43.7 77.4 12.2 10.4 22.6 2003 33.7 1.3 0.6 35.6 35.6 44.6 81.2 10.5 8.3 11.6 9.7 21.3 2004 34.7 1.2 0.7 36.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.9 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2007 34.9 1.2 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2007 34.9 1.2 0.8 37.7 44.9 81.9 10.2 7.9 18.1 2008 1 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2008 1 35.2 1.2 0.9 3.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.8 16.6 16 16 16 16 16 16 16 16 16 16 16 16 16	1993 1994												
1996 31.3 1.2 0.5 33.0 39.8 72.9 14.7 12.4 22.1 1997 28.7 1.2 0.5 30.3 42.9 73.2 14.5 12.3 26.8 1998 28.2 1.2 0.4 29.8 44.8 74.6 13.6 11.7 25.4 1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 2000 30.9 1.2 0.5 32.5 43.7 77.4 12.2 10.4 22.6 2001 32.0 1.2 0.5 33.7 43.7 77.4 12.2 10.4 22.6 2001 32.0 1.2 0.5 35.0 43.7 77.4 12.2 10.4 22.6 2002 33.2 1.2 0.5 35.0 43.7 77.4 12.2 10.4 22.6 2003 33.7 1.3 0.6 35.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.9 81.2 10.5 8.3 18.8 2004 34.7 1.2 0.7 36.6 44.9 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2007 34.9 1.2 0.8 37.7 44.9 81.9 10.1 8.0 18.1 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.8 16.6 16.0 16.0 16.0 16.0 16.0 16.0 16.0	1995												
1998	1996	31.3	1.2	0.5		33.0			39.8	72.9	14.7	12.4	27.1
1999 30.0 1.3 0.4 31.8 42.1 73.9 14.1 12.0 26.1 2000 30.9 1.2 0.5 32.5 43.2 75.8 13.1 11.1 24.2 2001 32.0 1.2 0.5 33.7 43.7 77.4 12.2 10.4 22.6 2002 33.2 1.2 0.5 35.0 43.7 78.7 11.6 9.7 21.3 2003 33.7 1.3 0.6 35.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.8 81.2 10.5 8.3 18.8 2006 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2006 35.6 1.3 0.8 37.7 44.9 81.9 10.1 8.0 18.1 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2008 1 35.2 1.2 0.9 37.4 45.8 83.1 9.6 7.3 16.9 2009 1 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 8t.													
2001 32.0 1.2 0.5 33.7 43.7 77.4 12.2 10.4 22.6 2002 33.2 1.2 0.5 35.0 44.9 80.5 10.8 8.7 19.5 20.3 2003 33.7 1.3 0.6 35.6 36.6 44.9 80.5 10.8 8.7 19.5 20.4 34.7 1.2 0.7 36.6 44.9 80.5 10.8 8.7 19.5 20.6 35.6 1.3 0.7 36.6 44.9 81.2 10.5 8.3 18.8 2005 35.6 1.3 0.8 37.7 44.4 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 35.2 1.2 0.9 37.4 45.8 83.1 9.6 7.3 16.9 2009 1 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 ft forecast.	1999												
2002 33.2 1.2 0.5 35.0 43.7 78.7 11.6 9.7 21.3 2003 33.7 1.3 0.6 35.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.9 80.5 10.5 8.3 18.8 2005 35.6 1.3 0.7 37.6 44.4 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.4 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.9 81.9 10.1 8.0 18.1 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 35.2 1.2 0.9 37.4 45.8 83.1 9.6 7.3 16.9 2009 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 16.6 16.7 16.7 16.7 16.7 16.7 16.7	2000	30.9	1.2	0.5		32.5			43.2	75.8	13.1	11.1	24.2
2003 33.7 1.3 0.6 35.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.9 80.5 10.8 8.7 19.5 2004 34.7 1.2 0.7 36.6 44.6 81.2 10.5 8.3 18.8 2005 35.6 1.3 0.7 37.6 44.4 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2008 1 35.2 1.2 0.9 37.4 45.8 83.1 9.6 7.3 16.9 2009 1 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 16.6 15.1 16.6 16.6 16.6 16.6 16.6	2001												
2004 34.7 1.2 0.7 36.6 44.6 81.2 10.5 8.3 18.8 2005 35.6 1.3 0.7 37.6 44.4 81.9 10.1 8.0 18.1 2006 35.6 1.3 0.8 37.7 44.4 81.9 10.1 8.0 18.1 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 35.2 1.2 0.9 37.4 44.9 81.9 10.2 7.9 18.1 2009 1 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 ft forecast.	2002												
2006 35.6 1.3 0.8 37.7 44.7 82.4 9.9 7.8 17.6 2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 f 35.2 1.2 0.9 37.4 45.8 83.1 9.6 7.3 16.9 2009 f 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 f: forecast.	2004	34.7		0.7						81.2			
2007 34.9 1.2 0.8 37.0 44.9 81.9 10.2 7.9 18.1 2008 f 35.2 1.2 0.9 37.4 45.8 83.1 9.6 7.3 16.9 2009 f 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 ft forecast.	2005												
2008 f 35.2 1.2 0.9 37.4 45.8 83.1 9.6 7.3 16.9 2009 f 33.9 1.2 1.1 36.2 47.2 83.4 9.3 7.2 16.6 f: forecast.	2006 2007												
f: forecast.	2008 f	35.2	1.2	0.9		37.4			45.8	83.1	9.6	7.3	16.9
	2009 f	33.9	1.2	1.1		36.2			47.2	83.4	9.3	7.2	16.6
		ty precludes repo	rting provincial-	level insuranc	e data.							Sourc	ce: CIHI, 2009.

Ont.

			Total Health Exp	enditure, C	Ontario, 1985 to	2009 (cont'd)	Share of Dru	gs in Public, Private	and
_	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total		Health Expenditures Private	Total
			(\$ Millions)				(Pe	rcentage Share)	
	420.5	1,067.2	1,487.7	10,443.3		14,442.8	4.0	26.7	
	504.5 599.9	1,259.2 1,388.9	1,763.7 1,988.8	11,730.2 13,011.9		16,097.2 17.866.4	4.3 4.6	28.8 28.6	
	700.4	1,556.3	2,256.7	14,497.9		19,819.8	4.8	29.2	
	793.8	1,741.1	2,534.9	16,093.9	5,876.9	21,970.8	4.9	29.6	
	933.6	1,906.2	2,839.8	17,332.8	6,466.2	23,799.1	5.4	29.5	
	1,070.8	2,084.6	3,155.4	19,156.1		26,194.3	5.6	29.6	
	1,247.8 1,318.9	2,353.7 2,519.6	3,601.5 3,838.5	20,001.5 19,821.7		27,575.2 28,074.9	6.2 6.7	31.1 30.5	
	1,305.1	2,641.0	3,946.1	20,008.0		28,748.7	6.5	30.2	
	1,452.0	2,804.5	4,256.5	19,874.7		29,286.4	7.3	29.8	
	1,438.2	2,917.0	4,355.2	20,038.0		29,693.3	7.2	30.2	
	1,487.5	3,417.2	4,904.7	20,480.8		30,794.8	7.3	33.1	
	1,639.8	3,862.9	5,502.8	22,029.7		33,083.7	7.4	34.9	
	1,799.2	3,867.1	5,666.3	23,344.6	12,033.6	35,378.2	7.7	32.1	
	2,047.0	4,244.5	6,291.5	25,957.7		38,981.0	7.9	32.6	
	2,330.9	4,576.2	6,907.1	27,606.2		41,742.3	8.4	32.4	
	2,672.1	4,972.6 5.404.4	7,644.8	29,626.1		45,422.6	9.0	31.5	
	2,987.8 3,313.0	5,404.4 5,738.2	8,392.3 9,051.2	33,229.2 35,657.2		49,634.2 53,324.4	9.0 9.3	32.9 32.5	
	3,632.1 3,904.0	6,039.7 6,464.2	9,671.8 10,368.2	37,954.5 40,252.0		56,653.1 60,184.4	9.6 9.7	32.3 32.4	
	4,041.6	6,879.2	10,920.8	43,198.1		64,184.5	9.4	32.8	
	4,311.6	7,226.6	11,538.2	46,116.8		68,710.2	9.3	32.0	
	4,322.5	7,613.9	11,936.4 (Annual Percentage C	48,508.7	7 23,751.2	72,259.9	8.9	32.1	
_				nange,	***				
	20.0	18.0	18.6	12.3		11.5			
	18.9	10.3	12.8	10.9		11.0			
	16.7 13.3	12.1 11.9	13.5 12.3	11.4 11.0		10.9 10.9			
	17.6	9.5	12.0	7.7		8.3			
	14.7 16.5	9.4 12.9	11.1 14.1	10.5 4.4		10.1 5.3			
	5.7	7.0	6.6	-0.9		1.8			
	-1.0	4.8	2.8	0.9	5.9	2.4			
	11.3	6.2	7.9	-0.7	7 7.7	1.9			
	-1.0	4.0	2.3	0.8		1.4			
	3.4	17.1	12.6	2.2		3.7			
	10.2 9.7	13.0 0.1	12.2 3.0	7.6 6.0		7.4 6.9			
	13.8	9.8	11.0	11.2		10.2			
	13.9 14.6	7.8 8.7	9.8 10.7	6.4 7.3		7.1 8.8			
	11.8	8.7	9.8	12.2		9.3			
	10.9	6.2	7.9	7.3		7.4			
	9.6	5.3	6.9	6.4	1 5.8	6.2			
	7.5	7.0	7.2	6.1		6.2			
	3.5	6.4	5.3	7.3	5.3	6.6			
	6.7	5.0	5.7	6.8		7.1			
	0.3	5.4	3.5	5.2	2 5.1	5.2			
_	(Percenta	ge Share of Total Dro	ug Expenditure)						
	28.6	71.4	100.0						
	30.2	69.8	100.0						
	31.0	69.0 68.7	100.0						
	31.3	68.7	100.0						
	32.9	67.1	100.0						
	33.9 34.6	66.1 65.4	100.0 100.0						
	34.6 34.4	65.6	100.0						
	33.1	66.9	100.0						
	34.1	65.9	100.0						
	34.1 33.0	67.0	100.0						
	30.3	69.7	100.0						
	29.8	70.2	100.0						
	31.8	68.2	100.0						
	32.5	67.5	100.0						
	33.7	66.3	100.0						
	35.0	65.0	100.0						
	35.6	64.4	100.0						
	36.6	63.4	100.0						
	37.6	62.4	100.0						
	37.7	62.3	100.0						
	37.0	63.0	100.0						
	37.4 36.2	62.6 63.8	100.0 100.0						
		03.0	.00.0						

Ont.

Table B Ont.—per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Ontario, 1985 to 2009

					Prescribed Dr	ugs					Non-Prescribed Drugs Private (Out-of-Pocket)	
	Provincial	Federal	Publ Socia	ic I Security Funds	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Priva Over-	te (Out-of-Po Personal	cket) Total
	1104110101		WCB	Drug Insurance	Public	inodi oro	Pocket	Private	Prescribed	the-	Health	Non-Presc.
				Funds (Premium Component)					Drugs	Counter Drugs	Supplies	Drugs
Year				(Fremium Component)		(\$ per Capit	a)			Diags		
1985	42.96	1.49	0.78		45.23			62.31	107.54			52.47
1986	50.99	1.54	0.93		53.45			74.88	128.33			58.53
1987 1988	59.56 67.45	1.59 2.49	1.05 1.22		62.20 71.16			77.58 85.88	139.78 157.04			66.43 72.24
1989	74.16	3.04	1.34		78.53			94.18	172.71			78.08
1990	85.57	3.52	1.58		90.66			105.82	196.48			79.29
1991	97.11	3.64	1.93		102.68			115.18	217.86			84.72
1992	111.98	3.88	2.20		118.06			130.27	248.33	49.33	43.07	
1993 1994	116.76 114.23	4.37 4.69	2.26 1.71		123.39 120.64			138.67 139.46	262.06 260.09	52.29 56.97	44.77 47.71	97.06 104.67
1995 1996	125.99 122.95	4.83 4.86	1.78 1.95		132.60 129.76			151.60 156.57	284.20 286.34	56.23 57.86	48.29 48.77	
1997	125.36	5.13	1.98		132.48			187.33	319.81	63.26	53.74	
1998	136.36	5.80	2.10		144.26			216.97	361.23	66.04	56.83	
1999	147.75	6.41	2.21		156.37			207.51	363.88	69.50	59.07	128.57
2000	166.31	6.21	2.66		175.18			232.76	407.94	70.58	59.89	
2001	185.97	6.97	2.97		195.91			253.50	449.41	70.64	60.49	
2002 2003	209.57 230.73	7.81 8.69	3.42 4.23		220.80 243.65			276.35 307.12	497.15 550.77	73.36 74.22	61.19 59.39	
2004	252.89	8.76	5.09		266.74			324.80	591.54	76.81	60.39	
2005	273.69	9.66	5.71		289.06			341.47	630.53	77.86	61.32	139.18
2006	291.62	10.36	6.27		308.24			366.18	674.42	80.72	63.49	
2007	298.10	10.56	7.25		315.91			383.41	699.32	87.07	67.23	
2008 f 2009 f	314.26 309.97	10.79 11.05	8.43 9.77		333.48 330.79			408.55 431.32	742.03 762.11	85.23 85.28	65.17 66.07	
2009 1	303.37	11.05	5.77		330.79			431.32	702.11	65.26	00.07	151.55
						(Annual Percentage	Change)					
1985			10.0						10.2			
1986 1987	18.7 16.8	3.3 3.6	19.0 12.8		18.2 16.4			20.2 3.6	19.3 8.9			11.6 13.5
1988	13.2	56.2	16.8		14.4			10.7	12.3			8.8
1989	9.9	22.0	9.6		10.4			9.7	10.0			8.1
1990	15.4	15.8	17.6		15.4			12.4	13.8			1.5
1991	13.5	3.5	22.8		13.3			8.8	10.9			6.9
1992 1993	15.3 4.3	6.5 12.6	13.8 2.7		15.0 4.5			13.1 6.4	14.0 5.5	6.0	3.9	9.1 5.0
1994	-2.2	7.4	-24.2		-2.2			0.4	-0.8	8.9	6.6	
1995	10.3	3.1	3.9		9.9			8.7	9.3	-1.3	1.2	-0.1
1996	-2.4	0.6	9.6		-2.1			3.3	0.8	2.9	1.0	
1997	2.0	5.6	1.6		2.1			19.6	11.7	9.3	10.2	
1998 1999	8.8 8.4	13.0 10.5	6.1 5.0		8.9 8.4			15.8 -4.4	13.0 0.7	4.4 5.2	5.7 3.9	
2000 2001	12.6 11.8	-3.1 12.3	20.4 11.8		12.0 11.8			12.2 8.9	12.1 10.2	1.5 0.1	1.4 1.0	
2001	12.7	12.0	15.1		12.7			9.0	10.6	3.8	1.2	
2003	10.1	11.3	23.6		10.4			11.1	10.8	1.2	-2.9	
2004	9.6	0.7	20.5		9.5			5.8	7.4	3.5	1.7	2.7
2005	8.2	10.3	12.0		8.4			5.1	6.6	1.4	1.5	1.4
2006	6.5	7.3	9.8		6.6			7.2	7.0	3.7	3.5	
2007 2008 f	2.2 5.4	1.9 2.2	15.7 16.2		2.5 5.6			4.7 6.6	3.7 6.1	7.9 -2.1	5.9 -3.1	7.0 -2.5
2009 f	-1.4	2.4	16.0		-0.8			5.6	2.7	0.1	1.4	
				(Anr	nual Percentage Ch	ange in Excess of In	flation in the	Canadian Econ	omy)			
1985												
1986	15.9	0.5	16.2		15.4			17.4	16.5			8.8
1987 1988	12.1 8.7	-1.1 51.6	8.0 12.3		11.6 9.9			-1.1 6.2	4.2 7.8			8.7 4.2
1989	5.4	17.4	5.0		5.8			5.1	5.4			3.5
1990	12.4	12.8	14.6		12.4			9.3	10.7			-1.5
1991	10.7	0.7	20.0		10.5			6.1	8.1			4.1
1992	14.1	5.3	12.6		13.7			11.8	12.7			7.8
1993	2.8	11.2	1.3		3.1			5.0	4.1	4.6	2.5	
1994	-3.3	6.3	-25.3		-3.3			-0.5	-1.8	7.8	5.5	
1995	8.0	0.7	1.5		7.6			6.4	6.9	-3.6	-1.1	
1996 1997	-4.1 1.0	-1.1 4.6	7.9 0.6		-3.8 1.1			1.6 18.7	-0.9 10.7	1.2 8.3	-0.7 9.2	
1998	9.2	13.4	6.6		9.3			16.3	13.4	4.8	6.2	
1999	6.5	8.7	3.2		6.6			-6.2	-1.1	3.4	2.1	
2000	8.5	-7.2	16.3		7.9			8.1	8.0	-2.6	-2.7	
2001	10.5	10.9	10.4		10.5			7.6	8.8	-1.3 2.8	-0.4	
2002 2003	11.6 7.2	10.9 8.4	14.0 20.7		11.7 7.5			8.0 8.2	9.6 7.9	2.8 -1.7	0.1 -5.8	
2004	7.0	-1.9	17.9		6.9			3.2	4.8	0.9	-0.9	
2005	5.3	7.3	9.1		5.4			2.2	3.7	-1.5	-1.4	-1.5
2006	3.7	4.4	6.9		3.7			4.3	4.1	0.8	0.6	0.7
2007	-1.1	-1.4	12.4		-0.8			1.4	0.4	4.5	2.6	
2008 f 2009 f	0.8 0.5	-2.4 4.3	11.5 17.8		0.9 1.1			1.9 7.5	1.5 4.6	-6.8 1.9	-7.7 3.3	
f: forecast.	0.0				***			,.5	*.0	1.5	0.0	2.0
		rting provincial-l									_	e: CIHI, 2009

90

		Expenditur	e on Drugs per Capit Total Health Exp		-			Ont.—per Capit
		All Drugs	10ta: 110ata: <u>2</u> /4		Health Expenditure	,	GDP Implicit Price Index — Canada	
-	Public	Private	Total	Public	Private	Total	THE HOLE SUITED	
ar _			(\$ per Capita)				(1997 = 100)	
85	45.23	114.79	160.01	1,123.23	430.17	1,553.40	73.6	
86 87	53.45 62.20	133.42 144.01	186.87 206.21	1,242.85 1,349.18	462.71 503.36	1,705.55 1,852.54	75.6 79.2	
88	71.16	158.13	229.28	1,473.03	540.72	2,013.75	82.8	
89	78.53	172.26	250.79	1,592.27	581.43	2,173.70	86.6	
90 91	90.66 102.68	185.11 199.90	275.77 302.58	1,683.15 1,836.97	627.92 674.92	2,311.07 2,511.89	89.2 91.6	
92	118.06	222.68	340.74	1,892.32	716.54	2,608.87	92.8	
93	123.39	235.73	359.12	1,854.51	772.16	2,626.67	94.1	
94	120.64	244.13	364.76	1,849.47	807.95	2,657.43	95.2	
95 96	132.60 129.76	256.12 263.20	388.72 392.96	1,815.04 1,807.99	859.52 871.18	2,674.56 2,679.17	97.4 99.0	
97	132.48	304.34	436.81	1,824.04	918.57	2,742.61	100.0	
98 99	144.26	339.84 336.08	484.10	1,938.04 2,028.84	972.46	2,910.50	99.6 101.4	
	156.37		492.45		1,045.82	3,074.66		
00 01	175.18 195.91	363.23 384.63	538.41 580.54	2,221.39 2,320.31	1,114.49 1,188.14	3,335.87 3,508.45	105.5 106.9	
02	220.80	410.89	631.69	2,448.02	1,305.28	3,753.30	108.1	
03 04	243.65 266.74	440.73 462.00	684.38 728.74	2,709.81 2,870.88	1,337.80 1,422.45	4,047.62 4,293.33	111.2 114.1	
05 06	289.06 308.24	480.66 510.39	769.71 818.63	3,020.55 3,178.12	1,488.09 1,573.77	4,508.64 4,751.90	117.4 120.8	
07	315.91	537.71	853.62	3,376.55	1,640.39	5,016.93	124.8	
08 f 09 f	333.48	558.94	892.43	3,566.93	1,747.49	5,314.42 5,529.89	130.6	
091	330.79	582.67	913.46 (Annua	3,712.26 al Percentage Chan	1,817.63 ge)	5,529.69	128.2	
85								
86	18.2	16.2	16.8	10.6	7.6	9.8	2.8	
87 88	16.4 14.4	7.9 9.8	10.4 11.2	8.6 9.2	8.8 7.4	8.6 8.7	4.7 4.5	
89	10.4	8.9	9.4	8.1	7.5	7.9	4.6	
90	15.4	7.5	10.0	5.7	8.0	6.3	3.0	
91	13.3	8.0	9.7	9.1	7.5	8.7	2.8	
92 93	15.0 4.5	11.4 5.9	12.6 5.4	3.0 -2.0	6.2 7.8	3.9 0.7	1.3 1.4	
94	-2.2	3.6	1.6	-0.3	4.6	1.2	1.1	
95	9.9	4.9	6.6	-1.9	6.4	0.6	2.3	
96	-2.1	2.8	1.1	-0.4	1.4	0.2	1.7	
97 98	2.1 8.9	15.6 11.7	11.2 10.8	0.9 6.2	5.4 5.9	2.4 6.1	1.0 -0.4	
99	8.4	-1.1	1.7	4.7	7.5	5.6	1.8	
00	12.0	8.1	9.3	9.5	6.6	8.5	4.1	
01	11.8	5.9	7.8	4.5	6.6	5.2	1.4	
02	12.7	6.8	8.8	5.5	9.9	7.0	1.0	
03 04	10.4 9.5	7.3 4.8	8.3 6.5	10.7 5.9	2.5 6.3	7.8 6.1	2.9 2.6	
05	8.4	4.0	5.6	5.2	4.6	5.0	2.9	
06	6.6	6.2	6.4	5.2	5.8	5.4	2.9	
07	2.5	5.4	4.3	6.2	4.2	5.6	3.3	
08 f 09 f	5.6 -0.8	3.9 4.2	4.5 2.4	5.6 4.1	6.5 4.0	5.9 4.1	4.7 -1.9	
-		(Annual Percent	age Change in Excess of Infla	ation in the Canadia				
85								
16	15.4	13.4	14.0	7.8	4.8	7.0		
17 18	11.6 9.9	3.2 5.3	5.6 6.7	3.8 4.7	4.0 2.9	3.9 4.2		
39	5.8	4.4	4.8	3.5	3.0	3.4		
90	12.4	4.4	6.9	2.7	5.0	3.3		
91	10.5	5.2	7.0	6.4	4.7	5.9		
12	13.7 3.1	10.1 4.4	11.3 4.0	1.8 -3.4	4.9 6.3	2.6 -0.8		
14	-3.3	2.5	0.5	-1.4	3.5	0.1		
15	7.6	2.6	4.2	-4.2	4.0	-1.7		
6	-3.8	1.1	-0.6	-2.1	-0.3	-1.5		
7 8	1.1 9.3	14.6 12.1	10.2 11.3	-0.1 6.7	4.4 6.3	1.4 6.6		
9	6.6	-2.9	-0.1	2.9	5.7	3.8		
00	7.9	4.0	5.2	5.4	2.5	4.4		
01	10.5	4.5	6.5	3.1	5.3	3.8		
)2)3	11.7 7.5	5.8 4.4	7.8 5.4	4.5 7.8	8.8 -0.4	5.9 4.9		
)4	6.9	2.2	3.9	3.4	3.7	3.5		
)5	5.4	1.1	2.7	2.3	1.7	2.1		
06	3.7	3.3	3.5	2.3	2.9	2.5		
07 08 f	-0.8	2.0 -0.7	1.0 -0.1	2.9 1.0	0.9 1.9	2.3		
08 f 09 f	0.9 1.1	-0.7 6.1	-0.1 4.2	1.0 6.0	1.9 5.9	1.3 5.9		
		-		· •				

Man.

: forecast.

Table B Man. - Total Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Manitoba, 1985 to 2009 Prescribed Drugs Non-Prescribed Drugs Private (Out-of-Pocket) Public Private Sub-Total Federal Social Security Funds Insurers Sub-Total Over-Total Provincial Out-of-Total Personal WCB Health Drug Insurance Drugs Funds Druas Counter Supplies (Premium Component) Drugs (\$ Millions) 985 61.0 32.5 0.3 39.2 60.0 99.2 986 34.6 7.2 7.7 0.4 42.2 68.2 110.4 69.1 42.3 50.4 61.9 112.3 80.1 1988 47.5 9.3 0.5 57.3 68.1 125.4 75.4 1989 45.5 74.9 132.5 1990 48.5 13.8 0.7 62.9 86.2 149.1 75.3 51.5 41.6 1992 68.1 18.6 0.8 87.5 101.6 189.1 93.2 1993 68.1 61.1 21.9 24.6 0.7 90.7 86.5 118.5 129.1 209.2 215.6 50.4 52.3 41.9 92.2 94.8 42.5 1994 0.8 79.6 27.8 108.3 148.0 256.3 41.7 92.5 1996 73.8 28.6 0.9 103.2 163.4 266.7 54.2 47.3 101.5 73.7 106.0 186.7 292.7 48.1 43.7 1998 85.9 33.7 1.0 120.5 189.0 309.5 55.3 50.9 106.3 1999 105.6 36.9 1.1 143.6 180.5 324.2 58.4 50.8 109.3 2000 130.9 38.4 1.3 170.7 205.3 376.0 60.8 52.6 113.3 160.8 207.0 212.3 2002 189.6 52.0 1.7 243.3 239.4 482.7 65.6 54.8 120.4 2003 217.7 60.7 65.3 280.4 266.7 277.2 547.1 68.3 71.9 56.3 58.0 124.6 2.1 2.3 579.4 2004 234.6 302.2 129.9 616.1 687.0 2005 249.5 70.9 2.4 322.7 293.3 74.0 134.1 63.4 2006 260.2 79.4 2.6 342.3 344.8 78.9 142.3 362.5 410.3 63.4 67.1 2007 271 6 83.8 2.7 358.2 720.6 82.8 146.2 277.6 779.1 156.2 2008 1 3.2 368.8 88.1 89.1 2009 1 280.1 93.9 3.6 377.6 444.1 821.8 91.2 69.9 161.1 (Annual Percentage Change) 1985 1986 6.6 11.1 23.4 7.4 13.7 11.3 13.2 22.2 16.0 1988 12.4 19.8 25.2 13.6 10.1 11.7 -5.9 0.5 10.1 16.1 7.1 1990 6.5 19.7 9.3 15.0 12.5 6.2 14.3 17.8 11.2 1991 15.0 12.8 1992 22.9 14.4 17.9 20.9 6.1 12.5 14.4 1994 -10.2 12.1 5.3 -4.7 8.9 3.0 3.8 1.6 2.8 1995 30.2 13.3 9.2 25.2 14.6 18.9 -2.9 -1.9 -2.4 1996 -7.3 2.8 4.7 -4.6 10.4 6.7 13.3 9.7 2.7 1998 16.5 7.4 2.5 13.7 1.2 5.7 15.0 16.6 15.8 1999 22.9 9.7 13.8 19.2 -4.5 4.7 5.6 -0.2 2.8 2000 24.0 4.0 20.6 18.8 13.7 16.0 4.1 3.4 3.7 5.3 22.8 16.0 2.0 2002 17.9 16.7 7.9 17.6 12.8 15.1 2.2 2.3 2003 14.8 16.7 19.9 15.3 11.4 13.3 4.1 2.7 3.5 4.3 7.7 13.0 7.8 5.9 2004 3.5 2.9 2006 4.3 12.1 10.9 6.0 17.5 11.5 6.6 5.6 6.2 2007 2008 1 2.2 5.2 14.9 3.0 13.2 8.1 7.6 5.8 6.8 2009 1 0.9 6.6 15.1 2.4 8.2 5.5 2.4 4.1 3.2 entage Share (Per of Total Drug Expenditure 1985 20.3 4.1 0.2 24.5 37.4 61.9 38.1 19.3 22.0 38.5 1986 4.0 0.2 23.5 38.0 61.5 0.2 26.2 32.2 1988 23.7 4.6 0.3 28.5 33.9 62.5 37.5 1989 22.4 6.1 6.5 66.4 67.4 1990 21.6 0.3 28.0 38.4 33.6 0.3 38.4 1991 29.0 18.3 14.7 1992 24.1 6.6 0.3 31.0 36.0 67.0 33.0 1994 19.7 7.9 0.2 27.9 41.6 69.5 16.8 13.7 30.5 1995 22.8 8.0 0.2 31.0 42.4 73.5 14.6 12.0 26.5 12.8 11.4 1996 20.0 7.8 0.2 28.0 44.4 72.4 14.7 27.6 48.6 1998 20.7 8.1 0.2 29.0 45.4 74.4 13.3 12.2 25.6 33.1 74.8 13.5 2000 26.8 7.8 0.3 34.9 42.0 76.8 12.4 10.7 23.2 38.5 11.9 10.0 2001 30.0 0.3 39.5 2002 31.4 8.6 0.3 40.3 39.7 80.0 10.9 20.0 2004 33.1 9.2 0.3 42.6 39.1 81.7 10.1 8.2 18.3 2005 33.3 9.4 0.3 43.0 39.1 82.1 9.9 17.9 8.0 9.6 9.7 41.6 41.8 9.5 9.6 2006 31.4 0.3 41.3 82.8 17.2 31.3 0.3 41.3 83.1 7.3 16.9 2008 1 29.7 9.4 0.3 39.4 43.9 83.3 9.5 7.2 16.7 2009 1

Man.

	Expenditure	•	e, by Source of I xpenditure, Man		a Share of Public 2009 (cont'd)			
	All Drugs		-	ealth Expenditure			s in Public, Private ealth Expenditures	and
 Public	Private	Total	Public	Private	Total	Public	Private	Tota
						_		
 39.2	121.0	(\$ Million		415.6	1 726 5	3.0	centage Share) 29.1	
42.2	137.3	179.4	1,310.9 1,425.8	463.9	1,726.5 1,889.7	3.0	29.6	
50.4	141.9	192.4	1,530.2	449.9	1,980.2	3.3	31.5	
57.3 57.6	143.4 145.8	200.7 203.4	1,634.3 1,773.2	435.4 484.2	2,069.6 2,257.4	3.5 3.2	32.9 30.1	
62.9 72.4	161.5 177.3	224.4 249.6	1,951.1 2,006.0	533.2 570.0	2,484.3 2,576.0	3.2 3.6	30.3 31.1	
87.5	194.8	282.3	2,099.3	602.6	2,701.9	4.2	32.3	
90.7	210.8	301.5	2,088.9	660.2	2,749.1	4.3	31.9	
86.5	223.9	310.4	2,115.7	689.2	2,804.9	4.1	32.5	
108.3	240.5	348.8	2,179.4	736.1	2,915.5	5.0	32.7	
103.2 106.0	264.9 278.5	368.2 384.5	2,185.3 2,251.9	786.8 848.6	2,972.1 3,100.5	4.7 4.7	33.7 32.8	
120.5	278.5	415.8	2,388.6	893.3	3,281.9	5.0	33.0	
143.6	289.8	433.4	2,714.9	979.7	3,694.6	5.3	29.6	
170.7	318.6	489.3	3,005.3	1,040.4	4,045.7	5.7	30.6	
207.0	329.9	536.9	3,184.5	1,173.0	4,357.6	6.5	28.1	
243.3	359.8	603.1	3,366.5	1,224.8	4,591.3	7.2	29.4	
280.4 302.2	391.2 407.1	671.7 709.4	3,654.0 3,896.9	1,264.5	4,918.4 5.218.9	7.7 7.8	30.9 30.8	
	407.1	709.4	3,896.9	1,322.0	5,218.9	7.8	30.8	
322.7 342.3	427.4 487.1	750.2 829.4	4,199.3 4,438.7	1,408.1 1,446.3	5,607.5 5,885.0	7.7 7.7	30.4 33.7	
358.2	508.7	866.8	4,693.7	1,585.6	6,279.3	7.7	32.1	
368.8	566.5	935.3	4,977.0	1,739.5	6,716.6	7.4	32.6	
377.6	605.2	982.9	5,212.9	1,845.3	7,058.2	7.2	32.8	
		(Annual Percentaç						
		12.0						
7.4 19.6	13.5 3.4	12.0 7.2	8.8 7.3	11.6 -3.0	9.5 4.8			
13.6	1.1	4.4	6.8	-3.2	4.5			
0.5	1.7	1.4	8.5	11.2	9.1			
9.3	10.7	10.3	10.0	10.1	10.1			
15.0	9.8	11.2	2.8	6.9	3.7			
20.9	9.9	13.1	4.7	5.7	4.9			
3.6 -4.7	8.2 6.2	6.8 3.0	-0.5 1.3	9.6 4.4	1.7 2.0			
25.2	7.4	12.4	3.0	6.8	3.9			
-4.6	10.1	5.6	0.3	6.9	1.9			
2.7	5.1	4.4 8.1	3.0	7.9	4.3			
13.7 19.2	6.0 -1.8	4.3	6.1 13.7	5.3 9.7	5.8 12.6			
18.8	10.0	12.9	10.7	6.2	9.5			
21.3	3.5	9.7	6.0	12.7	7.7			
17.6	9.0	12.3	5.7	4.4	5.4			
15.3	8.7	11.4	8.5	3.2	7.1			
7.8	4.1	5.6	6.6	4.5	6.1			
6.8	5.0	5.8	7.8	6.5	7.4			
6.0 4.6	14.0 4.4	10.6 4.5	5.7 5.7	2.7 9.6	4.9 6.7			
3.0	11.4	7.9	6.0	9.7	7.0			
2.4	6.8	5.1	4.7	6.1	5.1			
 (Percenta	ge Share of Total Dr							
 24.5	75.5	100.0						
23.5	76.5	100.0						
26.2	73.8	100.0						
28.5 28.3	71.5 71.7	100.0 100.0						
28.0 29.0	72.0 71.0	100.0 100.0						
31.0	69.0	100.0						
30.1	69.9	100.0						
27.9	72.1	100.0						
31.0	69.0	100.0						
28.0	72.0	100.0						
27.6 29.0	72.4 71.0	100.0 100.0						
33.1	66.9	100.0						
34.9	65.1	100.0						
38.5	61.5	100.0						
40.3	59.7	100.0						
41.8	58.2	100.0						
42.6	57.4	100.0						
43.0	57.0	100.0						
41.3 41.3	58.7 58.7	100.0 100.0						
39.4	60.6	100.0						
38.4	61.6	100.0						

8.2

1.3

7.9

0.2

2.3

Confidentiality precludes reporting provincial-level insurance data

2007

2009 f

7.1

1.0

16.4

Table B Man.—per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Manitoba, 1985 to 2009

Non-Prescribed Drugs Prescribed Drugs Public Private (Out-of-Pocket) Private Sub-Total Sub-Total Provincial Federal Social Security Funds Insurers* Out-of-Total Over Total Drug Insurance Private rescribed Non-Presc Funds Drugs Counter Supplies Drugs (Premium Component) Drugs (\$ per Capita) 1985 36.26 55.40 56.35 29.98 6.00 0.28 91.67 101.10 102.25 986 31.68 6.60 0.34 38.62 62.48 63.26 1987 38.48 7.05 0.38 45.91 56.33 72.94 1988 43.10 8.42 0.47 51.99 61.78 113.77 68.38 67.91 0.51 64.25 41.26 52.20 120.11 1990 43.87 12.47 0.59 56.92 77.93 134.85 68.1 49.95 14.63 0.63 65.21 151.55 73.41 1991 86.34 1992 61 22 16 69 0.74 78 65 91.33 169 98 46 32 37 42 83 73 37.46 1993 60.90 19.59 0.66 81.15 106.06 45.06 82.52 1994 54.43 21.86 0.69 76.99 114.94 191.92 46.55 37.86 84.41 1995 70.49 24.65 0.75 95.89 131.08 226.97 44.97 81.93 36.96 0.78 1996 65.03 25.22 91.03 144.10 235.13 47 77 41.69 89 46 1997 64.88 27.59 164.30 257.61 42.34 38.45 80.79 93.31 1998 75.51 29.60 0.86 105.97 166.11 272.09 48.64 44.77 93.41 92.43 125.72 158.03 44.50 95.63 2000 114.11 33.47 1.17 148.75 178.93 327.68 52.97 45.82 98.79 184.40 46.57 47.43 2001 139.70 38.69 1.38 179.77 55.61 364.18 102.18 2002 164.09 45.00 1.48 210.57 207.17 417.74 56.75 104.18 187.38 ---49.58 2004 200.39 55.82 1.98 258.19 236.82 495.01 61.42 111.00 2005 212.51 60.36 2.00 274.87 249.84 524.71 63.01 51.18 114.19 2006 219.78 67.07 2.20 289.06 291.19 580.25 66.62 53.58 120.20 227.60 2.30 303.70 603.79 69.37 53.13 2008 1 229.78 72.93 2.61 305.32 339.70 645.01 73.74 55.56 129.30 2009 230.69 310.99 676.71 132.70 (Annual Percentage Change) 1985 1986 5.6 10.1 22.4 6.5 12.8 10.3 12.3 21.5 6.8 9.5 18.9 -9.8 15.3 1988 12.0 19.4 24.8 13.2 9.7 11.3 -6.3 1989 23.9 8.3 0.4 5.6 -6.0 6.0 7.8 1990 6.3 195 15.9 9.0 14 8 12.3 13.9 17.3 14.6 10.8 12.4 1991 6.8 1992 22.6 14.1 17.5 20.6 5.8 12.2 14.1 16.1 -10.6 1994 11.6 4.8 -5.1 8.4 2.5 3.3 1.1 2.3 ------18.3 1996 -7.7 2.3 4.2 -5.1 9.9 3.6 6.2 12.8 9.2 14.9 15.6 1998 16.4 7.3 2.4 13.6 5.6 16.4 1999 22.4 9.2 13.3 18.6 -4.9 4.3 5.1 -0.6 2.4 23.5 3.3 2000 3.5 20.1 18.3 13.2 15.5 3.6 3.0 22.4 15.6 17.6 5.0 2001 20.9 11.1 3.1 1.6 2002 17.5 16.3 7.5 17.1 12.3 14.7 2.0 1.8 2.0 2003 16.1 10.8 12.7 3.5 2004 6.9 6.9 12.1 7.0 3.2 5.1 4.5 2.3 3.5 2005 6.0 8.1 1.1 6.5 2.6 2.9 5.5 6.0 3.2 3.4 3.6 11.1 4.6 16.6 4.3 10.6 4.1 5.7 4.1 2006 9.9 4.3 5.2 4.7 3.8 -0.8 2007 2008 1 1.0 3.9 13.5 1.7 11.9 6.8 6.3 4.6 5.5 (Annual Percentage Change in Excess of Inflation in the Canadian Economy) 1985 1986 2.8 7.3 19.6 3.7 10.0 7.5 9.5 16.7 4.8 -14.6 -3.6 10.6 1988 7.5 14.9 20.2 8.7 5.1 6.7 -10.8 19.4 -4.2 5.3 1.0 1990 3.3 16.4 12.9 6.0 11.7 9.3 3.0 8.0 1992 21.3 12.8 16.3 19.4 4.5 10.9 12.8 1993 -1.3 2.2 3.7 1994 -11.7 10.5 -6.2 7.3 1.4 0.0 1.2 27.2 -4.7 1995 10.4 ---11.7 15.9 -5.7 -5.3 1996 -9.4 -1.2 0.6 2.6 -6.7 8.3 1.9 4.6 11.1 7.5 1997 13.0 -12.4 10.7 7.7 14.0 1998 16.8 2.8 1.5 6.1 15.3 16.9 16.1 1999 20.6 7.4 11.5 16.8 -6.7 2.5 3.3 -2.4 0.6 -0.6 16.0 2000 19.4 14.2 ---9.1 1.7 11.4 -0.5 -1.2 -0.8 14.3 15.2 3.6 2.1 6.4 11.3 13.7 2002 16.4 16.1 0.8 2003 11.3 13.2 16.3 11.7 7.9 0.6 -0.7 0.0 0.6 -0.3 2005 3.1 5.2 -1.8 3.5 2.6 3.1 -0.3 0.3 0.0

Man.

94 CIHI 2010

0.5

3.7

13.7

1.0

9.5

0.7

6.8

2.8

0.8

3.8

1.8

-4.2

5.5

-1.4 0.9

4.5

Man.

		Expenditure	e on Drugs per Capit Total Health Expe		•			Man. – per Capit
		All Drugs			lealth Expenditure	,	GDP Implicit Price Index—Canada	
_	Public	Private	Total	Public	Private	Total	· · · · · · · · · · · · · · · · · · ·	
ear			(\$ per Capita)				(1997 = 100)	
985	36.26	111.76	148.02	1,211.28	383.98	1,595.25	73.6	
986 987	38.62 45.91	125.74 129.27	164.36 175.18	1,306.04 1,393.62	424.97 409.78	1,731.01 1,803.40	75.6 79.2	
988	51.99	130.16	182.14	1,482.95	395.06	1,878.01	82.8	
989	52.20	132.15	184.35	1,606.82	438.77	2,045.59	86.6	
990	56.92	146.04	202.96	1,764.67	482.25	2,246.92	89.2	
991 992	65.21	159.76	224.97	1,807.82	513.71	2,321.53	91.6 92.8	
993	78.65 81.15	175.06 188.58	253.71 269.73	1,886.70 1,869.05	541.56 590.76	2,428.27 2,459.81	94.1	
994	76.99	199.34	276.33	1,883.55	613.62	2,497.17	95.2	
995	95.89	213.01	308.90	1,930.11	651.90	2,582.01	97.4	
996	91.03	233.57	324.60	1,926.73	693.69	2,620.42	99.0	
997 998	93.31 105.97	245.09 259.52	338.40 365.50	1,982.07 2,099.82	746.91 785.30	2,728.98 2,885.12	100.0 99.6	
999	125.72	253.66	379.38	2,376.29	857.55	3,233.84	101.4	
000	148.75	277.72	426.47	2,619.32	906.78	3,526.10	105.5	
001	179.77	286.58	466.36	2,766.07	1,018.88	3,784.95	106.9	
002 003	210.57	311.35 336.73	521.92 578.10	2,913.23	1,059.91	3,973.14	108.1 111.2	
004	241.36 258.19	347.82	606.02	3,144.82 3,329.13	1,088.30 1,129.39	4,233.12 4,458.52	111.2	
005	274.87	364.03	638.90	3,576.49	1,199.27	4,775.76	117.4	
006	289.06	411.39	700.45	3,748.83	1,221.48	4,970.31	120.8	
007	300.09	426.20	726.29	3,932.68	1,328.50	5,261.18	124.8	
008 f 009 f	305.32 310.99	469.00 498.42	774.32 809.41	4,120.19 4,292.85	1,440.07 1,519.57	5,560.25 5,812.42	130.6 128.2	
	310.55	450.42		al Percentage Chang		5,612.42	128.2	
985								
986	6.5	12.5	11.0	7.8	10.7	8.5	2.8	
987 988	18.9 13.2	2.8 0.7	6.6 4.0	6.7	-3.6 -3.6	4.2 4.1	4.7 4.5	
989	0.4	1.5	1.2	6.4 8.4	11.1	8.9	4.6	
990	9.0	10.5	10.1	9.8	9.9	9.8	3.0	
991	14.6	9.4	10.8	2.4	6.5	3.3	2.8	
992	20.6	9.6	12.8	4.4	5.4	4.6	1.3	
993 994	3.2	7.7	6.3 2.4	-0.9	9.1 3.9	1.3 1.5	1.4 1.1	
	-5.1	5.7		0.8				
995 996	24.6 -5.1	6.9 9.7	11.8 5.1	2.5 -0.2	6.2 6.4	3.4 1.5	2.3 1.7	
997	2.5	4.9	4.3	2.9	7.7	4.1	1.0	
998	13.6	5.9	8.0	5.9	5.1	5.7	-0.4	
999	18.6	-2.3	3.8	13.2	9.2	12.1	1.8	
000 001	18.3 20.9	9.5 3.2	12.4	10.2	5.7	9.0 7.3	4.1 1.4	
002	17.1	8.6	9.4 11.9	5.6 5.3	12.4 4.0	5.0	1.4	
003	14.6	8.2	10.8	7.9	2.7	6.5	2.9	
004	7.0	3.3	4.8	5.9	3.8	5.3	2.6	
005	6.5	4.7	5.4	7.4	6.2	7.1	2.9	
006 007	5.2 3.8	13.0 3.6	9.6 3.7	4.8 4.9	1.9 8.8	4.1 5.9	2.9 3.3	
008 f	1.7	10.0	6.6	4.8	8.4	5.7	4.7	
009 f	1.9	6.3	4.5	4.2	5.5	4.5	-1.9	
_		(Annual Percent	age Change in Excess of Infla	tion in the Canadiar	n Economy)			
985								
986	3.7	9.7	8.2	5.0	7.9	5.7		
987 988	14.1 8.7	-1.9 -3.8	1.8 -0.5	2.0 1.9	-8.3 -8.1	-0.6 -0.4		
989	-4.2	-3.0	-3.4	3.8	6.5	4.4		
990	6.0	7.5	7.1	6.8	6.9	6.8		
991	11.8	6.6	8.1	-0.3	3.8	0.6		
992	19.4	8.3	11.5	3.1	4.2	3.3		
993 994	1.7 -6.2	6.3 4.6	4.9 1.3	-2.4 -0.3	7.6 2.8	-0.1 0.4		
995 996	22.2 -6.7	4.5 8.0	9.4 3.4	0.1 -1.8	3.9 4.7	1.1 -0.2		
997	1.5	3.9	3.3	1.9	6.7	3.2		
998	14.0	6.3	8.4	6.4	5.6	6.2		
999	16.8	-4.1	2.0	11.4	7.4	10.3		
000	14.2	5.4	8.3	6.1	1.6	4.9		
001 002	19.5 16.1	1.8 7.6	8.0 10.9	4.2 4.3	11.0 3.0	6.0 3.9		
003	11.7	5.3	7.9	4.3 5.1	-0.2	3.6		
004	4.4	0.7	2.2	3.3	1.2	2.7		
005	3.5	1.7	2.5	4.5	3.3	4.2		
006	2.3	10.1	6.7	1.9	-1.0	1.2		
007 008 f	0.5 -2.9	0.3 5.4	0.4 2.0	1.6 0.1	5.4 3.7	2.5 1.0		
009 f	3.7	8.2	6.4	6.1	7.4	6.4		
								Source: CIHI, 200

Sask.

-	Prescribed Drugs Public Private						Non-Prescribed Drugs Private (Out-of-Pocket)					
Provin	ncial	Federal		Il Security Funds Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed	Over- the-	Personal Health	Total Non-Presc.
				Funds (Premium Component)					Drugs	Counter Drugs	Supplies	Drugs
-						(\$ Millions)						
	67.6 81.1	6.3 7.1	0.1		74.0 88.3			26.8 33.8	100.8 122.1			35. 40.
	67.8	7.1	0.1		75.7			42.5	118.2			46.
	63.0	9.7	0.3		73.1			53.5	126.5			58.
	74.8	12.2	0.2		87.2			67.3	154.5			73.
	88.7	14.5	0.3		103.5			79.5	183.0			74.
	93.5	16.8	0.3		110.6			89.2	199.8			73.
	85.0 57.8	19.0 22.4	0.3 0.4		104.3 80.6			99.5 126.7	203.8 207.3	40.6 49.9	35.6 44.9	
	56.2	25.0	0.4		81.6			141.3	222.9	51.7	45.5	
	63.8	28.0	0.5		92.2			146.8	239.0	50.1	44.7	94.
	66.6	28.8	0.8		96.2			148.1	244.3	47.4	44.8	
	69.3	31.2	0.8		101.3			161.2	262.5	48.9	47.3	
	78.9	33.7	0.9		113.6			167.4	280.9 303.0	47.6	46.7	94.
	89.1	38.8	1.1		129.0			174.0	303.0	52.8	48.7	101.
	100.2	42.3	1.3		143.8			185.6	329.4	55.9	51.0	106.
	116.3 133.9	48.1 55.2	1.6 1.9		165.9			216.1 222.5	382.1 413.6	57.1 58.1	50.5 51.3	
	151.4	62.5	2.2		191.0 216.1			252.3	468.4	57.4	50.0	
	168.1	64.9	2.5		235.5			274.1	509.6	60.4	51.8	
	185.4	68.2	2.7		256.3			286.1	542.4	61.9	53.6	115.
	201.9	73.1	2.9		277.9			282.5	560.4	63.3	54.2	
:	241.0	75.7	3.0		319.7			300.9	620.7	65.7	53.6	119.
	289.7 316.7	78.2 81.2	3.8 4.3		371.7 402.1			328.1 336.3	699.7 738.4	67.6 69.8	53.6 53.7	121. 123.
`	310.7	01.2	4.3		402.1	(Annual Percentage		330.3	730.4	09.0	53.7	123.
-									***			
	20.0	13.1	2.4		19.3			25.8	21.1			13.
	-16.4	8.9	42.4		-14.2			25.8	-3.2			16.
	-7.1 18.7	26.1 25.3	58.9 -28.9		-3.5 19.4			25.8 25.8	7.0 22.1			25. 25.
	18.7 5.4	18.6 16.1	9.8 5.4		18.6 6.9			18.2 12.2	18.5 9.2			1. -1.
	-9.1	12.9	20.3		-5.7			11.5	2.0			4.
	-32.0	18.1	32.9		-22.7			27.3	1.7	22.7	26.3	24.
	-2.8	11.7	-2.2		1.3			11.5	7.5	3.6	1.3	2.
	13.6	11.7	16.1		13.0 4.3			3.9 0.9	7.2 2.2	-3.0	-1.9 0.4	
	4.4 4.0	3.0 8.3	63.1 4.3		4.3 5.3			8.8	7.4	-5.4 3.1	5.5	-2. 4.
	13.9	8.1	9.6		12.1			3.9	7.0	-2.5	-1.2	-1.
	12.9	15.1	22.0		13.6			3.9	7.8	10.8	4.1	7.
	12.4	9.0	16.4		11.4			6.7	8.7	5.8	4.9	5.
	16.1	13.8	18.5		15.4			16.4	16.0	2.2	-1.0	
	15.1	14.9	20.9		15.1			3.0	8.2	1.7	1.5	
	13.1 11.0	13.1 3.8	14.4 17.3		13.1 9.0			13.4 8.6	13.2 8.8	-1.2 5.2	-2.5 3.7	-1. 4.
	10.3 8.9	5.1 7.3	5.4 8.4		8.8 8.5			4.4 -1.3	6.4 3.3	2.5 2.2	3.4 1.2	2. 1.
	19.4	3.5	3.8		15.0			6.5	10.7	3.8	-1.1	1.
	20.2	3.3	25.5		16.2			9.0	12.7	2.9	0.0	1.
	9.3	3.8	12.9		8.2			2.5	5.5	3.2	0.1	1.
	40.0					tage Share of Total D			74.4			0-
	49.6 50.0	4.6 4.4	0.1 0.1		54.4 54.5			19.7 20.8	74.1 75.3			25. 24.
	41.2	4.7	0.1		46.0			25.8	71.8			28.
	34.1	5.3	0.2		39.5			28.9	68.5			31.
	32.8	5.4	0.1		38.3			29.5	67.9			32.
	34.5	5.6	0.1		40.2			30.9	71.1			28.
	34.3	6.2	0.1		40.5			32.7	73.3	14.5	12.7	26.
	30.3 19.1	6.8 7.4	0.1 0.1		37.2 26.7			35.5 41.9	72.8 68.6	14.5 16.5	12.7 14.9	27. 31.
	17.5	7.8	0.1		25.5			44.1	69.6	16.1	14.2	30.
	19.1	8.4	0.1		27.6			44.0	71.6	15.0	13.4	28.
	19.8 19.3	8.6 8.7	0.2		28.6 28.2			44.0 44.9	72.6 73.2	14.1 13.6	13.3 13.2	27. 26.
	21.0	9.0	0.2		30.3			44.9 44.6	73.2 74.9	12.7	13.2	26. 25.
	22.0	9.6	0.3		31.9			43.0	74.9	13.1	12.0	25.
	23.0	9.7	0.3		32.9			42.5	75.5	12.8	11.7	24.
	23.7	9.8	0.3		33.9			44.1	78.0	11.7	10.3	22.
	25.6	10.6	0.4		36.5			42.6	79.1	11.1	9.8	20.
	26.3	10.9	0.4		37.5			43.8	81.3	10.0	8.7	18.
	27.0	10.4	0.4	***	37.9			44.1	81.9	9.7	8.3	18.
		10.4	0.4		39.0			43.5	82.4	9.4	8.1	17.
	28.2							41.7	82.7	9.3	8.0	17.
	29.8	10.8	0.4		41.0							
	29.8 32.6	10.8 10.2	0.4		43.2			40.7	83.9	8.9	7.2	16.
	29.8	10.8										16 14

Sask.

		Expenditure	•	e, by Source of Fi			, Private and	Table B Sasl	. — I Ot
		All Drugs	Total Health Exp	enditure, Saskatc	hewan, 1985 alth Expenditure	to 2009 (cont'd)	Share of Drugs	in Public, Private an	d
-	Public	Private	Total	Public	Private	Total		Private	Total
_			(\$ Millio	ns)			(Perc	entage Share)	
	74.0	62.1	136.1	1,195.5	333.2	1,528.8	6.2	18.6	8
	88.3 75.7	73.7 88.9	162.0 164.6	1,325.9 1,372.2	377.7 395.5	1,703.6 1,767.8	6.7 5.5	19.5 22.5	!
	73.1	111.7	184.8	1,468.3	369.3	1,837.6	5.0	30.2	10
	87.2	140.4	227.7	1,629.2	423.7	2,052.9	5.4	33.1	1
	103.5 110.6	153.9 162.2	257.4 272.8	1,792.1 1,828.9	460.1 490.9	2,252.2 2,319.8	5.8 6.0	33.4 33.0	1
	104.3	175.8	280.1	1,819.5	505.8	2,325.4	5.7	34.7	1
	80.6 81.6	221.5 238.5	302.1 320.1	1,727.8 1,778.8	574.1 606.4	2,301.9 2,385.2	4.7 4.6	38.6 39.3	1
	92.2	241.6	333.8	1,820.8	621.5	2,442.3	5.1	38.9	1
	96.2	240.4	336.6	1,862.3	627.7	2,490.0	5.2	38.3	1
	101.3	257.4 261.8	358.6	1,976.1	680.1	2,656.2 2,776.8	5.1 5.4	37.8	1
	113.6 129.0	275.4	375.3 404.5	2,103.5 2,250.4	673.3 725.0	2,975.4	5.7	38.9 38.0	1
	143.8	292.5	436.3	2,381.2	773.9	3,155.1	6.0	37.8	1
	165.9	323.8	489.7	2,581.5	869.6	3,451.1	6.4	37.2	1
	191.0 216.1	332.0 359.7	523.0 575.8	2,725.4 2,895.7	899.0 971.3	3,624.4 3,866.9	7.0 7.5	36.9 37.0	1
	235.5	386.3	621.8	3,105.3	1,021.4	4,126.7	7.6	37.8	1
	256.3	401.7	657.9	3,374.1	1,050.2	4,424.3	7.6	38.2	1
	277.9	400.1	678.0	3,602.1	1,160.0	4,762.1	7.7	34.5	1
	319.7 371.7	420.3 449.3	740.1 821.0	3,886.0 4,244.2	1,218.4 1,339.1	5,104.4 5,583.3	8.2 8.8	34.5 33.6	1
	402.1	459.8	861.9	4,488.1	1,406.3	5,894.3	9.0	32.7	1
_			(Annual Percenta	ige Change)					
	19.3 -14.2	18.7 20.5	19.0 1.6	10.9 3.5	13.4 4.7	11.4 3.8			
	-3.5	25.7	12.3	7.0	-6.6	4.0			
	19.4	25.7	23.2	11.0	14.7	11.7			
	18.6	9.6	13.0	10.0	8.6	9.7			
	6.9 -5.7	5.4 8.4	6.0 2.7	2.1 -0.5	6.7 3.0	3.0 0.2			
	-22.7	26.0	7.9	-5.0	13.5	-1.0			
	1.3	7.7	5.9	3.0	5.6	3.6			
	13.0	1.3	4.3	2.4	2.5	2.4			
	4.3 5.3	-0.5 7.1	0.8 6.6	2.3 6.1	1.0 8.3	2.0 6.7			
	12.1	1.7	4.6	6.4	-1.0	4.5			
	13.6	5.2	7.8	7.0	7.7	7.2			
	11.4 15.4	6.2 10.7	7.9 12.2	5.8 8.4	6.7 12.4	6.0 9.4			
	15.1	2.5	6.8	5.6	3.4	5.0			
	13.1	8.3	10.1	6.2	8.0	6.7			
	9.0	7.4	8.0	7.2	5.2	6.7			
	8.8 8.5	4.0 -0.4	5.8 3.0	8.7 6.8	2.8 10.5	7.2 7.6			
	15.0	5.1	9.2	7.9	5.0	7.2			
	16.2	6.9 2.3	10.9	9.2	9.9	9.4			
	8.2		5.0	5.7	5.0	5.6			
-		e Share of Total Dr		<u> </u>					
	54.4 54.5	45.6 45.5	100.0 100.0						
	46.0	54.0	100.0						
	39.5 38.3	60.5 61.7	100.0 100.0						
	40.2 40.5	59.8 59.5	100.0 100.0						
	37.2	62.8	100.0						
	26.7 25.5	73.3 74.5	100.0 100.0						
	27.6 28.6	72.4 71.4	100.0 100.0						
	28.2	71.8	100.0						
	30.3 31.9	69.7 68.1	100.0 100.0						
	32.9 33.9	67.1 66.1	100.0 100.0						
	36.5	63.5	100.0						
	37.5 37.9	62.5 62.1	100.0 100.0						
	39.0 41.0	61.0 59.0	100.0 100.0						
	43.2	56.8	100.0						
	45.3 46.7	54.7 53.3	100.0 100.0						
	40.7	33.3	100.0						

Confidentiality precludes reporting provincial-level insurance data

Table B Sask.—per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Saskatchewan, 1985 to 2009

Non-Prescribed Drugs Prescribed Drugs Public Private (Out-of-Pocket) Private Sub-Total Sub-Total Provincial Federal Social Security Funds Insurers* Out-of-Total Over Total Drug Insurance Private rescribed Non-Preso Funds Drugs Counter Supplies Drugs (Premium Component) Drugs (\$ per Capita) 1985 65.90 6.11 72.15 26.16 34.43 0.14 98.31 78.76 65.64 6.89 7.48 85.79 73.32 32.80 41.13 986 0.14 118.59 38.85 987 0.20 114.45 44.90 1988 61.28 9.47 0.32 71.08 52.00 123.08 56.67 73.37 11.97 0.23 71.80 85.58 66.00 151.57 1990 88.11 14.37 0.26 102.73 78.97 181.70 73.85 0.27 93.26 16.75 89.00 72.76 1991 110.29 199.30 1992 84 66 18 90 0.33 103.88 99 15 203.03 40 47 35 45 75 92 57.37 22.26 44.64 80.07 125.84 205.90 49.53 1994 55.63 24.80 0.43 80.85 139.94 220.79 51.18 45.12 96.29 27.57 1995 62.89 0.49 144.72 235.66 49.43 44.05 93.48 90.94 145.37 158.31 1996 65.33 28.25 0.80 94.39 239.76 46.51 44.00 90.51 1997 68.04 30.62 0.83 99.49 257.80 48.02 46.46 94.48 1998 77.57 33.12 0.91 111.61 164.51 276.12 46.83 45.92 92.75 87.81 127.15 171.45 47.95 100.01 2000 99.38 41.95 1.31 142.64 184.19 326.83 55 45 50.65 106.09 2001 116.26 48.10 1.56 165.92 216.10 382.02 57.12 50.52 107.64 2002 134.44 55.48 1.90 191.82 223.47 415.28 58.36 51.52 109.88 152.23 62.83 ---2004 168.98 65.19 2.55 236.72 275.48 512.20 60.72 52.11 112.84 2005 187.28 68.87 2.70 258.85 289.02 547.87 62.55 54.14 116.69 2006 203.49 73.72 2.92 280.13 284.76 564.90 63.81 54.68 118.49 241.12 301.04 620.88 65.76 53.66 119.42 2008 1 285.12 76.97 3.72 365.81 322.90 688.70 66.57 52.78 119.36 2009 312.29 396.55 121.76 (Annual Percentage Change) 1985 1986 19.5 12.7 2.1 18.9 25.4 20.6 12.8 -16.7 -14.5 8.5 41.9 25.4 -3.5 15.6 1988 -6.6 26.6 59.6 -3.1 26.4 7.5 26.2 1989 19.7 26.4 -28.3 20.4 26.9 23.2 26.7 2.8 -1.5 1990 20.1 20.0 11.1 20.0 19 7 19.9 5.9 12.7 1991 5.9 16.6 1992 -9.2 12.8 20.1 -5.8 11.4 1.9 4.3 22.4 11.2 1994 -3.0 11.4 -2.4 1.0 7.2 3.3 1.1 2.3 ---13.1 11.1 6.7 1996 3.9 4.1 2.5 62.3 3.8 0.5 1.7 -5.9 -0.1 -3.2 14.0 -1.8 1998 8.2 9.7 12.2 3.9 7.1 -2.5 -1.2 1999 13.2 15.4 22.3 13.9 4.2 8.1 11.1 4.4 7.8 17.2 6.5 5.6 6.1 2000 13.2 9.8 12.2 7.4 9.5 17.0 14.6 17.3 16.9 -0.3 2001 19.4 16.3 3.0 2002 15.6 15.3 21.4 15.6 3.4 8.7 2.2 2.0 2.1 2003 13.3 13.5 13.4 2004 11.0 3.7 17.2 9.0 8.6 8.8 5.2 3.7 4.5 2005 10.8 5.9 9.3 4.9 7.0 3.0 3.4 5.6 3.9 8.7 18.5 2.0 3.1 1.0 -1.9 2006 8.2 -1.5 3.0 9.9 0.8 2007 5.7 2008 f 18.2 1.7 23.5 14.4 7.3 10.9 1.2 -1.6 -0.1 (Annual Percentage Change in Excess of Inflation in the Canadian Econo 1985 1986 16.7 9.9 -0.7 16.1 22.6 17.8 10.0 -21.4 37.2 -19.3 20.7 10.8 1988 -11.2 22.1 55.1 -7.6 21.9 3.0 21.7 15.2 21.9 32.9 15.8 22.4 22.1 1990 17.1 17.0 8.1 17.0 16.6 16.8 ----0.2 10.0 13.8 1992 -10.5 11.5 18.9 -7.1 10.1 0.6 3.1 1993 31.1 -24.4 20.9 24.5 1994 10.3 -3.5 -0.1 2.2 0.0 1.2 -4.1 10.1 6.1 -4.7 1995 10.7 13.3 10.1 1.1 -5.3 1996 2.2 0.8 60.6 2.1 -1.2 0.1 -7.6 -1.8 -4.8 1997 2.3 10.1 12.6 -1.4 1998 14.4 8.6 4.4 7.5 -2.0 -0.7 1999 11.4 13.6 20.5 12.1 2.4 6.3 9.3 2.6 6.0 5.7 13.1 2.0 2000 9.1 8.1 3.3 5.4 2.4 1.5 15.6 14.6 13.3 14.3 15.0 14.6 1.7 16.0 15.5 2002 20.4 0.9 -5.3 1.1 2003 10.3 10.4 11.7 10.4 10.6 10.5 -4.0 -4.6 1.2 6.0 2.6 2005 7.9 2.7 3.0 6.4 2.0 4.0 0.1 1.0 0.5 -1.9 5.8 5.2 -0.9 5.3 2007 15.2 -0.6 -0.3 10.9 2.4 6.6 -0.3 -5.2 -2.5 2009 f 11.4 5.9 15.0 10.3 4.6 7.6 5.3 2.1 3.9

Sask.

Sask.

				oo,	5 to 2009 (cont		
	All Drugs			lealth Expenditure		GDP Implicit Price Index—Canada	
Public	Private	Total	Public	Private	Total		
		(\$ per Capita)				(1997 = 100)	
72.15		132.75	1,165.85	324.93	1,490.78	73.6	
85.79		157.44	1,288.21	366.97	1,655.19	75.6 79.2	
73.32 71.08		159.35 179.74	1,328.72 1,428.29	383.01 359.28	1,711.73 1,787.57	82.8	
85.58		223.37	1,598.43	415.71	2,014.15	86.6	
102.73	152.81	255.54	1,779.42	456.84	2,236.27	89.2	
110.29	161.76	272.06	1,824.01	489.59	2,313.60	91.6	
103.88		278.95	1,812.37	503.84	2,316.20	92.8	
80.07 80.85		300.07 317.09	1,716.06 1,762.05	570.20 600.67	2,286.26 2,362.72	94.1 95.2	
90.94						97.4	
90.94		329.14 330.27	1,795.42 1,827.39	612.84 615.97	2,408.26 2,443.36	99.0	
99.49		352.28	1,941.01	668.05	2,609.05	100.0	
111.61		368.86	2,067.33	661.74	2,729.07	99.6	
127.15	271.46	398.61	2,217.77	714.53	2,932.30	101.4	
142.64		432.93	2,362.85	767.94	3,130.79	105.5	
165.92 191.82		489.66 525.17	2,581.17 2,736.70	869.48 902.69	3,450.65 3,639.39	106.9 108.1	
217.24		578.84	2,911.00	976.42	3,887.42	111.2	
236.72		625.04	3,121.26	1,026.59	4,147.85	114.1	
258.85	405.71	664.56	3,408.05	1,060.73	4,468.77	117.4	
280.13	403.25	683.38	3,630.70	1,169.26	4,799.95	120.8	
319.84 365.81	420.46 442.25	740.30 808.06	3,887.19 4,177.39	1,218.78 1,318.05	5,105.97 5,495.44	124.8 130.6	
396.55		849.95	4,177.39	1,386.81	5,812.78	128.2	
		(Annu	al Percentage Chan	ge)			
18.9	 18.2	18.6	10.5	12.9		2.8	
-14.5		1.2	3.1	4.4	11.0 3.4	4.7	
-3.1	26.3	12.8	7.5	-6.2	4.4	4.5	
20.4	26.8	24.3	11.9	15.7	12.7	4.6	
20.0		14.4	11.3	9.9	11.0	3.0	
7.4		6.5	2.5	7.2	3.5	2.8	
-5.8 -22.9		2.5 7.6	-0.6 -5.3	2.9 13.2	0.1 -1.3	1.3 1.4	
1.0		5.7	2.7	5.3	3.3	1.1	
12.5	0.8	3.8	1.9	2.0	1.9	2.3	
3.8		0.3	1.8	0.5	1.5	1.7	
5.4		6.7	6.2	8.5	6.8	1.0	
12.2 13.9		4.7 8.1	6.5 7.3	-0.9 8.0	4.6 7.4	-0.4 1.8	
12.2 16.3		8.6 13.1	6.5 9.2	7.5 13.2	6.8 10.2	4.1 1.4	
15.6		7.3	6.0	3.8	5.5	1.0	
13.3	8.5	10.2	6.4	8.2	6.8	2.9	
9.0	7.4	8.0	7.2	5.1	6.7	2.6	
9.3		6.3	9.2	3.3	7.7	2.9	
8.2		2.8 8.3	6.5	10.2	7.4 6.4	2.9 3.3	
14.2 14.4		8.3 9.2	7.1 7.5	4.2 8.1	6.4 7.6	3.3 4.7	
8.4		5.2	6.0	5.2	5.8	-1.9	
	(Annual Percen	tage Change in Excess of Infli	ation in the Canadia	n Economy)			
16.1 -19.3		15.8 -3.5	7.7 -1.6	10.1 -0.4	8.2 -1.3		
-7.6		-3.5 8.3	3.0	-10.7	-0.1		
15.8		19.7	7.3	11.1	8.1		
17.0	7.9	11.4	8.3	6.9	8.0		
4.6	3.1	3.7	-0.3	4.4	0.7		
-7.1	7.0	1.3	-1.9	1.6	-1.1		
-24.4 -0.1		6.1 4.6	-6.8 1.6	11.7 4.2	-2.7 2.2		
10.1 2.1	-1.5 -2.6	1.5 -1.3	-0.4 0.1	-0.3 -1.2	-0.4 -0.2		
4.4		5.7	5.2	7.5	5.8		
12.6	2.2	5.1	6.9	-0.5	5.0		
12.1	3.7	6.3	5.5	6.2	5.6		
8.1	2.8	4.5	2.4	3.4	2.7		
15.0		11.8	7.9	11.9	8.9		
14.6 10.4		6.2 7.3	5.0 3.5	2.8 5.3	4.4 3.9		
6.4		5.4	4.6	2.5	4.1		
6.4	1.6	3.4	6.3	0.4	4.8		
5.3	-3.5	-0.1	3.6	7.3	4.5		
10.9		5.0	3.7	0.9	3.1		
9.7 10.3		4.5 7.1	2.8 7.8	3.5 7.1	3.0 7.7		
10.3				7.1	/./		

* Confidentiality precludes reporting provincial-level insurance data

Table B Alta.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Alberta, 1985 to 2009

Prescribed Drugs Non-Prescribed Drugs Private (Out-of-Pocket) Public Private Sub-Total Sub-Total Provincial Federal Social Security Funds Insurers* Over-Total Out-of-Total Personal WCB Health Non-Presc Funds Drugs Counte Supplies Druas (Pre ium Component) Drugs Year (\$ Millions) 1985 69.5 211.2 113.1 6.4 76.7 134.5 0.9 7.0 7.4 1986 83.2 1.2 91.4 147.9 239.3 128.1 95.7 104.6 153.1 257.7 1988 108.0 9.1 1.6 118.7 172.6 291.3 163.3 1989 159.7 172.7 367.2 179.6 1990 179.5 13.2 2.2 194.9 219.0 413.9 184.3 103.3 91.2 1992 205.6 17.1 3.0 225.6 256.8 482.4 194.4 1993 1994 205.8 20.4 3.7 229.9 234.2 297.0 526.9 114.2 119.3 98.7 106.1 213.0 225.4 309.4 543.7 208.1 22.8 1995 212.5 241.5 565.1 119.8 108.9 228.6 323.6 1996 232.6 26.3 3.5 262.4 360.2 622.6 128.3 112.5 240.8 1997 254.8 29.3 287.6 403.5 144.5 270.4 1998 278.1 32.8 4.2 315.0 430.1 745.1 153.1 135.0 288.1 1999 328.2 41.2 5.2 374.6 494.4 869.1 167.1 136.7 303.8 2000 387.1 45.1 5.7 437.8 556.5 994.3 173.4 150.0 323.4 451.0 617.5 1,127.7 368.6 2002 515.2 57.7 8.7 581.7 686.9 1,268.6 199.0 169.6 2003 588.2 64.9 67.8 10.2 10.9 663.2 754.3 1.417.5 220.0 177.3 397.3 2004 646.8 725.5 800.9 1,526.4 236.8 187.2 424.0 2005 709.3 71.6 10.9 791.7 1,640.2 240.8 194.9 435.6 845.8 271.9 213.9 2006 758.9 75.3 11.6 995.1 1,840.9 485.8 11.3 11.4 224.8 227.6 2007 792.5 76.8 880 6 1.045.1 1 925 7 294.8 5195 78.1 1,150.8 2008 989.0 2,139.7 302.1 529.6 899.5 2009 f 991.8 80.4 11.5 1.083.7 1.209.9 2.293.6 308.1 232.8 540.9 (Annual Percentage Change) 1985 1986 19.8 9.8 33.7 19.1 10.0 13.3 13.2 15.1 1988 12.7 22.8 13.0 13.5 12.7 13.0 10.0 48.0 10.2 45.5 12.7 26.1 12.4 5.4 1990 18.0 22.6 12.9 12.6 12.7 2.7 1991 16.1 19.6 6.3 10.1 1992 8.7 11.8 11.9 8.9 6.5 7.6 0.8 10.6 1994 1.1 11.9 -11.4 1.9 4.2 3.2 4.5 7.4 5.8 1995 2.1 13.7 -5.1 3.1 4.6 3.9 0.4 2.6 1996 9.5 1.3 11.9 8.6 11.3 10.2 3.3 5.3 -0.3 12.0 12.6 1998 9.1 11.8 21.3 9.5 6.6 7.8 6.0 7.2 6.5 1999 18.0 25.8 22.9 18.9 15.0 16.6 9.2 1.3 5.5 2000 17.9 9.2 9.8 16.9 12.6 14.4 3.8 9.7 6.4 2001 2002 14.2 12.2 13.6 14.0 11.2 12.5 4.4 5.4 2003 14.2 12.4 16.2 14.0 9.8 11.7 10.5 7.6 4.6 2004 10.0 7.7 5.6 6.7 6.9 9.4 2005 1.7 2.7 2006 7.0 5.2 6.7 6.8 17.3 12.2 12.9 9.8 11.5 2007 2008 f 13.5 0.6 12.3 10.1 11.1 2.5 1.2 1.9 2009 f 10.3 3.0 1.3 9.6 7.2 2.0 2.3 2.1 (Pe of Total Dr Expendit 1985 21.4 2.0 0.3 23.7 41.5 65.1 34.9 1.9 40.3 37.7 1986 22.6 0.3 24.9 65.1 34.9 1987 23.6 25.8 63.4 36.6 1988 23.7 2.0 0.4 26.1 38.0 64.1 35.9 1989 67.2 0.4 1990 30.0 2.2 32.6 36.6 69.2 30.8 29.5 37.6 1991 32.3 69.9 30.1 15.3 13.5 1992 30.4 2.5 0.4 33.3 37.9 71.3 28.7 15.4 1994 27.1 3.0 0.4 30.5 40.2 70.7 15.5 13.8 29.3 71.2 1995 26.8 3.3 0.4 30.4 40.8 15.1 13.7 28.8 72.1 71.9 1996 26.9 3.0 0.4 30.4 41.7 14.9 13.0 27.9 15.0 28.1 1998 26.9 3.2 0.4 30.5 41.6 72.1 14.8 13.1 27.9 28.0 42.2 14.2 2000 29.4 3.4 0.4 33.2 42.2 75.5 13.2 11.4 24.5 3.5 12.9 2001 30.5 0.5 34.5 41.7 76.2 10.9 23.8 2002 31.5 3.5 0.5 35.5 42.0 77.5 12.2 10.4 22.5 2004 33.2 3.5 0.6 37.2 41.1 78.3 12.1 9.6 21.7 2005 34.2 0.5 40.9 79.0 11.6 9.4 21.0 3.4 38.1 0.5 42.8 42.7 2006 32.6 3.2 36.4 79.1 11.7 9.2 20.9 2007 32.4 36.0 78.8 12.1 21.2 2008 1 33.7 2.9 0.4 37.0 43.1 80.2 11.3 8.5 19.8 2009 f : forecast

Alta.

Alta.

_			i otai neallii	Expenditure, Al	valia, 1300 l0	EUUU WUUIL UI			
_		All Drugs		-	Health Expenditure			in Public, Private ar alth Expenditures	nd
	Public	Private	Total	Public	Private	Total		Private	Total
			(\$ Millio	ns)			(Perce	entage Share)	
	76.7	247.6	324.3	3,239.1	831.3	4,070.4	2.4	29.8	
	91.4 104.6	276.0 301.6	367.4 406.2	3,537.9 3,514.4	910.6 985.5	4,448.5 4,499.9	2.6 3.0	30.3 30.6	
	118.7	335.9	454.6	3,645.6	1,184.9	4,830.6	3.3	28.3	
	172.7	374.0	546.7	4,031.0	1,318.8	5,349.8	4.3	28.4	
	194.9	403.4	598.3	4,326.9	1,422.5	5,749.4	4.5	28.4	
	207.1 225.6	434.0 451.2	641.1 676.9	4,557.5 4,846.4	1,505.1 1,584.2	6,062.5 6,430.7	4.5 4.7	28.8 28.5	
	229.9	510.0	739.8	4,800.5	1,719.9	6,520.4	4.8	29.7	
	234.2	534.8	769.1	4,527.8	1,785.7	6,313.4	5.2	30.0	
	241.5 262.4	552.2 601.0	793.8 863.4	4,283.5	1,809.0	6,092.5	5.6 5.9	30.5	
	287.6	673.9	961.5	4,466.5 4,942.0	1,854.2 2,140.1	6,320.6 7,082.1	5.8	32.4 31.5	
	315.0	718.1	1,033.2	5,354.0	2,251.1	7,605.1	5.9	31.9	
	374.6	798.3	1,172.9	6,140.2	2,539.9	8,680.1	6.1	31.4	
	437.8	879.9	1,317.7	6,792.9	2,822.9	9,615.8	6.4	31.2	
	510.1 581.7	968.9 1,055.5	1,479.1 1,637.2	7,745.0 8,470.2	3,258.1 3,385.4	11,003.2 11,855.6	6.6 6.9	29.7 31.2	
	663.2	1,151.6	1,814.8	9,127.1	3,563.2	12,690.3	7.3	32.3	
	725.5	1,224.9	1,950.4	9,981.4	3,928.7	13,910.1	7.3	31.2	
	791.7	1,284.1	2,075.8	11,083.3	4,177.2	15,260.5	7.1	30.7	
	845.8 880.6	1,481.0 1,564.7	2,326.8 2,445.3	12,198.3 13,348.1	4,891.6 5,189.4	17,089.9 18,537.4	6.9 6.6	30.3 30.2	
	989.0	1,680.4	2,669.4	15,047.5	5,727.4	20,774.9	6.6	29.3	
	1,083.7	1,750.8	2,834.5 (Annual Percenta	16,009.4	6,003.3	22,012.7	6.8	29.2	
_									
	19.1 14.5	11.5 9.3	13.3 10.6	9.2 -0.7	9.5 8.2	9.3 1.2			
	13.5	11.3	11.9	3.7	20.2	7.3			
	45.5	11.4	20.3	10.6	11.3	10.7			
	12.9	7.8	9.4	7.3	7.9	7.5			
	6.3	7.6	7.2	5.3	5.8	5.4			
	8.9 1.9	4.0 13.0	5.6 9.3	6.3 -0.9	5.3 8.6	6.1 1.4			
	1.9	4.9	4.0	-5.7	3.8	-3.2			
	3.1	3.3	3.2	-5.4	1.3	-3.5			
	8.6	8.8	8.8	4.3	2.5	3.7			
	9.6 9.5	12.1 6.6	11.4 7.5	10.6 8.3	15.4 5.2	12.0 7.4			
	18.9	11.2	13.5	14.7	12.8	14.1			
	16.9	10.2	12.3	10.6	11.1	10.8			
	16.5	10.1	12.2	14.0	15.4	14.4			
	14.0 14.0	8.9 9.1	10.7 10.8	9.4 7.8	3.9 5.3	7.7 7.0			
	9.4	6.4	7.5	9.4	10.3	9.6			
	9.1	4.8	6.4	11.0	6.3	9.7			
	6.8	15.3	12.1	10.1	17.1	12.0			
	4.1 12.3	5.7 7.4	5.1 9.2	9.4	6.1 10.4	8.5			
	12.3 9.6	7.4 4.2	9.2 6.2	12.7 6.4	10.4 4.8	12.1 6.0			
_		Share of Total Dru							
_	23.7	76.3	100.0						
	24.9	75.1	100.0						
	25.8 26.1	74.2 73.9	100.0 100.0						
	31.6	73.9 68.4	100.0						
	32.6	67.4	100.0						
	32.3	67.7	100.0						
	33.3	66.7	100.0						
	31.1 30.5	68.9 69.5	100.0 100.0						
	30.4 30.4	69.6 69.6	100.0 100.0						
	29.9	70.1	100.0						
	30.5	69.5	100.0						
	31.9	68.1	100.0						
	33.2	66.8	100.0						
	34.5 35.5	65.5 64.5	100.0 100.0						
	36.5	63.5	100.0						
	37.2	62.8	100.0						
	38.1	61.9	100.0						
	36.4	63.6	100.0						
	36.0 37.0	64.0 63.0	100.0 100.0						

Table B Alta.—per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Alberta, 1985 to 2009

Non-Prescribed Drugs Prescribed Drugs Public Private (Out-of-Pocket) Private Sub-Total Sub-Total Over-Provincial Federal Social Security Funds Insurers* Out-of Total Total Drug Insurance Private the-Non-Presc Funds Drugs Counte Supplies Drugs (Premium Component) Drugs (\$ per Capita) 1985 28.91 2.65 47.07 0.37 31.93 55.96 87.89 52.69 60.99 986 34.23 2.87 0.48 37.59 60.86 98.44 1987 39.32 3.04 0.60 42.96 62.87 105.83 1988 43.98 3.71 0.67 48.36 70.31 118.67 66.53 1989 4.47 0.73 77.94 147.14 71.96 64.01 69.20 86.00 93.03 1990 70.48 5.16 0.87 76.52 162.51 72.36 1991 72.98 79.89 172.92 74.37 5.89 1.02 1992 78.09 6 48 1 13 85.70 97 53 183 24 39 22 34.62 73 84 77.14 111.35 37.01 79.83 1993 7.65 1.38 86.18 197.53 42.82 1994 77.07 8.46 1.21 86.74 114.58 201.32 44.18 39.28 83.46 77.70 1995 9.50 1.13 88.33 118.34 206.67 43.80 39.81 83.62 1.25 40.53 44.49 1996 83.81 9 4 9 94 55 129.79 224.34 46.23 86.77 1997 10.37 101.64 142.56 244.20 51.05 95.55 90.05 1998 95.90 11.31 1.45 108.66 148.33 256.98 52.80 46.55 99.36 111.14 1.74 167.42 46.29 2000 128.81 15.00 1.88 145.69 185.19 330.88 57.71 49.90 107.62 2001 147.55 16.82 2.52 166.89 202.01 368.91 62.35 52.62 114.96 2002 165.33 18.51 2.81 186.65 220.43 407.08 63.86 54.41 118.28 186.05 238.59 2004 21.13 201.62 3.39 226.14 249.65 475.78 73.81 58.34 132.16 2005 216.20 21.81 3.31 241.33 258.63 499.96 73.38 59.40 132.78 2006 221.83 22.00 3.39 247.22 290.87 538.09 79.47 62.53 142.00 225.73 3.22 250.81 297.69 83.95 64.03 2008 1 250.89 21.79 3.17 275.85 320.98 596.84 84.25 63.48 147.73 2009 273.59 3.18 333.76 632.72 64.21 149.20 (Annual Percentage Change) 1985 1986 18.4 8.6 32.2 17.7 8.7 12.0 11.9 1987 14.9 5.9 23.2 7.5 1988 11.9 21.8 12.1 12.6 11.8 12.1 9.1 1989 20.5 8.4 43.1 10.9 24.0 1990 10.1 15.6 20.1 10.6 10.3 10.4 0.6 3.5 17.5 1991 14.0 8.2 6.4 1992 7.0 10.1 10.2 7.3 4.8 6.0 -0.7 -0.1 4.5 1994 10.5 -12.5 0.6 2.9 1.9 3.2 6.1 0.8 1.8 1996 7.9 -0.2 10.3 7.0 9.7 8.6 5.5 1.8 3.8 1997 10.4 4.0 1998 6.5 18.4 6.9 4.0 5.2 3.4 7.2 4.6 1999 15.9 23.5 20.6 16.7 12.9 14.5 -0.6 3.6 4.6 2000 15.9 7.4 7.9 14.9 10.6 12.4 2.0 7.8 2001 14.6 12.2 33.8 14.6 11.5 8.0 9.1 2002 12.0 10.1 11.4 11.8 9.1 10.3 2.4 3.4 2.9 2003 12.5 10.8 12.4 9.0 2004 8.4 3.0 5.4 7.8 4.6 6.1 6.1 4.0 5.2 2005 -2.2 5.1 -0.6 0.5 7.2 3.3 6.7 3.6 1.8 0.9 2.4 1.5 2006 2.6 1.8 2.3 12.5 7.6 1.9 8.3 5.6 5.3 2.4 -5.1 2007 2.3 2008 1 11.1 -0.3 -1.5 10.0 8.8 0.4 -0.9 -0.2 (Annual Percentage Change in Excess of Inflation in the Canadian Econo 1985 1986 15.6 5.8 29.4 14.9 5.9 9.2 9.1 1987 10.1 18.5 9.5 2.8 1988 7.3 17.3 7.6 8.1 7.3 7.6 38.5 19.4 3.6 1990 7.1 12.6 17.1 7.5 7.3 7.4 -2.5 1992 5.7 8.8 8.9 6.0 3.6 4.7 -2.0 6.7 1993 7.7 2.1 1994 -1.2 9.4 -13.6 -0.4 1.8 0.8 5.0 1995 0.3 10.0 -8.6 -0.5 0.9 -3.2 -2.1 1996 6.2 -1.9 8.6 5.4 8.0 6.9 3.9 0.1 2.1 1997 8.3 7.9 5.7 3.9 1998 6.9 9.5 18.8 7.3 4.5 5.1 1999 14.1 21.7 18.8 14.9 11.1 12.7 5.4 -2.4 1.7 11.8 10.7 6.5 -2.1 0.5 2000 3.3 3.8 8.3 3.7 13.2 32.4 10.4 9.3 2002 9.0 10.8 8.1 2003 9.6 5.8 7.9 11.7 9.5 5.3 7.2 3.5 6.1 3.5 0.2 0.4 5.2 2.0 2005 4.3 0.3 -5.1 3.8 0.7 2.2 -3.5 5.4 -1.1 -2.4 -0.3 -0.6 2006 -2.0 -0.5 9.6 2007 -1.6 -4.0 -8.4 -1.9 -1.0 -1.4 2.3 -0.9 0.9 -4.3 2.8 -4.8 2.9 2009 f 10.9 2.0 10.3 3.0 Confidentiality precludes reporting provincial-level insurance data

Alta.

Alta.

Table B B.C.—Total Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, British Columbia, 1985 to 2009

_			Publi	c	Prescribed Dru	gs	Private				-Prescribed D te (Out-of-Po	
-	Provincial	Federal		Security Funds Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed	Over- the-	Personal Health	Total Non-Presc
				Funds (Premium Component)					Drugs	Counter Drugs	Supplies	Drugs
_						(\$ Millions)						
	128.5 151.4	7.8 8.6	1.4 1.5		137.7 161.5			121.1 105.6	258.8 267.0			157 178
	153.5	9.2	1.7		164.4			134.9	299.2			207
	169.8	14.0	2.0		185.7			159.6	345.3			219
	196.5	18.0	2.1		216.7			188.9	405.6			232
	232.6	21.2	2.4		256.3			216.8	473.0			248
	275.4 311.8	24.4 26.5	2.7 3.1		302.4 341.5			241.1 268.1	543.5 609.5	149.5	134.7	266 284
	346.0	32.1	3.1		381.6			303.1	684.7	164.4	146.0	
	339.4	35.8	4.0		379.2			323.2	702.5	183.5	156.9	
	349.5	40.5	4.2		394.1			353.5	747.6	186.0	163.8	349
	379.4	44.2	3.9		427.5			374.9	802.4	192.2	166.3	
	418.7	45.3	4.0		468.0			412.2	880.2	196.5	172.7	369
	457.8 515.6	49.5 54.2	5.1 5.9		512.4 575.7			480.0 505.7	992.4 1,081.5	208.5 226.4	185.0 196.7	393 423
	595.4	58.2	6.8		660.4			570.1	1,230.5	235.6	199.6	
	659.1 696.7	65.6 76.0	7.4 7.2		732.1 779.9			641.0 759.4	1,373.1 1,539.3	245.1 257.5	209.6 220.3	
	698.1	88.0	7.6		793.7			881.4	1,675.1	278.3	225.5	
	752.5	92.6	9.0		854.1			1,009.6	1,863.6	295.6	231.6	
	813.3	96.5	9.8		919.6			1,035.5	1,955.1	299.1	239.4	538
	864.7	101.4	10.8		976.8			1,224.0	2,200.8	309.6	245.3	
	904.9	104.5	11.3		1,020.7			1,232.4	2,253.1	288.8	223.4	
f f	945.6 984.3	106.8	12.0 12.6		1,064.4			1,420.8	2,485.2	292.7 294.4	224.2 229.3	
r	964.3	112.1	12.0	***	1,109.0			1,529.6	2,638.6	294.4	229.3	523
_						Annual Percentage	Cnange)					
	17.8	9.6	4.7		17.2			-12.8	3.2			13.
	1.4	7.3	15.5		1.8			27.8	12.1			16
	10.6	51.5	16.5		13.0			18.4	15.4			5
	15.8	29.1	9.0		16.7			18.4	17.5			5
	18.3	17.9	14.0		18.2			14.7	16.6			7
	18.4	14.6	10.1		18.0			11.3	14.9			7
	13.2 11.0	9.0 21.0	16.1 11.6		12.9 11.7			11.2 13.1	12.1 12.3	10.0	8.4	6
	-1.9	11.6	14.1		-0.6			6.6	2.6	11.6	7.4	9
	3.0	12.9	5.7		3.9			9.4	6.4	1.4	4.4	2
	8.6	9.1	-6.0		8.5			6.1	7.3	3.3	1.5	
	10.3	2.6	2.1		9.5			10.0	9.7	2.3	3.9	
	9.4 12.6	9.2 9.6	25.6 17.2		9.5 12.4			16.4 5.4	12.7 9.0	6.1 8.6	7.1 6.3	6 7
	15.5	7.3	15.1		14.7			12.7	13.8	4.1	1.5	
	10.7 5.7	12.7 15.8	8.3 -3.0		10.9 6.5			12.4 18.5	11.6 12.1	4.0 5.1	5.0 5.1	4 5
	0.2	15.8	6.4		1.8			16.1	8.8	8.1	2.3	
	7.8	5.1	17.9		7.6			14.5	11.3	6.2	2.7	4
	8.1	4.3	8.8		7.7			2.6	4.9	1.2	3.3	2
	6.3	5.0	10.4		6.2			18.2	12.6	3.5	2.5	
	4.7	3.1	4.9		4.5			0.7	2.4	-6.7	-9.0	
f f	4.5	2.2	5.7		4.3			15.3 7.7	10.3	1.4	0.4	
ī	4.1	4.9	5.1		4.2				6.2	0.6	2.3	'
_	30.9	1.9	0.3		33.1	ge Share of Total I	orug Expendi	29.1	62.1	***		37
	34.0	1.9	0.3		36.2			23.7	59.9			40
	30.3	1.8	0.3		32.5			26.6	59.1			40
	30.1	2.5	0.3		32.9			28.3	61.2			38
	30.8	2.8	0.3		34.0			29.6	63.6			36
	32.2	2.9	0.3		35.5			30.0	65.5			34
	34.0 34.9	3.0	0.3		37.3 38.2			29.8	67.1 68.2	16.7	 15.1	32 31
	34.8	3.0 3.2	0.3		38.3			30.0 30.5	68.8	16.5	14.7	31
	32.5	3.4	0.4		36.4			31.0	67.4	17.6	15.0	
	31.8	3.7	0.4		35.9			32.2	68.1	16.9	14.9	31
	32.7	3.7	0.4		36.8			32.2	69.1	16.6	14.9	
	33.5	3.6	0.3		37.5			33.0	70.5	15.7	13.8	
	33.0	3.6	0.4		37.0			34.6	71.6	15.0	13.4	
	34.3	3.6	0.4		38.3			33.6	71.9	15.0	13.1	28
	35.7	3.5	0.4		39.6			34.2	73.9	14.1	12.0	
	36.1	3.6	0.4		40.1			35.1	75.1	13.4	11.5	
	34.5 32.0	3.8 4.0	0.4		38.7 36.4			37.6 40.5	76.3 76.9	12.8 12.8	10.9 10.3	
	31.5	3.9	0.3		36.4 35.7			40.5	76.9 77.9	12.8	9.7	
	32.6 31.4	3.9 3.7	0.4		36.9 35.4			41.5 44.4	78.4 79.9	12.0 11.2	9.6 8.9	21 20
	31.4	3.7	0.4		35.4 36.9			44.4	79.9 81.5	10.4	8.9	18
f	31.5	3.6	0.4		35.5			47.3	82.8	9.7	7.5	
	31.1	3.5	0.4		35.1			48.4	83.4	9.3	7.3	
f ecast.												

		-		•		a Share of Publi			
			Total Health Expe			5 to 2009 (cont'	Share of Drugs	in Public, Private ar	nd
-	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total		alth Expenditures Private	Total
			(\$ Millio	ns)			(Perc)	entage Share)	
-	137.7	278.8	416.5	3,410.1	1,227.1	4,637.3	4.0	22.7	
	161.5 164.4	284.1 341.9	445.6 506.3	3,666.0 3,895.3	1,317.2 1,444.9	4,983.3 5,340.3	4.4 4.2	21.6 23.7	
	185.7	378.9	564.6	4,241.2	1,597.1	5,838.3	4.4	23.7	
	216.7	421.2	637.9	4,736.0	1,773.0	6,509.0	4.6	23.8	
	256.3 302.4	465.4 507.3	721.7 809.7	5,386.7 5,967.2	1,986.0 2,159.5	7,372.6 8,126.7	4.8 5.1	23.4 23.5	
	341.5	552.2	893.7	6,477.9	2,291.2	8,769.1	5.3	24.1	
	381.6 379.2	613.5 663.6	995.1 1,042.9	6,869.8 7,237.5	2,427.0 2,533.2	9,296.8 9,770.7	5.6 5.2	25.3 26.2	
	394.1	703.2	1,097.3	7,538.4	2,574.3	10,112.7	5.2	27.3	
	427.5	733.3	1,160.9	7,688.7	2,689.4	10,378.1	5.6	27.3	
	468.0	781.4	1,249.4	7,942.6	2,889.4	10,832.0	5.9	27.0	
	512.4 575.7	873.5 928.8	1,385.9 1,504.6	8,304.5 8,969.4	3,102.8 3,299.8	11,407.3 12,269.2	6.2 6.4	28.2 28.1	
	660.4	1,005.4	1,665.8	9,825.9	3,556.5	13,382.4	6.7	28.3	
	732.1	1,095.7	1,827.7	10,820.5	3,815.4	14,635.9	6.8	28.7	
	779.9 793.7	1,237.2	2,017.1	11,478.0	4,162.6 4,405.2	15,640.6 16,358.6	6.8	29.7	
	/93./ 854.1	1,385.1 1,536.8	2,178.8 2,390.8	11,953.4 12,257.3	4,405.2 4,840.2	16,358.6 17,097.5	6.6 7.0	31.4 31.8	
	919.6	1,574.0	2,493.6	13,244.6	5,043.0	18,287.6	6.9	31.2	
	976.8	1,778.9	2,755.7	13,928.1	5,853.2	19,781.4	7.0	30.4	
	1,020.7 1,064.4	1,744.5 1,937.6	2,765.2 3,002.0	14,803.6 15,763.2	5,799.7 6,248.8	20,603.3 22,012.0	6.9 6.8	30.1 31.0	
	1,109.0	2,053.3	3,162.3	16,703.0	6,569.6	23,272.7	6.6	31.3	
-			(Annual Percenta	ge Change)					
	 17.2	1.9	7.0	7.5	7.3	 7.5			
	1.8	20.3	13.6	6.3	9.7	7.2			
	13.0 16.7	10.8 11.2	11.5 13.0	8.9 11.7	10.5 11.0	9.3 11.5			
	18.2 18.0	10.5 9.0	13.1 12.2	13.7 10.8	12.0 8.7	13.3 10.2			
	12.9	8.9	10.4	8.6	6.1	7.9			
	11.7 -0.6	11.1 8.2	11.3 4.8	6.0 5.4	5.9 4.4	6.0 5.1			
	3.9	6.0	5.2	4.2	1.6	3.5			
	8.5	4.3	5.8	2.0	4.5	2.6			
	9.5	6.6	7.6	3.3	7.4	4.4			
	9.5 12.4	11.8 6.3	10.9 8.6	4.6 8.0	7.4 6.3	5.3 7.6			
	14.7	8.2	10.7	9.5	7.8	9.1			
	10.9	9.0	9.7	10.1	7.3	9.4			
	6.5 1.8	12.9 12.0	10.4 8.0	6.1 4.1	9.1 5.8	6.9 4.6			
	7.6	11.0	9.7	2.5	9.9	4.5			
	7.7	2.4	4.3	8.1	4.2	7.0			
	6.2	13.0	10.5	5.2	16.1	8.2			
	4.5 4.3	-1.9 11.1	0.3 8.6	6.3 6.5	-0.9 7.7	4.2 6.8			
	4.2	6.0	5.3	6.0	5.1	5.7			
_	(Percentag	e Share of Total Dr	ug Expenditure)						
	33.1	66.9	100.0						
	36.2 32.5	63.8 67.5	100.0 100.0						
	32.9	67.1	100.0						
	34.0	66.0	100.0						
	35.5	64.5	100.0						
	37.3 38.2	62.7 61.8	100.0 100.0						
	38.3	61.7	100.0						
	36.4	63.6	100.0						
	35.9 36.8	64.1 63.2	100.0 100.0						
	36.8 37.5	62.5	100.0						
	37.0	63.0	100.0						
	38.3	61.7	100.0						
	39.6 40.1	60.4 59.9	100.0 100.0						
	38.7	61.3	100.0						
	36.4 35.7	63.6 64.3	100.0 100.0						
	36.9 35.4	63.1 64.6	100.0 100.0						
	36.9	63.1	100.0						
	35.5 35.1	64.5 64.9	100.0 100.0						
	33.1	04.5	100.0						

Table B B.C.—per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, British Columbia, 1985 to 2009

			В	li-	Prescribed Dru	ıgs	Data				-Prescribed D	
	Provincial	Federal	Publ Socia WCB	l Security Funds	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed	Over-	Personal	Total Non-Presc.
			WCB	Drug Insurance Funds	PUDIIC		Pocket	Private	Drugs	the- Counter	Health Supplies	Drugs
ear ear				(Premium Component)		(\$ per Capit	a)			Drugs		
985	43.21	2.63	0.47		46.31			40.72	87.03			53.01
986 987	50.41 50.32	2.86 3.02	0.49		53.75			35.14	88.89 98.11			59.43
988	54.50	4.48	0.55 0.63		53.89 59.62			44.21 51.23	110.85			67.88 70.39
989	61.46	5.64	0.67		67.77			59.07	126.84			72.63
990	70.67	6.46	0.74		77.87			65.87	143.74			75.56
991	81.63	7.22	0.79		89.64			71.48	161.12			78.90
992 993	89.90 96.98	7.65 9.01	0.90 0.97		98.45 106.96			77.29 84.97	175.73 191.93	43.10 46.07	38.83 40.93	81.93 87.01
994	92.34	9.75	1.08		103.18			87.94	191.11	49.92	42.69	92.60
995	92.52	10.72	1.11		104.35			93.59	197.94	49.24	43.36	92.59
996	97.94	11.40	1.02		110.35			96.76	207.12	49.60	42.91	92.51
997 998	106.03 114.95	11.47 12.42	1.02 1.27		118.52 128.63			104.40 120.51	222.92 249.15	49.77 52.34	43.73 46.45	93.50 98.79
999	128.53	13.52	1.48		143.52			126.07	269.60	56.44	49.04	105.48
2000	147.40	14.41	1.69		163.50			141.14	304.64	58.34	49.42	107.76
1001	161.60	16.09	1.81		179.50			157.17	336.66	60.09	51.39	111.48
1002 1003	169.30 167.99	18.47 21.19	1.74 1.83		189.50 191.01			184.53 212.11	374.03 403.11	62.57 66.96	53.53 54.26	116.10 121.22
1003	179.01	22.02	2.14		203.16			240.15	443.32	70.31	55.10	125.41
:005	190.90	22.66	2.29		215.86			243.07	458.93	70.20	56.19	126.39
006	203.76	23.89	2.54		230.19			288.43	518.62	72.95	57.81	130.76
007	209.94	24.24	2.63		236.81			285.92	522.73	66.99	51.82	118.81
1008 f 1009 f	215.81 222.20	24.38 25.30	2.73 2.84		242.92 250.33			324.26 345.29	567.18 595.62	66.79 66.46	51.16 51.76	117.95 118.23
						(Annual Percentage	Change)					
985				***								
986	16.7	8.5	3.7	***	16.1			-13.7	2.1			12.1
987 988	-0.2 8.3	5.7 48.3	13.7 14.1		0.3 10.6			25.8 15.9	10.4 13.0			14.2 3.7
989	12.8	25.7	6.2		13.7			15.3	14.4			3.2
990	15.0	14.5	10.8		14.9			11.5	13.3			4.0
991	15.5	11.8	7.4		15.1			8.5	12.1			4.4
992 993	10.1 7.9	6.0 17.7	12.9 8.5		9.8 8.6			8.1 9.9	9.1 9.2	6.9	5.4	3.8 6.2
994	-4.8	8.3	10.7		-3.5			3.5	-0.4	8.3	4.3	6.4
995	0.2	9.9	2.8		1.1			6.4	3.6	-1.4	1.6	0.0
996	5.9	6.4	-8.4		5.8			3.4	4.6	0.7	-1.0	-0.1
997 998	8.3 8.4	0.6 8.2	0.2 24.5		7.4 8.5			7.9 15.4	7.6 11.8	0.3 5.2	1.9 6.2	1.1 5.7
999	11.8	8.9	16.4		11.6			4.6	8.2	7.8	5.6	6.8
000	14.7	6.6	14.3		13.9			11.9	13.0	3.4	0.8	2.2
001	9.6	11.6	7.3		9.8			11.4	10.5	3.0	4.0	3.4
002	4.8 -0.8	14.8 14.7	-3.9 5.3		5.6			17.4 14.9	11.1	4.1	4.2 1.3	4.1 4.4
004	6.6	3.9	16.6		0.8 6.4			13.2	7.8 10.0	7.0 5.0	1.6	3.5
:005	6.6	2.9	7.3		6.2			1.2	3.5	-0.2	2.0	0.8
006	6.7	5.4	10.9		6.6			18.7	13.0	3.9	2.9	3.5
007	3.0	1.5	3.3		2.9			-0.9	0.8	-8.2	-10.4	-9.1
008 f 009 f	2.8 3.0	0.6 3.8	4.0 4.0		2.6 3.1			13.4 6.5	8.5 5.0	-0.3 -0.5	-1.3 1.2	-0.7 0.2
					nual Percentage Cha							
985			 0.9							***		
986 987	13.9 -4.9	5.7 1.0	9.0		13.3 -4.5			-16.5 21.1	-0.7 5.6			9.3 9.5
988	3.8	43.8	9.6		6.1			11.4	8.5			-0.8
989	8.2	21.2	1.6		9.1			10.7	9.9			-1.4
990	12.0	11.5	7.8		11.9			8.5	10.3			1.0
991 992	12.7 8.9	9.0 4.8	4.6 11.6		12.4 8.6			5.8 6.9	9.3 7.8			1.7 2.6
993	6.4	16.3	7.0		7.2			8.5	7.8	5.5	4.0	4.8
994	-5.9	7.2	9.6		-4.6			2.4	-1.5	7.2	3.2	5.3
995	-2.1	7.6	0.5		-1.2			4.1	1.2	-3.7	-0.8	-2.3
996 997	4.2 7.3	4.7 -0.4	-10.1 -0.8		4.1 6.4			1.7 6.9	3.0 6.6	-0.9 -0.7	-2.7 0.9	-1.8 0.1
998	8.8	8.7	25.0		9.0			15.9	12.2	5.6	6.7	6.1
999	10.0	7.1	14.6		9.8			2.8	6.4	6.0	3.8	5.0
000	10.6	2.5	10.2		9.8			7.8	8.9	-0.7	-3.3	-1.9
001	8.3 3.7	10.3 13.8	5.9 -4.9		8.4 4.5			10.0 16.4	9.2 10.1	1.6 3.1	2.6 3.1	2.1 3.1
003	-3.7	11.8	2.4		-2.1			12.1	4.9	4.1	-1.5	1.5
004	4.0	1.3	14.0		3.8			10.6	7.4	2.4	-1.0	0.9
005	3.7	0.0	4.4		3.3			-1.7	0.6	-3.1	-0.9	-2.1
006	3.8 -0.3	2.5 -1.8	8.0 0.0		3.7 -0.4			15.8 -4.2	10.1 -2.5	1.0 -11.5	0.0 -13.7	0.6 -12.5
008 f	-1.9	-4.1	-0.7		-2.1			8.8	3.9	-5.0	-5.9	-5.4
009 f	4.8	5.7	5.9		4.9			8.4	6.9	1.4	3.1	2.1
forecast.												

Table Tabl	
Public P	
No.	ıblic
1985	.5.10
1985	
1985	
1986 20,70	
1927 1928	46.31
1988	53.75
1899 97.77 131.70 199.67 1.400.98 596.42 2.2036.11 69.68 190.00 190.11 190.00 1.400.00 1.400.00 1.60 190.11 190.00 1.400	
1999 1978 144.44	
1931 1946 150.38 240.03 1.786.95 540.15 2.269.00 91.6	
1922 98.48 199.22 277.66 1,807.66 60.05 2,528.24 92.8 1925 1926 1927 272.32 1,207.10 2,000.00 94.1 1926 1928 1927 232.32 1,207.10 2,000.00 94.1 1928 1928 1928 1928 232.32 1,207.10 2,000.00 1928 1928 1928 232.32 1,207.10 2,000.00 1928 1928 232.32 2,000.00 2,000.00 1928 1928 232.32 2,000.00 2,000.00 1928 1929 2,000.00 2,000.00 2,000.00 1929 1920 2,000.00 2,000.00 2,000.00 1920 1920 2,000.00 2,000.00 2,000.00 1920 1920 2,000.00 2,000.00 2,000.00 1920 1920 2,000.00 2,000.00 2,000.00 1920 1920 2,000.00 2,000.00 2,000.00 1920 1920 2,000.00 2,000.00 2,000.00 1920 1920 2,000.00 2,000.00 2,000.00 1920 1920 2,000.00 4,000.10 2,000.00 1920 1920 2,000.00 4,000.10 2,000.00 1920 1920 2,000.00 4,000.10 2,000.00 1920 1920 2,000.00 4,000.10 2,000.00 1920 2,000.00 4,000.00 2,000.00 2,000.00 1920 2,000.00 4,000.00 2,000.00 2,000.00 1920 2,000.00 4,000.00 2,000.00 2,000.00 1920 2,000.00 4,000.00 2,000.00 2,000.00 2,000.00 1920 2,000.00 4,000.00 2,000.00 2,000.00 2,000.00 1920 2,000.00 4,000.00 2,000.00 2,000.00 2,000.00 1920 2,000.00 4,000.00 2,000.00 2,000.00 2,000.00 1920 2,000.00 4,000.00 2,00	
1986 101.81 190.54 289.72 1.989.80 989.18 2.888.16 99.2 1986 101.35 180.28 289.03 1.989.80 981.57 2.277.42 99.0 1987 110.32 182.28 289.03 1.989.80 981.77 2.277.22 99.0 1989 110.32 182.28 289.03 2.289.02 227.10 2.287.22 99.0 1999 143.52 221.55 275.03 2.289.02 222.61 3.086.80 101.4 1990 143.52 221.55 275.03 2.289.02 222.61 3.086.80 101.4 1990 143.52 221.55 275.03 2.289.03 2.289.03 1.389.00 101.4 1990 143.50 248.64 444.14 2.485.08 3.685.0 3.131.13 101.5 2001 179.60 288.64 444.14 2.485.08 3.985.1 3.588.00 100.9 2002 189.50 3.00.33 2.289.03 2.289.03 2.289.00	
1986 104.8 110.35 110.28 200.53 1.991.80 691.52 2.077.43 92.4 1987 110.25 119.20 219.50 316.42 2.011.53 731.76 2.742.29 100.0 1988 124.53 2.91.50 316.42 2.011.53 731.76 2.742.29 100.0 1989 124.53 2.91.50 34.62 2.011.53 731.76 2.742.29 100.0 1980 124.53 2.91.50 34.62 2.742.20 100.0 1980 185.00 2.98.50 2.98.50 2.742.20 2.98.50 2.98.50 100.0 1980 185.00 2.98.50 44.20 2.742.20 2.98.50 2.98.50 100.0 2001 186.00 300.63 440.13 2.780.04 101.14 3.800.40 101.1 2002 186.00 300.63 440.13 2.780.04 101.14 3.800.40 101.1 2003 186.00 300.63 450.53 2.780.76 100.52 3.085.73 111.2 2004 2.01.16 3.00.63 450.53 2.780.76 100.12 3.085.73 111.2 2004 2.01.16 3.00.63 450.53 3.00.63 100.63 100.63 2005 2.01.16 3.00.63 460.53 3.484.7 1.482.73 4.00.16 111.4 2007 2.01.16 4.00.16 4.00.16 3.484.7 1.482.73 4.00.16 111.4 2007 2.01.16 4.00.16 4.00.16 3.484.7 1.485.1 4.780.1 1.144.8 2007 2.02.33 405.02 713.30 3.770.51 1.490.20 5.20.53 1.20.20 2008 2.02.33 405.02 713.30 3.770.51 1.490.20 5.20.53 1.20.20 2009 2.02.33 405.02 713.30 3.770.51 1.490.20 5.20.53 1.20.20 2009 2.02.33 10.0 11.2 4.76 5.0 5.0 4.7 2009 2.02.33 10.0 1.13 4.76 5.0 5.0 5.0 4.7 2009 2.00.31 10.0 5.9 6.4 6.3 6.4 6.2 2009 2.00.31 10.0 1.13 4.76 5.0 5.0 5.0 4.7 2009 2.00.31 10.0 1.13 4.76 5.0 5.0 5.0 4.7 2009 3.00 3.0	
1986	103.18
1957 118.52 197.50 314.42 2.011.53 721.75 2.744.29 100.0 1958 12.55 221.59 371.91 2.208.89 775.00 2.08.98 775.00	
1989	
1815	
175 175	143.52
175 175	163.50
2004 191-01 333-33 524-33 2.876-82 1.00-01-2 3.388-73 111-2 2004 200.14 388-57 588-57 588-57 2.481-7 1.151-39 4.007-15 114-1 2006 211-86 388-57	179.50
2004 200.16 305.57 588.73 2.915.77 1.151.39 4.097.15 114.1	
2006 218.68 369.46 885.32 3,106.80 1187.37 4,292.63 117.4	
2006 230.19	
2007	
1985	
1986	250.33
1986	
1986	
1988	
1889	
1900 144,8 7,4 9,9 10,5 8,8 10,1 3,0 1892 1893 18,8 18,3 17,3 18,4 19,4 14,4 14,4 11,1 10,7 2,3 18,6 18,6 18,6 18,6 18,6 18,6 18,6 18,6	
1991	
1992 9.8 5.9 7.3 5.6 3.2 4.9 1.3 1994 3.5 5.0 1.7 2.2 1.3 2.0 1.1 1994 3.5 5.0 1.7 2.2 1.3 2.0 1.1 1996 5.8 1.7 3.1 0.6 1.8 0.0 1.7 1998 8.5 10.8 10.0 3.6 6.5 4.4 1.0 1999 11.6 5.6 7.8 7.2 5.6 6.8 1.8 2000 13.9 7.5 9.9 8.8 7.0 8.2 4.1 2001 9.8 7.9 9.7 9.7 9.1 6.2 8.3 1.4 2002 5.6 11.9 9.4 5.1 8.1 5.9 1.0 2003 0.8 10.9 7.0 3.1 4.8 3.6 2.9 2004 6.4 9.7 8.5 1.4 8.6 3.3 2.6 2005 6.6 11.9 9.4 5.1 8.1 5.9 1.0 2006 6.6 3.3 10.9 7.0 3.1 4.8 3.6 2.9 2004 6.4 9.7 8.5 1.4 8.6 3.3 2.6 2005 6.6 3.3 10.9 7.9 5.8 6.5 2.8 5.5 2.9 2006 6.6 3.3 10.9 3.1 3.6 3.3 3.8 2007 2.9 3.1 4.8 4.2 4.8 4.0 4.6 4.7 2008 1.9 4.8 4.2 4.8 4.0 4.6 4.7 2009 1.9 4.8 4.2 4.8 4.0 4.6 4.7 2009 1.9 4.4 6.9 7.5 5.3 3.3 4.8 2009 1.9 4.4 6.9 7.5 5.3 3.3 4.8 2009 1.9 4.4 6.9 7.5 5.3 3.3 4.8 2000 1.9 4.4 6.9 7.5 5.3 3.3 4.8 2001 1.9 4.4 6.9 7.5 5.3 3.3 4.8 2002 3.6 6.6 6.8 6.7 5.3 3.3 4.8 2003 1.9 3.7 5.5 4.2 3.6 4.0 2004 4.5 13.8 7.2 0.1 3.4 4.6 2005 4.5 3.9 0.6 1.7 1.6 1.6 2007 1.9 4.4 6.9 7.5 5.8 7.0 2008 3.1 4.1 0.0 1.5 2.2 0.2 2009 1.9 4.4 6.9 7.5 5.8 7.0 2009 2.1 3.7 5.5 4.2 3.6 4.0 2001 3.8 7.1 0.0 1.5 2.2 0.2 2001 3.8 4.1 0.0 1.5 2.2 0.2 2001 3.8 4.1 0.0 1.5 2.2 0.2 2001 3.8 4.6 6.1 4.3 1.9 3.7 2002 4.5 10.9 8.3 4.1 7.1 6.1 6.1 2003 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 2004 3.8 7.1 5.9 1.1 3.7 7.7 4.9 7.0 2005 3.3 3.1 3.0 0.1 3.1 3.1 3.5 3.5 2007 4.5 10.9 8.3 4.1 7.7 4.9 7.0 2008 3.3 3.1 3.0 0.1 3.1 3.5	
1993	
1895	
1996 5.8 1.7 3.1 0.6 1.8 0.0 1.7 1997 7.4 4.6 5.6 1.4 5.6 4.4 0.4 1999 11.6 5.6 7.8 7.2 5.6 6.8 1.8 2000 13.9 7.5 9.9 8.8 7.0 8.3 4.1 2011 9.8 7.9 8.7 9.1 6.2 8.3 1.4 2012 5.6 11.9 9.4 5.1 8.1 5.9 1.0 2023 0.8 10.9 7.0 3.1 4.8 3.6 2.9 2034 0.4 9.7 8.5 1.4 6.6 3.3 2.6 2056 6.6 13.3 10.9 5.6 16.5 8.6 2.9 2077 2.9 3.5 1.2 4.6 2.4 2.5 3.3 2086 2.6 9.3 6.8 4.7 6.0 5.1 4.7 2096 3.1 4.8 4.2 4.6 6.2 4.8 4.0 4.6 2096 3.1 4.8 4.2 4.8 4.0 4.6 3.1 4.8 4.2 4.8 4.0 4.6 3.1 4.8 4.2 4.8 4.0 4.6 3.1 4.8 4.2 4.8 4.0 4.6 3.1 4.8 4.2 4.8 4.0 4.6 3.1 4.8 4.2 4.8 4.0 3.1 4.8 4.2 4.8 4.0 4.6 3.1 4.8 4.2 4.8 4.0 3.1 4.8 4.2 4.8 4.0 4.6 3.1 4.8 4.2 4.8 4.0 3.1 4.8 4.2 4.8 4.0 3.1 4.8 4.2 4.8 4.8 3.6 5.5 3.6 3.8 7.0 3.3 3.8 3.8 6.1 4.0 4.7 2.1 3.7 2.5 3.9 9.1 3.7 5.5 4.2 3.8 3.9 9.1 3.7 5.5	-3.5
1997 7, 4 4.6 5.6 1.4 5.6 1.4 5.4 2.4 1.0 1998 8.5 10.8 10.0 3.6 5.5 4.4 1999 11.6 5.6 7.8 7.2 5.6 6.8 1.8 2000 13.9 7.5 9.9 8.7 7.2 5.6 6.8 1.8 2001 9.8 7.9 8.7 9.1 6.2 8.3 1.4 2002 5.6 11.9 9.4 5.1 6.1 5.9 1.0 2003 0.8 10.9 7.0 3.1 4.8 3.6 2.9 2004 6.4 9.7 8.5 1.4 8.6 3.3 2.6 2006 6.6 1.1 2.9 6.6 6.2 8.5 5.2 2.9 2006 6.6 13.5 10.9 5.6 11.4 8.6 2.8 5.5 2007 2.9 3.5 1.2 4.6 2.4 2.5 3.3 20081 2.6 9.3 6.8 4.7 6.0 5.1 4.7 20091 3.1 4.8 4.2 4.8 4.0 4.6 2.4 2.5 3.3 20081 3.3 1.9 3.1 3.6 3.5 3.6 1888 6.1 3.3 1.9 3.1 3.6 3.5 3.6 1889 9.1 3.7 5.5 4.2 3.6 4.0 1890 11.9 4.4 6.9 7.5 5.8 7.0 1890 11.9 4.4 6.9 7.5 5.8 7.0 1890 11.9 4.4 6.9 7.5 5.8 7.0 1890 11.9 4.4 6.9 7.5 5.8 7.0 1890 11.9 4.4 6.9 7.5 5.8 7.0 1891 12.4 3.6 6.7 5.3 3.3 4.8 1892 8.6 4.6 6.6 6.7 5.3 3.3 4.8 1893 7.2 6.6 6.8 1.7 1.6 1.6 1.6 1894 4.6 3.9 0.6 1.2 0.2 0.9 1895 4.1 0.0 1.5 2.2 0.9 2006 9.8 3.4 5.8 4.7 1.0 3.4 1.6 1898 9.0 11.3 10.4 4.1 6.9 0.2 0.9 1899 9.8 3.8 6.0 1 1.0 0.4 4.1 6.9 2007 6.4 3.8 7.2 6.6 6.8 1.7 1.6 1.6 1899 9.8 3.8 6.0 1 1.0 0.4 4.1 6.9 2007 9.8 3.8 6.0 1 1.0 0.4 4.1 6.9 2007 9.8 3.8 6.0 1.1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 1 1.0 0.4 4.1 1.4 1999 9.8 3.8 6.0 5.4 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 9.8 3.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 6.3 4.1 2.1 2.0 1.0 0.7 2005 3.3 1.1 2.0 4.6 2.1 0.1 1.3 5.8 0.8 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 0.4 6.8 0.4 5.1 0.1 1.3 1.5 0.4	1.1
1998	
1999	
2000	
2001 9.8 7.9 8.7 9.1 6.2 8.3 1.4 2002 5.6 11.9 9.4 5.1 8.1 5.9 1.0 2003 0.8 10.9 7.0 3.1 4.8 3.6 2.9 2004 6.4 9.7 8.5 1.4 8.6 3.3 2.6 2005 6.6 1.5 1.1 2.9 6.6 2.8 5.5 2.9 2006 6.6 13.5 10.9 5.6 16.5 8.6 2.9 2007 2.9 3.5 1.2 4.6 2.4 2.5 3.3 20081 2.6 9.3 6.8 4.7 6.0 5.1 4.7 20091 3.1 4.8 4.2 4.8 4.0 4.6 1.9	
2002	
2004 6.4 9.7 8.5 1.4 8.6 3.3 2.6	
2005 6.2 1.1 2.9 6.6 2.8 5.5 2.9 2006 6.6 13.5 10.9 5.6 16.5 8.6 2.9 2007 2.9 3.5 1.1.2 4.6 2.4 2.5 3.3 2008 1 2.6 9.3 6.8 4.7 6.0 5.1 4.7 2009 1 3.1 4.8 4.2 4.8 4.0 4.6 1.1.9 **CAnnual Percentage Change in Excess of Inflation in the Canadian Economy!** **IRRADIAN STATE OF THE CANADIAN STATE OF THE CANADI	
2006 6.6 13.5 10.9 5.6 16.5 8.6 2.9 2007 2.9 3.5 -1.2 4.6 6.2.4 2.5 3.3 2008 f 2.6 9.3 6.8 4.7 6.0 5.1 4.7 2009 f 3.1 4.8 4.2 4.2 4.6 4.0 4.6	6.4
2007	
2008	
Cannual Percentage Change in Excess of Inflation in the Canadian Economy	
1986	3.1
1986 13.3 -1.9 3.1 3.6 3.5 3.6 1987 -4.5 13.8 7.2 -0.1 3.3 0.8 1989 9.1 3.7 5.5 4.2 3.6 4.0 1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000	
1986 13.3 -1.9 3.1 3.6 3.5 3.6 1987 -4.5 13.8 7.2 -0.1 3.3 0.8 1989 9.1 3.7 5.5 4.2 3.6 4.0 1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000	
1988 6.1 4.0 4.7 2.1 3.7 2.5 1989 9.1 3.7 5.5 4.2 3.6 4.0 1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 <	
1989 9.1 3.7 5.5 4.2 3.6 4.0 1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 <td></td>	
1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 -6.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 -6.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 -6.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 -6.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 -6.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 -6.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 -6.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 0.4	
1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 <t< td=""><td></td></t<>	
1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 <t< td=""><td></td></t<>	
1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 0.4 <td></td>	
1995	7.2
1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	-4.6
1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 1.2 6.0 0.7 2004 3.8 7.1 5.9 1.2 6.0 0.7 2005 3.3 1.19 0.0 3.7 0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 0.4 6.8 4.5 1.3 5.8 0.8 2008 1 2.1 4.6 2.1 0.1 1.3 0.4	
1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	
1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	
2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	
2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	9.8
2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.0 4.1 0.2 1.9 0.7 2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	8.4
2004 3.8 7.1 5.9 -1.2 6.0 0.7 2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	4.5
2005 3.3 -1.9 0.0 3.7 -0.1 2.6 2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 -2.1 4.6 2.1 0.1 1.3 0.4	
2006 3.7 10.6 8.1 2.7 13.6 5.7 2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	
2007 -0.4 -6.8 -4.5 1.3 -5.8 -0.8 2008 f -2.1 4.6 2.1 0.1 1.3 0.4	
2008 f -2.1 4.6 2.1 0.1 1.3 0.4	
2009 f	-2.1
i e	4.9
f: forecast.	

Table B Y.T.—Total Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Yukon, 1985 to 2009

Non-Prescribed Drugs Prescribed Drugs Private (Out-of-Pocket) Public Private Sub-Total Sub-Total Territory Federal Social Security Funds Insurers* Over-Total Out-of-Total Personal WCB Health Non-Presc Funds Drugs Counte Supplies Druas (Pre um Component) Drugs Year (\$ Millions) 1985 0.3 0.5 1.3 0.7 1986 0.3 0.3 0.0 1.2 1.9 1988 1.0 0.6 0.0 1.7 1.0 2.7 1989 1.2 3.1 1.3 1.6 1990 1.0 0.0 2.3 1.0 3.3 1.2 1.1 1992 2.0 1.3 0.0 3.4 1.2 4.5 2.3 1993 1994 2.3 2.1 1.5 3.8 2.3 1.6 1.3 1.4 2.4 2.4 1.1 1.1 0.0 1995 1.5 1996 1.5 1.9 0.0 3.4 2.2 5.6 1.7 1.5 3.1 1998 2.2 2.1 0.0 4.4 2.9 1.8 1.6 1999 2.7 3.1 0.0 5.8 3.0 8.8 1.9 1.7 3.6 2000 3.3 3.0 0.1 6.4 3.2 9.6 1.9 2.1 3.9 3.9 4.5 3.0 2002 3.5 0.1 8.1 3.9 12.1 2.0 2.1 4.1 2003 5.1 5.9 3.8 0.1 9.0 9.8 4.8 4.9 13.8 2.2 1.8 2.0 4.0 4.3 2003 14.7 4.1 4.2 2005 6.5 10.8 2.5 2.0 17.4 2006 7.2 0.2 11.6 5.8 2.8 2.1 7.0 7.8 2.5 2007 5.0 0.3 12.2 18.8 2.2 21.0 2008 5.3 13.5 2.3 0.3 7.6 2009 f 8.1 5.7 0.4 14.2 8.1 22.4 2.7 2.3 5.1 (Annual Percentage Change) 1985 -18.3 1986 53.7 10.9 27.7 -6.2 3.5 -5.0 126.4 1988 41.8 72.7 32.5 51.6 -13.2 18.0 -12.6 15.4 -42.2 -0.3 1990 5.9 17.1 98.0 10.8 -6.5 5.1 -6.2 26.2 16.5 -54.9 21.5 25.0 22.5 1991 1992 23.5 15.7 303.9 21.0 -4.1 13.4 77.9 2.3 1994 -8.4 10.1 -3.4 -1.0 -29.3 -11.5 4.3 -0.1 1995 -26.3 9.1 40.5 -10.1 8.0 -4.7 2.1 13.0 7.0 1996 -2.3 3.8 3.9 27.6 10.0 19.9 20.2 20.0 26.0 1998 17.8 4.0 -10.8 10.4 -15.7 -1.7 3.3 4.6 3.9 1999 21.9 44.5 28.0 32.9 4.8 21.7 7.5 4.7 6.2 2000 21.4 -0.9 15.1 9.6 6.0 8.4 -1.8 22.3 9.5 2001 2002 17.6 14.9 10.3 16.4 10.8 14.5 2.9 1.7 2.3 2003 12.1 15.0 10.0 15.7 11.2 20.7 7.2 8.6 -11.9 6.1 -2.5 7.5 2004 26.8 8.3 3.2 6.5 2005 4.5 11.1 26.8 2006 10.2 1.2 24.7 7.0 12.4 8.8 12.3 7.0 9.9 2007 20.0 26.4 2008 f 12.7 5.6 21.6 10.0 16.2 12.1 6.3 4.9 5.6 2009 f 3.5 7.8 22.5 5.7 6.3 4.1 2.4 3.3 (Pe of Total Dr Expendit 6.7 10.3 20.9 42.2 1985 9.5 0.3 16.6 41.3 57.8 10.6 1986 0.3 21.2 38.8 59.9 40.1 1987 10.0 0.3 31.2 33.6 64.9 35.1 1988 27.6 16.2 0.4 44.1 27.2 71.4 28.6 1989 49.3 0.4 53.5 52.7 1990 30.0 23.1 22.6 76.1 23.9 1991 30.7 17.9 15.6 1992 29.4 19.6 0.4 49.4 17.0 66.5 33.5 15.4 17.4 1994 26.5 21.5 0.3 48.3 20.5 68.8 13.9 31.2 1995 17.9 19.8 23.7 0.5 43.9 22.3 66.2 33.8 15.9 18.9 16.2 16.8 14.4 1996 17.0 21.7 0.4 39.1 25.1 64.3 35.7 17.7 19.1 37.2 1998 20.9 19.9 0.3 41.1 27.2 68.3 16.7 15.1 31.7 21.8 46.7 15.4 2000 24.3 22.4 0.4 47.1 23.8 70.9 13.9 15.2 29.1 26.5 13.6 2001 20.8 47.9 2002 28.1 21.6 0.6 50.2 24.3 74.5 12.6 12.9 25.5 2004 30.8 20.0 0.7 51.5 25.8 77.3 12.5 10.3 22.7 2005 31.8 20.2 0.8 52.9 78.1 12.1 9.8 21.9 25.3 0.9 2006 32.2 18.8 51.9 26.0 77.9 12.5 9.6 22.1 2007 29.8 21.4 27.8 80.2 10.5 19.8 2008 f 30.3 20.4 1.2 52.0 29.2 81.1 10.1 8.8 18.9 2009 f : forecast. * Confidentiality precludes reporting territorial-level ins



		Expenditure	on Drugs by Type				ic, Private and	Table B Y.	10
		All Drugs	Total Health	Expenditure, 1	/ukon, 1985 to	2009 (cont a)		s in Public, Private arealth Expenditures	nd
-	Public	Private	Total	Public	Private	Total	Public	Private	Total
			(\$ Million	ns)			(Pero	entage Share)	
-	0.5	2.6	3.2	32.9	6.8	39.7	1.6	38.9	
	0.7	2.5	3.2	37.0	5.6	42.6	1.8	44.4	
	1.1 1.7	2.4 2.1	3.5 3.8	39.1 40.6		44.7 45.8	2.8 4.1	43.3 40.8	
	2.1	2.1	4.2	44.2		49.5	4.7	40.3	
	2.3	2.0	4.3	48.5		53.6	4.7	39.6	
	2.8 3.4	2.5 3.4	5.3 6.8	56.5 60.6		62.6 67.5	4.9 5.6	41.0 49.7	
	3.8	4.7	8.5	69.0		79.6	5.5	44.1	
	3.8	4.0	7.8	83.3	9.9	93.2	4.5	40.7	
	3.4	4.3	7.7	84.4		94.9	4.0	41.2	
	3.4 4.0	5.3 6.7	8.8 10.6	91.3 85.4		109.5 102.7	3.8 4.6	29.3 38.7	
	4.4	6.3	10.6	87.3	16.3	103.7	5.0	38.4	
	5.8	6.6	12.4	91.8	16.9	108.7	6.3	39.2	
	6.4	7.1	13.5	98.9		123.6	6.4	28.8	
	7.0 8.1	7.6 8.1	14.6 16.2	115.9 123.4		143.4 156.5	6.0 6.6	27.7 24.3	
	9.0	8.8	17.8	124.6	32.2	156.8	7.3	27.2	
	9.8	9.2	19.0	133.1		168.7	7.4	26.0	
	10.8 11.6	9.6 10.7	20.4 22.3	152.1 178.1		188.7 217.6	7.1 6.5	26.3 27.2	
	12.2	11.1	23.4	178.1		231.1	6.8	27.2	
	13.5	12.5	25.9	197.2		251.4	6.8	23.0	
_	14.2	13.2	27.4 (Annual Percenta	208.0 ige Change)	58.4	266.4	6.8	22.6	
	 27.7	 -5.6	-0.1	 12.3		 7.2			
	65.5	-2.1	12.2	5.8		5.1			
	51.6	-12.9	7.3	3.8		2.3			
	23.0	-0.1	10.1	9.1		8.2			
	10.8 21.5	-6.3 25.1	2.1 23.2	9.7 16.4		8.2 16.8			
	21.0	38.2	29.1	7.2		7.9			
	13.5 -1.0	35.3 -13.1	24.5 -7.6	14.0 20.7		17.9 17.1			
	-10.1 1.1	7.4 23.0	-1.1 13.4	1.3 8.2		1.8 15.4			
	15.2	25.0	21.2	-6.4		-6.2			
	10.4 32.9	-6.1 5.5	0.0 16.8	2.2 5.1		0.9 4.8			
	9.6	7.9	8.7	7.7		13.8			
	9.8	6.4	8.0	17.3		16.0			
	16.4	6.3	11.1	6.4		9.2			
	11.2 8.3	8.8 5.2	10.0 6.7	1.0 6.9		0.2 7.6			
	10.4	4.3	7.4	14.2	3.0	11.9			
	7.0	11.3	9.0	17.1	7.7	15.3			
	5.9 10.0	4.0 11.8	5.0 10.8	0.7 9.9		6.2 8.8			
	5.7	5.9	5.8	5.5		6.0			
_	(Percentag	e Share of Total Dr	ug Expenditure)						
_	16.6	83.4	100.0						
	21.2	78.8	100.0						
	31.2 44.1	68.8 55.9	100.0 100.0						
	49.3	50.7	100.0						
	53.5	46.5	100.0						
	52.7	47.3	100.0						
	49.4 45.1	50.6 54.9	100.0 100.0						
	48.3	51.7	100.0						
	43.9	56.1	100.0						
	39.1	60.9	100.0						
	37.2 41.1	62.8 58.9	100.0 100.0						
	46.7	53.3	100.0						
	47.1	52.9	100.0						
	47.9	52.1	100.0						
	50.2 50.7	49.8 49.3	100.0 100.0						
	51.5	48.5	100.0						
	52.9	47.1	100.0						
	51.9	48.1	100.0						
	52.4 52.0	47.6 48.0	100.0 100.0						
	51.9	48.1	100.0						

Table B Y.T.—per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Yukon, 1985 to 2009

	-		Publi	c	Prescribed Dr	rugs	Private				Prescribed Di	
	Territory	Federal		Security Funds Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed	Over- the-	Personal Health	Total Non-Presc.
				Funds (Premium Component)					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ per Capit	a)					
1985 1986	8.73 13.36	12.38 13.65	0.40 0.33		21.51 27.34			53.66 50.07	75.17 77.41			54.79 51.78
1987	28.81	13.87	0.33		43.10			46.44	89.54			48.51
1988	39.46	23.14	0.53		63.12			38.94	102.06			40.97
1989	44.68	31.20	0.30		76.17			38.08	114.25			40.28
1990	46.19	35.65	0.58		82.41			34.77	117.18			36.89
1991 1992	56.02 66.44	39.91 44.31	0.25 0.97		96.18 111.72			41.78 38.47	137.95 150.19	40.52	35.28	44.38 75.80
1993	74.64	50.24	0.87		125.74			74.59	200.34	42.89	35.83	78.72
1994	69.86	56.56	0.86		127.28			53.92	181.20	45.73	36.58	82.32
1995	50.23	60.17	1.18		111.59			56.82	168.41	45.56	40.31	85.88
1996 1997	47.63 59.26	60.58 63.97	1.19 1.23		109.40 124.46			70.33 107.92	179.73 232.38	53.00 54.06	47.00 48.20	100.00
1998	71.27	67.89	1.12		140.28			92.92	233.20	57.00	51.46	108.45
1999	87.87	99.30	1.45		188.62			98.53	287.15	62.00	54.53	116.54
2000	107.91	99.59	1.69		209.19			105.64	314.83	61.61	67.49	129.10
2001 2002	128.25 150.84	100.91 115.93	2.73 3.01		231.89 269.78			118.12 130.84	350.02 400.62	65.69 67.55	68.33 69.46	134.02 137.01
2002	166.67	125.70	3.43		295.81			155.61	451.43	71.39	60.31	131.70
2004	189.79	122.99	4.31		317.10			159.07	476.17	76.78	63.36	140.14
2005	209.60	132.99	5.43		348.03			166.25	514.28	79.79	64.23	144.02
2006	222.31	129.48	6.52		358.31			179.83	538.14	86.17	66.10	152.27
2007 2008 f	213.77 236.80	153.98 159.90	8.16 9.75		375.91 406.46			199.80 228.19	575.71 634.65	75.40 78.75	66.89 68.94	142.28 147.70
2009 f	244.38	171.80	11.91		428.10			244.67	672.76	81.71	70.40	152.11
						(Annual Bassantona	Channe)					
	-					(Annual Percentage						
1985 1986	52.9	10.3	 -18.7		27.1			 -6.7	3.0			 -5.5
1987	115.7	1.6	26.2		57.6			-7.2	15.7			-6.3
1988	36.9	66.8	28.0		46.5			-16.2	14.0			-15.5
1989	13.2	34.8	-43.3		20.7			-2.2	12.0			-1.7
1990	3.4	14.3	93.3		8.2			-8.7	2.6			-8.4
1991 1992	21.3 18.6	11.9 11.0	-56.6 287.7		16.7 16.2			20.1 -7.9	17.7 8.9			20.3 70.8
1993	12.3	13.4	-9.8		12.6			93.9	33.4	5.8	1.6	3.9
1994	-6.4	12.6	-1.2		1.2			-27.7	-9.6	6.6	2.1	4.6
1995	-28.1	6.4	37.1		-12.3			5.4	-7.1	-0.4	10.2	4.3
1996 1997	-5.2 24.4	0.7 5.6	0.8 3.5		-2.0 13.8			23.8 53.5	6.7 29.3	16.3 2.0	16.6 2.6	16.4 2.3
1998	20.3	6.1	-9.0		12.7			-13.9	0.4	5.4	6.7	6.1
1999	23.3	46.3	29.5		34.5			6.0	23.1	8.8	6.0	7.5
2000	22.8	0.3	16.5		10.9			7.2	9.6	-0.6	23.8	10.8
2001	18.9	1.3	61.1		10.9			11.8	11.2	6.6	1.2	3.8
2002 2003	17.6 10.5	14.9 8.4	10.3 14.1		16.3 9.6			10.8 18.9	14.5 12.7	2.8 5.7	1.7 -13.2	2.2 -3.9
2003	13.9	-2.2	25.5		7.2			2.2	5.5	7.5	5.1	-3.8
2005	10.4	8.1	26.0		9.8			4.5	8.0	3.9	1.4	2.8
2006	6.1	-2.6	20.0		3.0			8.2	4.6	8.0	2.9	5.7
2007	-3.8	18.9	25.2		4.9			11.1	7.0	-12.5	1.2	-6.6
2008 f 2009 f	10.8 3.2	3.8 7.4	19.5 22.1		8.1 5.3			14.2 7.2	10.2 6.0	4.4 3.8	3.1 2.1	3.8
2000 1	5.2		22	(Ann		ange in Excess of In	flation in the			5.5		0.0
1005						. g Enddaa di III		Canadian Econ				
1985 1986	 50.1	7.5	-21.5		24.3			-9.5	0.2			-8.3
1987	110.9	-3.2	21.5		52.9			-12.0	10.9			-11.1
1988 1989	32.4	62.3	23.5		41.9			-20.7	9.5			-20.1
	8.7	30.3	-47.9		16.1			-6.8	7.4			-6.2
1990 1991	0.4 18.5	11.2 9.2	90.3 -59.4		5.2 13.9			-11.7 17.4	-0.5 15.0			-11.4 17.5
1991	17.3	9.2	286.5		14.9			-9.2	7.6			69.5
1993	10.9	11.9	-11.3		11.1			92.5	31.9	4.4	0.1	2.4
1994	-7.5	11.5	-2.3		0.1			-28.8	-10.7	5.5	1.0	3.5
1995	-30.4	4.1	34.7		-14.7			3.0	-9.4	-2.7	7.9	2.0
1996 1997	-6.9 23.4	-1.0 4.6	-0.9 2.5		-3.6 12.8			22.1 52.5	5.1 28.3	14.6 1.0	14.9 1.6	14.8 1.3
1998	20.7	6.6	-8.5		13.2			-13.5	0.8	5.9	7.2	6.5
1999	21.5	44.4	27.7		32.7			4.2	21.3	7.0	4.2	5.6
2000	18.7	-3.8	12.4		6.8			3.1	5.5	-4.7	19.7	6.7
2001	17.5	0.0	59.8		9.5			10.5	9.8	5.3	-0.1	2.5 1.2
2002 2003	16.6 7.6	13.8 5.5	9.2 11.2		15.3 6.8			9.7 16.0	13.4 9.8	1.8 2.8	0.6 -16.1	1.2 -6.8
2004	11.3	-4.7	22.9		4.6			-0.4	2.9	5.0	2.5	3.8
2005	7.5	5.2	23.1		6.8			1.6	5.1	1.0	-1.5	-0.1
2006	3.2	-5.5	17.1		0.1			5.3	1.7	5.1	0.0	2.8
2007 2008 f	-7.2 6.1	15.6 -0.8	21.9 14.9		1.6 3.5			7.8 9.6	3.7 5.6	-15.8 -0.2	-2.1 -1.6	-9.9 -0.8
2009 f	5.1	9.3	24.0		7.2			9.1	7.9	5.6	4.0	4.9
f: forecast.												
* Confidentia	lity precludes repo	rting territorial-l	level insurance	data.							Sourc	e: CIHI, 2009.

Y.T.



Table B N.W.T.-Total Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Northwest Territories, 1985 to 2009



					Prescribed D	rugs					-Prescribed D	
	Territory	Federal	Publi	Security Funds	Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Priva Over-	te (Out-of-Po Personal	cket) Total
	remory	- Leacial	WCB	Drug Insurance Funds	Public	mourers	Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Presc. Drugs
'ear				(Premium Component)		(\$ Millions)			•	Drugs		
985	1.1	2.4	0.0		3.5			2.3	5.8			4.1
1986	1.4	2.7	0.0		4.1			2.7	6.8			4.4
1987	1.7	3.0	0.0		4.7			3.0	7.7			4.7
1988 1989	1.9 2.1	3.2 3.7	0.0		5.1 5.8			3.4 3.9	8.6 9.7			5.1 5.4
1990 1991	2.4 3.0	4.3 4.9	0.0		6.6 7.9			3.9 5.0	10.6 12.9			5.1 6.0
1992	3.6	5.7	0.0		9.3			4.9	14.2	2.4	2.1	
1993	2.5	6.4	0.0		8.9			4.7	13.6	2.6	2.2	
1994	1.2	7.1	0.1		8.3			3.5	11.8	2.8	2.3	5.1
1995	1.1	7.7	0.1		8.9			3.8	12.6	2.9	2.5	
1996 1997	1.3 1.4	8.0 8.5	0.0		9.3 9.9			3.5 4.4	12.8 14.4	2.7 3.1	2.4 2.8	
1998	1.7	8.8	0.0		10.5			4.4	15.0	3.2	2.9	
1999	1.8	7.6	0.0		9.4			3.3	12.7	2.3	2.1	
2000	1.9	7.6	0.0		9.5			3.4	13.0	2.3	1.4	3.7
2001	2.2	8.8	0.0		11.0			3.6	14.7	2.2	1.4	
2002	2.4	10.7	0.0		13.1			4.0	17.2	2.3	1.5	
2003	3.2	9.0	0.0		12.3			5.3	17.5	2.2	1.5	
2004	3.6	8.1	0.1		11.8			5.4	17.2	2.2	1.4	
2005 2006	3.7 4.3	6.2 6.3	0.1 0.1		10.0 10.6			7.1 8.0	17.0 18.6	2.0 2.1	1.4 1.4	
2006 2007	4.3	6.3 8.3	0.1		13.2			8.0	21.9	2.1	1.4	
2008 f	4.5	9.2	0.1		13.8			9.5	23.2	2.5	1.5	
2009 f	5.1	9.7	0.1		14.9			10.1	25.0	2.6	1.5	4.1
						(Annual Percentage	Change)					
1985												
1986 1987	30.3 22.0	12.3 8.5	-5.7 6.9		17.7 13.1			14.6 12.7	16.5 12.9			8.2 6.2
1988	12.6	6.9	67.7		9.2			15.4	11.6			8.6
1989	7.6	17.3	-6.6		13.5			14.2	13.8			7.2
1990	13.9	14.8	-0.9		14.4			0.2	8.7			-6.0
1991	25.2	16.0	13.9		19.2			25.8	21.7			17.8
1992	21.7	14.9	1.0		17.4			-1.1	10.3			-25.1
1993 1994	-31.8 -50.0	13.3	27.0 32.1		-4.2			-4.2	-4.2 -13.2	7.3 9.0	3.0	
		10.0			-6.5			-25.9			4.3	
1995 1996	-8.1 14.4	9.1 3.3	0.9 -15.9		6.5 4.6			7.8 -6.7	6.9 1.3	1.5 -6.2	12.3 -6.0	
1997	9.9	6.5	-3.6		7.0			27.0	12.4	15.7	16.3	
1998	16.2	3.3	1.1		5.1			1.7	4.1	4.2	5.4	4.8
1999	10.2	-13.7	-14.2		-9.9			-27.4	-15.2	-27.8	-29.6	-28.7
2000	6.8	-0.1	0.1		1.3			5.1	2.3	-0.9	-32.0	
2001	13.6 7.4	16.2	22.9 4.0		15.7			5.8	13.1 16.9	-6.5 4.2	2.7	
2002 2003	34.8	21.8 -15.7	1.7		18.9 -6.5			11.0 30.7	2.2	-2.3	3.0 1.3	
2004	12.8	-9.6	56.6		-3.5			1.6	-2.0	-1.9	-8.6	
2005	3.7	-24.4	-14.2		-15.7			31.6	-1.0	-7.5	2.3	-3.7
2006	13.6	2.4	-3.2		6.6			12.8	9.2	3.0	0.2	
2007	14.2	31.1	13.5		24.2			8.7	17.6	3.2	3.2	
2008 f	-6.8	10.7	7.5		4.2			9.5	6.3	16.0	1.1	
2009 f	12.1	6.2	6.7	***	8.2			6.6	7.5	4.8	4.4	4.6
1005	10.0	24.5	0.2			tage Share of Total D	rug Expendi		F0.0			41.0
1985 1986	10.9 12.6	24.5 24.3	0.2 0.1		35.6 37.1			23.4 23.7	59.0 60.7			41.0 39.3
1987	13.9	23.9	0.1		38.0			24.2	62.2			37.8
1988	14.2	23.2	0.2		37.6			25.3	62.8			37.2
1989	13.7	24.4	0.2		38.3			25.9	64.2			35.8
1990	15.1	27.1	0.2		42.4			25.1	67.5			32.5
1991 1992	15.7 19.3	26.1 30.3	0.2		41.9 49.7			26.2 26.2	68.2 75.9	12.9	 11.2	31.8 24.1
1992	19.3	30.3 34.9	0.2		49.7 48.6			25.6	75.9 74.1	12.9	11.2	
1994	7.3	41.8	0.3		49.4			20.6	70.0	16.7	13.3	
1995	6.3	42.7	0.3		49.3			20.8	70.1	15.9	14.0	29.9
1996	7.3	44.6	0.2		52.0			19.6	71.6	15.0	13.3	28.4
1997	7.0	41.8	0.2		49.1			21.9	71.0	15.3	13.7	
1998 1999	7.8 10.7	41.4 44.2	0.2		49.5 55.1			21.4 19.2	70.9 74.3	15.3 13.7	13.8 12.0	
2000 2001	11.7 12.1	45.2 48.0	0.2		57.1 60.4			20.6 19.9	77.8 80.3	13.9 11.8	8.4 7.9	
	11.4	51.2	0.2		62.8			19.4	82.1	10.8	7.9	
2002		42.4	0.2		57.7			24.9	82.6	10.4	7.0	17.4
2002 2003	15.1	00.0	0.3		57.1			25.9	83.0	10.4	6.6	17.0
2002	17.4	39.3										
2002 2003 2004 2005	17.4 18.3	30.2	0.3		48.8			34.6	83.4	9.8	6.9	
2002 2003 2004 2005 2006	17.4 18.3 19.3	30.2 28.6	0.3		48.2			36.1	84.3	9.3	6.4	15.7
002 003 004 005 006	17.4 18.3 19.3 19.1	30.2 28.6 32.5	0.3 0.3		48.2 51.9			36.1 34.1	84.3 85.9	9.3 8.4	6.4 5.7	15.7 14.1
002 003 004 005 006	17.4 18.3 19.3	30.2 28.6	0.3		48.2			36.1	84.3	9.3	6.4	15.7 14.1 14.5

				by Source of Finance and as a Share of Public, Private and ure, Northwest Territories, 1985 to 2009 (cont'd)						
			tai nealtii Expend			200 to 2009 (cor	Share of Drugs	in Public, Private an	d	
-	Public	All Drugs Private	Total		h Expenditure Private	Total		Ith Expenditures Private	Total	
-			(\$ Million	s)			(Perce	ntage Share)		
	3.5 4.1	6.4 7.0	9.9 11.2	118.9 145.2	19.6 21.7	138.5 166.9	3.0 2.9	32.4 32.5	7.1 6.7	
	4.7	7.7	12.3	157.4	23.9	181.3	3.0	32.1	6.8	
	5.1	8.5	13.6	183.9	27.3	211.2 232.9	2.8	31.2 31.9	6.5	
	5.8 6.6	9.4 9.0	15.2	203.6	29.3		2.9 3.0	31.9	6.5	
	7.9	11.0	15.7 18.9	218.5 247.2	28.4 32.3	246.8 279.5	3.0	34.0	6.4 6.8	
	9.3 8.9	9.4 9.4	18.7 18.4	249.9 258.7	29.7 28.3	279.6 287.1	3.7 3.4	31.7 33.3	6.7 6.4	
	8.3	8.6	16.9	259.5	26.8	286.3	3.4	32.0	5.9	
	8.9	9.1	18.0	270.3	24.7	295.0	3.3	37.0	6.1	
	9.3	8.6	17.9	265.4	26.7	292.1	3.5	32.0	6.1	
	9.9 10.5	10.3 10.7	20.3 21.1	280.9 301.3	26.4 26.0	307.3 327.3	3.5 3.5	39.1 41.0	6.6 6.5	
	9.4	7.7	17.1	211.2	21.1	232.3	4.5	36.3	7.4	
	9.5	7.2	16.7	194.9	19.6	214.6	4.9	36.5	7.8	
	11.0 13.1	7.2 7.8	18.3 20.9	220.0 245.2	26.3 28.7	246.4 273.9	5.0 5.3	27.5 27.1	7.4 7.6	
	12.3	9.0	21.2	243.7	29.9	273.6	5.0	30.1	7.8	
	11.8	8.9	20.7	268.5	30.3	298.9	4.4	29.4	6.9	
	10.0 10.6	10.5 11.4	20.4 22.1	283.4 300.8	50.5 58.6	333.9 359.4	3.5 3.5	20.7 19.5	6.1 6.1	
	13.2	12.2	25.4	330.1	68.2	398.2	4.0	18.0	6.4	
	13.8 14.9	13.4 14.2	27.2 29.1	344.9 359.4	69.0 74.2	413.9 433.6	4.0 4.1	19.5 19.2	6.6 6.7	
			(Annual Percentag							
-										
	17.7	10.5	13.1	22.2	10.5	20.5				
	13.1 9.2	8.7 11.3	10.3 10.5	8.4 16.8	10.0 14.4	8.6 16.5				
	13.5	10.0	11.3	10.7	7.5	10.3				
	14.4	-3.4	3.4	7.3	-3.3	6.0				
	19.2	21.3	20.4	13.2	13.7	13.2				
	17.4 -4.2	-14.2 0.3	-1.0 -1.9	1.1 3.5	-7.9 -4.7	0.1 2.7				
	-6.5	-9.4	-8.0	0.3	-5.5	-0.3				
	6.5	6.9	6.7	4.1	-7.8	3.0				
	4.6 7.0	-6.4 20.5	-0.9 13.4	-1.8 5.8	8.3 -1.4	-1.0 5.2				
	5.1	3.4	4.3	7.3	-1.3	6.5				
	-9.9	-28.1	-19.1	-29.9	-18.8	-29.0				
	1.3 15.7	-6.7 1.2	-2.3 9.5	-7.7 12.9	-7.0 34.1	-7.6 14.8				
	18.9	7.4	14.3	11.4	9.0	11.2				
	-6.5 -3.5	15.5 -0.9	1.7 -2.4	-0.6 10.2	4.1 1.4	-0.1 9.2				
	-15.7	17.6	-1.4	5.5	66.5	11.7				
	6.6	9.3	8.0	6.2	16.0	7.6				
	24.2 4.2	7.1 9.6	15.3 6.8	9.7 4.5	16.4 1.2	10.8 3.9				
	8.2	6.0	7.1	4.5	7.5	4.7				
_	(Percentage	e Share of Total Dr	rug Expenditure)	<u> </u>						
	35.6	64.4	100.0							
	37.1 38.0	62.9 62.0	100.0 100.0							
	38.0 37.6	62.4	100.0							
	38.3	61.7	100.0							
	42.4	57.6	100.0							
	41.9 49.7	58.1 50.3	100.0 100.0							
	48.6	51.4	100.0							
	49.4	50.6	100.0							
	49.3 52.0	50.7 48.0	100.0 100.0							
	49.1	48.0 50.9	100.0							
	49.5	50.5	100.0							
	55.1	44.9	100.0							
	57.1 60.4	42.9 39.6	100.0 100.0							
	62.8	37.2	100.0							
	57.7 57.1	42.3 42.9	100.0 100.0							
	48.8 48.2	51.2 51.8	100.0 100.0							
	51.9	48.1	100.0							
	51.1	48.9	100.0							
	50.6 51.1	49.4 48.9	100.0 100.0						Source	

Table B N.W.T.—per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Northwest Territories, 1985 to 2009

Non-Prescribed Drugs Prescribed Drugs Public Private (Out-of-Pocket) Private Sub-Total Sub-Total Over-Territory Federal Social Security Funds Insurers* Out-of Total Total Drug Insurance Private the-Non-Presc Funds Drugs Counte Supplies Drugs (Premium Component) Drugs (\$ per Capita) 19.87 44.58 64.76 74.63 0.30 42.52 107.28 25.75 31.22 49.79 53.68 0.29 75.83 85.21 48.45 54.27 124.28 139.47 80.32 84.79 34.75 56.71 0.50 91.96 61.91 153.87 91.01 69.02 36.51 64.93 0.46 101.90 170.93 95.30 40.26 48.72 0.44 0.48 72.19 112.88 66.93 179.82 86.68 80.93 81.44 98.76 130.14 211.58 57 90 90.80 0.48 149 18 78 63 227 81 38 63 33.63 72 26 38.77 140.39 73.95 101.02 0.60 40.71 34.01 18.92 108.39 0.77 128.08 53.43 181.52 43.27 34.62 77.89 17.01 115.69 0.76 133.46 56.36 189.82 43.00 38.04 81.04 19.17 117.78 0.63 137.58 51.79 189.37 39.74 35.24 74 98 21.03 125.16 146.79 65.59 212.38 45.87 40.90 86.77 0.60 24.63 130.34 0.62 155.58 67.25 222.83 48.16 43.48 91.64 44.84 185.89 0.87 80.64 108.04 48.07 186.46 0.88 235.41 85.11 320.51 57.16 34.51 91.67 54.18 215.04 1.07 270.29 89.29 359.58 53.05 35.15 88.20 57.23 257.78 1.10 316.11 97.51 413.62 54.38 35.62 90.01 31.97 84.28 190.26 1.69 276.23 125.49 401.72 50.49 82.47 87.63 144.25 1.45 233.33 165.47 398.80 46.79 32.80 79.59 98.49 146.08 1.39 245.96 184.64 430.60 47.68 32.50 80.18 111.57 189.98 1.57 303.12 199.19 33.29 104.58 211.52 1.69 317.80 219.30 537.10 56.98 33.85 90.83 115.91 1.79 (Annual Percentage Change) 29.6 11.7 -6.3 17.1 14.0 15.8 21.2 12.0 6.3 12.4 12.2 11.3 5.6 65.8 7.9 14.1 10.3 7.3 5.1 -8.8 10.8 11.5 -3.0 21.7 10.3 11.2 -4 O 10.8 5.2 -9.1 21.0 10.2 17.7 13.9 12.1 15.3 18.8 12.2 -1.4 14.6 -3.4 7.7 -26.8 33.0 -27.7 -15.3 6.3 4.2 -51.2 7.3 28.8 -8.8 1.8 -10.1 -1.3 -0.6 12.7 1.8 -17.1 3.1 -8.1 -0.2 -7.6 -7.4 -7.5 17.1 6.0 2.5 4.9 5.0 6.3 5.6 82.1 42.6 41.8 48.9 19.9 40.1 19.3 16.3 17.9 -15.2 7.2 0.3 0.5 1.6 5.5 2.6 -0.6 -31.7 -7.2 12.7 15.3 22.0 14.8 4.9 12.2 -3.8 1.9 5.6 19.9 2.3 17.0 9.2 15.0 2.5 1.3 2.0 32.4 -17.2 -4.0 11.2 -10.8 54.4 -4.8 0.2 -3.3 -3.3 -9.8 -5.9 4.0 -24.2 -14.0 -0.7 -7.3 2.6 -3.5 -15.5 31.9 12.4 13.3 1.3 30.1 -4.2 12.7 8.0 16.7 -0.9 2.4 5.4 11.6 1.9 2.4 0.8 23.2 -6.3 11.3 8.1 4.8 10.1 6.9 16.7 1.7 10.6 7.0 (Annual Percentage Change in Excess of Inflation in the Canadian Econo 26.8 8.9 -9.1 14.3 11.2 13.0 4.8 16.5 7.6 6.8 1.1 61.2 3.4 9.6 5.8 2.8 0.5 13.4 6.2 0.1 7.2 8.1 -7.1 7.7 -6.1 2.2 -12.1 17.6 10.9 -2.6 13.4 -4.7 6.4 -28.1 23.3 27.7 4.0 -0.3 2.0 3.1 -52.3 -16.4 6.2 -28.8 5.2 0.7 -9.9 2.2 -12.4 -3.6 1.9 3.1 -3.0 7.6 11.0 0.1 -18.8 -9.8 -1.9 -9.3 14.4 -9.0 -9.1 8.7 17.5 5.7 11.2 2.3 4.6 6.4 3.0 5.4 5.4 6.7 6.1 80.3 40.8 40.0 47.1 18.1 38.3 17.5 14.5 16.1 -2.5 -19.3 3.1 -3.8 -3.6 1.4 -1.5 -4.7 -35.8 10.8 14.0 -8.5 1.5 20.6 4.6 18.8 1.2 15.9 8.2 0.3 -6.9 -5.9 29.5 -20.1 -3.0 -11.1 25.5 -2.5 -3.4 -5.5 8.6 -13.4 51.8 -2.4 -8.5 1.1 -27.1 -16.9 -18.4 28.9 -3.6 -10.3 -0.3 -6.4 -1.0 -3.8 -2.1 2.5 8.7 10.0 26.7 9.3 19.9 4.6 13.3 -0.9 -0.9 -0.9 12.7 6.9 7.4 8.8 8.2 5.5 5.1 5.3



1985

1988

1990

1991

1992

1993

1994

1995

1996

1997

1998

2000

2001

2002

2004

2005

2006

2008 1

2009

1985 1986

1987

1988

1989

1990

1991

1992

1994

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007 2008 t

1985 1986

1987

1988

1990

1992

1993

1994

1995

1996

1997

1998

1999

2000

2002

2003

2005

2006

2007

2008 f 2009 f

Confidentiality precludes reporting territorial-level insurance data

		•	• .	apita by Type, by				.a
			tal Health Expend	diture, Northwest 1		985 to 2009	GDP Implicit	
-	Public	All Drugs Private	Total	Public	Private	Total	Price Index—Canada	
			(\$ per Ca	pita)			(1997 = 100)	
5	64.76	117.15	181.91	2,185.68	361.05	2,546.73	73.6	NI V
6	75.83	128.77	204.59	2,655.45	396.69	3,052.14	75.6	Ν.\
7 8	85.21 91.96	139.05 152.93	224.26 244.89	2,859.77 3,302.40	433.59 490.09	3,293.37 3,792.49	79.2 82.8	
9	101.90	164.33	266.23	3,570.18	514.33	4,084.51	86.6	
D	112.88	153.61	266.49	3,708.35	481.64	4,190.00	89.2	
	130.14	180.20	310.34	4,057.16	529.44	4,586.61	91.6	
2	149.18	150.89	300.07	4,004.30	476.22	4,480.52	92.8	
3 ↓	140.39 128.08	148.68 131.32	289.07 259.40	4,071.51 3,983.42	445.89 410.95	4,517.40 4,394.37	94.1 95.2	
5	133.46	137.40	270.86	4,060.01	370.96	4,430.96	97.4	
5	137.58	126.77	264.35	3,927.17	395.82	4,322.99	99.0	
7	146.79	152.36	299.16	4,146.76	389.36	4,536.12	100.0	
3 9	155.58 231.61	158.89 188.69	314.48 420.29	4,484.12 5,194.03	387.25 519.57	4,871.36 5,713.59	99.6 101.4	
0 1	235.41 270.29	176.78 177.49	412.19 447.78	4,812.89 5,390.16	484.88 645.24	5,297.76 6,035.40	105.5 106.9	
2	316.11	187.52	503.63	5,909.52	692.07	6,601.59	108.1	
3	290.24	212.86	503.10	5,771.41	708.11	6,479.52	111.2	
4	276.23	207.96	484.18	6,271.13	708.16	6,979.29	114.1	
5	233.33	245.05	478.38	6,632.88	1,181.96	7,814.83	117.4	
)6)7	245.96 303.12	264.82 281.30	510.78 584.42	6,963.92 7,581.51	1,355.49 1,565.83	8,319.41 9,147.34	120.8 124.8	
8 f	317.80	310.13	627.93	7,969.62	1,594.13	9,563.75	130.6	
9 f	339.94	325.16	665.10	8,211.06	1,695.14	9,906.20	128.2	
_			U	Annual Percentage Change				
5							***	
6	17.1	9.9	12.5	21.5	9.9	19.8	2.8	
7	12.4	8.0	9.6	7.7	9.3	7.9	4.7	
B 9	7.9 10.8	10.0 7.5	9.2 8.7	15.5 8.1	13.0 4.9	15.2 7.7	4.5 4.6	
0 1	10.8 15.3	-6.5 17.3	0.1 16.5	3.9 9.4	-6.4 9.9	2.6 9.5	3.0 2.8	
2	14.6	-16.3	-3.3	-1.3	-10.1	-2.3	1.3	
3	-5.9	-1.5	-3.7	1.7	-6.4	0.8	1.4	
4	-8.8	-11.7	-10.3	-2.2	-7.8	-2.7	1.1	
5	4.2	4.6	4.4	1.9	-9.7	0.8	2.3	
96 97	3.1 6.7	-7.7 20.2	-2.4 13.2	-3.3 5.6	6.7 -1.6	-2.4 4.9	1.7 1.0	
18	6.0	4.3	5.1	8.1	-0.5	7.4	-0.4	
9	48.9	18.8	33.6	15.8	34.2	17.3	1.8	
00	1.6	-6.3	-1.9	-7.3	-6.7	-7.3	4.1	
1	14.8	0.4	8.6	12.0	33.1	13.9	1.4	
3	17.0 -8.2	5.6 13.5	12.5 -0.1	9.6 -2.3	7.3 2.3	9.4 -1.8	1.0 2.9	
4	-4.8	-2.3	-3.8	8.7	0.0	7.7	2.6	
5	-15.5	17.8	-1.2	5.8	66.9	12.0	2.9	
6	5.4	8.1	6.8	5.0	14.7	6.5	2.9	
7	23.2	6.2	14.4	8.9	15.5	10.0	3.3	
8 f 9 f	4.8 7.0	10.2 4.8	7.4 5.9	5.1 3.0	1.8 6.3	4.6 3.6	4.7 -1.9	
- '				Inflation in the Canadian I		0.0		
-								
5 6	14.3	7.1	9.7	18.7	7.1	17.0		
7	7.6	3.2	4.9	3.0	4.6	3.2		
3	3.4	5.5	4.7	11.0	8.5	10.6		
9	6.2	2.9	4.2	3.5	0.4	3.1		
) 1	7.7	-9.5	-2.9	0.8	-9.4	-0.4		
1 2	12.5 13.4	14.5 -17.5	13.7 -4.6	6.6 -2.6	7.2 -11.3	6.7 -3.6		
3	-7.3	-2.9	-5.1	0.2	-7.8	-0.6		
1	-9.9	-12.8	-11.4	-3.3	-8.9	-3.8		
	1.9	2.3	2.1	-0.4	-12.1	-1.5		
3	1.4	-9.4	-4.1	-4.9	5.0	-4.1		
7 3	5.7 6.4	19.2 4.7	12.2 5.6	4.6 8.6	-2.6 -0.1	3.9 7.8		
9	47.1	16.9	31.8	14.0	32.4	15.5		
0	-2.5	-10.4	-6.0	-11.4	-10.8	-11.4		
1	13.5	-0.9	7.3	10.6	31.7	12.6		
2	15.9	4.6	11.4	8.6	6.2	8.3		
3 1	-11.1 -7.4	10.6 -4.9	-3.0 -6.4	-5.2 6.1	-0.6 -2.6	-4.7 5.1		
5 6	-18.4 2.5	14.9 5.2	-4.1 3.9	2.9 2.1	64.0 11.8	9.1 3.6		
o 7	19.9	2.9	11.1	5.5	12.2	6.6		
8 f	0.2	5.6	2.8	0.5	-2.8	-0.1		
9 f	8.8	6.7	7.8	4.9	8.2	5.5		

2.9 7.4

11.3

36.6

47.5

47.7

41.4

39.9

0.5

0.5

0.4

0.4

0.3

0.2

0.3

0.3

22.6

21.9

21.9

16.1

14.9

15.4 15.9

14.3

2000

2001

2002

2004

2005

2006

2007

2008 f

2009 f f: forecast

Nun.

Table B Nun. - Total Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Nunavut, 1985 to 2009 Non-Prescribed Drugs Prescribed Drugs Private (Out-of-Pocket) Public Private Sub-Total Sub-Total Territory Federal Social Security Funds Insurers* Total Over-Total Out-of-Personal Prescribed WCB Non-Presc Drugs Funds Druas Counter Supplies (Premium Component) Drugs Year (\$ Millions) 1985 1986 1988 1989 ---1990 1992 1993 1994 1995 1996 1997 1998 1.1 1.3 1999 1.0 0.0 0.0 2.4 1.5 1.3 2.9 2000 1.2 0.2 0.0 1.4 1.5 2.8 1.6 0.9 2.5 1.5 2.1 4.5 1.6 2002 0.8 0.0 2.4 1.0 2.6 2003 2004 2.1 4.1 5.1 0.0 6.3 7.4 3.3 4.1 9.6 11.5 1.5 1.5 1.0 2.6 2.4 0.9 2005 2.4 0.0 10.2 3.7 13.9 1.4 1.5 1.0 2.8 8.9 2006 0.0 11.7 4.3 16.0 2.5 5.2 5.7 2007 2.9 2.7 7.7 7.5 0.0 10.7 15.9 1.6 1.8 10.3 16.0 2008 1 0.1 2009 f 3.4 8.0 0.1 11.5 6.8 18.3 1.9 1.1 3.0 (Annual Percentage Change) 1985 1986 1988 1989 1990 1991 1992 1994 1995 1996 1998 1999 9.4 4.7 2000 21.7 289.9 31.3 19.1 1.1 -30.6 -13.7 2001 13.6 36.1 6.0 5.5 2002 23.4 88.4 4.5 39.2 37.7 4.7 2003 36.7 6.3 421.2 1.4 57.0 165.5 56.6 24.9 114.5 -2.7 -1.6 -1.3 -4.3 2004 17.5 20.1 -8.3 2005 -13.5 -9.3 ---2006 17.2 14.3 -0.5 14.9 15.1 15.0 8.4 5.4 7.1 2007 -13.4 13.7 22.9 2008 f -8.4 -2.0 8.8 -3.8 9.5 0.6 15.5 0.6 9.4 2009 f 27.6 6.2 7.6 11.8 19.2 14.5 4.5 3.1 4.0 (Per of Total Dr Expenditu 1985 1986 1987 1988 1989 1990 1991 1992 1994 1995 1996 1998 1999 18.8 0.7 0.4 19.9 25.4 45.3 29.1 25.6 54.7

116 CIHI 2010

27.4

26.9

29.6

29.3

22.7

23.0 28.3

30.4

53.3

56.8

63.2

82.4

85.4

86.3

85.9

84.8

25.9

29.9

33.6

53.1

62.7

63.3 57.6

54.4

17.6 17.2

14.6

6.8

6.0

5.6

5.6

46.7

36.8 21.1 17.6

14.6

13.7

15.2

29.1

26.0

22.2

10.8

8.6

8.2 8.4

9.5

Nun.

		Expenditure	•	e, by Source of Fir expenditure, Nunav			c, Private and	Table B Nu
		All Drugs	Total Health L	•	th Expenditure	2003 (cont u)		in Public, Private a alth Expenditures
_	Public	Private	Total	Public	Private	Total	Public	Private
			(\$ Million				(Poro	entage Share)
_	***							

	1.1	4.2	5.3	133.6	 9.1	142.6	0.8	46.5
	1.4 1.7	4.0 4.0	5.3 5.7	159.2 173.7	9.3 10.6	168.5 184.3	0.9 1.0	42.5 37.5
	2.4	4.7	7.0	203.8	11.2	214.9	1.2	41.9
	6.3 7.4	5.8 6.5	12.1 13.9	279.2 294.0	13.3 13.9	292.5 307.9	2.3 2.5	43.8 47.0
	10.2	6.1	16.3	287.7	16.6	304.3	3.6	36.6
	11.7	6.8	18.6	317.4	17.6	335.0	3.7	38.6
	10.7 10.3	7.8 8.6	18.5 18.8	334.8 340.7	20.6 22.9	355.4 363.6	3.2 3.0	38.0 37.5
	11.5	9.8	21.3	347.3	25.3	372.7	3.3	38.7
			(Annual Percentag	ge Change)				

	31.3 23.1	-6.4 0.9	1.1 6.6	19.2 9.1	2.5 14.4	18.1 9.4		
	39.2	17.2	23.8	17.3	4.9	16.6		
	165.5 17.5	24.5 12.1	71.9 14.9	37.0 5.3	19.1 4.4	36.1 5.3		
	38.4	-6.9	17.2	-2.2	19.7	-1.2		
	14.9 -9.3	12.0 15.2	13.8 -0.3	10.3 5.5	6.0 17.1	10.1 6.1		
	-3.8	9.5	1.8	1.8	11.1	2.3		
	11.8	14.1	12.9	2.0	10.5	2.5		
_		Share of Total Dr	ug Expenditure)	_				
	19.9	80.1	100.0					
	25.9	74.1	100.0					
	29.9 33.6	70.1 66.4	100.0 100.0					
	51.9	48.1	100.0					
	53.1	46.9	100.0					
	62.7	37.3	100.0					
	63.3 57.6	36.7 42.4	100.0 100.0					
	54.4	45.6	100.0					
	53.9	46.1	100.0					

Confidentiality precludes reporting territorial-level insurance data

Table B Nun.—per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditure, Nunavut, 1985 to 2009

Prescribed Drugs Non-Prescribed Drugs Private (Out-of-Pocket) Public Private Federal Sub-Total Sub-Total Over-Territory Social Security Funds Insurers* Out-of Total Total Drug Insurance Pocket Private Prescribed the-Non-Presc Funds Drugs Counter Supplies Drugs (Premium Component) Drugs (\$ per Capita) 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 36.87 1.47 0.87 39.22 49.87 89.09 57.22 107.55 53.24 54.52 34.07 34.80 2000 43.76 5.60 0.88 50.24 103.47 56.42 90.49 2001 44.37 15.02 1.07 60.46 114.97 52.52 87.32 2002 53.59 27.68 1.10 82.36 72.60 154.96 54.45 35.67 90.12 327.49 2004 75.53 249.24 137.73 32.00 172.02 1.69 386.97 50.53 82.53 2005 80.98 258.19 1.44 340.62 123.30 463.92 46.57 32.64 79.22 92.52 94.17 138.35 167.55 2006 287.53 1.40 381.45 519.80 49.18 33.52 82.70 245.40 1.57 341.14 2008 1 85.68 238.88 1.69 326.25 182.26 508.52 56.98 33.85 90.83 2009 1 108.94 1.82 363.71 (Annual Percentage Change) 1985 1986 1988 1990 1991 1992 1994 ------1996 1997 1998 1999 18.7 28.1 6.7 -1.4 2000 280.3 0.5 16.1 -32.3 -15.9 1.4 11.1 2001 168.4 22.0 2.4 -6.9 2.2 -3.5 20.3 2002 20.8 84.3 2.3 36.2 33.2 34.8 3.7 2.5 3.2 2003 413.6 2004 4.6 21.0 54.5 15.7 22.9 18.2 -3.2 -9.7 -5.8 2005 -14.6 36.7 19.9 -7.8 2.0 -4.0 7.2 50.1 -10.5 14.2 11.4 -14.7 -3.1 12.0 12.2 21.1 2.7 2006 12.0 12.0 5.6 1.0 2007 -10.6 2008 1 -9.0 -2.7 8.1 -4.4 8.8 0.0 14.7 0.0 8.8 11.5 (Annual Percentage Change in Excess of Inflation in the Canadian Economy) 1985 1986 1987 1988 1990 1992 1993 1994 1995 1996 1997 1998 1999 2.6 1.0 32.1 14.6 276.2 -3.6 12.0 -5.5 2000 24.0 -36.4 -20.0 0.0 9.8 33.7 -8.3 2.6 167.0 20.6 2002 83.3 35.2 2003 31.8 410.7 -3.0 158.7 51.4 108.4 -7.0 -3.5 -5.6 18.4 52.0 13.1 20.3 15.6 -5.8 -8.4 2005 4.3 47.2 -17.5 33.7 -13.4 17.0 -10.7 -0.9 -6.9 9.3 17.8 4.1 20.7 -0.2 1.5 2006 8.5 -6.0 2007 -1.5 -18.0 8.7 -13.9 -5.5 -4.7 -2.3 -2.3 -2.3 4.1 5.5 16.0 2009 f 29.0 7.8 9.1 13.4 6.1 4.6

Nun.

Nun.

		Expenditur	e on Drugs per Capita Total Health Expe				ic, Private and	lun. – per Ca _l
_	D. LE.	All Drugs			Ith Expenditure		GDP Implicit Price Index—Canada	
	Public	Private	Total	Public	Private	Total		
=			(\$ per Capita)			,	(1997 = 100)	
			***				73.6 75.6	
			***				79.2	
			***				82.8	
						***	86.6	
							89.2 91.6	
							92.8	
			***				94.1	
			***			***	95.2	
			***				97.4 99.0	
							100.0	
		457.40					99.6	
	39.22	157.43	196.64	4,979.28	338.43	5,317.71	101.4	
	50.24 60.46	143.73 141.83	193.96 202.29	5,787.57 6,175.93	338.32 378.42	6,125.90 6,554.35	105.5 106.9	
	82.36	162.72	202.29	7,089.84	378.42	7,478.39	108.1	
	215.44	199.69	415.13	9,574.08	456.01	10,030.09	111.2	
	249.24	220.25	469.50	9,922.53	468.60	10,391.13	114.1	
	340.62 381.45	202.52 221.05	543.14 602.50	9,585.02 10,304.68	553.63 571.94	10,138.65 10,876.62	117.4 120.8	
	341.14	251.08	592.22	10,712.03	660.21	11,372.23	124.8	
	326.25	273.09	599.35	10,832.60	728.58	11,561.18	130.6	
	363.71	310.67	674.38	11,009.17	802.10	11,811.28	128.2	
=			(Aliliua	Percentage Change)				
							2.8	
			***				4.7 4.5	
			***				4.6	
			***				3.0	
							2.8	
							1.3	
							1.4 1.1	
			***				2.3	
							1.7	
			***				1.0	
			***				-0.4 1.8	
			1.4					
	28.1 20.3	-8.7 -1.3	-1.4 4.3	16.2 6.7	0.0 11.9	15.2 7.0	4.1 1.4	
	36.2	14.7	21.2	14.8	2.7	14.1	1.0	
	161.6	22.7	69.4	35.0	17.4	34.1	2.9	
	15.7	10.3	13.1	3.6	2.8	3.6	2.6	
	36.7 12.0	-8.1 9.2	15.7 10.9	-3.4 7.5	18.1 3.3	-2.4 7.3	2.9 2.9	
	-10.6	13.6	-1.7	4.0	15.4	4.6	3.3	
	-4.4	8.8	1.2	1.1	10.4	1.7	4.7	
	11.5	13.8 (Annual Percent	12.5 age Change in Excess of Inflat	1.6 tion in the Canadian E	10.1 (conomy)	2.2	-1.9	
-			age change in Excess of limat			***		

	24.0 19.0	-12.8 -2.7	-5.5 2.9	12.1 5.4	-4.1 10.5	11.1 5.6		
	35.2	13.7	20.1	13.8	1.6	13.1		
	158.7	19.8	66.5	32.1	14.5	31.2		
	13.1	7.7	10.5	1.1	0.2	1.0		
	33.7 9.1	-11.0 6.3	12.8 8.0	-6.3 4.6	15.2 0.4	-5.3 4.4		
	-13.9	10.3	-5.0	0.6	12.1	1.2		
	-9.0	4.1	-3.4	-3.5	5.7	-3.0		
	13.4	15.6	14.4	3.5	12.0	4.0		

Series C International Comparisons

Table C.1

The Share of Pharmaceutical Goods* in Total Expenditure on Health, in Descending Order, OECD Countries Reporting, 1985, 2006, 2007

1985			2007	2007	
(%)		(%)		(%)	
25.4	Hungary	31.8	Hungary	31.2	
25.3	Slovak Republic	29.7	Slovak Republic	27.9	
20.3	Poland	27.2	Greece	24.8	
18.0	Korea	25.6	Korea	24.7	
16.6	Mexico	22.9	Poland	24.5	
16.2	Czech Republic	22.8	Mexico	24.0	
15.7	Greece	22.7	Czech Republic	21.5	
14.7	Portugal	21.8	Spain	21.0	
14.1	Spain	21.7	Italy	19.3	
13.8	Italy	19.9	Canada	17.7	
13.3	Japan	19.6	France	16.3	
13.0	Canada	17.4	Belgium	15.7	
11.3	France	16.3	Germany	15.1	
9.7	Belgium	15.9	Australia	14.3	
9.6	Germany	14.8	Finland	14.1	
9.3	Finland	14.3	Iceland	13.5	
9.1	Australia	14.3	Sweden	13.4	
9.0	Iceland	14.2	Austria	13.3	
8.8	Sweden	13.7	United States	12.0	
7.0	Austria	13.3	Netherlands	11.0	
6.6	United States	12.2	Switzerland	10.3	
	Switzerland	10.4	New Zealand	9.8	
	New Zealand	10.3	Denmark	8.6	
	Norway	8.7	Norway	8.0	
	Denmark	8.5			
	25.4 25.3 20.3 18.0 16.6 16.2 15.7 14.7 14.1 13.8 13.3 13.0 11.3 9.7 9.6 9.3 9.1 9.0 8.8 7.0	25.4 Hungary 25.3 Slovak Republic 20.3 Poland 18.0 Korea 16.6 Mexico 16.2 Czech Republic 15.7 Greece 14.7 Portugal 14.1 Spain 13.8 Italy 13.3 Japan 13.0 Canada 11.3 France 9.7 Belgium 9.6 Germany 9.3 Finland 9.1 Australia 9.0 Iceland 8.8 Sweden 7.0 Austria 6.6 United States Switzerland New Zealand Norway	(%) (%) 25.4 Hungary 31.8 25.3 Slovak Republic 29.7 20.3 Poland 27.2 18.0 Korea 25.6 16.6 Mexico 22.9 16.2 Czech Republic 22.8 15.7 Greece 22.7 14.7 Portugal 21.8 14.1 Spain 21.7 13.8 Italy 19.9 13.3 Japan 19.6 13.0 Canada 17.4 11.3 France 16.3 9.7 Belgium 15.9 9.6 Germany 14.8 9.3 Finland 14.3 9.1 Australia 14.3 9.0 Iceland 14.2 8.8 Sweden 13.7 7.0 Austria 13.3 6.6 United States 12.2 Switzerland 10.4 New Zealand 10.3 Norway 8.7	(%) (%) 25.4 Hungary 31.8 Hungary 25.3 Slovak Republic 29.7 Slovak Republic 20.3 Poland 27.2 Greece 18.0 Korea 25.6 Korea 16.6 Mexico 22.9 Poland 16.2 Czech Republic 22.8 Mexico 15.7 Greece 22.7 Czech Republic 14.7 Portugal 21.8 Spain 14.1 Spain 21.7 Italy 13.8 Italy 19.9 Canada 13.3 Japan 19.6 France 13.0 Canada 17.4 Belgium 11.3 France 16.3 Germany 9.7 Belgium 15.9 Australia 9.6 Germany 14.8 Finland 9.1 Australia 14.3 Iceland 9.0 Iceland 14.2 Austria 8.8 Sweden 13.7 United States 7.0 Austria 13.3	

Notes

* The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Greece: Excludes other medical non-durables.

Hungary: Excludes subsidies by local governments.

Switzerland: Excludes other medical non-durables.

Turkey: Includes pharmaceutical consumption in hospitals.

Source

OECD Health Data 2009, November 2009. Organisation for Economic Co-operation and Development and IRDES, Paris.

Table C.2

The Share of Public Expenditure in Total Expenditure on Pharmaceutical Goods and Other Medical Non-Durables,* OECD Reporting Countries, 1985, 2006, 2007

OECD

1985		2006		2007	2007	
	(%)		(%)		(%)	
Turkey	90.0	Greece	75.8	Greece	79.0	
Luxembourg	86.0	Germany	74.3	Germany	75.9	
New Zealand	80.4	Slovak Republic	72.9	Spain	72.6	
Germany	71.9	Spain	72.3	France	69.4	
Sweden	70.1	Japan	71.7	Slovak Republic	69.1	
France	67.1	Czech Republic	70.8	Switzerland	67.6	
Portugal	64.7	France	69.3	New Zealand	66.8	
United Kingdom	64.1	Switzerland	68.3	Czech Republic	66.0	
Netherlands	63.3	Hungary	67.2	Austria	65.3	
Spain	62.5	New Zealand	67.1	Hungary	58.5	
Iceland	61.9	Austria	63.2	Sweden	58.1	
Japan	60.6	Sweden	59.4	Belgium	56.3	
Belgium	51.0	Norway	56.3	Denmark	55.8	
Australia	47.2	Portugal	55.9	Finland	55.1	
Denmark	45.5	Denmark	55.5	Korea	54.6	
Finland	44.5	Finland	55.4	Australia	54.0	
Norway	43.2	Belgium	54.8	Norway	53.7	
Canada	29.4	Australia	53.9	Italy	48.3	
Korea	13.2	Korea	53.4	Iceland	44.8	
United States	9.3	Italy	50.1	Canada	38.0	
		Iceland	44.9	Poland	37.5	
		Poland	38.6	United States	31.4	
		Canada	38.5	Mexico	21.2	
		United States	30.2			
		Mexico	15.4			

Notes

Country-specific definitions differ from the OECD proposed standard definition as follows:

Greece: Excludes other medical non-durables.

Hungary: Excludes subsidies by local governments.

Switzerland: Excludes other medical non-durables.

Turkey: Includes pharmaceutical consumption in hospitals.

Source

OECD Health Data 2009, November 2009. Organisation for Economic Co-operation and Development and IRDES, Paris.

^{*} The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Table C.3

The Share of Pharmaceutical Goods* in Public Expenditure on Health, in Descending Order, OECD Countries Reporting, 1985, 2006, 2007

1985		2006 2007			
	(%)		(%)		(%)
Portugal	30.1	Slovak Republic	31.7	Greece	32.5
Turkey	23.1	Hungary	29.4	Slovak Republic	28.9
Spain	15.7	Greece	27.7	Hungary	25.9
Japan	15.4	Korea	25.0	Korea	24.5
Luxembourg	14.2	Spain	22.0	Spain	21.2
France	13.8	Czech Republic	18.6	Czech Republic	16.6
Germany	12.8	Japan	17.3	Germany	14.9
New Zealand	12.3	Portugal	17.0	France	14.3
Iceland	11.8	Poland	15.0	Poland	13.0
Korea	11.4	Germany	14.4	Italy	12.1
United Kingdom	10.5	France	14.3	Switzerland	11.7
Netherlands	8.3	Italy	13.0	Australia	11.5
Australia	6.0	Switzerland	12.0	Austria	11.4
Finland	5.5	Australia	11.6	Mexico	11.3
Sweden	5.4	Austria	11.1	Finland	10.4
Norway	4.6	Finland	10.6	Canada	9.6
Canada	3.8	Sweden	9.9	Sweden	9.5
Denmark	3.5	Canada	9.6	New Zealand	8.3
United States	2.1	New Zealand	8.8	United States	8.3
		United States	8.1	Iceland	7.3
		Mexico	8.0	Denmark	5.7
		Iceland	7.8	Norway	5.1
		Norway	5.8		
		Denmark	5.6		

Notes

* The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Greece: Excludes other medical non-durables.

Hungary: Excludes subsidies by local governments.

Switzerland: Excludes other medical non-durables.

Turkey: Includes pharmaceutical consumption in hospitals.

Source

OECD Health Data 2009, November 2009. Organisation for Economic Co-operation and Development and IRDES, Paris.

125

Appendix A

Comparison of Provincial and Territorial Drug Subsidy Programs

Comparison of Provincial and Territorial Drug Subsidy Programs

Table 9 gives an overview of provincial and territorial drug subsidy programs as of December 31, 2009. The table was verified for accuracy with provincial/territorial programs. Information is also available from the following websites:

British Columbia Pharmacare

www.health.gov.bc.ca/pharmacare/#

Alberta Prescription Drug Program

www.health.alberta.ca/AHCIP/prescription-program.html

Saskatchewan Drug Plan

www.health.gov.sk.ca/drug-plan-benefits

Manitoba Pharmacare Program

www.gov.mb.ca/health/pharmacare/index.html

Ontario Drug Benefits

www.health.gov.on.ca/en/public/programs/drugs/funded drug/default.aspx

Régime général d'assurance médicaments du Québec (RGAM)

www.ramq.gouv.qc.ca/en/citoyens/assurancemedicaments/index.shtml

New Brunswick Prescription Drug Program

www.gnb.ca/0212/intro-e.asp

Nova Scotia Pharmacare

www.gov.ns.ca/health/pharmacare/family_pharmacare/family_pharmacare.asp

Prince Edward Island Pharmacy Services

www.gov.pe.ca/infopei/index.php3?number = 1019960&lang = E

Newfoundland and Labrador Prescription Drug Program

www.health.gov.nl.ca/health/nlpdp/newoverview.htm

Yukon Pharmacare

hss.gov.yk.ca/programs/insured hearing/pharmacare/

Northwest Territories

www.hlthss.gov.nt.ca/english/services/health care plan/default.htm

Nunavut

www.drugcoverage.ca/p benefit nu.asp

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
British Columbia	Fair Pharmacare Enhanced Assistance	Families in which at least one family member is born in 1939 or earlier and are not covered by other plans	None	Based on family net income: \$0: < \$33K to \$50K 2%: > \$50K	Pharmacare pays 75%	1.25%: <\$33K 2%: \$33K to \$50K 3%: >\$50K
	Fair Pharmacare	Families in which all family members are born in 1940 or later and are not covered by other plans	None	Based on family net income: \$0: <\$15K 2%: \$15K to \$30K 3%: >\$30K	Pharmacare pays 70%	2%: < \$15K 3%: \$15K to \$30K 4%: > \$30K
	Pharmacare Plan B	Permanent residents of licensed residential care facilities	None	None	None	N/A
	Pharmacare Plan C	Recipients of B.C. Income Assistance	None	None	None	N/A
	Pharmacare Plan D	Cystic fibrosis patients registered with a provincial cystic fibrosis clinic	None	None	None	N/A
	Pharmacare Plan F	Severely handicapped children registered in the At Home Program	None	None	None	N/A
	Pharmacare Plan G	Clients of mental health service centres meeting clinical and low- income criteria	None	None	None	N/A
	Pharmacare Plan P	Palliative care patients treated at home	None	None	None	N/A
Alberta	Seniors	Seniors age 65 and older and their eligible dependants	None	None	30% of prescription to a max. of \$25 per prescription*	N/A
	Widows	Residents age 55 to 64 who qualify for Alberta Widows' Pension and eligible dependants	None	None	30% of prescription to a max. of \$25 per prescription*	N/A

^{*} Costs incurred by the client choosing a high-cost product where cheaper alternatives are available are borne by the client.

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Alberta (cont'd)	Palliative	Palliative residents treated at home	None	None	30% of prescription to a max. of \$25 per prescription*	The maximum amount palliative patients pay out of pocket is \$1,000
	Non-Group	A universal plan available to all residents under the age of 65	Monthly rate is \$41 for singles and \$82 for families. Subsidized rates are available at \$28.50 for singles and \$57.40 for families.	None	30% of prescription to a max. of \$25 per prescription*	N/A
	Province-Wide Services	Residents with specific conditions may be eligible for high-cost drugs, mostly transplant and HIV drugs	None	None	None	N/A
	Income Support	Residents receiving social assistance and eligible dependants	None	None	None	N/A
	Assured Income for the Severely Handicapped (AISH)	Residents receiving AISH (an income- support program for adults with a permanent disability that severely impairs their ability to earn a living) and eligible dependants	None	None	None	N/A
	Alberta Adult Health Benefit	Qualified clients leaving Income Support for work	None	None	None	N/A
	Alberta Child Health Benefit	Children in low- income families	None	None	None	N/A

^{*} Costs incurred by the client choosing a high-cost product where cheaper alternatives are available are borne by the client.

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Saskatchewan [†]	Saskatchewan Drug Plan— Special Support Program	All residents with Saskatchewan health coverage (application required)	None	Income-tested (annual threshold based on 3.4% of adjusted family income)	Income-tested (based on benefit drug costs, to help spread cost out evenly over the year)	N/A
	Seniors' Drug Plan	Saskatchewan residents 65 and older. Individual annual net income must be below the limit for the federal age credit to be eligible for the cap of \$15 per prescription (application required to determine eligibility)	None	None	Maximum \$15 per prescription	N/A
	Seniors (Deductible Programs)	Seniors receiving the Seniors Income Plan supplement or receiving the federal Guaranteed Income Supplement and residing in a special care home	None	\$100 semi- annual family deductible	35% consumer copayment after deductible has been paid	N/A
		Seniors receiving the Guaranteed Income Supplement and living in the community	None	\$200 semi- annual family deductible	35% consumer copayment after deductible has been paid	N/A

† To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Saskatchewan (cont'd)†	Emergency Assistance Program	Residents who require immediate treatment with covered prescription drugs and are unable to cover their share of the cost. This is a one-time benefit, and individuals are encouraged to apply for incometested coverage for future assistance	None	None	The level of assistance provided is in accordance with the consumer's ability to pay	N/A
	Family Health Benefits	Eligibility is established by the Department of Social Services, based on the number of children in the family and the family's annual income	None	\$100 semi- annual family deductible	No charge for benefit prescriptions for children; 35% consumer copayment after deductible has been paid for adult benefit prescriptions	N/A
	Supplementary Health	Persons nominated by Saskatchewan Social Services for special coverage, including persons on social assistance, wards, inmates, etc.	None	None	Up to \$2 per prescription (some drugs covered at no charge; individuals younger than 18 and certain other categories receive benefit prescriptions at no charge)	N/A

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Saskatchewan (cont'd)†	Saskatchewan Aids to Independent Living (SAIL)	Persons registered under the following SAIL programs receive formulary and approved nonformulary drugs at no charge: Paraplegia Program, Cystic Fibrosis Program and Chronic End-Stage Renal Disease Program	None	None	None	N/A
	Palliative Care Program	Residents who are in the late stages of a terminal illness	None	None	None	N/A
	Workers' Health Benefits Program [†]	Employed or self-employed residents younger than 65 without dependent children, without access to private or employer-sponsored health plan and who are either • Single with income less than \$21,000; or • Married or common law with income less than \$26,000	None	\$100 semi- annual deductible	35% consumer copayment after deductible has been paid	N/A
		(application required)				

Notes

- † To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.
- [‡] The Saskatchewan Workers' Health Benefits Program was discontinued as of March 19, 2008. Working adults without children who are currently enrolled and receiving benefits will maintain coverage until June 2010, if they continue to remain eligible.

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Saskatchewan (cont'd) [†]	Children's Insulin Pump Program	Type 1 diabetic children (younger than 18) who require pumps to adequately stabilize blood sugar levels and are not eligible for benefits under a federal government program (such as the Non-Insured Health Benefits Program)	None	None	No charge for insulin pump. Insulin pump supplies subject to coverage (family deductible/copay)	N/A
	Children's Drug Plan	Children 14 and younger	None	None	Maximum \$15 per prescription	N/A
Manitoba	Pharmacare	All provincial residents who are eligible for benefits under The Prescription Drug Cost Assistance Act	None	Ranging from 2.69% to 6.08% based on total adjusted family income. Credit of \$3,000 for a spouse and each dependent younger than 18	None	N/A

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Manitoba (cont'd)	Employment and Income Assistance Program	Individual Manitobans that are receiving drug benefits pursuant to the Employment and Income Assistance Program	None	None	None	N/A
	Personal Care Home/Nursing Home	Manitoba residents of personal care homes	None	None	None	N/A
	Palliative Care Drug Access Program	Residents who are terminally ill and wish to remain at home	None	None	None	N/A
Ontario	Ontario Drug Benefit Program	Seniors (65 and older). Single seniors with annual income ≥ \$16,018 or seniors in couples with combined annual income of ≥ \$24,175	None	\$100 per recipient	After deductible, up to \$6.11 per prescription	N/A
		Seniors (65 and older). Single seniors with annual income <\$16,018 or seniors in couples with combined annual income of <\$24,175	None	None	Up to \$2 per prescription	N/A
		Residents of long-term care facilities	None	None	Up to \$2 per prescription	N/A
		Residents of homes for special care	None	None	Up to \$2 per prescription	N/A
		Residents receiving professional services under the home care program	None	None	Up to \$2 per prescription	N/A
		Residents receiving social assistance (Ontario Disability Support Program or Ontario Works Program)	None	None	Up to \$2 per prescription	N/A
	Trillium Drug Program	Residents with high drug costs in relation to income	None	Income- based	Up to \$2 per prescription	N/A
	Special Drugs Program	Residents with valid Ontario health insurance. Coverage is product-specific for a limited number of diseases or conditions.	None	None	None	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Quebec	Régime général d'assurance médicaments du Québec (RGAM)	Employment assistance (welfare) recipients (EAR) and other holders of a claim slip	None	None	None	None
		Seniors (65 and older) receiving at least 94% of the maximum Guaranteed Income Supplement (GIS)	None	None	None	None
		Seniors (65 and older) receiving less than 94% of the maximum GIS (partial GIS)	\$0 to \$585 per adult per year, depending on income	\$14.95 per month	32% of prescription costs	\$49.97 per month
		Seniors (65 and older) without GIS	\$0 to \$585 per adult per year, depending on income	\$14.95 per month	32% of prescription costs	\$79.53 per month
		General clientele (residents younger than 65 without access to a group plan)	\$0 to \$585 per adult per year, depending on income	\$14.95 per month	32% of prescription costs	\$79.53 per month
New Brunswick	Prescription Drug Program— Plan A	Seniors with Guaranteed Income Supplement (GIS)	None	None	\$9.05 for each prescription	\$250
		Seniors without GIS who qualify for benefits based on annual income as follows: a single senior with an annual income of \$17,198 or less; a senior couple (both ≥65) with a combined annual income of \$26,955 or less; a senior couple with one spouse younger than 65, with a combined annual income of \$32,390 or less	None	None	\$15 per prescription	N/A
	Prescription Drug Program— Plan B	Cystic fibrosis patients or patients with juvenile or infant sclerosis of the pancreas	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan C	Residents who have seen a health care provider and show symptoms of H1N1 influenza	None	None	None	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
New Brunswick (cont'd)	Prescription Drug Program— Plan E	Individuals residing in a licensed adult residential facility who hold a valid health card for prescription drugs issued by the Department of Social Development	None	None	\$4 for each prescription	\$250
	Prescription Drug Program— Plan F	Individuals holding a valid health card for prescription drugs issued by the Department of Social Development	None	None	\$4 per prescription for adults (18 and older) and \$2 for children (younger than 18)	\$250 per family
	Prescription Drug Program— Plan G	Special-needs children and children under the care of the Minister of Social Development	None	None	None	N/A
	Prescription Drug Program— Plan H	Residents in possession of a prescription written by a neurologist for the medications Avonex, Rebif, Betaseron or Copaxone are eligible to apply for assistance	\$50 yearly registration fee	None	Incometested (ranges from 0% to 100%)	N/A
	Prescription Drug Program— Plan R	Recipients of an organ or bone marrow transplant who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan T	Individuals with growth hormone deficiency or hypopituitarism who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan U	Individuals who are HIV positive and are registered with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan V	Individuals who reside in a registered nursing home	None	None	None	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Nova Scotia	Seniors Pharmacare Program	Seniors (65 and older) receiving Guaranteed Income Supplement (GIS) and covered by Medical Services Insurance (MSI) and not having coverage through Veterans Affairs Canada, Non-Insured Health Benefits, Nova Scotia Family Pharmacare or any other public or private plan that covers most medications and supplies	None	None	30% prescription cost	\$382
		Seniors (65 and older) not receiving GIS and covered by MSI and not having coverage through Veterans Affairs Canada, Non-Insured Health Benefits, Nova Scotia Family Pharmacare or any other public or private plan that covers most medications and supplies	Up to \$424 per year	None	30% prescription cost	\$382
	Department of Community Services Programs	Eligible clients and their dependents in receipt of income assistance; any client and/or dependent having access to another drug plan, be it from a public or private entity, will be required to use that plan and will not be eligible for the pharmacare program	None	None	All income- assistance clients and dependents are required to copay a flat fee of \$5 per prescription, unless the client or dependent is eligible for copay exemption	N/A
	Drug Assistance for Cancer Patients	Residents having a gross family income no greater than \$15,720 per year and not eligible for coverage under other drug programs	None	None	None	N/A
	Family Pharmacare Program	Residents with a valid Nova Scotia health card	None	Income- based	20% of the total prescription cost	Income- based

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Nova Scotia (cont'd)	Nova Scotia Diabetes Assistance Program	Residents younger than 65 with a valid Nova Scotia health card and who do not have drug coverage through Veterans Affairs Canada, First Nations and Inuit Health or any private drug plans that cover diabetes supplies, who have a confirmed diagnosis of diabetes	None	Income- based	20% of the total prescription cost	N/A
Prince Edward Island	Seniors Drug Cost Assistance Plan	Seniors 65 or older and eligible for P.E.I. Medicare	None	None	First \$11 of the medication cost plus the pharmacy professional fee for each prescription	N/A
	Children-in-Care	Persons eligible under the Social Assistance Act and persons in the temporary or permanent care of the Director of Child Welfare	None	None	None	N/A
	Family Health Benefit Program	Families (parents, guardians and children younger than 18 or younger than 25 and in full-time attendance at a postsecondary education institution), eligible for P.E.I. Medicare with a total net family income less than the threshold. Families must apply for coverage on an annual basis and provide income information to the program	None	None	The pharmacy professional fee for each prescription	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Prince Edward Island (cont'd)	Financial Assistance Program	Persons eligible under the <i>Social</i> <i>Assistance Act</i>	None	None	None	N/A
	Erythropoietin Program	Persons eligible for P.E.I. Medicare who have been diagnosed with chronic renal failure or are receiving kidney dialysis and registered with the program	None	None	None	N/A
	Diabetes Control Program	Persons with diabetes eligible for P.E.I. Medicare and who are registered with the program	None	None	Blood Glucose Test Strips: \$11 per prescription to a maximum of 100 strips every 30 days Oral	N/A
					Medications and Urine Testing Materials: \$11 per prescription	
					High-Cost Diabetes Medications: an income- based portion of the medication plus the	
					professional fee for each high-cost medication obtained	

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Prince Edward Island (cont'd)	High Cost Drugs Program	Persons eligible for P.E.I. Medicare and approved for coverage of one or more of the medications included in the program. Patients must apply for coverage on an annual basis and provide income information to the program	None	None	Income- based portion of the drug cost plus the pharmacy professional fee for each prescription	N/A
	Community Mental Health Program	Approved long-term psychiatric patients living in the community	None	None	None	N/A
	Sexually Transmitted Diseases (STD) Program	Persons diagnosed with sexually transmitted disease or identified contacts of a person with a sexually transmitted disease	None	None	None	N/A
	Nursing Home Program	Residents in government manors or private nursing homes eligible for coverage under the Long-Term Care Subsidization Act	None	None	None	N/A
	Disease-Specific Programs (for example, AIDS/HIV, cystic fibrosis, growth hormone, hepatitis, tuberculosis, hairy cell leukemia, AIDS-related Kaposi's sarcoma, basal cell carcinoma, meningitis, phenylketonuria and transplant drug programs delivered through the government-run provincial pharmacy)	Persons diagnosed with specific medical conditions or at risk for exposure to communicable diseases	None	None	None	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Prince Edward Island (cont'd)	Quit-Smoking Program	Persons eligible for P.E.I. Medicare and who have registered with the program	None	None	Patients are responsible for all medication costs approved, except for the first \$75, which will be paid by the program	N/A
	Nutrition Program	Children and high-risk pregnant women diagnosed with a nutritional deficiency	None	None	None	N/A
Newfoundland and Labrador	The 65Plus Plan	Seniors (65 and older) who are in receipt of the Guaranteed Income Supplement and who are registered for Old Age Security benefits	None	None	Markup and professional fee for identified benefits	N/A
	The Foundation Plan	Residents of the province who qualify for full benefit coverage under the Department of Human Resources, Labour and Employment, and certain individuals receiving services through the regional health authorities, including children in the care of Child, Youth and Family Services and individuals in supervised care	None	None	None	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Newfoundland and Labrador (cont'd)	The Access Plan	Residents with low incomes who access eligible prescription medications. The amount of coverage is determined by net income level and family status	None	None	Based on family net income: Family (with children) Income Copay < \$21K 20.0% \$22K 25.6% \$23K 31.1% \$24K 36.7% \$25K 42.2% \$26K 47.8% \$27K 53.3% \$28K 58.9% \$29K 64.4% \$30K 70.0% Couple (with no children) Income Copay < \$15K 20.0% \$16K 28.3% \$17K 36.7% \$18K 45.0% \$19K 53.3% \$20K 61.7% \$21K 70.0% Single individuals: Income Copay < \$13K 20.0% \$14K 28.3% \$15K 36.7% \$18K 45.0% \$19K 53.3% \$20K 61.7% \$21K 70.0% Single individuals: Income Copay < \$13K 20.0% \$14K 28.3% \$15K 36.7% \$16K 45.0% \$17K 53.3% \$18K 61.7% \$18K 61.7% \$19K 70.0%	Between 20% and 70%, depending on family net income and family status (single, couple or family)
	The Assurance Plan	Residents who experience the financial burden of eligible high drug costs, whether it be from the cost of one extremely high-cost drug or the combined cost of different drugs	None	None	Based on a combination of family net income and eligible family drug costs	Based on family net income: Income Max. < \$40K 5.0% ≥ \$40K to 7.5% < \$75K ≥ \$75K to 10.0% < \$150K
	The Select Needs Plan	Residents with cystic fibrosis or growth hormone deficiency	None	None	None, for identified benefits	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Yukon	Pharmacare	Seniors 65 or older (and seniors' spouses age 60 and older) registered with Yukon Health Care Insurance Plan and not having coverage through First Nations and Inuit Health. Residents with another third-party or group insurance must use that plan first. Program includes clients receiving palliative care.	None	None	None	N/A
	Chronic Disease Program	Residents who have a chronic disease or a serious functional disability as provided under the <i>Chronic Disease and Disability Benefits Regulations</i> and not having coverage through First Nations and Inuit Health. Residents with another third-party or group insurance must use that plan first. Program includes clients receiving palliative care.	None	Maximum \$250 per individual and \$500 per family (deductible may be waived, depending on income)	None	N/A
	Children's Drug and Optical Program	Children younger than 19 from low- income families and not having coverage through First Nations and Inuit Health	None	Maximum \$250 per child and \$500 per family (deductible may be waived, depending on income)	None	N/A

Table 9 Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2009 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Northwest Territories	Extended Health Benefits Program for Specified Diseases	Resident, non-native or Métis and have a specified disease condition	None	None	None	N/A
	Seniors' Benefit Program	Resident, Métis and non-native residents who are 60 years and older	None	None	None	N/A
	Métis Health Benefits Program	Resident, registered with territorial health care plan, descendent of Chipewyan, Slavey, Gwich'in, Dogrib, Hare or Cree people; and resided in or used and occupied the Mackenzie Basin on or before January 1, 1921, or is a Community Acceptance Member, or was adopted as a minor	None	None	None	N/A
	Indigent Health Benefits Program	Indigent individuals or families resident of the Northwest Territories, who meet the eligibility requirements according to the Indigent Health Benefits Policy	None	None	None	N/A
Nunavut	Extended Health Benefits Program	Non-Aboriginal residents, including seniors, who have a specific chronic condition or have reached the age of 65	None	None	None	N/A
	Indigent Health Benefits Program	Residents receiving income support	None	None	None	N/A

References

- Canadian Institute for Health Information, National Health Expenditure Trends, 1975 to 2009 (Ottawa, Ont.: CIHI, 2009).
- 2. Health Canada, *Non-Insured Health Benefits Program—Annual Report 2007/2008* (Ottawa, Ont.: Health Canada, 2009).
- 3. S. Morgan, "Sources of Variation in Provincial Drug Spending," *Canadian Medical Association Journal* 170, 3 (2004): pp. 329–330.
- S. Jacobzone, Organisation for Economic Co-operation and Development, *Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals*, Labour Market and Social Policy; Occasional Papers, No. 40 (Paris, France: OECD, April 2000).
- 5. Organisation for Economic Co-operation and Development, *OECD.Stat*, accessed on November 25, 2009, from http://stats.oecd.org/lndex.aspx>.
- 6. M. Aaserud et al., *Pharmaceutical Policies: Effects of Reference Pricing, Other Pricing and Purchasing Policies (Review)*, The Cochrane Collaboration, 4 (The Cochrane Library: John Wiley & Sons, Ltd., 2006): pp. 1–66, Cochrane Library Number CD005979.
- 7. S. Morgan et al., "'Breakthrough' Drugs and Growth in Expenditure on Prescription Drugs in Canada," *British Medical Journal* 331, 7520 (October 8, 2005): pp. 815–816, accessed on February 8, 2007, from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1246080, catalogue no. 38582.703866.
- 8. Patented Medicine Prices Review Board, *Patented Medicine Prices Review Board 2008 Annual Report* (Ottawa, Ont.: Patented Medicine Prices Review Board, 2009), pp. 1–60, accessed December 2009, from http://www.pmprb-cepmb.gc.ca/cmfiles/PMPRB-AR08-E.pdf>.
- 9. Z. Karaca and S. Wiggins, *The Impacts of Break-Through Drug Classes on Total Health Expenditures: Empirical Evidence From the 1996–2001 Medical Expenditure Panel Surveys*, eds., Z. Karaca and S. Wiggins (Texas: A&M University, November 11, 2006), pp. 1–40, accessed on February 14, 2007, from http://ssrn.com/abstract=947603, catalogue no. 947603.
- F. R. Lichtenberg, "Are the Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS," Health Affairs 20, 5 (September/October 2001): pp. 241–251.
- 11. Canadian Cancer Society, *A National Home Care Program*, accessed on February 9, 2007, from http://www.cancer.ca/ccs/internet/standard/0,3182,3172 335445 langld-en,00.html>.

- 12. Statistics Canada, Demography Division, *Demographic Estimates Compendium 2007* (Ottawa, Ont.: Statistics Canada, April 2008), catalogue no. 91-213-SCB.
- 13. S. Morgan, "Drug Spending in Canada: Recent Trends and Causes," *Medical Care* 42, 7 (July 2004): pp. 635–642.
- 14. B. Mintzes et al., "Volume IV: Pills, Persuasion and Public Health Policies," in An Assessment of the Health System Impacts of Direct-to-Consumer Advertising of Prescription Medicines (DTCA), eds., B. Mintzes, A. Kazanjian, K. Bassett and J. Lexchin (Report of an Expert Survey on Direct-to-Consumer Advertising of Prescription Drugs in Canada, the United States and New Zealand) (Vancouver, B.C.: Health Policy and Research Unit, Centre for Health Services and Policy Research, August 2001), pp. 1–48, accessed on February 14, 2007, from http://www.chspr.ubc.ca/files/publications/2002/dtca-v4-expertsurvey.pdf, catalogue no. HPRU 02:4D.
- 15. Statistics Canada, *Guide to the Income and Expenditure Accounts* (Ottawa, Ont.: Statistics Canada, 1996), pp. 137 and 139, catalogue no. 13-603E.
- 16. Organisation for Economic Co-operation and Development, *OECD Health Data 2009* (Paris, France: OECD, 2009).
- 17. Statistics Canada, *Family Expenditure in Canada* (Ottawa, Ont.: Statistics Canada), catalogue no. 65-555-XPB.
- 18. Statistics Canada, Your Guide to the Consumer Price Index (Ottawa, Ont.: Statistics Canada, 1996), pp. 7–9, accessed on February 9, 2007, from http://www.statcan.gc.ca/imdb-bmdi/document/2301_D6_T9_V1-eng.pdf, catalogue no. 62-557-XPB.

Production of this report is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government.

All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system now known or to be invented, without the prior permission in writing from the owner of the copyright, except by a reviewer who wishes to quote brief passages in connection with a review written for inclusion in a magazine, newspaper or broadcast.

Requests for permission should be addressed to:

Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6

Phone: 613-241-7860 Fax: 613-241-8120

www.cihi.ca

copyright@cihi.ca

ISBN 978-1-55465-733-9 (PDF)

© 2010 Canadian Institute for Health Information

How to cite this document: Canadian Institute for Health Information, *Drug Expenditure in Canada,* 1985 to 2009 (Ottawa, Ont.: CIHI, 2010).

Cette publication est aussi disponible en français sous le titre Dépenses en médicaments au Canada, de 1985 à 2009. ISBN 978-1-55465-734-6 (PDF)

Talk to Us

CIHI Ottawa

495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860

CIHI Toronto

4110 Yonge Street, Suite 300 Toronto, Ontario M2P 2B7 Phone: 416-481-2002

CIHI Victoria

880 Douglas Street, Suite 600 Victoria, British Columbia V8W 2B7 Phone: 250-220-4100

CIHI Edmonton

10235 101 Street Northwest, Suite 1414 Edmonton, Alberta T5J 3G1 Phone: 780-409-5438

CIHI Montréal

1010 Sherbrooke Street West, Suite 300 Montréal, Quebec H3A 2R7 Phone: 514-842-2226

CIHI St. John's

140 Water Street, Suite 701 St. John's, Newfoundland and Labrador A1C 6H6 Phone: 709-576-7006



